Mathematische Modellierung der zellulären Signaltransduktion by Wangorsch, Gaby
DOCTORAL THESIS FOR A DOCTORAL DEGREE AT THE
GRADUATE SCHOOL OF LIFE SCIENCES,
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG,
SECTION BIOMEDICINE
MATHEMATICAL MODELING OF
CELLULAR SIGNAL TRANSDUCTION
MATHEMATISCHE MODELLIERUNG DER
ZELLULÄREN SIGNALTRANSDUKTION
Submitted by
GABY WANGORSCH
from
MELLRICHSTADT
Würzburg, 2013

Submitted on: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Office stamp
Members of the Promotionskomitee:
Chairperson: Prof. Dr. Manfred Gessler
Primary Supervisor: Prof. Dr. Thomas Dandekar
Supervisor (Second): Prof. Dr. Ulrich Walter
Supervisor (Third): Prof. Dr. Jörg Schultz
Date of Public Defence: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Date of Receipt of Certificates: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

To Thomas T.
in Memoriam

Acknowledgements
This doctoral thesis comprises research results arising from interdisciplinary
collaborations of the Department of Bioinformatics at the University of Würz-
burg together with the University Hospital Würzburg. Starting in March
2008, I have been a fellow of the Graduate School of Life Sciences, section
Biomedicine, and member of the special research area (SFB688) on mecha-
nisms and imaging of cardiovascular cell-cell-interactions.
First and foremost, I would like to thank all the people who have accompa-
nied and supported me over the last years.
All members of my supervisory committee Prof. Thomas Dandekar, Prof.
Jörg Schultz and Prof. Ulrich Walter, for their support within the Doctoral
Study Program "Life Sciences" of the Graduate School of Life Sciences.
My primary supervisor Prof. Thomas Dandekar, for giving me the oppor-
tunity to meet the dynamic research field at the interface between mathe-
matics, biology and medicine. He supported me with his unwavering opti-
mism and encouraging guidance during the conductance of my research.
My second supervisor Prof. Walter, the former speaker of the special re-
search area (SFB688) on mechanisms and imaging of cardiovascular cell-
cell-interactions, for offering such a comfortable and stimulating research
environment. It was fascinating to immerse into the world of platelets,
being tiny and anucleate blood cells but representing a pivotal regulatory
target with regard to severe cardiovascular diseases. Following this, I am
grateful for the funding by the DFG project SFB688.
My third supervisor Prof. Jörg Schultz for introducing me into the myste-
rious world of Perl, many helpful comments on my thesis and his persistent
encouragement.
My external collaborators Prof. Harald Wajant (Division of Molecular In-
ternal Medicine, Department of Internal Medicine II, University Hospital
Würzburg) for sharing expert knowledge and data on inflammation signa-
ling. Prof. Elke Butt, Dr. Jörg Geiger, Dr. Katharina Hubertus and Dr.
Stepan Gambaryan (Institute of Clinical Biochemistry and Pathobiochemis-
try, University of Würzburg) for fruitful discussions and providing data on
platelets.
My former working group at the University of Freiburg for discussions and
support in data-based mathematical modeling.
All associated members from the SFB688 for prosperous collaborations, in
particular Prof. Stefan Frantz, Christina Pachel, Prof. Kristina Lorenz, Dr.
Attila Braun, for starting and establishing interdisciplinary collaborations.
My internal collaborators, for helpful and stimulating discussions and mee-
tings, showing that there is much more about Bioinformatics than BLAST
and alignments; Tobias Müller and Marcus Dittrich for training and support
in data analysis; Nicole Philippi and Muhammad Naseem for exchanging
ideas on computational modeling of biological systems; Desi and Santosh
- my brave "plateleteers" - for forming such a dense and interacting clot of
mutual information exchange; every thrombus may become envious of.
All actual and former colleagues at the Department, especially Karin Lus-
tre, Stefan Obermeier, Daniela Beißer, Christian Koetschan, Tina Schleicher,
Alex the Great, Bärtierchen Frank, Michael Seidl, Astrid Fieselmann and
the "plateleteers", for a very comfortable working atmosphere and many
nice chats over some cups of coffee. Thanks for the unforgettable time also
beyond room 116. Hopefully, the "interactions" we established during gra-
duation will also have high edge scores in the future.
The LATEX-command \usepackage[always]{coffee, chocolate} and Daniel for
donating the essential, motivating Leberwurscht.
My "Stoogemer Mädels" together with the whole "Mühlfeld- and Werner-
gang". The ties of our friendship are of incomparable value and helped a lot
in managing the ups and downs in my life.
My brother Klaus, for proof-reading, for always taking care of his little sister
and cheering me up with his music and extraordinary cooking experiments.
Lastly and surely the most, my entire family, especially my dear parents, for
all their unconditional and perpetual love and support.
8
Abstract
A subtly regulated and controlled course of cellular processes is essential
for the healthy functioning not only of single cells, but also of organs being
constituted thereof. In return, this entails the proper functioning of the
whole organism. This implies a complex intra- and inter-cellular communi-
cation and signal processing that require equally multi-faceted methods to
describe and investigate the underlying processes.
Within the scope of this thesis, mathematical modeling of cellular signa-
ling finds its application in the analysis of cellular processes and signaling
cascades in different organisms. First, a comprehensive systemic analysis
of signaling pathways in human platelets is presented. These tiny blood
cells play a key role in thrombosis and hemostasis. Based on an integrative
platelet-specific data base (PlateletWeb), I developed interaction networks,
qualitative and quantitative models of antagonistic signaling pathways in
the platelet. On the basis of phosphoproteomic data, this afforded the in-
tegration of potential substrates of key kinases into a functional network
context. By means of a discrete dynamic model of central signaling cas-
cades, I investigated the interplay between activatory and inhibitory signa-
ling pathways towards the ultimate platelet aggregation. Extensive model
simulations thereby documented the gradual activation of blood platelets
to the point of aggregation. Data-based dynamic modeling of the inhibiting
platelet cascade permitted quantitative model predictions of pivotal second
messengers and yielded for the first time the quantification of central regu-
lators. By comprehensively calibrating the dynamic model with time series
data, I deciphered the feed-back regulation of second messengers (cAMP,
cGMP) that lead to platelet inhibition. Model-based analyses of pathway
cross-talks demonstrated the wide-ranging scope of pharmacological mo-
dulation, not only in the platelet but also in other cell types such as cardio-
myocytes.
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Inflammatory processes are regulated by a multitude of signaling cascades
that are highly cross-linked as well. I here present a first mathematical mo-
del for simulating the apoptotic cross-talk between TNF receptors, crucial
mediators of inflammatory processes. In this type of signaling, the detailed
and receptor-specific formation of the signal at the respective receptor is
also of prime importance. Here, simulations of a structure-orientated ma-
thematical model offer valuable clues about the strengths of ligand-encoded
signal that is created at the particular receptor.
Likewise, mathematical modeling and simulations are beneficial to decode
the interplay of distinct phytohormones, as shown here using the example
of Arabidopsis and pathogen Pst DC3000. Model-based forecasting together
with profound validation by means of experimental data revealed multiple
cross-talk for the hormone cytokinin with respect to plant immunity.
Lastly, models describing intra- and inter-cellular signaling of different liver
cells demonstrate the impact of combining mathematical models to func-
tionally analyze the liver as a holistic cellular system.
Within the framework of this thesis, I present mathematical methods for
modeling cellular signaling cascades and their interplay in different orga-
nisms. Resulting models form the basis for a systemic description and ana-
lysis of cell-regulatory processes as well as for model-based predictions.
This way, models guide further experimental investigation and are capable
to indicate novel interaction points for pharmacological modulations.
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Zusammenfassung
Das fein regulierte und kontrollierte Ablaufen zellulärer Prozesse ist es-
sentiell für das gesunde Funktionieren einzelner Zellen, sowie der aus ih-
nen bestehenden Organe. Diese wiederum bedingen das Funktionieren des
gesamten Organismus. Genauso vielschichtig wie die Kommunikation und
Signalverarbeitung innerhalb und zwischen den Zellen, sind die Methoden
um diese Vorgänge zu beschreiben und zu untersuchen.
Die mathematische Modellierung zellulärer Signalverarbeitung findet im
Rahmen dieser Arbeit Anwendung in der Analyse zellulärer Prozesse und
Signalkaskaden in verschiedenen Organismen. Zunächst wird eine um-
fassende systemische Analyse von Signalwegen in humanen Blutplättchen
gegeben. Diese kleinen Blutzellen spielen eine Schlüsselrolle in Throm-
bose und Hämostase. Ausgehend von einer integrativen Blutplättchen-spe-
zifischen Datenbank entwickelte ich Interaktionsnetzwerke sowie qualita-
tive und quantitative Modelle zu antagonistischen Signalwegen der Blut-
plättchen. Auf der Basis von Phosphoproteom-Daten war es möglich, po-
tentielle Substrate wichtiger Kinasen in einen funktionellen Netzwerkkon-
text zu setzen. In einem diskret-dynamischen Modell zentraler Signalkas-
kaden untersuchte ich das Zusammenspiel aktivierender und inhibierender
Signalwege bis hin zur finalen Aggregation des Blutplättchens. Das durch
intensive Simulationen gezeigte Verhalten belegt die schrittweise Aktivie-
rung des Blutplättchens bis zur finalen Plättchen-Aggregation. Die daten-
basierte, dynamische Modellierung der inhibierenden Kaskade konnte quan-
titative Vorhersagen bezüglich wichtiger sekundärer Botenstoffe im Plätt-
chen erzielen, sowie erstmals wesentliche Regulatoren quantifizieren. Durch
umfangreiche Kalibrierung des dynamischen Modells mit Zeitreihendaten
entschlüsselte ich eine durch Rückkopplungsschleifen charakterisierte Re-
gulierung der Botenstoffe (cAMP, cGMP), die zur Inhibierung des Plätt-
chens führen. Modell-basierte Analysen zur Quervernetzung der inhibieren-
den Kaskade demonstrieren den breitgefächerten Spielraum für pharma-
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kologischen Modulierung und zeigen neue molekulare Angriffspunkte auf,
nicht nur in Blutplättchen, sondern auch in anderen Zelltypen wie beispiels-
weise der Herzmuskelzelle.
Entzündungsprozesse werden ebenfalls durch eine Vielzahl von Signalkas-
kaden geregelt, die miteinander stark wechselwirken. Ich präsentiere ein
erstes mathematisches Modell zur Simulation der apoptotischen Wechsel-
wirkung zwischen TNF-Rezeptoren, welche die Vermittlung von Entzün-
dungsprozessen bewerkstelligen. Hierbei ist auch die detaillierte, Rezep-
tor-spezifische Entstehung des Signals von Bedeutung, welches über den
Rezeptor weitergegeben wird. Simulationen eines strukturorientierten ma-
thematischen Modells geben Aufschluss über die mögliche Stärke des Li-
ganden-kodierten Signals am jeweiligen TNF-Rezeptor.
Ebenso nützlich ist die mathematische Modellierung und Simulation beim
Entschlüsseln des Zusammenspiels verschiedener Pflanzenhormone, wie
am Beispiel von Arabidopsis und dem Pathogen Pst DC3000 gezeigt wird.
Modell-basierte Vorhersagen in Verbindung mit intensiver Validierung mit-
tels experimenteller Daten konnten dabei dem Hormon Cytokinin eine Viel-
zahl vernetzter Effekte und Wechselwirkungen mit dem Pflanzenimmun-
system zuweisen.
Modelle zur Beschreibung von Signalwegen in und zwischen verschiede-
nen Typen von Leberzellen demonstrieren abschließend, wie eine Kombi-
nation von mathematischen Modellen die funktionelle Analyse der Leber
als gesamtzelluläres System unterstützt.
Die vorliegende Arbeit präsentiert mathematische Methoden zur Model-
lierung zellulärer Signalkaskaden und deren Zusammenspiel in verschiede-
nen Organismen. Resultierende Modelle bilden die Grundlage für eine sys-
temische Beschreibung und Analyse der zellregulierenden Vorgänge sowie
für Modell-basierende Vorhersagen. Auf diese Weise geben sie Ideen für
weitere Untersuchungen auf experimenteller Ebene und zeigen neue An-
satzpunkte für eine pharmakologische Modulation auf.
x
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Preface
MATHEMATICS IS BIOLOGY’S NEXT MICROSCOPE,
ONLY BETTER;
BIOLOGY IS MATHEMATICS’ NEXT PHYSICS,
ONLY BETTER.
(Joel E. Cohen)
Mathematics and the life sciences have always been intertwined and already
have a history of successful mutual interactions starting approximately 500
years ago. In 1628, physician William Harvey published his outstanding
work "De Motu Cordis" (White, 1999) and set a pivotal milestone in the early
history of biological quantitation. By meticulously observing the anatomy
and dynamics of the heart, he could reasonably demonstrate that blood cir-
culates in the body which was a revolutionary finding at that time. More-
over, the theoretical predictions based on mathematical calculations were
scientifically confirmed in the following decades, illustrating the tremen-
dous power of sensibly combining simple mathematics with thorough ob-
servations. Since then, all fields of mathematics have made remarkable
progress, which has also enriched biology and all life sciences. Mathematics
was and still is crucial for interpreting any kind of data. Or, to say it with
Charles R. Darwin’s words:
"Mathematics seems to endow one
with something like a new sense" (Bell, 1986).
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The development of medical imaging, the theory of evolution or population-
biological research are just some examples showing the benefit of mathema-
tical approaches.
Conversely, mathematics has gained profit and progress through scientific
and conceptual challenges from life sciences over the past years. Exem-
plary, the logistic equation for limited population growth (Verhulst, 1838),
correlation (Pearson and Lee, 1903), Markov chains, statistics of language
(Markov, 1906), the Hardy-Weinberg equilibrium in population genetics
(Hardy, 1908; Weinberg, 1908), biochemical kinetics (Menten and Michaelis,
1913), the dynamics of interacting species (Lotka, 1925; Volterra, 1931), game
theory (von Neumann and Morgenstern, 1953), threshold functions of ran-
dom graphs (Erdoes and Renyi, 1960) or the sampling formula for haplotype
frequencies (Ewens, 1972) show the diverse fields of mathematics which
arose from biological problems.
Nevertheless, a quantitative and mathematically based description of bio-
logy has been very slow in development, moving the mathematician Gian-
Carlo Rota to state this scathing remark:
"The lack of real contact between mathematics and biology
is either a tragedy, a scandal, or a challenge,
it is hard to decide which" (Rota et al., 1986).
However, much has changed in the almost three decades since Rota’s com-
ment. This includes the rise of complete new disciplines in the field of com-
putational life sciences such as bioinformatics and systems biology, the in-
terdisciplinary union of data-based mathematical modeling and cell biology
(Chuang et al., 2010).
We gain more and more insight into the complexity of biological systems,
their multi-scale regulation and organization by accumulating loads of in-
creasingly precise data. Technological advances (e.g. high through-put pro-
cessing) and improved laboratory analysis methods have made biology a
data-rich science demanding increasingly ingenious mathematical and com-
putational concepts and tools. Computational methods based on a solid
theoretical and numerical foundation have been established, especially tai-
lored to investigate adaptive and dynamic systems in biomedicine. These
techniques now allow for representing and analyzing large, multi-scale com-
2
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plex systems and studying their emergent properties. Moreover, they offer
tools to make both qualitative and quantitative predictions in order to inves-
tigate inherent system properties. Machine learning, numerics and bioinfor-
matics support the efficient data mining and its analysis as well as the ex-
traction of the most useful data from within an overwhelming amount. Ad-
vances in computer-aided approximation approaches and algorithms per-
mit the simulation and optimization of large biological networks and help
to reveal the dynamics of more focused non-linear systems. By novel phy-
sical, mathematical and computational methods, the folding of proteins and
the binding between a ligand and its target site can be predicted, suggesting
insights into highly specific molecular interactions. This in turn highlights
points of interaction for targeted drug interventions.
The relevant disciplines complement each other in such a way that the "ex-
plosive synergy" (Cohen, 2004) among them will revolutionize not only bio-
logy and medicine but also other fields including environmental science,
food production and drug development.
Modeling and simulation of intracellular molecular networks and cellular
signal transduction is one challenging example how biology can inspire ma-
thematical research and vice versa. The analysis of these cell communica-
tion processes has become an inevitable part of systems biological investiga-
tion. This thesis covers a set of examples of applied mathematical methods
to model processes in cell biology and signal transduction in different cell
types and organisms.
3
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INTRODUCTION
1 Introduction
DIMIDIUM FACTI, QUI COEPIT, HABET.
HE WHO HAS BEGUN HAS HALF DONE.
(Horace)
Models in Life Sciences
The use of models in cell biology is both, familiar and enigmatic. On the
one hand, biologists always used models as an abstraction of reality such
as diagrams, laws, graphs, plots, chemical formulas and relationships. In
the same way, "model organisms" like yeast, Arabidopsis thaliana, Escherichia
coli, Drosphila melanogaster or mice are extensively studied to understand
particular biological phenomena. Their role lies in being similar to many
organisms without being the same. Thus, one expects that discoveries will
provide insight into the workings of other organisms as well.
On the other hand, a mathematical description of biological systems and
processes can also be understood as a model, constituting a relatively new
sector of the biological science. According to Eykhoff (1974), a mathematical
model is "a representation of the essential aspects of an existing system (or a
system to be constructed) which presents knowledge of that system in usab-
le form." Mathematical models may take many forms and are particularly
useful for a data-integrative study of interactions between different compo-
nents of biological systems, and how these interactions holistically impact
the function and behavior of a system. This systems biological way of mode-
ling links fundamental chemical and physical principles, prior knowledge
about the investigated system and experimental data to a powerful tool for
extending and formalizing traditional cell biology.
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Why Mathematical Modeling?
A very first step towards the comprehension of mechanisms in living cells
is certainly unscrambling the genome of an organism, however, a more de-
tailed picture is needed to really gather the regulatory properties of genetic,
metabolic and cellular signaling networks. This is sustained by mathema-
tical formulation, the generation of hypotheses and comparative valida-
tion with experimental data. Data-based calibrated models potentially lead
to new hypotheses and predictions and represent a guided way of desig-
ning promising continuative experiments to explore questions that are not
amenable to experimental inquiry. At the same time, experimental measure-
ments are often too complex to be understood by visual inspection and can
be brought into relation.
Generally two main steps are involved in the modeling process: First, the
building of a model of the biological system of interest, a suitably structured
representation that incorporates existing knowledge and experimental ob-
servations. Secondly, this established model can be subjected to various
conditions as well as be allowed to evolve in time, a step typically called
simulation, used to generate qualitative or quantitative predictions on the
overall behavior of the system. Therefore, systems biological modeling ap-
proaches are also of great impact for medical investigation as well as drug
development and discovery.
Modeling Approaches
Mathematical modeling approaches comply with two key properties of bio-
logical systems: their static structure and their dynamics. Thus, modeling
approaches differ in the choice of suitable model structures:
Networks, the visualization of interaction graphs (e.g. protein-protein in-
teraction networks) suitably represent the static structure and serve as a
foundation for further integrative network analyses (Arrell and Terzic, 2012;
Goh et al., 2007), the category of regression models uses algebraic equations
(Seber and Wild, 1989), discrete Boolean models are composed of logical
gates (Saez-Rodriguez et al., 2009), Bayesian networks (Jensen, 1996) and
stochastic models (Turner et al., 2004; Gillespie, 2007) are based on probabi-
lity distributions and continuous dynamic models comprise either ordinary
differential equations (Aldridge et al., 2006) or partial differential equations
(Murray, 2003) in the more general case, agent- and rule-based modeling
6
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allows dynamic modeling trying to reduce combinatorial complexity which
would occur when using an approach purely based on ordinary differential
equations (Faeder et al., 2009). All approaches imply assumptions about
the considered system, require certain types of measurements, and allow
conclusions at different levels of accuracy and detail.
Modeling of Cell Signaling Processes
The term "biological system" allows various interpretations at different or-
ganization levels demanding individual ways and methods for their mode-
ling and analysis. This comprises metabolic systems, cell cycle regulation,
development and differentiation as well as intra- and intercellular signa-
ling and cell communication. Most of the underlying involved processes
are characterized by its dynamic behavior. This includes changes in gene
expression patterns or profiles of metabolites as well as fluctuations of pro-
tein and hormone levels, especially in response to changed environmental
conditions or drug modulation.
This thesis puts the main emphasis on modeling and analyzing cellular sig-
nal transduction, a highly dynamic process in both, time and space (Kholo-
denko, 2006; Timmer and Mueller, 2004). Cellular signaling is plugged into
a complex system communication, governing basic but also cell-type spe-
cific cellular activities and coordinating cell actions in uni- and multicellular
organisms. Starting with the activation of a cell surface receptor, intracellu-
lar signaling molecules are subsequently altered propagating the elicited
initial signal to its targeted cell response. These signaling events do not
necessarily proceed in a linear cascade that relay and regulate information
from cell surface receptors to effectors such as transcription factors or tar-
geted enzymes. Cellular signaling networks are constituted of highly con-
nected modules regulating multiple functions in a context dependent man-
ner including regulatory feedback (Jordan et al., 2000). Moreover, signaling
cascades also interact with one another, forming a functional network com-
plex in its organization and abundant in targets for signal amplification.
The cellular ability to sense and to correctly respond to its environmental
conditions is essential for pivotal processes such as development, tissue re-
pair, hemostasis, inflammation and immunity. Consequently, errors in cel-
lular information processing are likely to cause severe diseases including
cancer, autoimmunity, altered hemostasis and diabetes. Thus, a meticulous
understanding of cell signaling, e.g. the identification of signaling modules
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and hubs, is necessary for an effective therapeutic intervention and preven-
tion of diseases.
Exemplary, blood platelets represent a pivotal target of pharmacological
intervention in systematically affecting platelet signaling to protect from
pathological effects due to impaired signaling. Platelets, also called throm-
bocytes, are small blood cells of major importance in playing a pivotal role
in processes mainly connected with primary hemostasis and thrombosis:
Under physiological conditions, they circulate quiescently in the blood. In
case of a disruption of the vessel wall, platelets undergo a rapid shape
change and activation process during which they adhere to the site of vas-
cular injury and form a hemostatic plug. This protects against bleeding and
seals smaller lesions. However, under pathological conditions, unwanted
platelet aggregation and thrombus formation may cause a complete occlu-
sion of the blood vessel. Consequently, this leads to disorders like myo-
cardial infarction and stroke which represent the leading causes of death
worldwide according to the World Health Organization (2011). Moreover,
platelets also have impact on inflammatory processes, antimicrobial host
defense, angiogenisis as well as on disorders like Diabetes Mellitus, can-
cer, Alzheimer’s Disease or psychiatric disorders (Michelson, 2006). Thus, a
deep understanding of platelet physiology, biochemistry, signal transduc-
tion and pathology is essential to eventually develop new strategies for
pharmacological interventions.
Modeling Approaches Tailored for Analyzing Signaling Pathways
Traditionally, cell biological research has focused on studying individual
parts of cell signaling pathways and gained enormous progress over the last
three decades. However, the analysis of cell signaling networks requires a
combination of experimental and theoretical approaches including the de-
velopment and analysis of simulations. Computational models provide a
basis to unravel the complex relationships between the stimuli and the cel-
lular responses, and to reveal the underlying structure of cell signaling net-
works, and the mechanisms that are responsible for signal amplification.
To fulfill this task, a variety of different modeling approaches have emerged
and have been adapted and partially find its application within this the-
sis. The range of modeling approaches is vast and highly dependent on the
modeling task and the available data. For qualitative predictions of the be-
havior of a signaling network and to focus on the network structure, it is
8
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useful to analyze Boolean networks. Here, logically connected nodes rep-
resenting the signaling components are either in an "on" or "off" state. The
logic interconnection can be interpreted as gates through which a signal is
propagated (Morris et al., 2010). By translating these pure interaction net-
works into continuous dynamic systems, they also serve as basis for semi-
quantitative modeling and prediction (Di Cara et al., 2007). Parametric, dy-
namic approaches and models focus on the time-resolved cell signaling, the
change of signaling components, e.g. its protein concentrations over time
and can serve for quantitative fore-casts (Becker et al., 2010; Timmer and
Mueller, 2004). This is especially important for modeling and predicting to
dose-dependent pharmacological effects (Iadevaia et al., 2010). Moreover,
modeling enables data-based calibration and estimation of model parame-
ters that are not accessible by experimental methods, but are crucial to verify
whether a proposed molecular mechanism is correct or not.
Despite substantial progress in biochemistry, cell and molecular biology to-
gether with high-throughput techniques for detecting protein-protein in-
teractions, data acquisition and experimental determination of kinetic pa-
rameters still represent a bottleneck in systems biological pathway analysis.
Nevertheless, modeling and the use of data-driven computer simulations
enables to rapidly test and generate hypotheses about functions of the sig-
naling network and its structure, to simulate data and also to sustain the
design of further efficient experiments.
Overview of this Thesis
In this thesis, we present mathematical models of signaling cascades at dif-
ferent scales and show how computational models can be applied to guide
experimental design by model-based simulations, to investigate the struc-
ture of signaling networks, and to verify and test hypotheses concerning the
regulation and signal propagation of investigated signaling networks.
First, relevant prerequisites are presented in Section 2. This forms the ne-
cessary background on cell signaling and mathematical modeling to under-
stand and to establish the subsequent modeling applications. Foundations
range from in-depth information on cell signaling to signaling characteris-
tics focused on different cell-types and cellular processes. We thereby focus
on the biology and function of blood platelets as this represents the relevant
background for a comprehensive in silico platelet systems analysis. Addi-
tionally, it provides a short introduction into the computational analysis of
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This is followed by the detailed description of used materials and relevant
methods for data analysis and mathematical modeling of signal transduc-
tion in Section 3. As the choice of appropriate modeling approaches strongly
depends on the modeling task and the available data, we applied different
strategies for the pathway analyses. For studying the molecular interactions
and relating signaling components within a signaling context we exerted
static network analyses relying on cell-type specific data bases and phos-
phoproteomic studies. This sustains the establishment of suitable network
topologies which then can be simulated either in a discrete or dynamic man-
ner for further computational analyses and data-based validation.
In Section 4, the different and multi-scaled modeling approaches are imple-
mented. More precisely, we investigated and analyzed signaling cascades
of regulatory importance in special cell-types, the blood platelets (Section
4.1) but also in globally relevant, crucial cellular processes such as inflam-
mation (Section 4.2). These biomedically and pharmacologically motivated
models and approaches can easily be transferred to different cell-types to
model organismic processes such as signaling in cardiomyocytes, plant im-
munity in Arabidopsis or to elucidate the cross-talk between different liver
cells (Section 4.3).
The resulting conclusions and the applied approaches are critically inspected
and compared in Section 5. We conclude with future prospects of mathema-
tical modeling in systems and computational biology.
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2 Foundations and Principles
THE ONLY SOURCE OF KNOWLEDGE IS EXPERIENCE.
(Albert Einstein)
2.1 Background: Cellular Signal Transduction
2.1.1 Transduced and Regulated Processes
Signal transduction in cell biology involves the binding of extracellular sig-
naling molecules and ligands to receptors at the cell surface that trigger
events inside the cell. Receptor activation upon ligand binding, inter-cellular
communication or cellular stress responses cause the cell’s ultimate respon-
ses (effect) to the messenger such as gene activation (Lalli and Sassone-
Corsi, 1994) and altered metabolism (Rosen, 1987).
Diverse signal transduction processes influence the reaction of a single-cel-
led organism to environmental chances (Kollmann et al., 2005), but also co-
ordinate cell-cell communication (Fontana et al., 1986) and holistic regula-
tion within multicellular organisms. Thus, signaling cascades are particu-
larly involved in regulatory processes like aging (Kenyon, 2010), inflamma-
tion (Hotamisligil, 2006), cell cycle control (Malumbres and Barbacid, 2009),
apoptosis and cell survival (Dragovich et al., 1998) and hormonal regula-
tions (Santner and Estelle, 2009). Moreover, a variety of diseases such as
diabetes (Hotamisligil, 2003), heart disease (Lorenz et al., 2009) and cancer
(Sawyers, 2004) arise from impaired signal transduction processes, high-
lighting the biological and medical importance of this process. These trig-
gered multiple responses are all directly due to changes in particular cell
proteins - a highly dynamic process.
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2.1.2 Typical Signaling Cascade and Main Constituents
Cellular signaling pathways comprise typical molecular constituents such
as receptors, G proteins, phosphorylation cascades (MAP kinase cascade)
and first and second messengers to receive and process signals. Albeit it
exists a huge variety of signaling cascades, a typical sequence of signal
transduction and its core modules are depicted in Figure 1. The general
cellular signal transduction proceeds as follows.
Figure 1 : Signaling paradigm. Upon stimulation by a ligand or another kind of sti-
mulus, the receptor gets activated and initiates the internal signaling propagation.
This includes a series of protein phosphorylation state changes and the subsequent
alteration of transcription factor activation. Thereby, the transcription rate of target
genes is regulated, leading to a change in protein concentrations which in turn trigger
the actual cellular responses to the initial signal. Figure construction follows Klipp
et al. (2009).
A substance that acts as a ligand or physical stimulus (signal) binds to a
transmembrane receptor which changes its state from susceptible to an ac-
tivated state. This triggers an internal signaling cascade including a series
of changes of phosphorylations states to propagate the signal. Phosphory-
lated or activated proteins may enter the nucleus to eventually de- or acti-
vate transcription factors. As a consequence, transcription factors change
their binding properties to regulatory regions on the DNA which alters the
12
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transcription rate of genes that lie downstream. This finally results in newly
synthesized proteins or changes in protein concentrations causing the actual
cellular response to the signal. In addition, several control mechanisms such
as feedback and feed-forward activation and inhibition or cross-talk effects
from different signaling pathways may potentially influence and regulate
the signal cascade.
Ligand - Receptor Interactions There exist several concepts of the inter-
action between a ligand L and its receptor R. The simplest concept is the
reversible binding, forming an intermediate active complex LR. This be-
havior is characterized by the dissociation constant
KD =
[L] · [R]
[LR]
,
where [L], [R], and [LR] denote the concentrations of the respective reac-
tants. KD can be derived from the law of mass action (see Section 2.3.3).
Other receptors need to form a cluster to initiate the further signal propa-
gation, or act through strategies that involve the mobilization and turnover
of free receptors from intracellular pools or the internalization and degra-
dation. These strategies are exemplary investigated by mathematical mo-
deling for the information processing at the erythropoietin receptor (Becker
et al., 2010).
G Proteins G proteins are involved in many signal cascades and play an
essential role in the regulation of signal processing and mediation (Blumer
and Thorner, 1991; Dohlman et al., 1991; Buck, 2000). Their name arise from
the guanine nucleotides GDP (guanosine diphosphate) and GTP (guano-
sine triphosphate) they are bound to. They are heteromers consisting of
three different subunits and are associated to cell surface receptors, the G
protein-coupled receptors (GPCR). The activation and inactivation of G pro-
teins follow a cycle. A G protein that binds GDP is inactive and the G pro-
tein α subunit (Gα) is associated with the G protein βγ heterodimer (Gβγ).
Upon ligand binding to a GPCR, guanine nucleotide exchange is promoted:
Gα releases GDP, instead binds GTP and dissociates from the Gβγ dimer.
Both subunits Gα and Gβγ are free in order to activate their target proteins
downstream the GPCR. There are several isoforms of each subunit which al-
low high combinatorial signal transduction options. They can be classified
13
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according to their effects into subfamilies like the Gαs- and Gαi-subfamily,
stimulating or inhibiting the production of cAMP from ATP, respectively.
Hydrolysis of GTP enables the subunits to reassociate (Marks et al., 2009).
Second Messengers The intracellular signal transduction is often mo-
dulated by second messengers, which greatly amplify the signal strength.
They can be grouped into water-soluble or -insoluble molecules or gases.
Hydrophilic molecules like cyclic adenosine and guanosine monophosphate
(cAMP and cGMP), inositol 1,4,5 trisphosphate (IP3), or calcium ions (Ca2+)
are usually located within the cytosol or stored in special cellular organelles.
Hydrophobic molecules such as diacylglycerol (DAG) and phosphatidyli-
nositols are membrane-associated and diffuse from the plasma membrane
into the intermembrane space to regulate membrane-associated effector pro-
teins. Gases, e.g. nitric oxide (NO), carbon monoxide (CO) and hydrogen
sulphide (H2S) diffuse both through the cytoplasm and across cellular mem-
branes to exhibit their effects. Normally, second messengers are enzymati-
cally synthesized, activated or deactivated or released by opening of ion
channels (Ca2+ signaling) (Nelson, 2009).
Feedback Regulations Signal cascades can exhibit special regulatory feed-
back features (see Figure 2) such as feed-forward loops and negative feed-
back. These features contribute to stability but also manifest interesting
dynamics. Negative feedback is very common in transcription networks
and also for regulating metabolic pathways. On cellular dynamics, nega-
tive feedback exhibits various effects such as the stabilization of systems
states, the acceleration of response time or the introduction of oscillatory
behavior (Hoffmann et al., 2002). Feed-forward loops often appear as mo-
tifs in transcriptional networks. One distinguishes two forms, coherent and
incoherent feed-forward loops, which allow the differential regulation of a
gene Z via two other genes (Mangan and Alon, 2003).
Signaling Cross-talk Signaling pathways cannot be considered separa-
tely, but influence each other at different scales: They can share pools of
proteins, e.g. some proteins of one signaling pathway interact with proteins
assigned to another cascade or an activated protein may have several tar-
gets that in turn affect different signal cascades (Fraser and Germain, 2009;
Natarajan et al., 2006). Or, signal cascades may have the same target gene
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Figure 2 : Motifs in signaling networks. Frequent regulatory network motifs include
negative and positive autoregulation and feedback loops. Figure construction follows
Marks et al. (2009) and Klipp et al. (2009).
as it is highly the case for the transcription factor NFκB (Oeckinghaus et al.,
2011). These interactions may include feedback regulations or activatory
and inhibitory effects also at the transcriptional level to alter the amplitude
of a transduced signal. Cross-talk between signaling pathways provides for
multiple non-linear responses to combinations of stimuli, but only little is
known about the density of these interactions in any specific cell. Thus, the
definition of a quantitative measure for signaling cross-talk is a crucial task.
In the following we introduce the key concepts we applied for the analysis
of signal transduction and its cross-talk.
2.1.3 Signaling in Inflammatory Processes
Exemplary, inflammation and inflammation-related diseases are highly con-
nected with cell signaling processes at the molecular level. One has to dis-
tinguish between two types of inflammatory processes. The initial response
of the body to harmful stimuli - acute inflammation - is achieved by the
increased movement of plasma and leukocytes (in particular granulocytes)
from the blood into the injured tissues. The inflammatory response is propa-
gated and matured by a cascade of biochemical events that involve the local
vascular system, the immune system, and various cells within the injured
tissue. However, prolonged inflammation, the so-called chronic inflamma-
tion, can cause severe diseases such as rheumatoid arthritis or inflammatory
bowel disease. Moreover, the onset of cancer (Coussens and Werb, 2002)
and cardiovascular diseases (Pearson et al., 2003) have also been linked to
inflammation. Therefore, a deep understanding as well as an investigation
of inflammation and regulatory cross-talks (Beck et al., 2009), especially at
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the molecular level, is indispensable in medical research.
Inflammation at the Molecular Level Inflammatory signaling progresses
upon pro-inflammatory stimuli mediated by cytokines, such as interleukin-
1 (IL-1), the tumor necrosis factor (TNF), interferon gamma (IFNγ), IL-12,
IL-18. On the other hand, inflammation is resolved by action of anti-inflam-
matory cytokines including IL-4, IL-10, IL-13, IFNγ, and the transforming
growth factor (TGF) (Hanada and Yoshimura, 2002). The intracellular sig-
nal transduction pathways that are triggered by cytokines ultimately lead
to the activation of transcription factors such as NFκB, a tightly regulated
process (Oeckinghaus et al., 2011). Under normal conditions, NFκB acti-
vation is transient and mediates the expression of genes being involved in
inflammation and immunity (Vallabhapurapu and Karin, 2009), however its
chronic activation is associated with human autoimmune diseases and can-
cer (Wang et al., 2009).
We focus here on NFκB regulating pathways that are mediated by TNF re-
ceptors. TNF is well known for its role in leading immune defenses that
protect a localized area from invasion or injury. Additionally, TNF is also
involved in controlling whether target cells live or undergo apoptosis. Be-
sides the basic signaling steps described here, we present a mathematical
model on TNF receptor cross-talk and clustering in Section 4.2.
TNF and its Receptors Tumor necrosis factor (TNF) plays a multifunc-
tional role in inflammatory processes and the regulation of immune cells
(Croft, 2009; Tracey and Cerami, 1993; Bradley, 2008). TNF can function
in interacting with the death-domain-containing TNF receptor 1 (TNF-R1)
and the non-death-domain-containing receptor 2 (TNF-R2), both belonging
to the TNF receptor superfamily (Bazzoni and Beutler, 1996; Cabal-Hierro
and Lazo, 2012; Tansey and Szymkowski, 2009). TNF-R1 is pervasively ex-
pressed in nearly all cell types of the body, whereas TNF-R2 expression is
limited (Faustman and Davis, 2010) and is found especially in immune cells,
endothelial and neuronal tissue (Grell and Scheurich, 1997). One can distin-
guish between the primarily produced membrane-integrated form of TNF
(memTNF) and soluble TNF (sTNF) which can be released thereof by the
metalloprotease TNF alpha converting enzyme (TACE). The two distinct
forms of TNF bind to both, TNF-R1 and TNF-R2, but differ in their abil-
ity to stimulate the receptors: While both receptors can be fully activated
by memTNF, the soluble form mainly stimulates TNF-R1 but has limited
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capacity for triggering efficient TNF-R2 signaling (Grell, 1995; Grell et al.,
1995). Due to its regulatory key role TNF and its signal transduction mech-
anisms, especially via TNF-R1, have been extensively studied (Chen and
Goeddel, 2002; Jin and El-Deiry, 2005).
TNF-R1 Signaling Main down-stream effects of TNF-R1 mediated sig-
naling involve the activation of NFκB (classical NFκB pathway) as well as
the activation of caspases that result in cell death (apoptosis) as depicted in
Figure 3.
Figure 3 : TNF -R1 signal transduction pathway. Binding of TNF with its receptor
TNF-R1 results in the formation of a receptor-proximal complex containing the im-
portant adaptor proteins TRADD, TRAF2, RIP, and FADD. These adaptor proteins
in turn recruit additional key pathway-specific enzymes (including the IKK1-IKK2-
NEMO complex or caspase8) to the TNF-R1 complex, where they become activated
and initiate downstream signaling events leading to apoptosis and canonial NFκB
activation. Figure in adaption to (Chen and Goeddel, 2002) and Figure 1.
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Upon the initial binding of the TNF trimer to the extracellular domain of
TNF-R1, the adaptor protein TNF receptor-associated death domain
(TRADD) is recruited, which itself recruits additional adaptor proteins such
as receptor-interacting protein (RIP), TNF receptor associated factor 2
(TRAF2), and Fas-associated death domain (FADD). Subsequently, this trig-
gers the activation of key enzymes being responsible for initiating further
signaling events. The apoptotic branch is initiated by either a RIP-dependent
or RIP-independent process involving caspase 8 resulting in active effector
caspases that are responsible for apoptotic effects (Wang et al., 2008). This
is opposed by anti-apoptic and pro-inflammatory signaling. TRAF2 recruits
cellular inhibitors of apoptosis 1 and 2 (cIAP1, cIAP2), two anti-apoptotic
proteins that also have ubiquitin protein ligase activity to the receptor (Ma-
honey et al., 2008). c-IAPs and both TRAFs contribute to the ubiquitination
of RIP upon TNF-R1 stimulation via ubiquitin chains linked through lysine
63 (K63) (Wajant and Scheurich, 2011). The LUBAC (linear ubiquitin chain
assembly complex), generates a recently detected type of linear polyubi-
quitin chain and specifically regulates the canonical NFκB pathway via the
linear ubiquitination of RIP (Tokunaga and Iwai, 2012). Polyubiquitinated
RIP serves as a docking site for both the TGFβ-activated kinase 1 (Tak1)
and Tak1 binding proteins 2/3 (Tab2/3) heterocomplex and the inhibitor of
κB (IκB) heterocomplex (Wu et al., 2006) including NFκB essential modula-
tor (NEMO) (Ea et al., 2006). Upon assembly of this complex, Tak1 phos-
phorylates IKK2 that in turn phosphorylates IκB, an inhibitory protein that
normally retains NFκB dimers (typically p50/p65) within the cytoplasm of
unstimulated cells (Ghosh and Karin, 2002). IκB phosphorylation signals for
its ubiquitination and proteasomal degradation allowing NFκB to translo-
cate into the nucleus and regulate target genes. This involves the activation
of the transcription of genes that promote inflammation as well as trigger
the termination of NFκB activation (A20, Cyld). Exemplary, A20 can block
activation of NFκB by the cytokine TNF through a ubiquitin-editing pro-
cess (Wertz et al., 2004), modifying RIP that is thereby targeted for protea-
somal degradation. Consequently, the activation of the IKK complex is pre-
vented, which negatively regulates NFκB activation (Heyninck and Beyaert,
2005). Moreover, NFκB promptly induces the resynthesis of IκB and other
inhibitory molecules, such as the cIAP molecules, thereby adding another
layer for regulating the duration and amplitude of TNF signaling.
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TNF-R2 Signaling In contrast, there is limited knowledge on the exact
TNF-R2 associated signal transduction. Having no death domain, TNF-R2
mainly induces a long-lasting NFκB activation (Rothe et al., 1995a). Signa-
ling starts with recruitment of the adaptor proteins TNF receptor-associated
factor 1 (TRAF1) and TRAF2 (Rothe et al., 1995b) and cIAPs upon binding
of TNF. TNF-R2 is preferentially activated by membrane-integrated TNF,
whereas soluble TNF binds TNF-R2 but fails to properly stimulate TNF-
R2 signaling (Grell et al., 1995). Down-stream, the classical (canonial) and
non-classical (non-canonial) NFκB mobilization (via NFκB-inducing kinase
(NIK)) promote the transcription of target pro-survival genes (Rauert et al.,
2010; Marchetti et al., 2004). Furthermore, as it involves TRAF and cIAP
molecules, the TNF-R2 signaling cascade is capable to mediate TNF-R1 sig-
naling via regulatory cross-talk (Faustman and Davis, 2010; Fotin-Mleczek
et al., 2002).
The TWEAK/Fn14 system The multi-functional cytokine TNF-like weak
inducer of apoptosis (TWEAK) and its cognate receptor Fn14 are mem-
bers of the TNF- and TNFR-superfamilies, respectively. Besides inflamma-
tion, TWEAK controls many cellular activities such as proliferation, mi-
gration, differentiation, apoptosis and angiogenisis (Winkles, 2008). The
TWEAK-Fn14-axis resembles the one of TNF-R2 triggered by TNF, as the
signaling cascade involves the recruitment of TRAF molecules a prime step,
leading to NFκB activation and subsequent gene transcription (Saitoh et al.,
2003). Like the TNF-TNF-R2-axis, TWEAK-Fn14 interaction can induce cell
death (Nakayama et al., 2002), albeit the receptor itself has no death domain.
Moreover, TWEAK acts specifically on Fn14, in comparison to TNF, which
is capable to activate both, TNF-R1 and TNF-R2. Hence, the TWEAK/Fn14
system represents a valuable system for investigating the TNF receptor sig-
naling cross-talk and for pinning out cross-talk specific regulations.
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2.2 Platelet Biology and Signaling
2.2.1 Platelet Structure and Morphology
Among many cell types that are circulating in the blood, platelets are the
smallest cells. Its diameter ranges from only 2.0 µm to 5.0 µm, its thickness
measures 5.0 µm resulting in a mean cell volume of 6 to 10 fL (Michelson,
2006). Platelets are formed and released by bone marrow megakaryocytes
(Figure 4B) which are derived from hematopoietic stem cells (see Figure 4A).
Thrombocytes are circulating in the blood for seven to ten days, before they
are cleared by macrophages.
Figure 4 : The hematopoietic stem cell (HSC) pathway (A) and platelet formation
(B). Cell differentiation occurs through the common lymphoid progenitor (CLP),
the common myeloid progenitor (CMP), the granulocyte/macrophage progenitor
(GMP) and megakaryocyte/erythrocyte progenitor (MEP). Platelets originate from
proplatelets, which are formed and released by bone marrow megakaryocytes (B).
Subfigures adapted from Blank et al. (2008) and Battinelli et al. (2007).
Platelets are anucleate cell fragments and thus lacking a nuclear regulation.
Nevertheless, platelets are highly communicative via divers surface recep-
tors, signal transduction pathways and secreted messengers. Altogether,
this ensures the intra- and inter-cellular information exchange and platelet
functions.
Resting platelets have a discoid shape (Figure 5A) which rapidly changes
upon activation to a more spherical shape with spiky pseudopods (Figure
5B).
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Figure 5 : Shape change of platelets. Shape of resting platelets (A) and activated
platelets (B). Figure adapted from Willoughby et al. (2002).
The plasma membrane encloses several components: internal membranes
(open canalicular and dense tubular systems), a cytoskeleton (microtubules
and microfilaments), mitochondria, glycogen granules, lysosomes and per-
oxisomes or storage granules. One distinguished between α-granules, which
store matrix adhesive proteins including von Willebrand factor (vWF) and
fibrinogen, and dense granules, containing small anorganic molecules (e.g.
adenine nucleotides (ADP, ATP), serotonin, calcium and magnesium ions)
(Michelson, 2006)
It is noteworthy that platelets contain messenger RNA (mRNA) even though
at very low levels (Fink et al., 2003). [fill SAGE data analyis] This is not sur-
prising, because due to the fact that platelets are anucleate they cannot tran-
scribe mRNA to supplement the megakaryocyte-derived mRNA remaining
in the thrombocyte. However, platelets are able to translate mRNA into
proteins upon activation (Lindemann et al., 2001b), e.g. the inflammatory
cytokine IL-1β (Lindemann et al., 2001a). This indicates a regulatory role of
platelets in inflammatory processes (Weyrich et al., 2004). Nevertheless, the
impact of protein synthesis in platelets is not clear.
The plasma membrane of thrombocytes is interspersed with multiple re-
ceptors and gylcoproteins that are essential for the activation but also the
inhibition of platelets (Figure 6).
Circulating platelets are continually exposed to various activating factors
such as fibrinogen, thrombin, collagen, ADP, thromboxane and vWF, but
also inhibitory factors including ADPase, endothelial-derived nitric oxide
(NO) and prostaglandin I2 (PGI2) (Ruggeri and Mendolicchio, 2007; Davi
and Patrono, 2007; Varga-Szabo et al., 2008; Walter and Gambaryan, 2009).
A subtle equilibrium between these opposing processes is essential for nor-
mal platelet and vascular functioning. In the following sections, the related
thromboregulatory signal transduction events via surface proteins are intro-
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Figure 6 : Major receptors and effectors involved in the inhibition, activation and
aggregation of platelets. Platelet activation: Initial platelet tethering (binding of von
Willebrand factor (vWF) with glycoprotein (GP) Ibα) allows the engagement of colla-
gen receptors GPVI and integrin α2β1. This thereby triggers the release of adenosine
diphosphate (ADP) and thromboxane (TXA2), which bind to the P2Y12 and TP re-
ceptors, respectively. Consequently, levels of cytosolic Ca2+ and 1,2-diacylglycerol
(DAG) are raised, which triggers a plethora of subsequent reactions including plate-
let shape change, granule secretion and aggregation. Platelet inhibition is mainly in-
duced by endothelial-derived nitric oxide (NO) and prostaglandin I2 (PGI2) leading
to the formation of cyclic nucleotides triggering inhibitory effects. Figure construction
follows Broos et al. (2012).
duced. I will mainly focus on signaling pathways which are investigated by
computational methods in this thesis.
2.2.2 Platelet Activation and Thrombus Formation
Platelet-activated generation of hemostatic plugs or thrombus formation
comprises three steps: (1) platelet tethering and adhesion, (2) extended pla-
telet activation and additional recruitment and aggregation of platelets and
(3) firm adhesion, thrombus stabilization and growth (Figure 7).
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Figure 7 : The three steps of thrombus formation. The initial contact (tethering)
to the endothelial cell membrane (ECM) is mediated by the GPIbα-vWF interaction
which thereby enables GPVI interaction with collagen. Consequently, this shifts inte-
grins to a high-affinity state and triggers the release of adenosine diphosphate (ADP)
and thromboxane (TXA2). Concurrently, thrombin formation is locally triggered by
tissue factor (TF) which additionally contributes to the activation of the platelet.
Finally, activated α2β1 and αIIbβ3 integrins trigger the firm adhesion to collagen,
resulting in sustained GPVI signaling and enhanced procoagulant activity. Figure
adapted from Varga-Szabo et al. (2008).
Platelet Adhesion
In the initial step of primary hemostasis, platelets interact with the exposed
extracellular matrix (ECM). This matrix contains a large number of adhesive
macromolecules including laminin, fibronectin, collagens, and vWF, serv-
ing as ligands for the different platelet surface receptors. Platelets roll, ad-
here and spread to form an activated monolayer of thrombocytes. Tethering
and adhesion is mediated by the interaction between von Willebrand factor
(vWF) with the GPIb-V-IX receptor complex as well as between the GPVI
and GPIa proteins with collagen at injury sites. By this, adherent platelets
get arrested and activated.
At low shear rates, e.g. in larger arteries and veins, platelets primarily ad-
here to collagen, laminin and fibronectin. Soluble vWF particularly interacts
with the GPIbα of the GPIb-V-IX complex under conditions of high shear
(Varga-Szabo et al., 2008), such as in small arteries or atherosclerotic vessels.
Due to the fact that the binding of GPIbα to vWF has a fast off-rate, it is in-
sufficient to mediate stable platelet adhesion. It rather maintains the platelet
in close contact with the ECM. This so-called "rolling" of platelets facilitates
the contact with the thrombogenic ECM protein collagen through the GPVI
receptor and α2β1 receptor. This triggers intracellular signals that shift pla-
telet integrins to a high-affinity state. Additionally, this induces the release
of adenosine diphosphate (ADP) and thromboxane A2 (TXA2) which func-
tion as secondary mediators in contributing to cellular activation together
with locally produced thrombin.
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Platelet Activation
There are two main pathways involved in platelet activation (Stegner and
Nieswandt, 2011). GPVI and C-type lectin receptor (CLEC2) (May et al.,
2009) transduce activation via tyrosine phosphorylation cascades occurring
downstream of the receptor associated immunoreceptor tyrosine activation
motif (ITAM). This leads to a full platelet activation. The other activatory
pathway processes through soluble agonists including thrombin, ADP and
TXA2, which stimulate signal transduction through G protein-coupled re-
ceptors (GPCR) (Offermanns, 2006).
ITAM-coupled Receptors The major activating collagen receptor GPVI
is associated with the FcRγ-chain, bearing an ITAM motif for signal trans-
duction. The cross-linkage and clustering of GPVI by collagen leads to the
activation of the Src tyrosine kinases Fyn and Lyn, which themselves are
phosphorylating the ITAMs. This, but also the activation of CLEC2, enab-
le the recruitment of Syk leading to the activation of phospholipase Cγ2
(PLCγ2) due to the tyrosine phosphorylation of its SH2 domains. Among
other signaling proteins which have been implicated in GPVI-dependent
platelet activation (e.g. Rap1. Rac1, Vav1, Vav3, PI3 kinase, Grb2, Gab2,
Gads) the Bruton’s tyrosine kinase (BTK) is essential for PLCγ2 phosphory-
lation in vivo (Liu et al., 2006), ultimately leading to calcium mobilization,
degranulation, integrin activation and aggregation (Figure 6).
G Protein-coupled Receptors Platelet activation through GPCR are most-
ly triggered by ADP, thrombin and thromboxane. Thrombin activates
through its protease-activated receptors (PARs), mainly PAR1 and PAR4.
Thromboxane result from increased Ca2+ levels and associated activation
of phospholipase A2 (PLA2) and signals through the TP receptor. PAR1,
PAR4 and TP are coupled to Gq to activate PLCβ2, which is besides PLCγ2
a key protein in platelet activation and calcium mobilization (Stegner and
Nieswandt, 2011).
ADP Signaling Adenosine diphosphate was one of the earliest identi-
fied platelet agonists and is also an important autocrine via secretion from
platelet-dense granules. However, ADP associated receptors have only re-
cently been definitively identified (Hechler and Gachet, 2011).
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Released ADP is an important amplifier of platelet activation by acting on
platelets through two G protein-coupled receptors P2Y1 and P2Y12. While
the P2Y1 receptor initiates platelet aggregation P2Y12 is responsible for com-
pletion of the aggregation in response to ADP.
P2Y1 triggers the mobilization of calcium from internal stores required for
shape change and platelet aggregation (Hechler et al., 1998; Léon et al.,
1999). This is mediated by its coupled Gq protein being responsible for the
activation of PLCβ2 (Figure 6). In contrast, P2Y12 is coupled to Gαi2, that in-
hibits the adenylyl cyclase (AC). Hence, it prevents the formation of cyclic
adenosine monophosphate (cAMP) which is crucial for triggering platelet
inhibition (see Section 2.2.3). The G protein Gαi2 also stimulates phospho-
inositide 3-kinase β (PI3Kβ) leading to various downstream effects inclu-
ding the mobilization of calcium (Garcia et al., 2010).
Generally, all platelet-activating receptors trigger an elevation of calcium
concentrations in the cytosol. Both, activated PLCγ2 and PLCβ2 convert
phosphatidylinositol 4,5 bisphosphate (PIP2) to produce inositol 1,4,5 tri-
phosphate (IP3) and 1,2-diacylglycerol (DAG). While the latter activates pro-
tein kinase C (PKC) and is involved in Ca2+ entry from the extracellular
compartment, IP3 represents a critical molecule for the regulation of Ca2+
release in platelets (Stegner and Nieswandt, 2011).
Calcium Signaling Changes in cytosolic calcium level play a central role
in signaling processes in almost all eukaryotic cells and also in platelet ac-
tivation (Varga-Szabo et al., 2009). In platelets, elevations in intracellular
Ca2+ contribute to a various steps of cellular responses including activa-
tion of integrins, granule release, cytoskeletal rearrangements essential for
shape change and spreading as well as coagulant activity (Hathaway and
Adelstein, 1979; Heemskerk et al., 2002; Mazzucato et al., 2002; Rink et al.,
1982). The major pathway of Ca2+ entry pathway is a process referred to as
store-operated calcium entry (SOCE). It involves receptor-mediated release
of intra-cellularly stored Ca2+ which triggers the Ca2+ influx through the
plasma membrane. The second main mechanism for Ca2+ entry is mediated
by the direct receptor-operated calcium (ROC) channel, P2X1. Besides, also
non-SOCE mechanism exist in platelets, mediated by DAG which directly
activates Ca2+ channels (e.g. canonial transient receptor potential channel
TRPC6) in the plasma membrane (Hassock et al., 2002). Processes under-
lying calcium release from the stores has been well investigated. In con-
trast, mechanisms leading to calcium entry as well as signaling pathways
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triggered by elevated intracellular Ca2+ remain mostly unknown (Varga-
Szabo et al., 2009; Stegner and Nieswandt, 2011).
Calcium Store Release and SOCE The agonist-induced activation of phos-
pholipase C isoforms leads to the formation of IP3 which induces the cal-
cium release from the intracellular stores by directly activating the IP3 recep-
tor (IP3R). This Ca2+ release triggers the Ca2+ entry from the extracellular
compartment (store-operated calcium entry). Recently, the stromal interac-
tion molecule-1 (STIM1) (Grosse et al., 2007) and Orai1 (Braun et al., 2009;
Bergmeier et al., 2009) were identified as important players in platelet SOCE.
The transmembrane protein STIM1 acts like a Ca2+ sensor. Its EF-hand mo-
tif detects decreased Ca2+ levels in the intracellular stores. This opens the
store-operated calcium (SOC) channels in the plasma membrane, allowing
Ca2+ entry from the outside. Orai1 was recently detected as the major SOC
channel on the platelet surface (Tolhurst et al., 2008), opened by STIM1.
As there is continuous leakage of Ca2+ from the intra-cellular stores, and
already small increases in intracellular Ca2+ concentration would rapidly
lead to platelet activation (Grosse et al., 2007; Rolf et al., 2001), counteract-
ing mechanisms are of great importance. In platelets, two counteracting
processes have been identified, ensuring the maintenance of a stable cal-
cium concentration to keep platelets in a resting state in the circulation but
also to bring the raised Ca2+ levels back to the basal amounts: The sarcoplas-
mic/endoplasmic Ca2+ ATPases (SERCAs) pump Ca2+ back to the intracel-
lular stores and the plasma membrane Ca2+ ATPases (PMCAs) transport it
out of the cell (Enyedi et al., 1986).
Firm Adhesion
Upon activation, the aggregation and spreading of platelets on the exposed
ECM at sites of injury is mediated by the activated integrin α2bβ3 by buil-
ding fibrinogen bridges (Varga-Szabo et al., 2008). These crosslinks between
activated thrombocytes are responsible for thrombus growth and stabiliza-
tion (Varga-Szabo et al., 2008).
The increased Ca2+ level in activated platelets triggers the activation of
CalDAG-GEFI, the Ca2+ and diacylglycerol regulated guanine nucleotide
exchange factor I (Crittenden et al., 2004). Subsequently, CalDAG-GEFI ac-
tives Rap1b, a small GTP binding protein which itself interacts with Rap1-
interacting adapter molecule (RIAM) and talin (Rodius et al., 2008; Banno
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and Ginsberg, 2008). This enables talin to the integrin β3-tail, inducing a
conformational change of α2bβ3 now capable to bind fibrinogen and vWF
(Shattil et al., 2010). Also kindlin3 was recently revealed as an important
mediator of integrin activation and platelet aggregation (Moser et al., 2008).
2.2.3 Platelet Inhibitory Pathways and Regulation
Platelet activation is finely regulated through a plethora of cell signaling
mechanisms and involves multiple waves of regulation leading to throm-
bus formation and protection from blood loss. However, in the absence
of vessel injury or disease, inhibitory signals ensure that platelets stay in
a quiescent state (resting platelet) and prevent uncontrolled aggregation.
Strong inhibitory signals are derived from endothelial cells in producing
and releasing bioactive NO and prostacyclin. In this connection, cyclic nu-
cleotides play a pivotal role by mainly limiting platelet activation through
two intracellular pathways regulated by either cAMP- or cGMP-elevating
agents. The endogenous inhibitory effects on platelets are mediated by
cGMP- and cAMP-dependent protein kinases, respectively (Figure 8). How-
ever, the exact mechanisms of cAMP/cGMP-mediated platelet inhibition
are not fully understood. Many aspects of platelet activation can be blocked
by cyclic nucleotides. This includes early activatory signals (Ca2+ release),
adhesion, granule release, platelet aggregation and apoptosis (Rukoyatkina
et al., 2011; Schwarz et al., 2001)
Besides the endothelium-derived platelet inhibition, receptors such as plate-
let-endothelial cell adhesion molecule-1 (PECAM-1) (Newman, 1999; Cicmil
et al., 2002) and carcinoembryonic antigen cell adhesion molecule 1 (CEA-
CAM1) (Wong et al., 2009) are known to be responsible for weak platelet
inhibition. Recently, inhibitory mechanisms emerged which surprisingly
involve intracellular receptors (e.g. retinoic X receptor (RXR), glucocordo-
coid receptor (GR), liver X receptor (LXR) or isoforms of the peroxisome
proliferator-activated receptor (PPAR)) which are normally associated with
the regulation of gene transcription (Jones et al., 2012). Additionally, in-
hibitory pathways including canonical Wnt signaling, Semaphorin 3A, en-
dothelial cell specific adhesion molecule, and junctional adhesion molecule-
A are emerging (Jones et al., 2012). As these inhibitory mechanisms played
a minor role regarding the development and the purpose of mathemati-
cal models we established on platelet signaling, I will mainly focus on the
endothelium-triggered inhibitory mechanisms in the following.
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Figure 8 : Model of cyclic nucleotide signaling network in platelets. Endothelial cells
release prostacyclin (PGI2) and nitric oxide (NO). PGI2 binds to its IP receptor stimu-
lating the synthesis of cAMP by adenylyl cyclase (AC). NO activates soluble guanylyl
cyclase (sGC) leading to cGMP synthesis. Thrombin, von Willebrand factor (vWF)
and collagen may also activate sGC but to a lesser extent than NO. cGMP inhibits
PDE3A but activates PDE2A and PDE5A resulting in cGMP and cAMP degradation.
cAMP stimulates the cAMP-dependent protein kinase (PKA). The C subunit of PKA
is also associated with a NFκB-IκB complex, from which it can be set free upon throm-
bin and collagen signals. PKA and PKG phosphorylate substrates triggering platelet
inhibition. They are functionally grouped (see Table 12). Glycoprotein (GP), heat
shock protein 27 (HSP27), inositol 1,4,5-trisphosphate receptor (IP3R), Lim and SH3
domain protein (LASP), phosphodiesterase (PDE), transient receptor potential chan-
nel 6 (TRPC6), vasodilator-stimulated phosphoprotein (VASP). Figure adapted from
Smolenski (2012).
Cyclic Nucleotide Levels in Human Platelets
The most potent endogenous mechanism of platelet inhibition is mediated
by the elevation of intracellular cyclic nucleotide levels of cGMP and cAMP.
Since the 1960s, cAMP has been identified as a strong inhibitor of plate-
let aggregation (Kloeze, 1966; Marquis et al., 1969) and cGMP was found
to inhibit platelet functions around 1980 (Mellion et al., 1981). In the res-
ting state, basal concentrations remain at 4 µM (cAMP) and 0.4 µM (cGMP)
(Eigenthaler et al., 1992). These levels can be modulated by adenylyl and
guanylyl cyclases (AC, GC) which both synthesize cyclic nucleotides. In
contrast, phosphodisterases downregulate cyclic nucleotide levels by degra-
dation (Figure 8).
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Regulation of Adenylyl and Guanylyl Cyclase Activity
There exist various isoforms of adenylyl cyclases (ACs), from which isoform
AC3, AC6, AC7 (Dittrich et al., 2008) and AC5 (Lewandrowski et al., 2009)
are expressed in human platelets. ACs are integral membrane proteins cata-
lyzing the synthesis of cAMP from adenosine triphosphate (ATP) resulting
in an increased level of intracellular cAMP. The activity of ACs is regulated
by G-proteins: Inhibitory G-proteins such as Gαi2 which is coupled to P2Y12
(see section 2.2.2) reduce AC activity whereas stimulatory G-proteins Gαs
have an activatory effect on cAMP production. Gαs is coupled to receptors
for adenosine, β-adrenergic agents as well as to the IP receptor for prosta-
cyclin (PGI2) and prostaglandin receptors, which leads to the stimulation
of cAMP formation upon ligand binding. Prostaglandins can modify plate-
let function through different prostanoid receptors which can be coupled to
both activatory G-proteins like the IP receptor (for PGI2) and to inhibitory
G-proteins (Iyu et al., 2011; Hubertus, 2012).
In platelets, cGMP production is solely dependent on one single enzyme,
the soluble form of guanylyl cyclase (sGC) which is sensitive to NO and
other NO-generating agents. NO derives from endothelial cells where the
endothelial NO synthase (eNOS) is located. Detailed analyses have been
published of both mouse and human platelets, to rule out the presence of
any significant nitric oxide synthase enzyme within platelets (Gambaryan
et al., 2008; Ozüyaman et al., 2005; Rowley et al., 2011). Recently novel
sources of NO have been identified in mice which might be of importance
in platelet inhibition (Moore et al., 2010). NO is capable to stimulate sGC
which in turn generates cGMP. Additionally, vWF, thrombin or collagen
might activate sGC, resulting in a small increase in cGMP (Gambaryan et al.,
2008; Zhang et al., 2011; Riba et al., 2006, 2005), but these findings could not
be confirmed by all studies (Ozüyaman et al., 2005; Gambaryan et al., 2010;
Marshall et al., 2004).
Platelet Phosphodiesterases
Platelet phosphodiesterases (PDEs) control cyclic nucleotide levels by PDE-
mediated degradation. In human platelets, the isoforms PDE2A, PDE3A
and PDE5A of phosphodiesterases are expressed (Haslam et al., 1999) and
represent the major regulatory PDEs. Furthermore, PDE4D could be iden-
tified on proteomic level (Zahedi et al., 2008) as well as PDE7A, PDE8B
and PDE9A on mRNA-level (Dittrich et al., 2006). PDE2 and PDE3 are
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able to degrade both, cAMP and cGMP, whereas PDE5 specifically degrades
cGMP. PDEs provide targets for feedback regulation of cyclic nucleotide sig-
naling: cGMP has a regulatory impact on all three platelet PDEs (Figure
8). It stimulates PDE2 and PDE5 activity by binding to a specific cyclic
nucleotide-binding domain, called GAF domain. In contrast, PDE3 acti-
vity is inhibited by cGMP because of competitive binding with cAMP at
its catalytic site. PDE3 helps in maintaining low basal concentrations of
cAMP in platelets (Dunkern and Hatzelmann, 2005; Feijge et al., 2004; Sim
et al., 2004). It gets activated by the cAMP-dependent protein kinase (PKA)-
mediated phosphorylation, providing a negative feedback loop for cAMP
signaling (Macphee et al., 1988; Zhang and Colman, 2007). The main func-
tion of PDE5 is the regulation of cGMP levels. PDE5 enables a negative feed-
back on cGMP levels: cGMP activates PDE5 and cGMP-dependent protein
kinase (PKG) additionally phosphorylates PDE5 resulting in an increased
catalytic activity of PDE5 and also long-term desensitization of cGMP re-
sponses (Mullershausen et al., 2003).
cAMP/cGMP-dependent Protein Kinases
The translation of cAMP and cGMP levels into protein phosphorylation pat-
terns is the major role of cAMP- and cGMP-dependent kinases. PKA is com-
posed of four subunits, two have a regulatory and two have a catalytic func-
tion. Upon cAMP binding to the regulatory subunits, the catalytic subunits
dissociate from the heterotetrameric complex and phosphorylate their sub-
strates, leading to the suppression of platelet activation (Eigenthaler et al.,
1992). Furthermore, Gambaryan et al. (2010) could show that the stimula-
tion of human platelets by collagen and thrombin activates a distinct feed-
back inhibitory mechanism based on cAMP-independent activation of PKA.
This activation process involves the release of the catalytic PKA-subunit
from a NFκB-IκB complex.
PKG combines regulatory and catalytic subunits within one molecule which
dimerizes upon cGMP binding (Hofmann, 2005; Lohmann and Walter, 2005).
The dimeric complex then fulfills further processes leading to platelet inhi-
bition.
There is some evidence for localized cyclic nucleotide function in platelets
(Wilson et al., 2008; Bilodeau and Hamm, 2007) as it is known for many
other cell types. A-kinase anchoring proteins (AKAPs) often coordinate lo-
calized cAMP signaling as recently reviewed in Vandamme et al. (2012).
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AKAPs bind PKA and other signaling components such as phosphodieste-
rases, forming subcellular cAMP signaling compartments. In this regard,
particularly AC5 and AC6 can be targets for PKA-mediated cAMP feed-
back inhibition (Iwami et al., 1995; Beazely et al., 2005; Chen et al., 1997).
These adenylyl cyclases directly interact with AKAP 79/150 which facili-
tates the phosphorylation of AC5 and AC6 by PKA to inhibit cAMP synthe-
sis (Bauman et al., 2006). Mass spectrometry-based screening recently re-
vealed seven AKAP isoforms (AKAP1, AKAP2, AKAP7, AKAP9, AKAP10,
AKAP11, and microtubule-associated protein 2) to be present in platelets
(Margarucci et al., 2011). At the transcriptomic level, data analysis suggests
the expression of AKAP5, AKAP8, AKAP8L and AKAP13 in platelets (Row-
ley et al., 2011). Regarding PKG, its substrate IRAG represents up to now the
only known platelet G-kinase anchoring protein (GKAP) (Antl et al., 2007).
Substrates of PKA and PKG
Several steps in platelet activation and aggregation including adhesion and
granule release are inhibited by cAMP and cGMP signaling cascades (Smolen-
ski, 2012; Schwarz et al., 2001). The functional outcome of blocked platelet
activation is transduced by PKA and PKG (Figure 8). Table 12 (Annex B.3)
lists PKA and PKG substrates, their phosphorylation sites and proposed
roles.
Here, I will focus on the vasodilator-stimulated phosphoprotein VASP as
it is a suitable protein to monitor cyclic nucleotide-dependent PKA/PKG
activation in vitro and in vivo and to analyze cross-talk between different
receptor signaling pathways (Schwarz et al., 1999). Furthermore, informa-
tion on phosphorylation kinetics is available (Eigenthaler et al., 1992; Butt
et al., 1994; Smolenski et al., 1998) VASP therefore constitutes a suitable pro-
tein especially for computational dynamic modeling (Section 4.1.4). VASP
was one of the first substrates of PKA and PKG that were discovered in
platelets (Halbrügge and Walter, 1989). Its main phosphorylation sites are
Ser157, preferentially phosphorylated by PKA, and Ser239, preferred by
PKG (Smolenski et al., 1998). Against both sites, phosphosite specific an-
tibodies have been developed, which have been widely used as markers of
cyclic nucleotide activity, not only in platelets but also in other cells (Smolen-
ski et al., 1998; Schäfer et al., 2003).
Platelet activation induces actin cytoskeletal reorganization that results in
platelet shape change and is crucial for the secretion of intracellularly stored
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granules. Apart from other downstream effects of VASP, it is an important
regulator of actin dynamics as phosphorylated VASP inhibits its binding to
F-actin and decreases F-actin bundling in vitro (Harbeck et al., 2000). VASP
also regulates platelet activation in mediating NO-dependent inhibition of
platelet adhesion to the vessel walls (Hauser et al., 1999; Massberg et al.,
2004). Moreover, VASP is involved in directing the inhibitory effects of PKA
and PKG to fibrinogen binding and further platelet aggregation but does
not trigger the inhibition of Ca2+ release and granule secretion (Aszódi et al.,
1999). In this connection, integrin β3 might control the PKA-mediated phos-
phorylation of VASP on site Ser157 (Worth et al., 2010).
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2.3 Mathematics of Biological Systems Analysis
2.3.1 Interaction Graphs
The study of networks and graphs has gained importance in all fields of
science requiring the analysis of complex relational data. It reaches back to
the year 1736 when Leonard Euler found the solution to the noted problem
"Seven Bridges of Königsberg" (Euler, 1736). Euler introduced the mathe-
matical description of vertices and edges which is deemed to be the founda-
tion of the so-called graph theory, the field of mathematics that became the
framework of complex network analysis and theory. Biological systems and
networks such as signaling systems can formally be represented as graphs.
A graph G is defined as a tuple (V,E), with V being as set of vertices and
E ⊆ V × V being a set of edges:
G = (V,E).
Edges can be interpreted as the relation between vertices connecting them
in a directed or undirected manner (see Figure 9).
Figure 9 : Types of generic networks. (A) Directed graph (gene A regulates the ex-
pression of gene B). (B) Undirected graph (protein-protein interaction network). Pro-
teinsX1, X2, X3 form an interacting complex at the activated receptor R∗. (C) Graphi-
cal interpretation of phosphorylation: Kinase X1 phosphorylates protein X2 at site
S123, which then interacts with protein X3. Static networks may also contain bidirec-
tional edges (D) or regulation (E) such as inhibition (red arrow) or activation (blue)
including feedback loops.
Adapted to cell biology, vertices can represent signaling components such
as genes and proteins (kinases, enzymes), ligands or receptors. Protein-
protein interaction (PPI) networks are typically formulated as undirected
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graphs (Figure 9B). In contrast, transcriptional regulatory networks are ty-
pical examples of a directed graph. Here, nodes denote genes and edges
represent interactions between them. As a gene A might regulate the ex-
pression of gene B but the opposite is not inevitably the case, the choice of
a directed graph is reasonable (Figure9A). A directed edge can also be inter-
preted as a node-to-node activation or phosphorylation process (Figure 9C),
mapped onto a PPI network. Static networks may also include bidirectional
interactions (edges) (Figure 9D) and regulatory effects such as this inhibi-
tion or activation of a protein interaction by a protein (node) and feedback
loops (Figure 9E).
The representation of a signaling pathway as a graph allows the analysis of
its structural properties by means of graph-theoretical techniques (Barabási
and Oltvai, 2004; Newman, 2003). The static, graphical representation also
allows relating signaling components of interest with a functional (sub)net-
work of signal transduction and revealing contextual interactions. Thus,
static analyses focus more on the connectivity of system components and
their interactions in assigning a functional and regulatory meaning. In this
thesis, we focus on analyzing platelet signaling components of interest to-
gether with their functional network context applying PlateletWeb (Boyanova
et al., 2012), a platelet-specific workbench.
2.3.2 Boolean Networks
The history of Boolean networks applied to biological processes reaches
back to Stuart A. Kauffman. In his seminal paper (Kauffman, 1969), he pro-
posed large-scale random Boolean models as generic models of gene regula-
tory networks. These networks are later referred to as Kauffman networks.
Kauffman’s models of gene regulation are one of the simplest kinds of mo-
dels for complex dynamic systems. Here, genes are described by binary
variables which take only discrete values 0 or 1. These binary states can be
understood in the sense of gene regulation as "off" (0) and "on" (1) or to inter-
pret them more meaningfully as "inactive" and "active", or "not expressed"
and "expressed."
Boolean network models are a special case of discrete dynamic models. Si-
mulation of those networks is done in discrete time steps. At each time-
point, the value of a variable is deterministically calculated by so-called
update rule, the Boolean functions. Thereby, the state of a variable in the
next time-step depends upon the values of (a subset of) the other variab-
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les (inputs) at the previous time-point. The average number of inputs per
variable is defined as the (mean) connectivity of the Boolean model. The
update rules are often expressed in terms of Boolean operators, including
logical NOT (¬), AND (∧) and OR (∨), where the name of these models come
from. The operators are named after George Boole, a British mathematician
and philosopher, who is deemed to be the inventor of Boolean logic (Boole,
1847, 1854). Thus, Boolean models code the complex system of gene regu-
lation or signal transduction in terms of classic binary choices in a discrete,
deterministic and parameter-free way. These choices are not based on any
kinetic or biophysical law. Here, the state of a variable is determined by an
abstract combination of inputs from other variables.
In terms of complexity, Boolean networks lie between static network models
and continuous dynamic models (Kahlem and Birney, 2006), making them
a tractable and powerful approach to modeling large-scale biological sys-
tems. After assembling the individual network components and regulatory
interactions involved in a system into a coherent network representation,
Boolean models can serve to describe the qualitative temporal behavior of
a system. Furthermore, they can be used to understand how perturbations
may alter its behaviors and lead to predictive testable hypotheses especially
valuable in large-scale systems which are poorly understood (Assmann and
Albert, 2009; Gross, 2006).
Several small- and medium-scale Boolean models of biological processes
have been developed representing an integrative part of many systems bio-
logy research projects (Saez-Rodriguez et al., 2007, 2009; Samaga et al., 2009;
Schlatter et al., 2009). They focus on the analysis of biological processes in-
cluding signaling systems with the main goal of generating hypothesis and
qualitative predictions about possible regulatory interactions. Boolean net-
works represent an intuitive approach towards assessing signaling systems.
Here, networks comprise hardwired connections and signaling events that
happen on a discrete time scale. Boolean update rules can be understood
as "gates" through which the signal is proceeding over the network (Morris
et al., 2010).
2.3.3 Dynamic ODE-based Modeling
It is probably one of Newton’s major achievements to have developed the
language of differential equations and dynamical systems to describe the
statement of his laws of gravity and motion. Ever since, this language was
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applied in many fields of science, including biochemistry and biomathe-
matics to formulate dynamic processes. Dynamic modeling aims at formu-
lating a set of mathematical equations which are able to predict computa-
tionally the dynamic behavior of a real system, e.g. of a signaling network
(Swameye et al., 2003). The dependence of certain properties on time and
space can deterministically be described by a set of ordinary differential
equations (ODE).
Ordinary Differential Equations The dynamic behavior of a (biological)
system comprising several variables xi can be approximated by a system of
ordinary differential equations (ODEs) (see Equation 2.1). Exemplary, it can
be derived from the reaction mechanism and describes the time-resolved be-
havior away from equilibrium. Mathematically, the change in concentration
of a variable xi over time t can be represented as a function fi
d[xi]
dt
= fi(x1, x2, . . . , xn, p1, p2, . . . , pl, t) i = 1, . . . , n. (2.1)
where xi denotes the variables (e.g. concentrations) and pj (j = 1, . . . , l)
represents the set of parameters (e.g. enzyme concentrations, kinetic cons-
tants) as detailed in the following Section.
2.3.4 Biochemical Reaction Kinetics
Law of Mass Action Deterministic kinetic modeling of biochemical reac-
tions is based on the mass action law, which was introduced by Guldberg
and Waage in the nineteenth century (Guldberg and Waage, 1864, 1879).
The law of mass action governs reaction rates in biochemical systems. It
states that for reactions in a homogeneous medium the reaction rate is pro-
portional to the probability of a collision between molecular reactants. This
in turn is proportional to the concentration of the reactants to the power of
the molecularity according to the specific reaction.
Assuming a simple balance equation where two substrates S1 and S2 form
a product P and vice versa
S1 + S2 
 2P. (2.2)
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Thus, the reaction rates of the forward reaction ν+ and backward reaction
ν− result in
ν+ = k+ · [S1] · [S2] and ν− = k− ·P 2.
The proportionality factors k+ and k− are also called kinetic or rate cons-
tants. Thus, the net reaction rate ν can be expressed by
ν = ν+ − ν− = k+ · [S1] · [S2]− k− · [P ]2 (2.3)
or in a more general way:
ν = ν+ − ν− = k+ ·
∏
i
[Si]
mi − k− ·
∏
j
[Pj]
mj .
Here, mi and mj denote the molecularities of the substrates Si and the pro-
ducts Pj , respectively (Heinrich and Schuster, 1996). In equilibrium, reac-
tion rate ν+ equals ν− so that one can declare the equilibrium constant K
characterizing the ratio of substrate Seq and product concentrations Peq in
equilibrium:
K =
k+
k−
=
∏
[Peq]∏
[Seq]
.
Regarding reaction (2.2), the dynamic behavior of substrate and product
concentrations over time t (see Equation 2.3) ensues from the system
d[S1]
dt
=
d[S2]
dt
= −ν and d[P ]
dt
= 2ν.
The time course of the reactants S1, S2 and P is then obtained by integrating
the ODEs.
Michelis-Menten Kinetics In 1913, Michaelis and Menten proposed a
mathematical model (Menten and Michaelis, 1913) approximating the ki-
netics of enzyme reactions. The enzymatic reaction mechanism involves an
enzyme E binding to a substrate S to form a enzyme-substrate complex ES,
which in turn is converted into a product P and the enzyme E. This may be
represented schematically as
S + E
k1
GGGGGBF G
k−1
ES
k2
GGGGA E + P,
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where k1, k−1 and k2 denote the rate constants and the double arrows repre-
sent the reversible enzyme-substrate binding process. The Michaelis-Menten
theory allows a quantitative description of the rate of enzymatic reactions
by relating reaction rate ν to the concentration of a substrate S. It can be
derived by applying the law of mass action, which states that the rate of a
reaction is proportional to the product of the concentrations of the reactants.
This leads to a system of four non-linear ordinary differential equations that
define the rate of change of reactants over time:
d[S]
dt
= −k1 · [S] · [E] + k−1 · [ES] (2.4)
d[E]
dt
= −k1 · [S] · [E] + (k−1 + k2) · [ES] (2.5)
d[ES]
dt
= k1 · [S] · [E]︸ ︷︷ ︸
complex formation
−(k−1 + k2) · [ES]︸ ︷︷ ︸
complex dissociation
(2.6)
d[P ]
dt
= k2 · [ES] = ν, with k+/−1  k2. (2.7)
The overall reaction rate ν is given by the negative decay rate of the sub-
strate as well as by the rate of product formation:
ν = −d[S]
dt
=
d[P ]
dt
. (2.8)
The ODE system (Equation 2.4 - 2.8) can not be solved analytically so that
several assumptions have been used for reformulation:
The so-called quasi-equilibrium (Briggs and Haldane, 1925) between a free
enzyme and the enzyme-substrate complex reflects that the reversible con-
version of enzyme and substrate to the complex is much faster than the
subsequent dissociation into enzyme and product (k+/−1  k2). Thus, the
latter reaction does not disturb the balance between complex formation and
degradation (quasi-steady state) so that
d[ES]
dt
= 0.
To justify this assumption, the initial substrate concentration [S]0 has to be
much larger than the enzyme concentration because otherwise, the steady
state will never be reached. Thus, reaction rate k2 dominates the velocity
of the overall reaction and ν = d[P ]
dt
= k2 · [ES] (Equation 2.7). Furthermore,
we regard the total enzyme concentration [Etot] as constant, meaning an en-
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zyme may be free or part of the complex but is never produced or consumed
in the reaction. Consequently, substituting E with Etot − ES and exploiting
the quasi-equilibrium
d[ES]
dt
= k1 · [S] · [E]− (k−1 + k2) · [ES] = 0,
the following condition for the concentration ofES arises from Equation 2.6:
k1 · [S] · ([Etot]− [ES])− (k−1 + k2) · [ES] = 0
⇔ k1 · [S] · [Etot]− k1[S] · [ES]− (k−1 + k2) · [ES] = 0
⇔ k1 · [S] · [Etot]− (k1 · [S] + k−1 + k2) · [ES] = 0
⇔ [ES] = k1 · [S] · [Etot]
k1 · [S] + k−1 + k2
=
[S] · [Etot](
k−1 + k2
k1
)
︸ ︷︷ ︸
Km
+[S]
. (2.9)
Substituted in Equation 2.7, this results in the Michaelis-Menten equation
ν =
k2 · [S] · [Etot](
k−1+k2
k1
)
+ [S]
=
Vmax · [S]
Km + [S]
, (2.10)
with enzyme-specific Michaelis-Menten constant Km =
k−1+k2
k1
and maximal
velocity Vmax = k2 · [Etot]. At high substrate level, all free enzyme molecules
are occupied and bind to a substrate. Thus, the maximal reaction velocity
Vmax can be expressed by
ν = k2 · [ES] ≡ k2 · [Etot] = Vmax. (2.11)
The Michaelis-Menten constant Km is a measure for the affinity of an en-
zyme towards its substrate. It is equal to the substrate concentration which
yields the half-maximal reaction rate: Putting Km = [S], Equation 2.10 re-
sults in
ν =
Vmax · [S]
[S] + [S]
=
Vmax
2
.
Figure 10 shows typical time courses for [S], [E], [ES] and [P ] as well as for
the reaction rate ν.
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Figure 10 : Time courses (Michaelis-Menten kinetics). (A) Solution of the ODE sys-
tem (Equation 2.4 - 2.7) over time. (B) Plot of the reaction speed ν versus substrate
concentration. Dashed lines indicate Km and Vmax values. Utilized parameters: k1 =
4, k−1 = 0.5, k2 = 2, Km = 0.625, Vmax = 2, [S]0 = 9, [E]0 = 1, [ES]0 = [P ]0 = 0.
Hill Equation The binding of reactants, e.g. of a substrate to its enzyme
may positively or negatively influence the affinity to further ligands (coope-
rative binding). The Hill-equation
ν =
Vmax · [S]h
Khm + [S]
h
, (2.12)
accounts for cooperative binding (Figure 11A). A Hill-coefficient h larger
than 1 corresponds to positive cooperativity, where the binding of one reac-
tant facilitates binding of another reactant. In contrast, h < 1 denotes nega-
tive cooperativity, where binding of further reactants is made more difficult
(Cornish-Bowden, 2012).
Enzyme Inhibition Michaelis-Menten kinetics is modified in case of in-
hibition of both, the substrate and the enzyme. A comprehensive list can
be found in Cornish-Bowden (2012). We applied the following Michaelis-
Menten-like rate equation to model the drug-mediated competitive enzyme
inhibition of platelet enzymes (Floreani et al., 2003)
ν =
Vmax · [S](
1 + [I]
ki
)
·Km + [S]
. (2.13)
Modified reaction rates upon different concentration of an inhibitor I and
its characteristic inhibition constant ki = 0.5 are displayed in Figure 11B.
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Figure 11 : Time courses: (A) Hill equation (B) Competitive enzyme inhibition. (A)
Reaction rate ν for different Hill coefficients h = 0.5, 1, 2, and 4 showing cooperative
binding behavior (Equation 2.12). Utilized kinetic parameters (see legend of Figure
10). (B) Influence of different concentrations of an competitive inhibitor I and inhibi-
tion constant ki = 0.5.
Conventional equations for (enzyme) kinetics are based on the mass-action
law, a mathematical model that explains and predicts behaviors of solu-
tions in dynamic equilibrium. Thus, the question is whether it also holds
under dimensionally-restricted in vivo conditions. There are several ap-
proaches (Kopelman, 1988; Savageau, 1995; Schnell and Turner, 2004; Grima
and Schnell, 2006; Chen et al., 2010) trying to adjust the kinetic assumptions
to the disordered media within cells.
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3 Materials and Methods
IT DOESN’T MATTER HOW BEAUTIFUL YOUR THEORY IS,
IT DOESN’T MATTER HOW SMART YOU ARE.
IF IT DOESN’T AGREE WITH EXPERIMENT, IT’S WRONG.
(Richard P. Feynman)
3.1 Platelet Preparation and Immunoprecipitation
Concentration-dependent experiments with human platelets were of key
importance with respect to data-based modeling. Moreover, we suggested
experiments by computer-based model predictions. Therefore, chemicals
and measurement methods are briefly described in the following. These ex-
periments have been performed in the laboratory of the Institute of Clinical
Biochemistry and Pathobiochemistry, Würzburg.
Platelet preparation Human platelets were washed (Aktas et al., 2003)
and prepared as detailed in Geiger et al. (1998) to reduce leukocyte contami-
nation. In brief, after informed consent whole human blood was drawn by
venipuncture from volunteers. They had not been treated with any platelet
or cyclic nucleotide affecting drugs in the past two weeks. Blood was col-
lected in weakly acidic citrate/dextrose buffer (4:1 v/v) and centrifuged at
300 xg for 10 min at 20 ◦C. Subsequently, the obtained platelet rich plasma
was centrifuged (380 xg, 20 min at 20 ◦C). The platelet pellet was resus-
pended in HEPES buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM
HEPES, 10 mM glucose, pH 7.4) resulting in a final cell density of 108/mL.
Experiments were conducted by incubation of the platelet suspension at
37 ◦C with the respective compounds and for the time. For clarity and vali-
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dation of the data, all experiments were repeated with at least three different
preparations.
Chemicals For platelet inhibition, we used the following chemicals:
Forskolin (Sigma, Munich, Germany), Iloprost (Schering, Berlin, Germany),
Milrinone (Sigma, Munich, Germany) and Cilostamide (Tocris Cookson,
Avonmouth, UK).
Measurement of cyclic nucleotide levels Levels of cyclic adenosine mo-
nophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were
measured as follows: The stimulation of platelets with the respective com-
pound was stopped by adding twice the sample volume of ice cold ethanol
(100%). Afterwards, the precipitate was removed by centrifugation and
washed again with 100 µL ethanol. The supernatants were combined and
subsequently dried in the vacuum. The resulting dried platelet samples
were dissolved and acetylated. Finally they were analyzed with cAMP or
cGMP enzyme-immuno assays commercially available (ENZO Life Scien-
ces, Loerrach, Germany) following the manufacturer’s instructions.
Determination of phosphodiesterase concentrations Concentration of
phosphodiesterase 2 (PDE2) and PDE5 were determined from calibration
curves with lysates from recombinant expression systems (Butt et al., 1994).
Briefly, E. coli BL21-T1 strain was transformed with plasmids which con-
tain inserts coding for PDE2A (C-terminal fragment aa1-207 deletion, C-
terminal His6-tag), PDE3A (aa675-1164 fragment, N-terminal GST-tag) or
PDE5A (full length, C-terminal His6) and lysed after Isopropyl-β-D-thio-
galactopyrano ß-sid (IPTG) induction. Afterwards, the resulting lysates
were purified by affinity chromatography. The GST tagged PDE3A frag-
ment was bound to a GST-sepharose column (Glutathione Sepharose 4B,
Amersham Biosciences) and was eluted following the manufacturer’s pro-
tocol. Similarly, the His6-tagged PDE2A and PDE5A were purified on a Ni-
NTA column (Ni-NTA Superflow Kit, Quiagen) and eluted according to the
manufacturer’s protocol. The obtained protein content of the eluents was
determined by the bicinchoninic acid (BCA) protein assay (Thermo Scien-
tific) and dilution series were prepared. Subsequently, platelet lysates and
dilution series of recombinant protein were submitted to acrylamide gel-
electrophoresis and transferred on a nitrocellulose membrane. They were
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detected with an appropriate antibody and chemoluminescence reaction
(ECL plus, Amersham). The intensities of protein bands were quantified af-
ter scanning with ImageJ software (v1.43, NIH) and the platelet expression
was quantified from the calibration curves which were obtained from the
dilution series. Phosphodiesterase PDE2 and PDE5 were determined from
calibration curves with lysates in over-expression systems (Butt et al., 1994).
The quantitative PDE3 amount was taken from Eigenthaler et al. (1992), the
kinetic and binding data from Butt et al. (1994) and Poppe et al. (2008).
VASP phosphorylation/immunoflourenscence Vasodilator-stimulated
phosphoprotein (VASP) has two characteristic phosphorylation sites (pS239
and pS157) to monitor the corresponding cyclic nucleotide-dependent pro-
tein kinase activity. Both sites were determined according to Geiger et al.
(2010) with the phosphosite specific antibodies 16C2 (pS239) or 5C6 (pS157)
and the total VASP antibody IE273. A more detailed description can be
found in the original publication (Wangorsch et al., 2011).
3.2 Static and Discrete Modeling Methods
3.2.1 Protein-protein Interaction Networks
The PlateletWeb knowledge base is a comprehensive human platelet reposi-
tory for systems biologic analysis of platelets in the functional context of in-
tegrated networks (Boyanova et al., 2012) of protein-protein interactions. It
integrates various information and data of the platelet proteome, transcrip-
tome, site-specific phosphorylation reactions, disease associations, drugs,
along with human protein-protein interactions (see Figure 12).
Database assembly Information on protein-protein interactions was ob-
tained from the Human Protein Reference Database (HPRD; Version 9.0,
April 2010) (Keshava Prasad et al., 2009) and the Entrez Gene National Cen-
ter for Biotechnology Information (NCBI) server (Maglott et al., 2007). It was
combined with data on protein phosphorylation from HPRD and Phospho-
Site (Hornbeck et al., 2004). A comprehensive list of human kinases was ex-
tracted from Manning et al. (2002) and used for reference and validation of
the HPRD phosphorylation data. Furthermore, integrated Drug data (Drug-
Bank Version 3.0) (Knox et al., 2011) includes detailed information on drugs,
drug targets and Gene Ontology (GO) information (GO database; Decem-
47
3.2 Static and Discrete Modeling Methods
Figure 12 : PlateletWeb - a platelet-specific knowledge base. (A) PlateletWeb com-
bines data from various sources leading to a comprehensive resource for the platelet-
specific integrated network analysis such as the investigation of signaling pathways,
kinase distribution and functional enrichment in platelets. It includes data from
protein-protein interactions and modifications complemented with drug and disease
association data, pathway information, kinase-substrate data and predictions for ki-
nases and transmembrane domains. (B) The systems biology workbench can be ac-
cessed online to interactively analyze platelet proteins and their related information.
(C) The possibility to extract subnetworks allows in-depth analysis of multiple pro-
teins with their modification type, kinase-substrate relationships and drug associa-
tion. Figure adapted from Boyanova et al. (2012).
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ber 2010) (Ashburner et al., 2000) can be accessed for functional enrichment
analysis. A detailed listing of all integrated platelet data sources used is
available in Boyanova et al. (2012).
The integrative database PlateletWeb provides the background for the in-
vestigation of signal transduction and involved proteins and interactions
in humans and especially human platelets. The internet platform (http:
//plateletweb.bioapps.biozentrum.uni-wuerzburg.de)
offers an interface for advanced data-mining and the visualization of sub-
networks for functional network analyses. Extracted subnetworks comprise
integrated information on site-specific phosphorylations and interactions of
all investigated network proteins. Moreover, a novel network-based Net-
worKIN algorithm (Linding et al., 2007; Miller et al., 2008) is included to
predict potential kinases for phosphorylation sites of which no associated
kinase is known. This leads to a total kinase annotation of 95% of all phos-
phosites. Unraveling site-specific information of phosphorylation events is
especially interesting for analyzing signal transduction cascades, as phos-
phorylating kinases play a main role in propagating a signal to its targets.
The extraction and graphical visualization of specific subnetworks allow
placing proteins of interest in relationship to signaling modules involved
in e.g. platelet activation or inhibition. As the visualization of particu-
larly large networks is challenging, PlateletWeb features the export of crea-
ted networks to Cytoscape (Shannon et al., 2003; Smoot et al., 2011) a well-
established software for visualizing and analyzing biological networks.
3.2.2 Boolean Models
Methodologically, we typically apply the simplest Boolean algebra to ana-
lyze signaling pathways by Boolean modeling. Boolean variables are rep-
resented by a set of n binary elements Xi, (i = 1, . . . , n) having values 0 or
1 corresponding to the logical values FALSE and TRUE, connected by the
logical operators ∧ (AND), ∨ (OR) and ¬ (NOT). Thus, a Boolean function
with n binary variables is a mapping B : {0, 1}n → {0, 1} from the set of
all n-tuples over {0, 1} to the binary output determined and based on lo-
gical operations from n binary inputs (Boole, 1848). Truth tables represent
Boolean functions, wherein each row lists the respective combination of bi-
nary Boolean variables and according to the logical connection. For two
variables this results in truth tables as defined in Table 1.
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Table 1 : Truth tables of the Boolean operators ¬ (NOT, negation) ∧ (AND, conjunc-
tion) and ∨ (OR, disjunction).
¬x x=0 x=1
1 0
x ∧ y x=0 x=1
y=0 0 0
y=1 0 1
x ∨ y x=0 x=1
y=0 0 1
y=1 1 1
Example Lets assume a small network of three Boolean variables X1, X2
and X3, e.g. components of a signaling pathway logically connected. This
small Boolean network model can easily be projected to a directed graph
G(V,E), and directly related to a pathway diagram commonly used for vi-
sualizing signaling pathways and biological regulatory systems (see Figure
13). Here, the node set V represent the Boolean variables and the edge set E
is implicitly defined by the Boolean function set-up.
Figure 13 : Boolean Network - an example. Simple Boolean network model compri-
sing three Boolean variables X1, X2 and X3, represented as a directed graph. Edges
with sharp arrows denote positive, activatory effects, edges with blunt arrows rep-
resent negative effects towards their target nodes. In addition to the directed and
signed graph, Boolean models contain more specific information, since the same dia-
gram can correspond to several alternative Boolean functions (e.g. the specification
of AND/OR connections).
Each edge has a sign specifying whether the input node has a positive or
negative effect on the target node. As the network has three elements, it
may show 2N different states (X1X2X3).
Assuming the update rules:
X1(t+ 1) = X1(t) ∧X2(t)
X2(t+ 1) = X1(t) ∨X2(t)
X3(t+ 1) = X1(t) ∨ (¬X2(t) ∧X3(t)) .
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By updating the nodes’ states at each time step synchronously, the model
evolves over time following a trajectory of states, as represented in Table 2.
Table 2 : Successively developed states for the Boolean network (see Figure 13). The
states are synchronously updated at the same time point.
Current state (t= t0) 000 001 010 011 100 101 110 111
Next state (t = t0 + 1) 000 001 010 010 011 011 111 111
The model update according to the rules eventually reaches a steady state
(fixed point) or a set of recurring states, commonly referred to as attractors.
The set of initial states leading the model to a specific attractor is called the
basin of attraction. Referring to the example model, the states (000), (001),
(010), and (111) are fixed points (steady states) but in contrast, the states
(000), (001), (100), (101), and (110) cannot be reached from a different state.
Software Several software packages have been developed that focus on
qualitative modeling and the simulation of Boolean networks (Schlatter et al.,
2011). Notably Genetic Network Analyzer (GNA) (De Jong et al., 2003),
GINSim (Gonzalez et al., 2006), BooleanNet (Albert et al., 2008), MetaReg
(Ulitsky et al., 2008), CellNetOptimizer (Saez-Rodriguez et al., 2009) and
CellNetAnalyzer (CNA) (Klamt et al., 2007) have been shown to qualita-
tively reproduce the activation patterns of experimentally validated regula-
tory networks. For our analyses we applied CellNetAnalyzer, a MATLAB
toolbox, capable to model, simulate and analyze metabolic as well as sig-
naling networks. Besides others, CNA allows the involvement of a certain
quantity by allowing stoichiometric assumptions within the modeled equa-
tions serving as update rules (see Equation 3.1). This feature extends the
classical binarity of Boolean network being relevant for logical networks
with multiple-valued discrete states.
X1(t+ 1) = ¬X2(t) ∧ 2X3(t). (3.1)
Additionally it allows the setting of different time scale for interactions.
CNA facilitates the analysis of signaling networks solely on their network
topology, i.e. independent of kinetic mechanisms and parameters in pro-
viding a powerful collection of tools and algorithms for structural network
analysis.
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3.3 Dynamic Transformations for Semi-quantitative Mode-
ling
Simulations based on Boolean networks give a first idea of the signaling
behavior, however, as stated in an Editorial in Nature: " . . . to really under-
stand . . ., one needs to have numbers attached to the arrows, and equations
relating to the numbers" (Campbell, 1999). In other words, the qualitative
network structure one needs to be enriched with kinetic information to an-
alyze the full signaling behavior. A first step towards this goal is the trans-
formation of the qualitative network into a set of ordinary equations. The
Java-based tool SQUAD (Di Cara et al., 2007) implements this step allowing
the qualitative modeling using a set of non-linear ordinary differential equa-
tions.
SQUAD While data on the connectivity among molecules is becoming
increasingly available, the stoichiometry and particular kinetic data of the
biochemical reactions behind the majority of these connections remain scarce.
Currently, this bottleneck is one of the major problems, especially when
studying highly dynamic signaling cascades. To cope with this issue, a
methodology called Standardized Qualitative Dynamical Systems was de-
veloped by Mendoza and Xenarios (2006), where SQUAD got its name from.
Hybridizing discrete Boolean and continuous modeling methodologies, this
approach masters the dynamic simulation of regulatory networks even in
the absence of kinetic data.
In a first step, the network is converted into a discrete dynamical system,
representing the network as a series of interconnected elements that have
solely two possible activation states, 0 (inactive) and 1 (active). Based on
this, the following set of Boolean equations completely describes the net-
work.
Xi(t+1) =

(Xa1 (t) ∨Xa2 (t) . . . ∨Xan(t)) ∧ ¬ (X i1(t) ∨X i2(t) . . . ∨X im(t)) i)
Xa1 (t) ∨Xa2 (t) . . . ∨Xan(t) ii)
¬ (X i1(t) ∨X i2(t) . . . ∨X im(t)) iii)
Here, the set of activators of a node Xi are represented as {Xan}, whereas
{X im} denotes the set of inhibitors affecting Xi. In case i), X will be in an
active state in the next time step if any of its activators and at the same time
none of its inhibitors are acting upon it. Similarly, case ii) or case iii) holds,
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if any of its activators or non of its inhibitors is acting upon it. To cap-
ture this connective information, SQUAD reads networks in xml-format,
ideally created with CellDesigner version 3.5.1 (Funahashi et al., 2008) or
other tools. The stable steady states of this network can be located using a
Reduced Order Binary Decision Diagram (ROBDD) algorithm (Garg et al.,
2007) in SQUAD.
In a second step, the software automatically converts the static network into
a continuous dynamical system using the following set of differential equa-
tions:
dXi
dt
=
−e0.5h + e−h(ωi)
(1− e0.5h)(1 + e−h(ωi−0.5)) − gi ·Xi, with (3.2)
0 ≤ Xi ≤ 1, gi, h ≥ 0,
where the right-hand side is composed of two parts: an activation function
and a term for decay. Activation can be expressed as a sigmoid function of
ω, which represents the total input to the node:
ωi =

(
1−∑αn∑
αn
)( ∑
αnXan
1+
∑
αnXan
)(
1−
(
1+
∑
βm∑
βm
)( ∑
βmXim
1+
∑
βmXim
))
i)(
1−∑αn∑
αn
)( ∑
αnXan
1+
∑
αnXan
)
ii)(
1−
(
1+
∑
βm∑
βm
)( ∑
βmXim
1+
∑
βmXim
))
iii)
Analogous to the discrete system, function ω is written so that it describes
different combinations of activatory and inhibitory inputs (cases i) to iii)).
These inputs are weights by αn > 0 and βm > 0 so that ω is bounded in
the closed interval [0, 1]. Initially, the weights and parameters h and g are
assigned to default values, however, they may modified to fine-tune the dy-
namical behavior of the equations.
ODEfy Just for reasons of completeness, ODEfy also fulfills the task of
transforming discrete into dynamic systems. CNA (version 9.9) comprises
ODEfy (Krumsiek et al., 2010) a MATLAB- and Octave-compatible toolbox
for the automatically transforming Boolean models into systems of ordi-
nary differential equations. This is achieved by multivariate polynomial in-
terpolation and optional application of sigmoidal Hill functions describing
cooperativity and also applied in enzyme kinetics (see Section 2.3.3).
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3.4 Data-based Dynamic Modeling
3.4.1 Approach
The different steps of the data-based modeling approach from model crea-
tion to the design of new experiments are displayed in Figure 14.
Figure 14 : Modeling phases. Different modeling phases from the model creation to
experimental design.
Finding the appropriate model structure and predictive model parameters
the most crucial step in dynamic modeling. Moreover, the model comple-
xity always needs to be supported by data, to finally result in a meaningful
description of a biological process for quantitative model prediction and
suggesting experimental designs (steps 6 and 7, Figure 14).
Having established a parametric set of ordinary differential equations (step
1, Figure 14), the parameters have to be determined, which is a crucial step
and task. Usually it is preferable to use as much a priori information as
possible to render the model more accurate. This includes the consultation
of pathway data bases (e.g. Kyoto Encyclopedia of Genes and Genomes
(KEGG), Ingenuity Pathways Knowledge Base (IPKB), Signal Transduction
Knowledge Environment (STKE)) or screening of literature-based knowled-
ge. However, biochemical parameter may unfortunately differ by orders of
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magnitude according to the experimental conditions. Therefore it is diffi-
cult to decide whether discrepancies between experimental and simulated
data arise from inadequate parameters of from an insufficient model (Tim-
mer et al., 2000). One approach to solve this simulation dilemma is the pa-
rameter estimation and model selection from experimental data (steps 2 - 5,
Figure 14). We applied this data-driven approach throughout the dynamic
analysis of platelet signaling pathways (Section 4.1.4).
3.4.2 Fitting and Evaluating Dynamic Models
Section 3.4.2 introduces statistical methods to estimate parameters in a data-
driven way. Experimental data is always prone to a certain measuring inac-
curacy (noise). To explain the data most accurately, one can establish several
models Mi of different complexity, each comprising a corresponding set of
parameters θ = {p1, . . . , pr}. The evaluation and comparison of these mo-
dels leads to the following questions: Which parameter set can explain the
biological observations? Are these parameters identifiable, given the model
and data? Which model gives a good fit to the data while having the least
number of parameters to avoid overfitting? These questions can be answe-
red by statistical methods being introduced in the following.
Maximum Likelihood Estimation
The least-square method and the method of maximum likelihood (ML), re-
spectively, are common methods to fit a model to data while estimating the
inherent model parameter θ = {p1, . . . , pr}. In other words, it exists a class
of models Mi depending of a parameter vector θi ∈ Θ ⊂ Rr. Vector θ deter-
mines the values which can be expected from the modelM = {m1, . . . ,mN}.
Principle of the ML method is to find the parameter vector θML of a model
with which the observed data D = {d1, . . . , dN} is the most plausible:
θML = argmax
θ
(P (D|M, θ)).
P represents the probability density of the observed data, given a model M
and the parameter vector θ. In order to estimate θML, one has to consider
1√
2piσi
e
− (di−mi)
2
2σ2
i ,
describing the dispersion of measured data values di around the model-
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based values mi. Note that one assumes Gaussian distributed measurement
error (N(0, σ2i )).
Given a series on N independent measurements, the joined probability can
be written as a product of Gaussian distributions:
L(θ|D,M) := P (D|M, θ) =
N∏
i=1
1√
2piσi
e
− (di−mi)
2
2σ2
i . (3.3)
The so-called likelihood L(θ|D,M) is a function of θ. It provides upon ma-
ximization an optimal estimation θML of model parameter with which the
observed data is most plausible so that
L(θML|D,M) ≥ L(θ|D,M) ∀ θ.
It is often more convenient to maximize the log-likelihood
L(θ|M,D) := logL(θ|D,M) (3.4)
= −
∑
i
(di −mi)2
2σ2i
−N log
√
2pi −
∑
i
log σi
with respect to θ or to minimize the negative log-likelihood. As the last two
terms in 3.4 are constants and independent of θ that depend solely on the
data and the error model, they can be neglected during the optimization
process. Thus, the optimization problem is reduced to minimizing the sum
∑
i
(di −mi)2
2σ2i
.
In other words, θML is estimated so that the sum of squared error between
data and model gets minimal (least-square method). The sum of squared
errors is called χ2-value and it holds: Assuming Gaussian distributed resi-
duals di−mi or standardized residuals di−miσi , respectively. Then, the sum of
squared residuals is χ2-distributed with (N − r) degrees of freedom (Annex
A.1):
χ2 =
∑
i
(di −mi)2
σ2i
∼ χ2N−r. (3.5)
The Kolmogorov-Smirnov test (Silvey, 1975) is a suitable test for normally
distributed residuals.
Thus, the relation between χ2-value and the optimized log-likelihood can
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be formulated as:
χ2 = −2 ·L(θML|M,D). (3.6)
Goodness-of-fit
χ2-values express the difference between data and model trajectories and
therefore indicate the quality of the model fit, the goodness-of-fit. The smal-
ler the value, the better the fit. Given a certain level of significance, this
allows the statistical evaluation of the fit quality (χ2-test). Besides, there
are different goodness-of-fit measures to characterize statistically the fitting
quality such as the Akaike’s information criterion AIC (Akaike, 1973) and
Bayesian information criterion BIC (Schwarz, 1978) and derivatives thereof
(Burnham and Anderson, 2002) which can also serve as a basis for model
selection (see section 3.4.3 and Annex A.3). Exemplary, the AIC measure
AIC = −2L(θML|M,D) + 2 · r = χ2 + 2 · r, (3.7)
directly penalizes the number r of free parameter to account for the problem
of overfitting.
Multi-experiment Fitting
We used the MATLAB (2010) toolbox PottersWheel (Maiwald and Timmer,
2008) in order to fit our model to different time series data simultaneously,
a useful feature for model calibration. Multi-experiment fitting is based on
the assumption that kinetic system parameters stay unchanged if different
initial values or input functions are applied. This way, the statistical power
to estimate parameter values or to discriminate competing model hypothe-
ses are strongly increased. The multi-experimental approach allows the es-
timation of global and local parameters. Global parameters are assigned
to the same value for each experiment, reflecting structural parameters like
rate constants. In comparison, local parameters obtain different values de-
pending on the experiment.and helps to keep the model as parsimonious as
possible.
The parameter estimation often leads to minimization problems which can
be solved with a variety of global and local optimization algorithms. Here,
we applied the trust region algorithm in logarithmic space (Coleman and
Li, 1996) for multi-experiment fitting purposes.
The PottersWheel toolbox also features the conduction of fit sequences. Ini-
tial parameter values are repeatedly disturbed to a certain percentage and
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subsequently fitted to the data. Thus, the distribution of estimated parame-
ter values resulting from sequential fitting can be used for an identifiability
analysis. This includes the evaluation of the χ2 landscape which indicates
local or global minima or the confidence intervals for each parameter, indi-
cating how definite the parameters can be estimated from the data.
Parameter Identifiability
In parameter estimation it may occur that different sets of parameter may
happen to agree equally well with the data or several parameters mutually
compensate their effects, e.g. an increased value for parameter k1 and a de-
creased value for k2 may lead to the same time course of the observation.
Then, the model might suffer from a so-called non-identifiability. One dis-
tinguishes between structural and practical reasons for non-identifiability:
Structural Non-identifiability If two parameters k1 and k2 only appear
in a model only in form of a product or quotient c = k1
k2
they can not be
determined independently from each. Thus, a maximum likelihood estima-
tion may suffice to determine the quotient c but not the individual param-
eter values k1 and k2, respectively. This is referred to as structurally non-
identifiable. The replacement of c by a new, possibly identifiable parameter
k3 may resolve the problem. Structural non-identifiability can result from
several kinds of formulas and may be difficult to discover and to resolve. A
data-based algorithm to identify linear and non-linear relations of arbitrari-
ly many parameters is described in Hengl et al. (2007).
Practical Non-identifiability Even a structurally identifiable model may
still comprise parameters which are practically non-identifiable if the data
are not sufficient. There is either too few data available or the wrong kind
of data is used to estimate the model parameters. Generally, if the number
of parameters exceeds the number of measured data points, the parame-
ters can not be clearly determined. Sontag (2002) gives a rule for the mini-
mum number of experimental data needed to construct models of differen-
tial equations. An approach for identifiability analysis utilizing the profile
likelihood was proposed by Raue et al. (2009).
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3.4.3 Model Comparison and Selection
Selecting an adequate model structure is a crucial part of the modeling pro-
cess for which no perfect solution exists. A suitable model renders possible
new approaches to identify therapeutic strategies and to assess the feasi-
bility of a research agenda minimizing the cost in terms of animals, time,
and money. But in most cases, there exist more than one plausible model
which supports the experimental data. Evidently, more complex models
are advanced in fitting the observed data as they comprise more degrees of
freedom (parameters). However for reasons of parameter estimation and
calibration, one has to correct for the advantage of complex models. To find
models with reliable parameter estimates and good potential for model pre-
dictions, there are different strategies including forward selection (bottom-
up) and the top-down method. Following a bottom-up procedure, one starts
with a very simple model which is extended until no significant improve-
ment can be detected. The top-down method, in turn, takes a very com-
plex model as starting point which is reduced until the fit gets significantly
worse. For both procedures, a likelihood ratio test (LRT) can be applied to
favor models with few parameters.
Likelihood Ratio Test (LRT)
The LRT (Vuong, 1989; Timmer and Mueller, 2004) compares two models
M1 and M2 of different complexity by their maximal likelihood values. Re-
ducing a model’s complexity raises the question whether the reduced mo-
del sufficiently explains the data, or whether the more complex model is
needed. We assume model M1 is the more complex model comprising r1
parameters and model M2 is the reduced model having a set of r2 parame-
ters. The models are called nested, if model M1 contains additional r1 − r2
parameters besides the r2 parameters of model M2. The comparison of the
corresponding maximal likelihoods leads to hypothesis testing:
The null hypothesis H0 states, model M2 with its corresponding parame-
ter set θ2 describes the data equally well as the more complex model M1
with additional parameters (θ2 ⊂ θ1). In contrast, the alternative hypothe-
sis implies, that M1 significantly improves the model fit to the data. Hy-
pothesis testing compares the log-likelihoods of both modelsL(θ1,ML|M1, D)
and L(θ2,ML|M2, D), respectively. As the more complex model always has a
higher likelihood, it has to be tested whether the ratio of log-likelihoods is
significant or not.
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It can be shown that the log-likelihood ratio is χ2-distributed with r1 − r2
degrees of freedom (see Annex A.1, A.2). For nested models M1 and M2 this
yields
2(L(M1)− L(M2)) ∼ χ2r1−r2 . (3.8)
Density functions and cumulative distributions of the χ2 distribution with
different degrees of freedom are displayed in Figure 15. For a given level
Figure 15 : χ2 distribution. (A) The probability density function according to diffe-
rent degrees of freedom (df). (B) The cumulative distribution functions.
of significance, this distribution is used for statistically testing, whether the
null hypothesis can be rejected or not. However, the distributional result
(3.8) only holds if the so-called standard conditions are given (Cox and
Hinkley, 1974; Vuong, 1989). The most important conditions of these are:
1. The models M1 and M2 are nested.
2. The true parameters are not at the limit of the parameter space.
3. The parameters are identifiable under the null hypothesis.
For non-standard conditions and non-nested models however, one has to
consider different strategies for model selection (Self and Liang, 1987; Hall
and Wilson, 1991).
Akaike Information Criterion (AIC)
In the context of model selection, also criteria derived from information
theory such as the Akaike information criterion (AIC) can be used (Akaike,
1973, 1974). It suggests to compare the models by
AIC = −2L(θML|M,D) + 2 · r = χ2 + 2 · r, (3.9)
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and to choose the model with the smaller AIC value (see Annex A.3).
Sensitivity Analysis
Having established a suitable model structure with identifiable parameters,
one may further predict and analyze how sensitive the model variables and
observables themselves or their characteristics will react upon parameter
changing. This may accompany the design of new experiments. Charac-
teristic measures include the integral over a certain time period, the peak
hight, last value or the area under the curve. This impact is quantified by
calculated sensitivity values or control coefficients. We used the summation
laws derived by Hornberg et al. (2005) and implemented in MATLAB to de-
scribe and quantify the influence of parameter change on the characteristics.
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3.5 Rule-based Modeling
Rule-based modeling (RBM) is a powerful and increasingly popular ap-
proach that allows the use of available information about complex protein-
protein interactions in a precise and compact manner. It is hence a conve-
nient tool for constructing large executable models of complex cell signaling
network, containing a starting set of molecules, with possible interaction be-
haviors defined by biochemical reaction rules. (Hlavacek et al., 2006; Faeder
et al., 2009). Molecules are represented as structured objects whereas their
interactions are defined as rules for transforming the attributes of these ob-
jects. A rule can be understood as an implicit definition of a class of re-
actions, all involving a common transformation. Thereby, RBM allows to
systematically incorporate site-specific details about protein-protein inter-
actions into a model for the dynamics of cellular signal cascades (Figure 16).
The ability to involve site-specific information renders RBM a highly appro-
priate method, tailored to model complex binding and signal processing at a
receptor comprising several binding domains such as the epidermal growth
factor (EGF) receptor Danos et al. (2007) or the cluster formation upon li-
gand binding (Monine et al., 2010). The multiplicity of sites, e.g. possible
phosphorylation states, the many ways that signaling molecules can com-
bine and be modified, give rise to combinatorial complexity (Hlavacek et al.,
2003), a problem modelers of signaling networks have to cope with.
The domain-oriented, rule-based approach addresses this problem as it pro-
vides a powerful alternative to approaches that require an explicit enumer-
ation and description of all possible molecular species and reactions of a
system such as ODE-based models. Rule-based models can appropriately
be specified and analyzed on the basis of the BioNetGen language (Faeder
et al., 2009).
Software Several RBM-related software is available (cf. Hlavacek et al.
(2006); Faeder et al. (2009); Colvin et al. (2010)). We applied RuleBender (Xu
et al., 2011a; Smith et al., 2012) for model implementation as it serves for
editing, visualizing and simulating models based on BioNetGen language.
Furthermore, this user-friendly tool can be combined with NFSim (Sneddon
et al., 2011), a network-free stochastic simulator.
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Figure 16 : Concept of rule-based modeling. Rule-based modeling concepts and en-
coding in BioNetGen language. (A) Basic building blocks: Molecules, represented
as structured objects, composed of components denoting functional elements of pro-
teins such as domains. These elements may have associated states that describe cova-
lent modifications or conformations (e.g. phosphorylations, ubiquitinations, bonds).
Through bonds linking components of different molecules, they may be assembled
into complexes. (B) Patterns: By using patterns, one can select particular attributes
of a reacting molecules in species, here shown in bold. In the depicted example, the
pattern selects all states of molecules of B that have a free b1 binding site. In par-
ticular, this is regardless of the phosphorylation or binding status specifying the b2
component of molecule B. (C) Rules and network generation: Rules represent the
biochemical transformations which can occur in the system and are utilized to build
up a network of species and related reactions (a complete description of the entire rule
syntax is given in Faeder et al. (2009)). The reaction center, meaning the components
that undergo direct modification, is underlined for reasons of clarity. The network
is created as follows: By starting with the seed species, rules are applied in order to
generate new reactions and species by mapping the described reactant patterns onto
species and applying the implemented transformation(s) as specified. Species that
have been generated by new reactions may be affected by other rules to again gene-
rate new reactions and species. This process continues until there is no new reaction
or a stopping criteria is satisfied. Figure: Faeder et al. (2009)
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ALL MODELS ARE WRONG, BUT SOME ARE USEFUL
(George Box)
4.1 Systems Analysis of Platelet Signaling
4.1.1 Introduction
The small anucleate blood platelets are pivotal for the maintenance of he-
mostasis. This is achieved primarily by the formation of aggregatory blood
clots (thrombi) in case of an injured endothelium of blood vessels. On the
converse, thrombus formation has to be inhibited at times when the en-
dothelium is undamaged. Impaired platelet signaling may disturb this sub-
tle hemostatic balance leading to pathophysiological cardiovascular diseases
as well as inflammatory processes and metastasis. Thus, a systemic descrip-
tion, examination and analysis is key to understand and control platelet sig-
naling also under clinical conditions.
Data on the platelet and its proteome is rapidly accumulating due to ad-
vanced techniques including mass spectrometry (Garcia et al., 2004; Zahedi
et al., 2008; Premsler et al., 2011) and systematic yeast two hybrid assays
(Stelzl et al., 2005; Rual et al., 2005). The assembly of platelet-specific (phos-
pho)proteome, transcriptome and interactome data together witch func-
tional annotations and drug information form an integrative platform for
the creation of an virtual in silico platelet model. Such a basis (Boyanova
et al., 2012; Dittrich et al., 2008) allows the modeling of platelet signaling and
interactions in more detail which potentially reveals biological functions or
drug targets, building a bridge to pathophysiological processes. It deepens
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the understanding of platelet (patho)physiology, biochemistry, signal trans-
duction being essential to eventually develop new strategies for pharma-
cological interventions. This is supported by mathematical modeling and
systems biological approaches, underpinning the drug developmental pro-
cess (Nikolsky and Kleemann, 2010; Ramsey et al., 2010), (Chatterjee et al.,
2010; Diamond, 2009).
Here, we present different methods for analyzing platelet signaling on dif-
ferent scales. This ranges from a global network-based approach to give
systemic insights in cell signaling and the interlinking of signaling path-
ways (Section 4.1.2). Building on this static approach, we then zoom in on
the Boolean modeling of specific signaling pathways of platelet inhibition
and activation, bringing the temporal component to signal cascade models
(Section 4.1.3). This is followed up by a dynamic ODE-based model which
precisely describes platelet inhibition with focus on the feedback-regulated
cAMP level. Calibrated by adaption to time series data, the model quan-
titatively serves as a predictor for testing anti-aggregatory drugs (Section
4.1.4).
4.1.2 Interactome, Subnetworks and Static Network Analysis
Cross-talk of Inhibitory and Activatory Pathways
The response of platelets to changes in the immediate environment is al-
ways a balance between activatory and inhibitory signals and related plate-
let signaling cascades. The cumulative effect of these signals is either plate-
let activation or quiescence (cf. Section 2.2). Besides the bivalent definite ef-
fect on the platelet, signaling cascades are highly interlinked (see Figure 17)
and the unraveling of interactions represent a challenging subject of ongo-
ing research. Exemplary, our experimental collaboration partners recently
demonstrated cross-talk between platelet stimulatory and inhibitory path-
ways Gambaryan et al. (2010). They discovered that an activation of human
platelets by vWF caused NO-independent activation of soluble guanylyl
cyclase and stimulation of cGMP production and PKG. Thus, vWF which
is mainly triggering platelet activation also initiates a feedback inhibitory
pathway (Gambaryan et al., 2008).
66
RESULTS
Figure 17 : Main platelet signaling cascades and cross-talk. Graphical representa-
tion (subnetworks) of three main platelet signaling pathways: key nodes of cyclic
nucleotide signaling (yellow), crucial for platelet inhibition; vWF signaling (red),
and integrin signaling (blue) triggering the platelet activation. Platelet proteins
are depicted in grey. Common proteins assigned to two or more pathways are
shown with different colors: vWF−integrin (violet), vWF−cyclicNucleotide (orange),
AcyclicNucleotide−integrin (green), cyclicNucleotide−vWF−integrin (white). Figu-
re: Modified after Boyanova et al. (2012).
Integrative Subnetwork Extraction
Static network analysis and bioinformatical investigation of platelet-specific
protein-protein interactions are a first step to gain insight into interactomics
and platelet signaling. By offering functional, drug- and pathway-associa-
tions, the comprehensive platelet repository PlateletWeb (Boyanova et al.,
2012) provides a first systemic insight into various aspects of platelet func-
tionality, pharmacologic regulation and pathway interlinking. It allows an
integrated network analysis sustaining a further inspection of cross-talking
signaling proteins, their regulatory interactions and site-specific phospho-
rylations. This systems biological approach helps to underpin predictions
or observations that have arisen from experiment. Particularly important
candidates are set into a known or even novel or predicted network context
highlighting their connections to platelet activation or inhibition, respec-
tively.
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Moving towards probing modulatory interactions, central activatory and
inhibitory mechanism and main signaling cascades are extracted from the
entire platelet interactome database. This results in enriched protein-protein
subnetworks (see Figure 18) comprising pivotal network proteins whose
connectivity show the information flow throughout the network.
Figure 18 : Platelet activatory (A) and inhibitory (B) subnetworks. For illustration
of subnetworks we show the topology and key nodes of the activatory vWF cas-
cade (A) and the inhibitory cyclic nucleotide signaling pathways (B). Proteins (cir-
cles) are trianglar if they constitute phosphorylated kinases, or diamond shaped in
case they represent phosphorylated phosphatases. Human proteins (red) are blue-
colored if they show platelet specific phosphorylations, and yellow-colored if they
are non-phosphorylated. Protein-protein interactions (gray lines) are further divided
into dephosphorlyation (green line) and phosphorylation (red arrow), specified by the
corresponding phosphosite, a (de)phosphorylated serine (S), tyrosine (Y) or threoni-
ne (T) residue. If it exists a kinase prediction for such a phosphorylation, the arrow is
blue-colored. Extracted subnetworks can be enriched with drug information (panel
B, greenish modifications) or are manually refined by adding additional signaling
molecules (orange nodes) or enzymatic transformations and reactions.
To further investigate cross-talk proteins and their functions, we focus on
the integration of site-specific information of phosphorylations within the
platelet interactome. Protein phosphorylation and dephosphorylation via
kinases and phosphatases, respectively, are the most abundant and cen-
tral mechanisms involved in the regulation of almost every cellular pro-
cess (Sauro and Kholodenko, 2004). In eukaryotes, kinases phosphorylate
at specific serine (S), threonine (Y) or tyrosine (T) residues thereby altering
protein activities. This holds for anucleate platelets in particular, as phos-
phorylation events predominate the mediation of signal transduction.
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Integration of Platelet Proteins into Signaling Contexts
By phosphoproteome analysis, recently several phosphorylation sites were
identified in resting platelets which were located on potential PKA and
PKG substrates. Involved in platelet inhibitory pathways, activated PKG
and PKA antagonize platelet aggregation. Among the detected candidates
for protein kinase substrates, CalDAG-GEFI, phosphatidylinositol transfer
protein, membrane-associated 2 (PITPNM2) together with protein tyrosine
kinase 2 (PYK2), nardilysin (NRD1) and stathmin (STMN1) are to be ranked
highly interesting for further investigation according to our experimental
collaborators. Exemplary, protein CalDAG-GEFI integrates signaling for
platelet aggregation and thrombus formation (Crittenden et al., 2004) and
plays a key role in the activation of Rap family GTPases involved in pla-
telet integrin activation (Jeyaraj et al., 2011). The activation of PKA/PKG
inhibits Rap activity, however the underlying mechanisms are not exactly
known. We hypothesize that activated PKA is phosphorylating CalDAG-
GEFI which inhibits Rap1 activity. Experimentally, we found that CalDAG-
GEFI is a substrate for PKA/PKG and identified its in vivo phosphorylation
site (Ser587). Bioinformatically, we support further investigations by pre-
dicting and analyzing the possible involvement of these proteins in platelet
activatory and inhibitory signaling cascades (see Figure 19), critically mod-
ified and balanced by specific phosphorylations. Furthermore, potential ki-
nases are predicated algorithmic-based (Linding et al., 2007; Miller et al.,
2008) with respect to detected phosphosites, which hints at probable func-
tional possibilities and may guide further experiments.
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Figure 19 : Network-integrated potential PKA/PKG substrates. Interesting proteins
(named after gene name identifier) and potential PKA and PKG substrates (phos-
phatidylinositol transfer protein, membrane-associated 2 (PITPNM2); protein tyro-
sine kinase 2 (PYK2); CalDAG-GEFI (RASGRP2); stathmin (STMN1)) are integrated
into the network context for platelet activation including PKA (PRKACA) and PKG
(PRKG1). These central proteins are highlighted (green). Established protein-protein
interaction network is superimposed with phosphorylation data (experimentally va-
lidated as well as predictions): Proteins (circles) are depicted in trianglar shape if
they represent phosphorylated kinases, or diamond shaped in case they constitute
phosphorylated phosphatases. Human proteins (red) are yellow-colored if they are
non-phosphorylated and blue-colored in case they show platelet specific phosphory-
lations. Protein-protein interactions are represented by grey lines. Dephosphorlya-
tions (green line) and phosphorylations (red arrow) are specified by the correspon-
ding phosphosite, either a (de)phosphorylated serine (S), tyrosine (Y) or threonine
(T) residue. Algorithm-based kinase predictions for such phosphorylation events are
depicted by blue arrows.
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4.1.3 A Boolean Model of Platelet Inhibition and Activation
Outline
As described in Section 4.1.2, we explored detailed data on the platelet
(phospho)proteome and interactome to establish a simplified Boolean mo-
del of the central platelet cascades. Here, we focus on activatory pathways
and its interplay with platelet inhibition. Activatory pathways are versatile
to cope with diversified environmental conditions. Platelet activation and
aggregation occurs on several activation levels including receptor activa-
tion, G-proteins and calcium mobilization, activation of central kinases and
integrins as key steps (cf. Section 2.2). The interplay with the inhibitory
cyclic nucleotide system manifests the behavior of the systems. Down-
stream of the receptor level, this results in a highly interlinked network
of kinases, executing proteins and small molecules ensuring the signal re-
sponses. However, for the establishment of a predictive in silico model, it is
indispensable to focus on key signal interactions of modulatory pathways
(cf. Figure 18) out of a complex PlateletWeb of all protein-protein interactions
within the platelet (Boyanova et al., 2012).
The analysis and simulations of the key-node focused model show the step-
wise coalescence of different signaling events into a fully activated system
state that includes positive feedback regulation. System stability analysis
distinguishes the networks inherent biphasic threshold behavior: a sub-
threshold phase which is characterized by integration over different activa-
tory and inhibitory conditions, opposed by a beyond threshold phase where
counter-regulatory pathways are outweighted towards irreversible platelet
aggregation. Model-based predictions are verified by monitoring phospho-
rylations marking different proposed activation phases.
Model Setup and Implementation
Focusing on the platelet interactome and key signaling nodes, we construc-
ted a logically connected model of the key activating platelet cascades and
modulatory inhibitory pathways (Figure 20).
Network Topology The network topology comprises a set of key nodes
of each activating phase, that govern the overall-behavior of the respective
sub-part. Starting with signal initiation, we include the collagen receptor
GPVI, being a strong platelet activator. Upon stimulation, a cascade of ki-
nases, including protein kinase C (PKC), Akt and Src is engaged, initially
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Figure 20 : Boolean network represented as directed graph. Arrows denote activa-
tory (→) and inhibitory ( |) effects on the corresponding target node. Pivotal key-
nodes in the network context involved in different activatory and inhibitory platelet
signaling cascades: collagen receptor (GPVI); phospholipase Cβ2 (PLCB); inositol-
1,4,5-triphosphate (IP3); IP3 receptor (IP3R); 1,2-diacylglycerol (DAG); protein kinase
C (PKC); thromboxane A2 (TXA); thromboxane receptor (TBXA2R); arachidonic acid
(ARAC); ATP receptor (P2X1); ADP receptors (P2Y12, P2Y1); adenosine diphosphate
(ADP); talin (Talin); phosphoinositide 3-kinaseβ (PI3); integrins (Inta2b3); phosoholi-
pase A2 (PLA2); Akt kinase (Akt); prostaglandin receptor (PTGDR); cyclic adenosine
monophosphate (cAMP); protein kinase A (PKA) and substrates phosphodiesterase
3 (PDE3), vasodilator stimulated phosphoprotein (VASP), Rap1, Src kinase (Src), Rho
kinase (RhoK); cytosolic calcium (CaC); extra-cellular calcium (CaE); calcium in endo-
plasmatic reticulum (CaER); CalDAG-GEFI (CalDAG); calcium channel Orai1. Figure
modified after Mischnik et al. (2013).
leading to a rearrangement of the platelet cytoskeleton (shape change) and
the formation of unstable aggregates. At first, membrane-bound phospho-
lipase Cβ2 (PLCB) gets activated, triggering the production of the second
messengers inositol-1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG).
IP3 diffuses through the cytoplasm, subsequently binding to its IP3-receptors
at platelet organelle membranes, which causes the release of calcium ions
from intra-cellular storage pools (Authi and Crawford, 1985), whereas DAG
remains at the plasma-membrane potently activating of PKC (Lapetina et al.,
1985). Besides shape change and the formation of pseudopodia, this re-
sults in the activation of CalDAG-GEFI (Crittenden et al., 2004) directly ac-
tivating Rap1, thereby transmitting the signal via talin to integrin α2bβ3.
Thus, integrin switches to the active state characterized by exposed fib-
rinogen binding sites. Activated PKC entails Src kinase phosphorylation
(Liebenhoff et al., 1994), which potentially transmits the signal to the Akt
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kinase (Xiang et al., 2010). The latter also receives signals from phospho-
inositide 3-kinaseβ (PI3) and acts directly on integrin α2bβ3 (Kirk et al.,
2000), which strengthens the platelet activation state. Increased intracellu-
lar calcium concentration also leads to the fusion of platelet granules with
the plasma-membrane, thereby releasing small molecules such as ATP, ADP
or serotonin and pro-coagulatory proteins into the extra-cellular space (Cat-
taneo et al., 1990). ADP subsequently binds to its receptors P2Y1 and P2Y12,
further amplifying the kinase cascade, and inhibiting the cAMP-production
by means of P2Y12 on the other hand (Cattaneo and Gachet, 2001). Thus,
the inhibiting part (prostaglandin receptor (PTGDR)/cAMP/PKA-system)
is suppressed, further increasing platelet activation. Emptying the calcium
stores finally elicits a secondary calcium entry by means of Orai1, TRPC
channels and ATP-receptor P2X1. A positive feedback loop from the ac-
tivated integrin back to the inner side of the plasma-membrane stabilizes
the activated system, by which phosoholipase A2 (PLA2) gets activated.
As a result, thromboxane A2 (TXA) is synthesized from arachidonic acid
(ARAC), catalyzed by cyclooxigenase (Jin et al., 2002) and released for bind-
ing at platelet thromboxane receptors (TBXA2R). This increases the path-
way activity to the highest extent and switching the signal response from
reversible to irreversible aggregation. In terms of the counter-regulatory, in-
hibiting pathway, protein kinase A (PKA) and its activating second messen-
ger cAMP are to be designated as key nodes. Cyclic adenosine monophos-
phate (cAMP) production is triggered upon stimulation of prostaglandin
receptors, here represented by PTGDR. cAMP exerts its main effects via its
corresponding protein kinase PKA. It phosphorylates targeted serine and
threonine residues on substrate proteins that prevent or reverse platelet ac-
tivation (Smolenski, 2012) such as other kinases (Src), receptors (IP3R) and
proteins linked to cytoskeletal organization like the vasodilator-stimulated
phosphoprotein VASP (Abrahamsen et al., 2003; Murthy et al., 2002; Weber
et al., 1999). cAMP levels are tightly regulated by means of several negative
and positive feedback loops, comprising directly or indirectly modulation
via phosphodiesterases (PDE3) and the ADP receptor P2Y12 (Feijge et al.,
2004; Hechler and Gachet, 2011). This step-wise activation process is high-
lighted by transforming the known interactions into a multi-level Boolean
network.
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Implementation The multi-level connectivity and node selection was
carried out in a literature-based way as well as according to a priori know-
ledge on platelet signaling (cf. Section 2.2). The logical model was imple-
mented and simulated by means of CellNetAnalyzer (CNA) (Klamt et al.,
2007) (see Annex B.1 Table 10 for key nodes and edges; Annex B.2 Table 11
for connectivity of the logical interaction hypergraph model). It can suitab-
ly be represented as a directed graph (Figure 20) denoting activatory and
inhibitory effects on target nodes. Besides CNA for simulation in discrete
time steps, we applied SQUAD (Di Cara et al., 2007) for semi-quantitative
continuous simulations.
Model Simulation
The course of model simulation (CellNetAnalyzer) mimics the gradual pla-
telet activation towards irreversible platelet aggregation over different time
steps which is in accordance with a priori knowledge. The simulation in-
volves four phases (Figure 21A-D), monitoring the propagating and acti-
vating signal throughout the network and time.
We start the model simulation from a point in phase space, where the activa-
tion levels of all pathway constituents are in the resting state (level 0). The
first activation step (Figure 21A) comprises the initial binding of a strong
activator to its receptor (GPVI) which competes with the inherent platelet
inhibition (prostaglandin/cAMP pathway). Depending on the initial condi-
tions, the subsequent signal transduction cascade activates integrin α2bβ3
to level 1 or 2 (if the initial inhibitory signals are absent). The second activa-
tory step (Figure 21B) affects ADP being released as result of a calcium tran-
sient enhancing the signaling cascade. This heightens the integrin α2bβ3
activation state to level 2 or 3. The third step of platelet activation (Figure
21C) involves the store-operated calcium entry (SOCE). It is mediated by
the release of calcium from intra-cellularly stored calcium pools which sub-
sequently activates the calcium channel Orai1. This process further ampli-
fies the activatory signal represented by integrin α2bβ3 activation of level
4. The final time-step (Figure 21D) comprises a positive feedback loop from
integrin (level 4) strengthening the activatory signal and intercalating the
synthesis of thromboxane (TXA) from arachidonic acid (ARAC). Thereby
integrin achieves activation level 5 and forces the systems state towards ir-
reversible aggregation.
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Figure 21 : Different system states after logical steady state computation. (A)-(D):
Boolean model represented as a directed graph (Figure 20). Arrows denote activatory
(→) and inhibitory ( |) effects on the corresponding target node.
Appropriately added network functions coalesce (within 4 simulation time steps t0,
t1, t2, t3) into a fully activated system (D) passing different intermediate systems
states (A) to (C). (A): t0. Solely reactions triggered by pure GPVI signaling are in-
volved. (B): t1. Effects from autocrine ADP signaling are added. (C): t2. Signaling is
complemented by store-operated calcium entry (SOCE). (D): t3. Addition of a posi-
tive feedback loop established by integrin signaling results in the most driven system
towards irreversible aggregation. Activation levels are color-coded (level 0 to 5 ac-
cording to the CellNetAnalyzer simulation). Figure modified after Mischnik et al.
(2013).
System Stability and Dynamic Behavior
To check for system stability and transformation to a continuous system
for dynamic simulations of the logical network, we refer to the software
SQUAD (Di Cara et al., 2007) (cf. Section 3.3)
Steady State Analysis The analysis of the discrete systems reveals two
distinct steady states. A general off-state where all network nodes have an
activation level of 0, which is opposed by an on-state, depicting the fully-
excited system and being stabilized by positive feedback. Here, all network
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nodes exhibit an activation-level of 1 (scaled activation units between 0 and
1), except those being involved in the platelet inhibitory cAMP-pathway
(cAMP, PKA, VASP and PDE3).
Threshold Analysis Dynamic simulations indicated two phases of acti-
vation in the model: The first step is characterized by a sub-threshold be-
havior allowing rapid comparison and integration between different recep-
tor signals and stimuli, both activatory and inhibitory. In a second phase,
after inherent system thresholds were crossed and a specific signaling deci-
sion is made, all other pathways are competitively turned off.
To study this threshold behavior we combined several activatory and in-
hibitory stimuli and its combinations. We started from the resting (non-
stimulated) off-state and excited the system with a GPVI-input pulse of
strength 1. Activating the downstream cascade components, the signal is
transduced towards integrin, which leads to aggregation and shape change.
Akt kinase activity undergoes an initial increase, but diminishes as the ac-
tivatory input via GPVI and thus Src signaling flattens. Due to the positive
feedback, its activity increases again, ultimately leading to the fully acti-
vated enzyme (Figure 22A). A constant activatory impulse instead of the
decaying GPVI-input drives the system straight to the on-state.
In the second scenario, the GPVI-pulse is accompanied by a half-maximal
PTGDR input strength of 0.5. Akt kinase and calcium ions are slightly mobi-
lized, but due to the inhibitory effect exerted by PKA, the system returns to
its deactivated resting state (Figure 22B). Constant activatory and inhibiting
inputs render the system oscillating (data not shown).
If the half-maximal PTGDR input is opposed by a stronger GPVI-pulse (Fi-
gure 22C), the system passes the integrative threshold, ending up in its ma-
ximal activation state. The minimal GPVI-value that leads to threshold-
transgression, given a PTGDR inhibiting strength of 0.5, is estimated to
1.168. Here, the system is alternating between both, the on- and off-steady-
state, respectively. Assuming a activating stimulus of 1.2 (Figure 22D) close
to the threshold value, integration of the competing inputs proceeds, finally
reaching the on-state. Akt kinase for instance receives activating signal via
GPVI in accordance to the pure activatory scenario (Figure 22A), but as Src
kinase also sustains inhibition via PKA, its activity tumbles until it reaches
full mobilization. The dynamics of calcium levels occur as a result of coa-
lescing IP3, Orai1 and PKA effects which could be reproduced by measure-
ments (data not shown).
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Figure 22 : Threshold analysis by dynamic simulation. (A): GPVI signal (input) with
strength 1. System turns towards the on-state. (B): Combined activatory GPVI input
with strength 1 and inhibitory prostaglandin (PTGDR) input with strength 0.5: Sys-
tem is forced to the off-state. (C): Combined GPVI input with strength 1.5 and in-
hibitory input via PTGDR with strength 0.5: System turns to the on-state. (D): GPVI
input with strength 1.2 combined with PTGDR input with strength 0.5: System be-
havior is close vicinity of the threshold. Figure modified after Mischnik et al. (2013).
Different inhibitory input strengths together with the necessary activating
input value to exceed the threshold are given in Table 3. Values denote full
(≥ 1.0) or no (0.0) activation in arbitrary units.
The comparison of inhibiting and activating signals shows that the relative
activating strength (GPVIthr/PTGDR) that leads to threshold-crossing, de-
creases with elevating inhibiting inputs. Hence, this underpins the system
ability to adapts for higher prostaglandin-concentrations by increasing its
sensitivity for platelet activators.
Pharmacological Modulation and Validation
The power of mathematical models arises from the opportunity to simulate
the effects of knock-out mutations or drugs. Exemplary, drug Clopidogrel
influences platelet signal transduction in an anti-thrombotic way (Li et al.,
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Table 3 : Combinations of inhibitory and activatory input strengths GPVIthr to ex-
ceed the activation threshold. Table modified after Mischnik et al. (2013).
Inihibitory input GPVI-value Relative activating strength
via PTGDR GPVIthr GPVIthr/PTGDR
0.25 0.946 3.784
0.5 1.168 2.336
0.75 1.456 1.941
1.0 1.625 1.625
2012). Therefore, it is of high medical relevance and widely applied in the
treatment of heart diseases. Clopidogrel acts as an antagonist of the ADP
receptor P2Y12, which entails both, a crucial activating effect on the pla-
telet kinase machinery and the down-regulation of the inhibitory pathway
branch by turning down the production of cAMP.
Within the logical network, P2Y12 is positively connected to PI3 kinase, and
negatively to cAMP (Figure 20). Thus, a blocking of P2Y12 results in a re-
markably weaker activation of all subsequent pro-thrombotic kinases after
the activatory input, and a higher PKA activity, due to an increased cAMP
level, which is in accordance with current experimental data (Haberstock-
Debic et al., 2011; Iyú et al., 2011).
To further elucidate the kinase machinery being active within the different
activation phases (Figure 21), we zoom into the phosphorylation events sur-
rounding the respective kinases (Figure 23), according to experimental data
(Boyanova et al., 2012). PKA is active during phase 0 and switches to level
0 during the following activation phases, which is in accordance with ex-
perimental data projected on the signaling network as depicted in Figure
23A, B. PKC is mainly active in phases 2 and 3 (Figure 23C,D). Akt becomes
activated during phase 3 (Figure 23C), whereas Src kinase is moderately ac-
tive during phase 1,2 and 3 (Figure 23B-D). Experimental data in terms of
key phosphorylation events support this direction of signal processing (cf.
Figure 23) and agree well with key activation steps postulated by the model.
Findings resulting from Boolean and semi-quantitative modeling together
with data validation has led to the publication entitled "A Boolean view
separates platelet activatory and inhibitory signalling as verified by phos-
phorylation monitoring including threshold behaviour and integrin modu-
lation" (Mischnik et al., 2013). My expertise in platelet signaling and mo-
deling strategies sustained the model set-up and interpretation of resulting
model simulations.
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Figure 23 : Model validation : PlateletWeb. ADP signaling networks visualized and
colored according to the postulated model phases of platelet activation ((A): phase 0;
(B): phase 1; (C): phase 2; (D): phase 3). The key phosphorylation events according
to experimental data are shown beside each network (phase 0: sub-network around
PKA, phase 1: around Rap1A/RAP1B; phase 2: around Akt kinase (Akt1); phase 3:
around the thromboxane receptor TBXA2R). Here, the Boolean model (Figure 20) is
validated by data on phosphorylation, kinases and substrates not used for setting up
the Boolean model but according to experimental data available from the PlateletWeb
knowledgebase (Boyanova et al., 2012). Interactions (gray lines), site-specific phos-
phorylation events (red arrows with labeled sites) and dephosphorylation events
(green lines) are extracted from literature studies based on the PlateletWeb knowledge
base; kinase predictions (blue lines) were additionally considered. Kinases are de-
picted as triangles and proteins as circles. Phosphorylated proteins are represented in
red, blue labels denote proteins from the initial ADP model network. Further proteins
were added for maintaining the network structure and improving the visualization
of the signal flow (for example G-proteins) but were not part of the Boolean model.
Metabolites and small molecules such as NO and Ca2+ are presented in light blue
circles. Figure modified after Mischnik et al. (2013).
79
4.1 Systems Analysis of Platelet Signaling
80
RESULTS
4.1.4 Cyclic Nucleotide Signaling: A Dynamic Model
Synopsis
Cyclic nucleotides play a major role in platelet signaling, as they strongly
mediate inhibition of platelets. This counterpart to platelet activation is cru-
cial for countervailing unwanted platelet activation and therefore a pivotal
target regarding the prevention of pathological platelet aggregation. Thus,
platelet inhibition and its regulators are of great medical interest and ob-
ject of pharmaceutical invention (antiplatelet therapies). Mathematical and
pharmacodynamic modeling of thrombosis and hemostasis and associated
signal transduction allows quantitative predictions upon drug modulation
and supports the precise description of pivotal targets for pharmacological
modulation.
I developed a dynamic mathematical model of the main inhibitory path-
way in human platelets and its downstream effects. By means of a data-
based in silico approach, we established a time-resolved description of the
feedback regulation of cAMP levels which serves as a quantitative model
for investigating combinatorial drug effects at multiple strengths. This in-
cludes dynamic effects of PDE-specific inhibitors (Milrinone, Cilostamide)
and activators of adenylyl cyclase (Forskolin, Iloprost).
Modeling Approach and Model Setup
As kinetic information is available of most of the signaling components, as
well as time-resolved quantitative data for validation, we opt for a data-
based dynamic modeling approach offering model-based quantitative pre-
dictions such as drug effects. The dynamic model, based on a system of
ordinary differential equations (ODEs) is set up following the data-based
approach as described in Section 3.4. Starting with the most parsimonious
model of basal cyclic nucleotide signaling in non-stimulated platelets we
successively refined and adapted it to drug stimulation leading to plate-
let inhibition. This includes iterative model fitting to experimental time-
series data and statistical testing for data-based model selection (Figure 24).
Thus, careful validation resulted in the overall model topology of feedback-
regulated cyclic nucleotide signaling depicted in Figure 25.
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Figure 24 : Model development processes. Modeling approach and main phases
from the platelet signaling network creation to model-based design of new experi-
ments leading to quantitative predictions (cf. Figure 14) Black boxes specify the steps
tailored to the platelet study. Figure: modified after Wangorsch et al. (2011).
Formed by their corresponding cyclases, cAMP and cGMP are degraded by
phosphodiesterases modulating the activation of cyclic nucleotide depen-
dent protein kinases. They in turn mediate the respective inhibitory effects
e.g. on VASP (cf. Section 2.2.3). Information about model components and
enzyme isoforms in platelets, gathered from transcriptome and proteome
databases (Boyanova et al., 2012; Dittrich et al., 2006) and literature mining
are presented in Table 13 (Annex B.4).
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Figure 25 : Topological scheme of the modeled branches of cyclic nucleotide sig-
naling. Main components of cyclic nucleotide signaling pathways and their cross-
talk and downstream effects are illustrated: Pivotal signaling components of the sim-
plified cAMP signaling pathway are shown in yellow, major components of cGMP
signaling branch in green. The three central cyclic nucleotide degrading phospho-
diesterases (PDEs) are depicted in blue. Both, cAMP and cGMP signaling share in
downstream effects on phosphoprotein VASP (brown). VASP is differentially phos-
phorylated at both phosphorylation sites, Ser157 and Ser239 upon cyclic nucleotide
dependent activation of their corresponding protein kinases (PKA, PKG). Concen-
trations of cAMP and cGMP, respectively, react sensitively to pathway modulating
compounds such as inhibitors of PDEs (Cilostamide, Milrinone) as well as adenylyl
cyclase (AC) stimulating drugs (Iloprost, Forskolin) shown in red rectangles. This di-
rect activation (green dashed arrow) and/or inhibition (red arrow) results in elevated
cAMPs level which subsequently feeds back via cAMP-dependent PKA. This way,
PDE3 gets phosphorylated (activatory feedback) and AC gets inhibitied. Feedback
regulation is indicated by bold green and red colored arrows. Figure: Wangorsch
et al. (2011).
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Basal Model of Non-stimulated Platelets As experimentally observed
(Eigenthaler et al., 1992), non-stimulated platelets show basal cAMP and
cGMP levels of 4 µM and 0.4 µM, respectively, maintained by AC and GC as
well as the three major platelet phosphodiesterases PDE2, PDE3 and PDE5
(Figure 26).
Figure 26 : Reaction scheme (basal conditions). Reaction scheme representing as-
sumed regulations to maintain basal concentrations of the cyclic nucleotides cAMP
and cGMP in non-stimulated platelets. The constant generation of cyclic nucleotides
by the corresponding cyclases AC and GC (reaction r1,r2) is in turn balanced by PDE-
mediated degradation (PDE2, PDE3, cGMP-specific PDE5). This is accomplished by
active phosphodiesterases (reactions r8-r13) degrading the cyclic nucleotides (reac-
tions r3-r7). For explicit formulations of the underlying reactions (r1 - r13) see Table
4. Figure modified after Wangorsch et al. (2011).
Their enzymatic activity is modeled by Michaelis-Menten kinetics with ki-
netics constants detailed in Bender and Beavo (2006). Regarding PDE2 cata-
lysis, cAMP shows a positive cooperativity resulting in a Hill coefficient of
2 (Matsumoto et al., 2003). Besides PDE2, essentially PDE3 (80%) provides
the degradation of cAMP (Butt and Walter, 1997), whereas PDE5 mainly and
specifically adjusts the level of cGMP.
Under basal conditions, we assume an overall guanylyl cyclase activity of
0.6− 1.0 µM/min and an AC activity of 7± 2 µM/min according to reported
data (Hines and Tabakoff, 2005; Parsian et al., 1996; Juska and Farndale,
1999; Schmidt et al., 2001). The following set of ordinary differential equa-
tions covers these kinetic assumptions under basal conditions:
84
RESULTS
System of ODEs (basal conditions)
dx1
dt
= +ν1 − ν3 − ν4; (4.1)
dx2
dt
= +ν2 − ν5 − ν6 − ν7; (4.2)
dx3
dt
= +ν8 − ν9; (4.3)
dx4
dt
= +ν10 − ν11; (4.4)
dx5
dt
= +ν12 + ν13; (4.5)
dx6
dt
= −ν8 + ν9; (4.6)
dx7
dt
= −ν10 − ν11; (4.7)
dx8
dt
= −ν12 + ν13; (4.8)
dx9
dt
= +ν3 + ν4; (4.9)
dx10
dt
= +ν5 + ν6 + ν7. (4.10)
The reactions r and its rates ν are defined as given in Table 4. Dynamic va-
riables x and constants k are declared in Table 5.
Table 4 : Reactions and rates for modeling the dynamics in cyclic nucleotide signaling
under resting conditions, defined in the system of ODEs (cf. Equation 4.1 - 4.10).
Reaction Rate
Basal AC influx of cAMP (r1): ν1 = k11;
Basal GC influx of cGMP (r2): ν2 = k12;
cAMP turnover via PDE2 (r3): ν3 =
k1 ·xk191 ·x3
k
k19
2 +x
k19
1
;
cAMP turnover via PDE3 (r4): ν4 = k3 ·x4 ·x1k4+x1 ;
cGMP turnover via PDE2 (r5): ν5 = k5 ·x3 ·x2k6+x2 ;
cGMP turnover via PDE3 (r6): ν6 = k7 ·x4 ·x2k8+x2 ;
cGMP turnover via PDE5 (r7): ν7 = k9 ·x5 ·x2k10+x2 ;
(De)activation (r8 -r13): ν8 = k14 ·x6;
ν9 = k13 ·x3;
ν10 = k16 ·x7;
ν11 = k15 ·x4;
ν12 = k18 ·x8;
ν13 = k17 ·x5;
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Table 5 : Dynamic variables and constants implemented in the systems of ODEs (cf.
Equations 4.1 - 4.10). Constants concerning the cAMP and cGMP turnover by PDE
isoforms are extracted from Bender and Beavo (2006); Butt and Walter (1997).
Model parameter Value Foundations/assumptions Reference
Dynamic variables
x1 : c(cAMP) 4µM basal levels (Eigenthaler et al., 1992)
x2 : c(cGMP) 0.4 µM basal levels (Eigenthaler et al., 1992)
x3 : c(PDE2) active 0.05 mg/l model-based simulation this study
experimentally: 63.46 mg/l
x4 : c(PDE3) active 2.3 mg/l model-based simulation this study
experimentally: 225 mg/l
x5 : c(PDE5) active 1 mg/l model-based simulation this study
experimentally: 1359 mg/l
x6 : c(PDE2) inactive (63.46 - x3) mg/l
x7 : c(PDE3) inactive (225 - x4) mg/l
x8 : c(PDE5) inactive (1359 - x5) mg/l
x9 : c(AMP) µM; simulated
x10 : c(GMP) µM; simulated
Constants
k1 : VmaxPDE2 120 µmol/min/mg cAMP turnover
k2 : KmPDE2 50 µM cAMP turnover
k3 : VmaxPDE3 3 µmol/min/mg cAMP turnover
k4 : KmPDE3 0.2 µM cAMP turnover
k5 : VmaxPDE2 120 µmol/min/mg cGMP turnover
k6 : KmPDE2 35 µM cGMP turnover
k7 : VmaxPDE3 0.3 µmol/min/mg cGMP turnover
k8 : KmPDE3 0.02 µM cGMP turnover
k9 : VmaxPDE5 5 µmol/min/mg cGMP turnover
k10 : KmPDE5 5 µM cGMP turnover
k11 : kcAMP 8 µmol/min basal influx of cAMP (Hines and Tabakoff, 2005)
(Parsian et al., 1996)
(Juska and Farndale, 1999)
k12 : kcGMP 1 µmol/min basal influx of cGMP (Schmidt et al., 2001)
(Wu et al., 1995)
k13 : Deactivation PDE2 this study
k14 : Activation PDE2 k13 - k13 = 0 this study
k15 : Deactivation PDE3 for simulation of this study
k16 : Activation PDE3 basal levels this study
k17 : Deactivation PDE5 (resting state) this study
k18 : Activation PDE5 this study
k19 : hPDE2 2 Hill coefficient (Matsumoto et al., 2003)
(Butt and Walter, 1997)
Estimation of PDE Concentrations Although kinetic parameters for many
PDE isoforms are available, data on enzyme concentrations in human plate-
lets is lacking. Therefore, we determined experimentally intra-cellular con-
centrations of the major PDE isoforms which yielded 63.46 mg/L (3.3 ng/107
platelets) for PDE2, 225 mg/L (11.7 ng/107 platelets) for PDE3 and 1359 mg/L
(70.7 ng/107 platelets) for isoform PDE5. The total molar levels are calcu-
lated assuming a platelet volume of 5.2 fL (Eigenthaler et al., 1992). How-
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ever, integrating the experimentally determined concentrations and kinetic
assumptions, simulations from the basic model indicate that the basal levels
of cyclic nucleotides cannot be maintained but are rather rapidly diminished
(Figure 27). Mathematical calculations revealed a cAMP hydrolysis activity
of 1846.1 µM/min for PDE3 isoform (75% of the total activity) and 642.9
µM/min concerning PDE2 (≈ 25% of the total activity).
Figure 27 : Simulated levels of cyclic nucleotides (human platelets) under resting
conditions. Simulated time courses of basal cyclic nucleotide concentrations (cAMP,
cGMP) over a time span of 25 minutes. (A) Experimentally quantified levels of cAMP-
degrading PDE isoforms are assumed compared to calculated PDE concentrations (B)
involving prior knowledge of kinetic constants and PDE turnover (Table 5). Black
circles represent the simulated cAMP levels (y) at distinct time points together with
calculated standard deviation (Gaussian distribution error: 0.10 · y + 0.05 · max(y)).
Red curves denote the simulated model trajectories of cAMP and cGMP. The strong
enzymatic activity of measured PDE concentrations would fail to maintain the basal
levels of cAMP (4 µM) and cGMP (0.4 µM) in platelets. In contrast, they would be
diminished fast. In contrast, the setting of calculated levels of active PDE concen-
trations for model simulation results in a precise reproduction of these basal levels.
Figure modified after Wangorsch et al. (2011).
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In fact, this would entail a total cAMP hydrolysis rate of 2.5 mM/min, which
corresponds to a turnover rate of the entire cAMP pool in the platelet of 625
times per minute. These calculations suggest that not the total amount of
PDE is enzymatically active but the main part of enzymes remains quies-
cent in the resting platelet. Parameter optimization constrained on a con-
stant level of basal cAMP (4 µM) achieved 0.05 mg/l for PDE2 and 2.3 mg/l
for PDE3, respectively, in terms enzymatically active PDE concentrations,
precisely reproducing the cyclic nucleotide levels under resting conditions
(Figure 27). This predicts an in vivo activity of 1.5 µM/min for PDE2 as well
as 6.5 µM/min for PDE3, resulting in a total cAMP hydrolysis activity of 8
µM/min. Hence, either the enzyme activity under in vivo conditions is sig-
nificantly lower compared to the in vitro activity and/or there are substan-
tial amounts of cAMP degrading phosphodiesterases not being catalytically
active. These assumptions are underpinned by the experimental evidence
indicating the compartmentalization of PDE isoforms (Wilson et al., 2008;
Baillie, 2009; Houslay, 2010). Thus, to incorporate all experimental findings,
we extended the model by assuming the equilibrium between the active and
inactive PDE state (Figure 26).
Model Adaption to Anti-platelet Conditions and Validation
After developing and calibrating the basal model of cyclic nucleotide signa-
ling under resting conditions, we extended and adapted it to model path-
way effects of drugs causing elevated cyclic nucleotide levels (anti-platelet
effect). This was accompanied by time-resolved drug stimulation exper-
iments, probing the effect of varying drug doses on the cAMP pathway
branch.
Time Series Data from cAMP elevating Compounds Three indepen-
dent cAMP measurements were quantified per distinct time point and drug
dosage. Phosphodiesterase inhibitors like Milrinone and Cilostamide de-
crease the cAMP degrading action. Inhibition of PDE3 by Milrinone in doses
of 1, 5, 10, 50 and 100 µM, or Cilostamide (0.5, 1, 5, 10, 50 µM) resulted in a
slightly delayed increase in cAMP levels (Figure 28A, B, respectively). Mil-
rinone treatment exerted a larger effect resulting in higher cAMP concen-
trations compared to those induced by administration of comparable doses
of Cilostamide. Other anti-platelet drugs like Forskolin and Iloprost stim-
ulate the cAMP production itself. Stimulation of the prostacyclin receptor
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by Iloprost in doses of 1, 5, 10, 50 and 100 nM (Figure 28C) and an allosteric
activation of ACs by Forskolin (1, 3, 10, 30, 100, 200, 500 µM) evoked a
prompt and pronounced dosage-dependent cAMP increase (Figure 28D).
Stimulation by the stable prostacyclin analog Iloprost thereby led to ele-
vated cAMP plateaus with saturation beyond the administration of a drug
dosage of 50 nM (Figure 28C). Similarly, stimulation by diterpene Forskolin
(500 µM) provokes high cAMP concentrations and a plateau (700 µM cAMP)
after a time span of approximately five minutes (Figure 28D).
Figure 28 : Multi-experiment data fit. cAMP time series: Administration of va-
rying drug doses of cAMP elevating platelet drugs acting as PDE3 inhibitors
(A: Cilostamide, B: Milrinone) and activators of adenylyl cyclase (C: Iloprost, D:
Forskolin) caused increased cAMP levels. Depicted are means of three independent
cAMP measurements (circles) together with the corresponding estimated standard
error of the mean. Model trajectories: Depicted curves reflect predicted model trajec-
tories of the optimized and calibrated ODE models. Models for PDE inhibition and
AC activation were fit simultaneously to all available data (number of data points N
=155) resulting in a significantly good model fit (χ2 = 129.08) by precisely estimating a
set of only 23 model parameters in total. Colors indicate the different shades of drugs.
Figure: Wangorsch et al. (2011).
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Adaption of the Model Structure To incorporate the entire range of time-
resolved data, we iteratively expanded and refined the established basal
model. This was statistically supervised by fitting the resulting models re-
flecting PDE inhibition and AC stimulation simultaneously to all collected
data sets. We therefore modified the formula representing the enzymatic
catalysis mediated via PDE3 by incorporating the kinetics for competitive
inhibition (Figure 29A) as reported in Floreani et al. (2003) for this enzyme.
This results in the observed Michaelis-Menten-like reaction rate:
ν =
Vmax(PDE3) · c(PDE3) · (cAMP)
(1.0 + ui
ki
) ·Km(PDE3) + c(cAMP)
. (4.11)
Here, ui denotes the concentration of the respective PDE inhibitor (Milri-
none, Cilostamide), whereas ki represents the corresponding inhibition con-
stant. These drug-specific constants function in adjusting the apparent Km-
value of the competitively inhibited enzyme.
Figure 29 : Reaction scheme (elevated cAMP conditions). Reaction scheme for
feedback-controlled regulation of cAMP levels with regard to cAMP-elevating treat-
ment (PDE3 inhibition, AC activation). (A) Modeled reactions concerning the inhi-
bition of platelet PDE3 (competitive inhibition via Milrinone and Cilostamide). The
cAMP influx (reaction r1) and cAMP degradation (reaction r2,r7) via active PDE2,
PDE3 (reactions r3-r6) are counterbalancing each other. (B) Modeled reaction con-
cerning the activation of AC via Iloprost and Forskolin. Elevated cAMP levels evoked
by the increased AC activity (reaction r8) are enzymatically degraded (reaction r2,r3)
which is mediated by active platelet PDEs (reactions r4-r7). Figure modified after
Wangorsch et al. (2011).
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To adapt for drug-stimulated AC activation, we introduced additional rates
ν = xForskolin, ν = xIloprost, (4.12)
respectively, representing the increased cAMP formation by adenylyl cy-
clase (Figure 29B). These rates have been estimated locally in a data-based
way for the concentration of both AC activators, Forskolin and Iloprost. De-
tails on the corresponding system of ODEs and rates are given in Annex B.5.
Parameter Optimization by Multi-experiment Fitting We conducted and
evaluated a series of fit sequences by slightly disturbing all variable model
parameters before the model was again adapted to time series. This way, the
optimization process samples over the fitting ranges of unknown parame-
ters chosen according to mean values extracted from literature if possible
or selected a broad range for not limiting the parameter space during fitting
(Annex B.5). Resulting multi-experiment fitting sequences provided us with
χ2 values, indicating the quality of model fits (Table 6).
Table 6 : Model evaluation (feedback loops). We assumed the following competing
hypotheses: H0 - no integrated assumption of feedback loops; H1 - positive feedback
of cAMP-dependent PKA to PDE3 (one additional parameter); H2 - negative feedback
of elevated cAMP levels to AC (one additional parameter); H3 - both assumptions
(H1, H2) are implemented in the mathematical model (two additional parameters).
To evaluate the model under each hypotheses, the χ2-value, number of data points
(N ), number of estimated model parameters (p) and the Akaike information criterion
(AIC) are calculated while fitting to time series data. Table: Wangorsch et al. (2011).
Hypotheses χ2 N p χ2/N AIC
H0 530.19 155 21 3.42 857.04
H1 185.52 155 22 1.2 514.395
H2 133.00 155 22 0.9 461.825
H3 129.08 155 23 0.8328 459.952
This reveals that the adapted model, according to equations 4.11 and 4.12,
could not explain all experimental data (AIC, χ2/N  1).
Statistical Hypothesis Testing and Model Selection Facing this discre-
pancy, we considered two possible regulations to further expand and re-
fine the model: Feedback regulation of the cAMP level is known to be me-
diated through activation of PDE3 and inhibition of AC, which both have
been observed by experiments (Macphee et al., 1988; Iwami et al., 1995;
Murthy et al., 2002; Hunter et al., 2009; Chen et al., 1997). The cAMP-
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dependent mechanism of PDE3 activation is indicated by possible PDE3
phosphorylation at Ser312, a PKA phosphorylation site, which is also re-
ported in PlateletWeb (Boyanova et al., 2012), has shown up in a phophopro-
teomic study of resting human platelets (Zahedi et al., 2008).
We therefore modified the underlying model equations 4.11 and 4.12 by in-
troducing a cAMP-dependent increase of the Vmax value of characterizing
the PDE3 enzyme activity:
Vmaxnew = Vmax(PDE3) + kf1 · c(cAMP). (4.13)
Here, factor kf1 weights the feedback exerted by cAMP resulting in a raised
PDE3 activity. Analogously, we implemented a cAMP-dependent term for
mimicking the AC inhibition in rate equations 4.12 for i = Forskolin and
Iloprost, respectively:
νnew = xi − kf2 · c(cAMP). (4.14)
Feedback constant kf2 adjusts the cAMP-mediated strength of this negative
feedback loop.
Using likelihood ratio tests, we inspected whether both model refinements
are statistically necessary to expand the model structure, thus to explain the
observed data. During this statistical procedure we investigated competing
nested pairs of models (Cox and Hinkley, 1994). The resulting p-values for
testing hypotheses on both feedback loops are listed in Table 7.
We elaborated the following hypotheses: Positive feedback of cAMP-de-
pendent PKA on PDE3 activity is present (H1), negative feedback of PKA
inhibiting the AC activity (H2) or both feedback loops happen simulta-
neously (H3). They were tested against the null hypothesis stating that the
parameter (kf1, kf2) with regard to each feedback loop equals zero (H0),
meaning the feedback regulations are ignored. Although the assumption of
one feedback solely (H1 or H2) enhanced the overall model fit significantly
(p < 0.05), it failed in explaining all time-resolved data simultaneously. Thus,
given a level of significance of 0.05, likelihood ratio tests of nested models
evidenced a significantly better model fit to all data by the inclusion of both
feedback assumptions (H3 vs H2, p = 0.0477; H3 vs H1, p = 5.80·10−14).
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Table 7 : Hypothesis testing. Assuming the level of significance of 0.05, four compe-
ting hypotheses on feedback regulation are tested. For each test scenario, we therefore
conducted the appropriate likelihood ratio test for nested models, based on χ2-values
of resulting model fit sequences (Table 6). This indicates the statistical relevance to se-
lect the model that integrates both additional feedback constants as it thereby explains
all time-resolved data on cAMP elevating drugs. Table: Wangorsch et al. (2011).
Test scenario p-value
H1 versus H0 < 10−15
H2 versus H0 < 10−15
H3 versus H1 5.80 −14
H3 versus H2 0.0477
Hence, we concluded that the inclusion of both feedback regulations statis-
tically led to the most reasonable model structure. The adapted model re-
sulted in model trajectories explaining all data simultaneously (Figure 28A-
D) not differing significantly from the experimental data (χ2/N = 0.8328 <
1; N = 155, number of data points). During the multi-experiment fitting pro-
cedure, a small set of 23 specific parameters were estimated from the data
(Annex B.6, Table 18). The validated in silico model thus reflects pivotal
processes of platelet inhibition and models correctly the experimental drug-
stimulated measurements by considering low effective PDE concentrations,
activation of PDE3 by PKA at increased cAMP levels and the negative feed-
back loop of PKA towards a degraded activity of adenylyl cyclase.
Simulation Studies and Model Predictions
Sensitivity Analysis For investigating the influence of model parameters
on the platelet cAMP signal, indicating the state of inhibition, we analyzed
several characteristics of this inhibitory signal. Results were shown exem-
plified for one PDE3 inhibitor (Cilostamide) and one AC stimulator (Ilo-
prost) indicating that the cAMP signal is mainly controlled by the basal for-
mation of cAMP in case of PDE3 inhibition (low and high dose; Figure 30A,
B). Calculations also revealed that the impact of drug-specific and PDE-
specific constants augments with the increase of the dosage of inhibitory
drugs. For low-dose AC stimulation (Figure 30C), a similar sensitivity pro-
file for parameters can be observed. This is opposed by the high dosage
cage, where particularly the feedback constant kf2 (AC inhibition) gains im-
pact and outweighs the influential effect of basal cAMP formation (Figure
30D). These findings corroborate the crucial role of feedback regulation of
the cyclic nucleotide levels in platelets.
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Figure 30 : Detailed sensitivity analysis (high- and low-dose stimulation). Shown are parameter-dependent effects towards two distinct charac-
teristics of the cAMP signal: Area under Curve (green) as a measure of the overall cAMP signal and Last Value (orange) denoting the magnitude of
the cAMP plateau. PDE inhibition (A, B) and AC activation (C, D) were investigated separately and under low-dose (A, C) as well as high-dose
inhibition (B, D) of the platelet. Control coefficients denote the tendency of the parameter-dependency of the characteristic value evoked by a change
of parameter values. Coefficients indicate the increase of the signal property related to the increased parameter value. Calculating this ratio for
all model parameters results in similar profiles for both signal characteristics per drug concentration. Furthermore, a main sensitivity of the cAMP
signal to the basal formation of cAMP (PDE inhibition) is indicated, whereas the impact of drug- and PDE-specific constants raises with the increase
of inhibitory drug doses. Low-dose AC stimulation (C) yield similar characteristic profiles, however for high-dose stimulation (Iloprost, 100 nM) the
cAMP-dependent feedback constant kf2 (feedback AC inhibition) outweighs the influence of the basal cAMP production (D). Figure modified after
Wangorsch et al. (2011).
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Figure 31 : Sensitivity analysis of feedback constants. Sensitivity on the cAMP sig-
nal with respect to the feedback constants kf1 (feedback activation of PDE3, blue) and
kf2 (feedback inhibition of AC, red, only modeled for AC stimulation conditions).
To investigate strength-sensitive effects, constants were multiplied by factors ran-
ging from 0.1, 0.2, 0.5, 0.9, 1.11, 3 and 5 to 10. Black trajectories represent the effect
on cAMP of the actual (fitted) parameter value (factor 1). Starting from low to high-
dose inhibition of PDE3, simulations show that the variation of kf1 cause cAMP signal
spans ranging from 3 to 5 µM (A, B). Overall, the analysis indicates a high sensitivity
of the cAMP signal to feedback constant kf2 (C, D). Figure modified after Wangorsch
et al. (2011).
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It is equally interesting to investigate the potential effects of the feedback
constants kf1 (equation 4.13) and kf2 (equation 4.14) on the model predic-
tions for the cAMP signal. To highlight this, constants were perturbed (mul-
tiplication with factors ranging from 0.1 to 10) and the corresponding cAMP
signals were plotted (Figure 31A-D). Variation of constant kf1, describing
the feedback activation of PDE3, resulted in cAMP signal spans ranging
from 3 to 5 µM (Figure 31A, B). However, this range widely expanded up to
300 µM (500 µM Forskolin). Even at low concentration (1 nM) of Iloprost (Fi-
gure 31C), the cAMP signal is highly sensitive to perturbations concerning
the AC feedback inhibition (constant kf2). These findings are also reflected
in the model selection procedure (Table 7) which again indicates a subtle
feedback regulation of cAMP levels in platelets.
Prediction of Combined Drug Effects Having established a calibrated
dynamic model on the basis of time-resolved data evoked by four distinct
anti-platelet drugs at varying concentrations, it thus can be applied to pre-
dict and to study drug combination effects in detail. Here, we investigated
the combined effects of PDE3 inhibitors (Milrinone and Cilostamide) and
AC activators (Iloprost and Forskolin).
Explicitly, we experimentally measured cAMP levels caused by the effect
of Iloprost and Cilostamide individually (Cilostamide: 10, 50, 100 µM; Ilo-
prost: 2, 5, 20 nM) as well as the drug response on the cAMP level of all drug
doses in combination (Figure 32A). The resulting cAMP plateaus which
have been experimentally detected and reached for each drug combination
are depicted in Figure 32C (black dots). The bar charts clearly revealed an
over-additive effect of the two drugs when applied in combinations. More-
over, synergistic effects of PDE inhibitors in combination with Iloprost have
been described to occur in human platelets (Nolte et al., 1994; Hanson et al.,
2008; Netherton et al., 2002). We therefore embedded an additional cAMP-
dependent constant k to capture this over-additive effect. Based on this, we
forecast cAMP levels evoked by different drug combinations (Figure 32B-
E): Simultaneous stimulation of AC and inhibition of PDE3 was exemplary
simulated by combining Iloprost (2, 5 and 20 nM) and Milrinone (10, 50 and
200 µM; Figure 32B) or Cilostamide, respectively (Figure 32C). The surface
of cAMP level resulted from interpolating the evoked cAMP plateaus at the
corresponding drug combinations. Its origin marks the basal cAMP level,
whereas each axis denotes the effect of each single drug solely.
96
RESULTS
Figure 32 : Predicted time course and experimentally measured cAMP levels un-
der different combinatory drug conditions. Besides results solely based on model
predictions (B, D, E), panel A and C show experimentally measured cAMP concen-
trations, indicated by black dots. Single effects of Cilostamide (drug doses range: 10,
50, 200 µM ) and those in combination with Iloprost (drug doses range: 2, 5, 20 nM)
on the cAMP level (A): The resulting evoked cAMP signals, depicted as the mean of
triplicate measurements (± SEM), successively rise due to the corresponding elevated
drug doses. Moreover, this shows a clear synergistic effect. 3D-plots depict interpo-
lated cAMP levels (z-axis; cAMP surface) of estimated or experimentally monitored
plateaus of cAMP at various synergistically activating or inhibitory drug in combina-
tion (x- and y-axes): (B) Combination of Iloprost and Milrinone (AC activation, PDE
inhibition); (C) combination of Iloprost and Cilostamide (AC activation, PDE inhibi-
tion); (D) of Forskolin and Milrinone (AC activation, PDE inhibition); (E) of Milrinone
combined with an unspecified inhibitor of AC (PDE and AC inhibition). Dots mark
(C) experimental measured cAMP level (mean) and accordingly predicted cAMP con-
centration levels (B, D, E) evoked after the administration of respective concentrations
and combinations of drugs. See Table 19 (Annex B.7) for further details. Figure: Wan-
gorsch et al. (2011).
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In adaptation to quantitative data of experiments (Cilostamide and Iloprost
combinations), we find the calculated cAMP level surface in close accor-
dance to the measured cAMP concentrations (Figure 32C), resulting in k
= 1.443 ± 0.004. The predicted cAMP levels describe the subsequent ex-
perimental measurements significantly better compared to assuming an ad-
ditive effect of drug combinations (p < 0.05). This indicates a continuous
synergistic effect of Cilostamide and Iloprost interaction potentiating the
respective single drug stimulation (Figure 32A).
Furthermore we simulated combined effects of Forskolin and Milrinone
by predicting cAMP concentrations affected by combining Forskolin drug
doses (10, 30, 100, 200, 500 µM) with Milrinone doses of 10, 50 and 200 µM
(Figure 32D). The resulting surface of cAMP level interpolates calculated
cAMP level plateaus reached due to the distinct drug combination. Ana-
logously, we predicted cAMP levels for the simultaneous inhibition of AC
and PDE3 (Figure 32E) showing the successive decrease of elevated cAMP
levels due to Milrinone (1-100 µM) by combining this PDE3-affecting drug
with several doses of an inhibitor of AC (e.g. 2’5’Dideoxyadenosine; non-
synergistic, k = 1). In addition, several important platelet drugs are given in
Table 19 (Annex B.7), together with their specific parameters which serve as
a basis for modeling and investigating effects of drug combinations.
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Pathway Integration: Prediction of VASP Phosphorylation An impor-
tant downstream effector of cyclic nucleotide signaling is the phosphopro-
tein VASP (Smolenski et al., 1998). It bears two major phosphorylation
sites (Ser157 and Ser239) which both negatively regulate platelet aggrega-
tion down-stream of the cyclic nucleotide cascade. Since this protein is a
major target for both, PKA (cAMP pathway) and PKG (cGMP pathway),
respectively, VASP functions as integrator of input from these inhibitory
pathway branches. It therefore represents a paradigm for complex combi-
nation effects regarding phosphorylation events and its monitoring. Here,
we quantitatively capture the downstream effect on VASP by investigating
phosphorylation events of individual VASP phosphorylation sites (Figure
33).
Figure 33 : Time-resolved and dosage-dependent VASP phosphorylation evoked
by cAMP elevating drugs. Ratios of phosphorylated VASP sites (Ser157, Ser239)
to the total amount of VASP in platelets are experimentally measured after the ad-
ministration of AC stimulator Iloprost in different doses (2 nM, 5 nM, 10 nM). Ratios
are detected at distinct time points, indicated by black circles ± calculated standard
deviation. The experimentally measured cAMP time course (top panel of each row)
serves as model input for simulations. As indicated by data and model curves (red
trajectories), VASP phosphosite Ser157 is phosphorylated prior to Ser239 by cAMP-
dependent PKA . Figure: Wangorsch et al. (2011).
For this, we modeled the differential effect of PKA on both of these phos-
phorylation sites, including the assumption that site Ser157 is a 15-fold bet-
ter substrate for phosphorylation by PKA than the phosphosite Ser239
(cf. Annex B.5). The latter is also targeted by the cGMP-dependent protein
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kinase PKG (Smolenski et al., 1998; Butt et al., 1994). Moreover, this differen-
tial phosphorylation of protein kinase A has to be considered for the read-
out of diagnostic VASP assays (Geiger et al., 2010). Phosphosite-specific
modeling resulted in a good fit to experimental measurements (Figure 33)
allowing again predictions of effects for different drug strengths and com-
binations. However, modeled parameters were highly non-identifiable and
could not be estimated definitively and independently from each other from
the time-resolved data.
Probing Different Time-scales of Drug Stimulation To probe the sig-
naling network sensitivity, we tested and simulated different perturbations
and network cross-linking. We analyzed the model performance by probing
different drug stimuli, e.g. inhibition of PDE2 with EHNA (1, 50, 100 µM)
and PDE3 (Figure 34). Thereby, we varied different time-scales of drug sti-
muli (transient vs. long-term stimulation, concurrent vs. successive stimuli)
and monitored the resulting effect on the cAMP level. Simulations showed
that the network sensitively responds to transient stimuli even at low drug
doses (Figure 34).
Transient Prostacyclin Stimulation Besides transient drug effects, also
a transient prostaglandin receptor activation (Geiger et al., 2010) may oc-
cur under physiological conditions. This receptor is transiently activated by
prostacyclin, having a half-life of less than 5 minutes (Gomberg-Maitland
and Olschewski, 2008)) and being produced by the endothelium. Hence, in
case of an injured vessel wall, some parts of the endothelium remain with-
out prostacyclin production so that only a deficient signal is evoked and
the platelet lacks inhibition. Similarly, patho-physiological conditions such
as prostacyclin receptor mutations (Patrignani et al., 2008; Arehart et al.,
2008) contribute to a differential platelet inhibition resulting in a decreased
protection against unwanted platelet activation and aggregation. We moni-
tored this gradual and transient platelet inhibition due to different prostacy-
clin doses (100, 200, 500nM) experimentally by detecting cAMP-dependent,
time-resolved phosphorylation events on site Ser157 of VASP (Figure 35A).
As Iloprost represents a prostacyclin-analogon, we reused the established
AC inhibition model for model simulations. Instead of Iloprost, the mo-
del was perturbed by driving prostacyclin inputs (sine-pulse) of different
amplitudes. Resulting model trajectories were in close accordance to the
experimentally measured prostacyclin-dependent responses (Figure 35B).
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Figure 34 : Simulations of different time-scales of drug stimuli. (A) Simulation of
continuous inhibition of phosphodisterase 2 with EHNA, a specific inhibitor (as-
sumed ki-value: 0.7µM). Resulting model simulations show in increased cAMP
plateau depending on the respective inhibitor concentration. (C) The stimulation
period of a single transient drug stimulus (EHNA) is mirrored in the model-based
predicted cAMP concentration, depending on the time delay between the stimula-
tive sine pulses. Successive continuous stimuli have additive effects on the resulting
cAMP concentration (B). This holds also if stimulation occurs simultaneously in suc-
cessive transient drug stimuli (D). Additional to drug doses, the signal magnitude
(cAMP level) depends on the time interval between single drug pulses as well, as
exemplified here for pulses of one single or two different PDE inhibitors (Milrinone,
EHNA). Figure: Wangorsch et al. (2011).
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Figure 35 : Probing transient prostacyclin stimuli. (A) Experimentally measured and
(B) simulated responses to transient prostacyclin stimulations of various doses (100
nM, 200 nM and 500 nM). Transient effects on the cAMP level (B) and on the subse-
quent phosphorylation (VASP phosphorylation site Ser157 (A), are monitored. They
increase and are prolonged with augmentation of the respective prostacyclin concen-
tration. Figure: Wangorsch et al. (2011).
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Cross-talk between cAMP and cGMP Signaling Branches Experimental
data and model predictions evidenced that the cAMP signal and response
in human platelets is highly specific. There is no cross-talk to the cGMP
branch of the inhibitory pathway as indicated by the monotonous cGMP
levels while stimulating with cAMP stimulating compounds (Figure 36).
Even at very high cAMP concentrations raising up to the millimolar range
e.g. evoked by extreme AC stimulation by Forskolin (500 µM), the cGMP
concentrations remained almost totally unaffected (Figure 36A, C-D). Sim-
ilarly, PDE3 inhibition by Cilostamide (50 µM) and Milrinone (100 µM) as
well as AC stimulation (Iloprost, 100 nM) exclusively elevate the cAMP pro-
duction (Figure 36B).
Figure 36 : cAMP to cGMP cross-talk. (A) Bar plots depict fold changes (mean of
three measurements ± SEM) of different cyclic nucleotide levels for cGMP (black)
and cAMP (white) evoked by Forskolin stimulation (1-500 µM) with respect to the
corresponding basal cyclic nucleotide levels. Strong stimulation by Forskolin result
in high cAMP levels (A, D), however does not change low cGMP levels (C). Similarly,
comparatively high doses of Cilostamide (50 µM), Milrinone (100 µM) and Iloprost
(100 nM) solely leads to an increase in cAMP levels, leaving cGMP levels unaffected
(B). Figure: Wangorsch et al. (2011).
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Predicted Cross-talk from cGMP to the cAMP Branch In contrast to the
finding that an elevation of platelet cAMP level has no effect on the cGMP
pathway, the converse cross-talk has been described (Schwarz et al., 2001;
Omori and Kotera, 2007; Aktas et al., 2002). It is mainly mediated through
cross-linking of the platelet phosphodiesterases (Figure 37). Cyclic GMP
evokes the activation of PDE2 but is also capable to reduce PDE3 activity,
thereby affecting the cAMP pathway.
Figure 37 : Pathway states and intermediate regulations. Different system nodes
being involved in different cyclic nucleotide pathway stages are depicted: Resting
state (gray nodes), activated cAMP path (yellow) and cGMP path (green) activated by
endothelium-derived relaxing factor (EDRF) like nitric oxide (NO) or by tyrosine ki-
nases and phosphodiesterase type 5 inhibitors. Components which are subsequently
activated due to cGMP-evoked cross-talk are framed in green. Activatory effects (+)
are depicted in green lines, inhibitory effects (-) in red. Figure: Wangorsch et al. (2011).
Therefore, we speculated on the effect of different cGMP concentrations by
incorporating identified PDE interconnections into the model structure. The
monitored cAMP levels are depicted in Figure 38. Predicted time-courses
show that cAMP levels are highly dependent on actual cGMP concentra-
tions in a both, dynamic and dose-dependent manner. Thus, future work
will include the detailed modeling of the cGMP-branch including its cross-
talk to the cAMP-pathway. Currently, time-resolved data concerning the
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cGMP-to-cAMP cross-talk are collected by our collaborating team around
Dr. Stepan Gambaryan at the Institute for Clinical Biochemistry and Patho-
biochemistry. Exemplary, increased cGMP levels are evoked by inhibiting
the cGMP-specific PDE5 in the human platelet. The effects of different doses
of Silendafil, a potent PDE5 inhibitor, are measured quantitatively. The re-
sulting time-series data can be used to train the appropriately extend dy-
namic model against.
Figure 38 : Modeling the potential cross-talk via cGMP. cGMP is known to poten-
tially decrease (via PDE2-stimulation) or enhance (via inhibition of PDE3) cAMP re-
sponses. To model this cGMP-mediated cross-talk effect to PDE, we included two
cGMP-dependent feedback constants (set to 0.1) in the basal model of nucleotide sig-
naling. Assuming an constant additional cGMP stimulus of 30 µM (B), the cAMP con-
centration does not remain at basal level (A) but is increased (C). Thus, model-based
cAMP predictions indicate a higher cGMP-dependency for PDE3 inhibition compared
to PDE2 activation. However, the increase of the feedback constant representing the
cGMP-dependent PDE2 activation (2.5 fold) leads to an intensified degradation of
cAMP (D). Figure: Wangorsch et al. (2011).
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The presented study on mathematically modeling the dynamic, feedback-
regulated inhibitory signaling in human platelets has led to the publication
"Time-resolved in silico modeling of fine-tuned cAMP signaling in plate-
lets: feedback loops, titrated phosphorylations and pharmacological mo-
dulation" (Wangorsch et al., 2011). Besides assembling profound and spe-
cific information about platelet signaling, I established the entire model,
conducted the data-based calibration, model-fitting and statistical testing
and validation. Moreover, I suggested appropriate model-based predictions
and simulations for probing the network sensitivity and strengthening the
application-oriented impact of both, the model and approach.
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4.2 Modeling Inflammatory Signaling
4.2.1 Introduction
Mammalian inflammatory signaling is an exquisite example demonstrating
how cellular signaling pathways can be regulated to produce different yet
specific responses to diverse inflammatory insults. NFκB represents a prin-
cipal transcription factor and inflammatory mediator, whose activation is
evoked by inflammatory signaling (cf. Section 2.1.3). Mathematical mode-
ling with tight links to experiments have been instrumental in unraveling
different forms of regulation in NFκB signaling as well as the underlying
molecular mechanisms (Cheong et al., 2008), e.g. regulatory feedback or
NFκB oscillations. This includes a variety of mathematical models mainly of
the IκB - NFκB signaling module (Carlotti et al., 2000; Hoffmann et al., 2002)
or IKK-focused models (Lipniacki et al., 2004), that are listed and compared
in Cheong et al. (2008). The dynamics of molecular levels such as NFκB
and their regulations are physiologically of immense importance and can
quantitatively captured by mathematical modeling. Within this context, the
exploration of signaling pathways in silico allows the description of how
changes in signaling occur in space and time.
Adding to this, cross-talk between signaling modules and between entire
signaling pathways is a central regulatory issue. Exemplary, NFκB is acti-
vation as a response to numerous inflammatory and non-inflammatory sig-
nals (Hayden and Ghosh, 2004). We here present a mathematical description
of the TNF receptor interplay between TNF-R1 and TNF-R2 (Section 4.2.2).
TNF-R2 influences TNF-R1 signaling by evoking an apoptotic cross-talk and
by triggering a shift in NFκB activation.
Besides a detailed understanding of the down-stream signaling events of
TNF receptors, a profound comprehension of the creation and processing of
transduced signals is of equal importance. Ligand binding on the targeted
receptor, e.g. TNF to TNF-R1, causes a variety of structural changes such
as receptor clustering. Mathematical modeling sustains the identification of
receptor properties determining the processing of ligand-encoded informa-
tion (Becker et al., 2010). We show here first results of such a mathematical
rule-base model on receptor cluster formation (Section 4.2.3).
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4.2.2 Cross-talk Model of Inflammatory Signaling Pathways
TNF Receptor Cross-talk An interesting feature of the TNF-R1 and as-
sociated signaling events is the existence of extensive signaling cross-talk.
This includes receptor signaling mediated by members of the TNF-receptor
superfamily (Naudé et al., 2011; Nakayama et al., 2002) and other receptor
types (Beyer and MacBeath, 2012). With respect to inflammatory signaling,
this mainly affects the differential activation of the transcription factor NFκB
(Oeckinghaus et al., 2011), being a critical regulator of immunity, stress re-
sponses, apoptosis and differentiation.
In the following, we focus on the interplay of TNF-R1 and TNF-R2 : The
distinct signaling pathways initiated by TNF-R1 and TNF-R2 stimulation
can mutually influence each other via signaling cross-talk (Figure 39). This
maintains a delicate balance between cell survival and apoptosis (Thakar
et al., 2006; Wajant, 2011; Wicovsky et al., 2009b,a).
Figure 39 : Apoptotic cross-talk. Signaling outcome of TNF-R1 is influenced by co-
and prestimulation of TNF-R2, respectively, in a time-dependent manner. Signaling
due to exclusive stimulation of TNF-R1 (A) is slightly shifted towards apoptosis if
TNF-R2 is stimulated simultaneously (C). Prestimulation effects reduced NFκB sig-
naling accompanied with a strong shift towards apoptosis (B). Figure: Modified after
Fotin-Mleczek et al. (2002).
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However, the molecular basis for the mutual interplay of these TNF recep-
tors with the apoptotic pathway and the signaling cascades that lead to ac-
tivation of NFκB is not fully understood. This pertains to the cross-talk in
NFκB signaling pathways (Oeckinghaus et al., 2011) and to the direct cross-
talk between both receptors (Cabal-Hierro and Lazo, 2012; Naudé et al.,
2011). This emphasizes the need to set up mathematical models and in silico
descriptions of signaling networks as a first step to better understand and
predict cellular behavior in complex signaling settings.
In recent years, several signaling proteins have been identified for being
capable to interact either directly or indirectly with domains of both recep-
tors. Regarding the question of TNF receptor cross-talk, the TNF receptor-
associated factor (TRAF)1 and 2 (Fotin-Mleczek et al., 2004; Wajant and
Scheurich, 2001; Wicovsky et al., 2009a), as well as the cellular inhibitor
of apoptosis proteins (cIAPs) are of special interest (Wajant, 2011). These
adaptor proteins are suggested to form critical integration points for pro-
and anti-apoptotic signals (Fotin-Mleczek et al., 2002). The balance between
anti-apoptotic (TRAF1/TRAF2/cIAP1/cIAP2) complexes and proapoptotic
(FADD/caspase-8) complexes being recruited to TNF-R1 might determine
the signal transduction pathways activated through TNF-R1. This in turn
induces either gene expression or apoptosis. Hence, these regulatory pro-
teins make up potential targets for therapeutic intervention, e.g. in anti-
cancer therapy (de Almagro and Vucic, 2012) or myocardial infarction (Schulz
and Heusch, 2009).
Multi-valued Boolean Model Deciphering this molecular puzzle will
greatly help to interpret the cause of specific outcome of TNF receptor sig-
naling in distinct biological contexts. Approaching this issue, we developed
a multi-valued Boolean model of TNF-R1 and TNF-R2 cross-talk that com-
prises signaling events as depicted in Figure 40.
We used the CellNetAnalyzer, for implementing the underlying logical con-
nectivity between signaling nodes. Thereby we could capture two main
features of the signaling cross-talk, (i) the stepwise apoptotic cross-talk ef-
fect regarding the different stimulatory scenarios (cf. Figure 39A-C) as well
as (ii) the time-dependent component. A binary Boolean approach would
have failed in modeling the multi-step apoptotic cross-talk effect, as nodes
are assigned by just two values, either 1 (on) or 0 (off).
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Figure 40 : Network topology of TNF receptor cross-talk. Components that can
physically be detected in the immunoprecipitates of TNF-R1 and TNF-R2, respec-
tively, are depicted in green and yellow. Cytoplasmatic components are depicted in
white. Gray box: TNF-R1- induced complex activating caspase8. Arrow thickness
reflects its functional effect. Currently, a regulatory connectivity between the alterna-
tive NFκB pathway and cell death is not known. Therefore, it is just modeled as one
single black box. Secondary processes resulting from NFκB activation are depicted
with dashed lines. The activation of effector caspases through caspase8 is divided in
a BH3 interacting-domain death agonist (BID)-dependent and direct activation. The
activatory pathway via BID however is only relevant in cell having an abundance of
X-linked inhibitor of apoptosis proteins (XIAPs). TNF-R1 mediates the activation of
caspase8 in a RIP-independent and RIP-dependent manner. The latter is inhibited
by k63-ubiquitinated NEMO which is of equal importance for NFκB signaling. A20
und Cyld are induced by NFκB and prevent the ubiquitination of NEMO via LUBAC.
This way, NFκB is inhibited but the RIP-dependent caspase8 activation is sensitized.
NFκB-induced FLIP inhibits both, the RIP-independent and the RIP-dependent path-
way. The inhibition of NFκB signal transduction is indicated by blocking the p65-p50
activation.
Model development occurred in three steps. First we set up the reactions for
the distinct pathways (TNF-R1, TNF-R2) separately. Therefore, we defined
TNF-R1 and TNF-R2 stimuli (cf. Table 20, Reaction 27, 28) that specifically
activate the distinct receptors. TNF in general would result in the activation
of both receptor types and thus can serve for modeling the costimulation
condition. Finally, the prestimulation condition was realized by setting a
so-called ’time scale scenario’ in CellNetAnalyzer that assures the update of
logical reactions at a given, pre-defined time point. We assumed that first,
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signaling molecules that protect from apoptosis are engaged in TNF-R2 sig-
naling (costimulation), shifting TNF-R1 signaling slightly to apoptosis. Af-
ter prestimulation, this effect is intensified and shifts TNF-R1-mediated sig-
naling strongly towards apoptosis. Additionally, prestimulatory TNF-R2
signaling and the thereby evoked gene expression affects and lowers the
the TNF-R1-triggered NFκB activation. Details on the implemented reac-
tions are given in Table 20 (Annex C).
Model Simulations Simulation of the implemented logical model could
precisely describe the differential NFκB activation as well as the apoptotic
cross-talk (Figure 39). Table 8 summarizes the resulting activation values
(NFκB, apoptosis) according to the different receptor activation scenarios.
Values are in close accordance to those that were experimentally observed
and previously reported by Fotin-Mleczek et al. (2002).
Table 8 : Simulations of multi-valued Boolean model with repect to different recep-
tor activation. Scenario 1: TNF-R1 solely; apoptosis: 1, NFκB: 3.Scenario 2: TNF-R2
solely; apoptosis: 0, NFκB: 1. Scenario 3: Costimulation; apoptosis: 3, NFκB: 3. Sce-
nario 4: Prestimulation of TNF-R2; apoptosis: 5, NFκB: 1. Underlying reactions are
given in Table 20 (Annex C).
Scenario TNF-R1 stimulus TNF-R2 stimulus apoptosis NFκB
Scenario 1 1 0 1 3
Scenario 2 0 1 0 1
Scenario 3 1 1 3 3
Scenario 4 1 1 5 1
The established multi-valued Boolean model can serve as a basis for semi-
quantitative model simulations and allows the testing of hypotheses on re-
gulatory questions. Ultimately, model development is extend to quantita-
tively describe the full dynamics of the mutual receptor cross-talk as more
detailed time series data for model calibration are available. Data collection
and model validation is realized in cooperation with Prof. Wajant (Division
of Molecular Internal Medicine, Department of Internal Medicine II, Uni-
versity Hospital Würzburg). Current findings together with data-driven
model extensions and predictions will result in a systems biological publi-
cation which is currently in preparation.
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4.2.3 Clustering of TNF Receptors: A Rule-based Approach
Differential Binding Tumor necrosis factor (TNF) exists as a homo-tri-
meric molecule that is able to bind up to three moldecules of receptors be-
longing the TNF receptor superfamily (Smith and Baglioni, 1987; Bazzoni
and Beutler, 1996). This implies differential binding characteristics of TNF
receptor type 1 (TNF-R1) and type 2 (TNF-R2). Different oligomerization
states, in particular trimers of receptor or ligand, modify the binding be-
havior (Boschert et al., 2010). The affinity of soluble TNF binding to TNF-R1
(dissociation constant KD = 1.9 · 10−11 M) is remarkably high, compared to
the significantly lower affinity for TNF-R2 (KD = 4.2 · 10−10 M) (Grell et al.,
1998). Besides the causal link to association-dissociation kinetics, the insuf-
ficient induction of strong signaling via TNF-R2 by TNFs has been linked to
the capability of TNF to form larger and stable signaling clusters (Krippner-
Heidenreich et al., 2002).
On the molecular level, the so-called pre-ligand binding assembly domain
(PLAD) is critical for cluster formation. Like other receptors of the TNF
superfamily, the structure of TNF-R1 contains a PLAD, facilitating the oli-
gomerization prior to ligand binding. Thus, this enables a fast signal proces-
sing and transduction (Heidbreder et al., 2012; Chan et al., 2000). These data
explain the predominant role of TNF-R1 in mediating cellular responses by
TNFs and indicate stable TNF-TNF receptor complexes as plausible cause
for differential signaling efficacy. This is particulary important to allow ac-
tivation of different cell physiological responses such as inflammatory re-
sponse or apoptosis (Ho and Harrington, 2010).
Models of Receptor Cluster Formation To identify the molecular basis
of this differential binding behavior, binding studies including TNF-R1 and
TNF-R2 were carried out by our experimental collaborators (Prof. Harald
Wajant). Previous studies and experimental data has led us to different mo-
dels, explaining the differential behavior of TNF in binding to both receptor
types (Figure 41).
We compare and model here the behavior of TNF-R1 and TNF-R2 with
respect to signal formation at the respective receptor. TNF-R1 activation
works already with interacting monomers (receptor, ligand) while TNF-R2
relies on trimer formation (Chan et al., 2000; Mukai et al., 2010). Indeed,
experiments showed that preclustering of TNF-R2 monomers increased the
affinity for the TNF-homotrimer in comparison with the receptor monomer.
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Figure 41 : TNF receptor clustering. Model assumptions for differential binding be-
havior of TNF to TNF-R1 and TNF-R2, respectively. TNF trimers, hexamers are de-
picted in yellow, distinct receptor conformations in blue.
Moreover, stimulation with a hexameric ligand resulted in a stronger signa-
ling response as well, indicating that this conditions also prefers the trimeric
receptor conformation. Differential receptor clustering in small or large ag-
gregates, hence the creation of graded down-stream signal strengths, repre-
sents a manipulative and therefore attractive aspect in cell signaling. Thus,
testing of different hypotheses experimentally as well as in silico is valuable
for understanding both, the formation of clusters and their role in signal
creation and down-stream signaling.
Rule-based Modeling I applied the rule-based approach to model the
multivalent ligand-receptor interactions. As introduced in Section 3.5, this
approach appropriately captures structural information about signaling mo-
lecules and interactions thereof. Using the rule-based approach, a receptor
can be expressed as a molecule comprising three different binding sites, one
for the ligand and two for receptors to accomplish the clustering (Figure
42A,B).
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Concerning receptor-ligand interactions, these sites are assigned with affi-
nity values (ki), characterizing the modeled reactions and leading to diffe-
rent cluster sizes, according to the given interaction strengths. This way, all
combinations of receptor-ligand configurations can be considered. More-
over, screening over a broad range of affinity values indicate how strong
the resulting signal would be generated. This is reflected in the cluster-size
that result from simulating the implemented rules. The process of cluster
formation is mainly accomplished in three steps: Receptor-ligand binding,
further receptor cross-linking and dissociation (Figure 42B).
Figure 42 : Rule-based moldes of receptor clustering. (A) Assumed cases: combina-
tions of different receptor-ligand conformations. (B) Exemplarly, rules in BioNetGen
language (three steps of cluster formation) for simulating case 1. Coefficients ki cha-
racterize the development of connecting receptor R() and ligand L() molecules.
Executing the formulated rules (BioNetGen language) with RuleBender (Xu
et al., 2011a), we could indeed show that the stronger the ligand-receptor
initial affinity, the greater the resulting cluster size. These preliminary re-
sults indicate that modeling is an appropriate method to capture and to
study receptor-ligand interactions in more detail. As soon as model refine-
ments and the training against experimental data is perfected, the study can
be adapted to other clustering systems such as the Fas receptor (Stel et al.,
2007). The achieved systems biological view (data and model) on the dif-
ferential ligand-receptor binding behavior is furthermore beneficial to test
how cluster formation and signaling can be perturbed in the sense of phar-
macological interventions.
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4.3 Modeling Cell Signaling in Different Cell Types
4.3.1 Introduction
Concepts of mathematical modeling the signal transduction through cells
are omnipresent in supporting biological and biomedical research. This
ranges from pharmacological and clinically-driven applications to those that
are related with the so-called "green systems biology" (Weckwerth, 2011) fo-
cusing on the systemic understanding of plants and the ecosystem.
Cell signaling models of different cell types to which I contributed are in-
troduced in the following. Protein-protein interaction (PPI) networks com-
bine experimental observations and give first hints for analyzing informa-
tion flow in biological networks. In Section 4.3.2 we present such a PPI
network that shows the shifted balance between proliferation and apopto-
sis for TWEAK-treated cardiomyocytes. With respect to green systems bio-
logy, I contributed to the development of a Boolean model for mimicking
plant-pathogen interactions in Arabidopsis (Section 4.3.3). Furthermore, we
succeeded in integrating different Boolean models of hepatocyte signaling
(Section 4.3.4), a technique which enables the extension and combination of
already existing models to enlarge possible model simulation applications
and advance biological insights.
4.3.2 Heart Cells and Cardiovascular System
Inflammation and Cardiac Damage Collaborators associated with the
SFB688 (Prof. Frantz, University Hospital Würzburg) currently investigate
the regulatory and causal connection between inflammation and cardiac
damage. The interaction of inflammatory cells e.g. macrophages and neu-
trophils on the one hand, and of non-inflammatory cells such as fibroblast
or cardiomyocytes on the other hand is tightly regulated by paracrine fac-
tors. These factors play a key role in cardiac healing as well as in cell re-
sponses to injury. Inflammatory mediators regulate involved cell- cell in-
teractions, however, their role in cardiac injury is not yet fully understood.
Cytokines, macrophages and neutrophils are among others all part of the
so called innate immune response. This indicates that the activation of the
innate immune system may play an important role for regulating cell-cell-
interactions after cardiac injury (Linde et al., 2007). Activation of inflam-
matory cytokines, e.g. TNF, interleukins or TWEAK, was reported to be in-
volved in experimental and human heart failure (Aukrust et al., 2005; Anker
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and von Haehling, 2004). Furthermore, they all share the downstream ac-
tivation of the transcription factors such as NFκB, that is activated in heart
failure (Frantz et al., 2003). Consecutively, investigation of the cell specific
role and regulation of NFκB in cardiac myocytes and inflammatory cells in
cardiac ischemic injury is of major clinical importance.
TWEAK-induced Effects The TNF like weak inducer of apoptosis tightly
regulates NFκB activation that in turn controls the expression of different
proinflammatory cytokines and chemokines. Moreover, the TWEAK/Fn14-
system affects cardiac remodeling (Ren and Sui, 2012). Our collaborators
have established a mouse in vivo-model of myocardial ischemia reperfusion
to study the effects of TWEAK treatment and its connection to myocardial
infarction. Studies revealed that TWEAK affects the infarct size after is-
chemia reperfusion as well as the distribution of immune cells e.g. leuko-
cytes in scar cell and raises the occurrence of ruptures (data in the process
of being published by Prof. Frantz et al.). Moreover, a statistical evaluation
of a cytokine array indicates the upregulation of genes being important for
recruitment (namely MIP2, MCP-1 and MCP-5) and differentiation of leuko-
cytes (IL-5, IL-12 and IFNγ) upon TWEAK treatment.
Data Integration For further evaluation and analysis, cytokine array data
were mapped on the interactome. The human interactome network inclu-
ding kinases and phosphorylation substrate information was established for
the cardiomyocyte as described previously for the platelet (Boyanova et al.,
2012). Briefly, different proteome and transcriptome databases were collated
regarding protein nodes with expression evidence in the cardiomyocyte.
This generates an integrative protein-protein interaction-network focused
on the global view of involved signaling cascades and their connectivity (Fi-
gure 43). Gray lines indicate protein-protein interactions, red arrows denote
phosphorylation reactions. Short gene names are given for each node (pro-
tein nodes are shown as circles except kinases which are shown as triangles).
Green-labeled proteins indicate upregulation in the TWEAK condition.
Functional clusters denote interleukins and chemokine pathways and en-
tities, connected by the JAK/STAT pathway (Subramaniam et al., 2001),
that is stimulated by a variety of chemokines, growth factors or hormones.
TWEAK stimulation interacts with the TNF pathways, thereby potentially
changing the balance between proliferation and apoptosis. Links to the cy-
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tokines and JAK/STAT pathway are given by NFκB and Rac1 (Figure 43).
In summary, the shifted balance between proliferation and apoptosis for
TWEAK and TWEAK inhibition leads to changes transmitted by the inter-
actome regarding a number of interleukins and chemokines. These findings
could not have been observed from the data alone and may be beneficial to
create further experiments for elucidating the connection between inflam-
mation and cardiac damage.
Figure 43 : Protein-protein interaction network. The protein-protein interaction net-
work shows the shifted balance between proliferation (green cloud) and apoptosis
(red cloud) and functional context for TWEAK stimulation and TWEAK inhibition.
Circles indicate proteins; kinases are depicted in triangular shape, each specified by
gene names. They are connected either by gray lines indicating protein-protein inter-
actions or red arrows denoting phosphorylation reactions. The functional entities are
highlighted (interleukins, chemokines, JAK/STAT pathway). Green-colored nodes
show upregulation in the TWEAK stimulation (orange) condition.
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4.3.3 Modeling Arabidopsis Immune Response
Phytohormones and Signaling Molecular genetic studies and the com-
pletion of the sequencing of the Arabidopsis thaliana genome have enormous-
ly increased the knowledge of hormonal regulation in plants within the last
two decades. This advanced the research on plant signal transduction and
gene regulation, however, the understanding of the complex interplay and
pathway regulation is yet not fully understood. Thereby, mathematical mo-
deling represents a valuable tool for investigating the pathway dynamics
and cross-talks particularly in cases that are not accessible by experiments.
Plant development and immunity is tightly coordinated by plant hormones.
Plant immune networks and the ultimate phenotype are often critically de-
termined by small molecules with hormonal properties such as salicylic acid
(SA), jasmonic acid (JA), auxin (Aux), ethylene (ET), gibberellic acid (GA),
abscisic acid (ABA), and various cytokinins (CK) (Robert-Seilaniantz et al.,
2011). The mediated signaling cascades are highly inter-linked (Gazzarrini
and McCourt, 2003), maintaining the physiological equilibrium in the plant.
Especially the cross-talk regarding auxin and cytokinin (Moubayidin et al.,
2009) and the auxin-cytokinin antagonism is important for both, plant de-
velopment and immunity (Naseem and Dandekar, 2012). Pathogens, e.g.
Pseudomonas syringae pv tomato DC3000 (Pst) that attack the plant enhance
host susceptibility by modulating the hormonal balance of the plant cell.
This involves cytokinin but its detailed function concerning plant immu-
nity remains to be fully unraveled.
Outline We here present a mathematical model addressing plant immu-
nity in Arabidopsis, the model system in green systems biology. Based on
extensive data mining, including pathogenicity factors, host regulatory pro-
teins, enzymes of hormone biosynthesis, and signaling components, we set
up an integrated signaling network (Naseem et al., 2012). Dynamic simu-
lations and system analysis elucidated the regulatory role of cytokinin and
revealed multiple cytokinin-mediated regulatory interactions within plant
disease networks. This comprises specific synergism between cytokinin and
salicylic acid pathways as well as novel aspects of the antagonistic rela-
tion between cytokinin and auxin in plant immunity. Subsequently con-
ducted experiments confirmed the model-based predicted interactions and
hormonal effects on plant immunity.
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Model Topology and Set-up Taking extensive a priori knowledege of hor-
monal cross-talks in plant signaling and inter-linkage with pathogen Pst
into account, we set up a comprehensive integrative Boolean model of 105
nodes and 163 edges (Figure 44). It includes biosynthetic pathways of phy-
tohormones with defense signaling, immunologically important receptors,
transcription factors, repressor molecules and degradative complexes.
Figure 44 : Network topology of Pst-mediated hormone disease networks in Ara-
bidopsis. Nodes are inter-linked based either on activation (→) or inhibition ( |).
Color coding of nodes: light blue, enzymes of hormone biosynthesis and degra-
dation; yellow, active plant hormones; green, host regulatory factors; red, Pst-
evoked pathogenicity factors responsible for triggering immunity in Arabidopsis;
white, pathogenesis-related protein 1 (PR1), a marker for immunity against the in-
fection of Pst in Arabidopsis. See original publication (Naseem et al., 2012) for full
names, internodal interactions and literature on the behavior of these interactions.
Figure modified after Naseem et al. (2012).
Transforming this literature-based model into a dynamic system using
SQUAD (Di Cara et al., 2007), it serves for simulating and investigating va-
rious aspects of plant immunity. We applied the dynamic approach, as it is
the collective time-dependent dynamic of hormonal effects during infection
that determines the outcome of plant-pathogen interactions (Bari and Jones,
2009; Robert-Seilaniantz et al., 2007). Our focus lies on elucidating the role
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and impact of cytokinin. It’s role has not been assigned a conclusive role
in plant pathogen interaction, however, several pathogens pattern the cy-
tokinin secreting capability in plants (Walters and McRoberts, 2006; Pertry
et al., 2009). Moreover, cytokinin has been shown to promote resistance in
Arabidopsis thaliana to Pst infection (Choi et al., 2010). Hence, it is plausible
that cytokinin signaling has multiple interaction possibilities with respect to
plant pathogen immune networks.
Using dynamic simulations of the established logically connected network,
we elucidate the complex network interactions around plant immunity af-
ter pathogen attack. Main results gained from dynamic simulations are pre-
sented in the following. More detailed results including micro array experi-
ments can be found in Naseem et al. (2012)
Pst Infection To assess the dynamic behavior of nodes across the net-
work, we first considered and modeled the effect triggered by plant infec-
tion with pathogen Pst (Figure 45).
Plant receptors are instrumental in the recognition of pathogen-associated
molecular patterns (PAMPs) and effectors (Figure 44, red nodes) that evoke
changes in system states of the plant cell. Dynamic simulations of Pst infec-
tion denoted the resulting activation states for individual nodes across the
whole network (Figure 45). Our dynamic model for Pst infection showed ac-
tivation of SA, JA, ET, ABA, and auxin, whereas GA and cytokinin remained
unaffected. Furthermore, immunity can be understood as the sum of va-
rious components such as PAMP-triggered immunity (PTI) and effector-
triggered immunity (ETI) (Jones and Dangl, 2006). Modeling of both forms
showed a clear distinction of the corresponding activation patterns with re-
spect to each type of plant immunity and in accordance with current litera-
ture (Naseem et al., 2012).
Hormonal and Cytokinin Cross-talk As demonstrated, plant hormones
are differentially engaged in plant infection evoked by Pst. To model and
simulate the hormonal impact on plant immunity, we performed SQUAD
simulations by assuming the individual hormones as input nodes while
distinguishing between Pst presence or absence, respectively. The route of
the injected signal can be followed through the network gates reaching the
marker node PR1 (Figure 44, white node) that reflects the resulting immuno-
logical response of the host plant (Mukhtar et al., 2011).
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Figure 45 : Effects of pathogen Pst on components of plant immunity. Pst is as-
sumed to be fully active (activation value of 1.0 for simulations, red-dashed line). The
dynamic simulation using SQUAD assigns activation states (response curves) to each
network node within the assembled network (Figure 44). X-axis: arbitrary units of
time (SQUAD simulations are carried out in 12.5 time steps). Y-axis: activation states
ranging from no (0) to full (1) activation. Each trajectory represents the response curve
of one distinct network node, differentiated by color-codes and line-styles. Full names
are given in the supplement of the original publication of Naseem et al. (2012). Figure
modified after Naseem et al. (2012).
The activation of PR1 over time was used as an index of plant immunity as a
result of different hormone-pathogen inputs, depicted in Figure 46. Simula-
tions indicated three hormones ET, SA, and GA that activate PR1 in contrast
to JA, ABA, and auxin (Figure 46A, left panel). Interestingly, SA and GA
further enhanced the signal strength of PR1-activity in the presence of Pst
(Figure 46A, right panel). This sustains the fact that unlike the promoting
effect of SA and GA on immunity, auxin, JA, and ABA mediate the sus-
ceptibility of Arabidopsis against Pst-evoked infection. The phytohormone
cytokinin thereby seems to have multi-faceted effects on signaling in plant
diseases. Regarding their connection to the SA-JA/ET backbone of plant
immunity, positive cross-talk between cytokinin and the SA pathway was
found (Choi et al., 2010) but also negative cross-talk among them (Argueso
et al., 2012). Our own observations from both experiments and modeling in-
trigued us to investigate the specific cross-talk by cytokinin as this seemed
to enhance immunity in plants (Figure 46B).
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Figure 46 : Impact of plant hormones on the pathogenicity of Pst. (A) Plant hor-
mones change the immunity of the host which can be monitored by PR1. Activation
states of PR1 over arbitrary units of time are shown in form of a heat map for plant
hormones with (right panel) and without (left panel) the infection of Pst. (B) Impact of
cytokinin and auxin regarding the infection by Pst in Arabidopsis monitored by PR1.
Y-axis (left): Activation states of combined input signals or Pst infection alone (red
line with black dots), with cytokinin (green line with red dots) and with auxin (black
line with red dots). Y- axis (right): activity of read-out node PR1 as resonse to Pst (red
curve), Pst with cytokinin (green curve), and Pst with auxin (black curve). X-axis:
arbitrary units of simulation time. Figure modified after Naseem et al. (2012).
Assuming Pst as input together with cytokinin (modeling the increased cy-
tokinin status of the plant during pathogen infection), SQUAD analysis re-
sulted in the activation of nodes including PR1 (Figure 46B). Subsequent si-
mulations also highlighted that cytokinin solely (without Pst) is capable to
cause the activation of PR1 and hence promote plant immunity. Modeling
predictions could nicely be verified by experiments, showing that enhanced
plant cytokinin levels boost immunity against infection of Pst.
Analogously, modeling and experimental data substantiate that the inter-
action between cytokinin and SA is down-stream of SA biosynthesis, while
increased SA levels only fortify the cytokinin-mediated system state with
more extensive protection against infection with Pst (Naseem et al., 2012).
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Similarly, by modeling and experiments we could show and sustain the im-
portance of cytokinin in promoting PTI.
Auxin-Cytokinin Behavior and Interaction Both, auxin and cytokinin
have long been known to be involved in plant growth and development
(Liu et al., 2010). On the one hand, auxin promotes Arabidopsis susceptibili-
ty to infection with Pst via multiple cross-talk with JA and SA, respectively
(Navarro et al., 2006; Chen et al., 2007; Wang et al., 2007a; Llorente et al.,
2008). On the other hand, cytokinin boosts plant immunity against Pst (Fi-
gure 46). In contrast to their individual roles, the combined effect of auxin
and cytokinin in plant immunity is still not entirely known.
To investigate the interplay more closely, we modeled the combined ef-
fects of auxin and cytokinin on plant immunity, choosing various input
activation values (partial and full activation) for auxin and cytokinin in-
put nodes. Resulting dynamic simulations provided further insights into
the contrasting behavior of auxin and cytokinin in plant immunity and into
auxin-cytokinin interactions. Partially and fully activated nodes of auxin
and cytokinin as combinatory input signal changed the system states across
the entire network (Naseem et al., 2012). Again, we monitored the activa-
tion course of marker node PR1 as an indicator of immunity status. Re-
sulting time-resolved trajectories for each hormonal combination are de-
picted in Figure 47A. Simulations revealed that effects on PR1 activity are
opposed, depending of the auxin-to-cytokinin ratio: High input activation
value of auxin (1.0) and a low value of cytokinin activation (0.5) resulted in
low PR1 activity, whereas PR1 gained more activation if the input combina-
tion was reversed (Figure 47A). We sampled and combed different activa-
tion values for both, auxin and cytokinin. Resulting effects on the PR1-level
are depicted as 3D-visualization of the data (Figure 47B). This provides an
overview and shows that the auxin-to-cytokinin ratio is crucial for activa-
tion of PR1. More precisely, immunity is compromised if auxin supersedes
the activation of cytokinin, and immunity is achieved when cytokinin at-
tains higher activation in comparison to auxin.
123
4.3 Modeling Cell Signaling in Different Cell Types
Figure 47 : The Interaction between Auxin and Cytokinin Modulates Plant Immu-
nity. (A) SQUAD analysis on the balance between auxin-to-cytokinin (CK) ratio and
evoked plant immunity. Top panel: Auxin was partially activated (activation value:
0.5), while cytokinin was assumed fully activated (activation value: 1.0). Bottom
panel: Reversed case. Auxin was assumed to be fully activate (activation value: 1.0)
whereas cytokinin only to a partial degree (activation value 0.5). The triggered ef-
fect on plant system states (key network nodes) is shown concerned to the left y-axis,
while immunity in terms of the activity of marker node PR1 (blue curve), with a sca-
ling that belongs to the right y-axis. (B) 3D-visualization of auxin/cytokinin balance
and effects on PR1 activation. X-axis: activation values of cytokinin. Y-axis: activation
values of auxin. Z-axis: depicts the activation of PR1 at a given auxin-cytokinin input.
Figure modified after Naseem et al. (2012).
The entire systems biological study on networking hormones in plan immu-
nity, together with detailed information about experimental data resulted
in the comprehensive publication "Integrated Systems View on Networking
by Hormones in Arabidopsis Immunity Reveals Multiple Crosstalk for Cy-
tokinin" (Naseem et al., 2012). My main scientific contributions to this study
include the establishment and adaptation of the applied method of Boolean
modeling together with dynamic transformation as well as the subsequent
interpretation ans visualization of the resulting model simulations.
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4.3.4 Hepatocyte Signal Transduction
Systemic Understanding of Liver Functions Biomedical-driven mathe-
matical modeling of cells and their functions aims at understanding the
physiological regulatory processes on the molecular, cellular and ultimately
on the organ level. This directs at a systemic comprehension of organ func-
tion in normal and diseased states. The liver represents a prime example
of bringing these levels together. There is a comprehensive network of Ger-
man and international research groups actually working on the Virtual Liver
(http://www.virtual-liver.de), a dynamic mathematical model rep-
resenting, rather than fully replicating human liver physiology, morphol-
ogy and functions. Several models of liver pathways based on different
modeling techniques have already been set up (Philippi et al., 2009; Schlat-
ter et al., 2009; Saez-Rodriguez et al., 2011; Meyer et al., 2012), however,
the crucial task is to combine these sub-models into a multi-scale models of
liver signaling and function. The work of Krauss et al. (2012) is a recently
published example of such a multi-scale model of hepatocyte signaling al-
lowing the quantitative description of metabolic behavior in the context of
time-resolved metabolite concentration profiles in the body and in the sur-
rounding liver tissue. Huard et al. (2012) established a large-scale integrated
logical model connecting multiple signaling pathways and the cell cycle in
hepatocytes.
Integration of Boolean Models Following this integrative aspect, we
here demonstrate the coupling of two logical models of different hepatic
cell types for describing their interaction. However, for a direct combina-
tion of two mathematical models a compatible modeling approach is indis-
pensable. Combination of Boolean models that describe different aspects
of the same system is less complex compared the ODE-based model inte-
gration, although not trivial. Consistent modeling standards are required
for successful combination of Boolean models, independent of the mode-
ling tool. To encourage model convergence towards a more comprehensive
overall Boolean model, we proposed conventions on node values, quantita-
tive experimental data, time, input and output as well as on unknown com-
ponents as detailed in our original paper (Schlatter et al., 2011). We applied
the model integration strategy for the liver cell and its cell-cell interactions
as exemplified in the following. Cell-type specific SBML models were set up
with CellDesigner Version 3.5.1 and their interplay analyzed using SQUAD.
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Modeling Cell-Cell Interaction The liver is a multi-cellular organ, com-
prising hepatocytes and Kupffer cells (Bouwens et al., 1992) among other
cell types. We demonstrate here the direct unification of Boolean models of
both these cell types by considering aspects of their inter-cellular interaction
(Figure 48).
Figure 48 : Topology of the cell-cell interaction network. Hepatocyte-related signa-
ling pathways (apoptosis, proliferation and survival pathways) are shown on the top.
Pathways related to the Kupffer cell are shown on the bottom. Two interactions (TNF,
IL-6) manifest the inter-cellular interplay connecting both cell types. (Schlatter et al.,
2011)
The integrated model was set up on the basis of a mathematical logically
connected model, published earlier by our group (Philippi et al., 2009), that
models Fas ligand (FasL)-mediated apoptosis in liver cells. SQUAD-based
sampling over different network states identified four robust and stable sys-
tem states including cell survival and apoptosis. Moreover, the model repro-
duced a number of different conditions around apoptosis involving effects
of different growth substrates and viral infections.
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First, the signaling of both hepatic cell types was described by a similar
model of the FasL, TNF and IL-6 signaling cascades. Thereby, we focused
on the Fas-mediated extrinsic apoptotic pathway, the survival pathway that
is correlated to NFκB and on the Ras-/MAPK-triggered proliferative path-
way. Concerning cell-cell interaction, the integrated model considers two
connecting pathways between hepatocytes and Kupffer cells. On the one
hand, the activation of NFκB in Kupffer cells goes along with a secretion
of IL-6, that itself binds and activates the corresponding IL-6 receptor in
hepatocytes. Subsequently, this evokes the activation of the Ras-/MAPK-
dependent proliferative pathway in the hepatocyte. On the other hand, se-
creted TNF from Kupffer cells activates the TNF-R1- induced anti-apoptotic
signaling in hepatocytes, forming another way of inter-cellular interplay.
System States Steady state analysis using SQUAD revealed that the in-
tegrated cell-cell interaction model demonstrates four different stable states
(Table 9).
Table 9 : Steady state analyis of the combined cell-cell interaction model. All key
nodes are listed together with their activation values for each calculated stable steady
state. Values 1 denotes full activation and 0 indicates inactivation. Pathway classifi-
cations are only for demonstration issues as in fact, the exact differentiation between
the pathways is not trivial. Table: Schlatter et al. (2011).
Steady state 1 2 3 4 Pathway
Apoptosis 0 0 1 0 Apoptosis
Caspase6/7 0 0 1 0 Apoptosis
Caspase8 0 0 0.93 0 Apoptosis
Caspase9 0 0 1 0 Apoptosis
CytC 0 0 1 0 Apoptosis
IL6 1 1 0 0 Inflammation
IL6R 1 1 0 0 Inflammation
MAPK/ERK 0.93 0.91 0 0 Proliferation
Proliferation 1 1 0 0 Proliferation
AKT 1 0 0 0 Cytoskeleton
AKT∗ 1 0 0 0 Cytoskeleton
FLIP 0.93 0.93 0 0 Apoptosis
IKK 1 0.93 0 0 Inflammation
NFκB 1 1 0 0 Inflammation
NIK 1 1 0 0 Inflammation
PI3K 0.93 0 0 0 Phosphatidylinositol
RAS 1 0.93 0 0 Proliferation
Survival 1 1 0 0 Survival
TRAF2 0.91 0.91 0 0 Apoptosis
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Steady state 1 and 2 are characterized by inactive apoptotic nodes, whereas
all nodes of the survival pathway and proliferative nodes are active. Both
states can be distinguished by considering the activation of the proliferative
pathway. In steady state 1, all activation values of the model nodes except
the caspases are positive, denoting activation, and the hepatocyte gets its
proliferative signal via hepatocyte growth factor (HGF)-induced stimula-
tion. In contrast, Akt as well as PI3K are inactive in steady state 2, and the
hepatocyte gets its proliferation signal from IL-6-triggered stimulation from
the Kupffer cell. Considering steady state 3, solely apoptotic nodes are ac-
tive whereas proliferative and survival nodes are inactive. Finally, steady
state 4 represents the balanced state, where all nodes are inactive. Trans-
ferred to the physiological level, this situation guarantees stable population
of the liver since proliferation and apoptosis are each in cell-specific equili-
brations, adjusted by overarching interactions.
Model Simulations The complete cell-cell interaction model directly
connects the seperate models and integrates inter- and intra-cellular interac-
tions. It therefore allows model-based simulations of cell-specific signaling
as well as the interplay thereof. This offers a dynamic view of how the two
different cell types responds with apoptosis (Figure 49) or proliferation and
how IL-6 or TNF may influence this interactions.
Figure 49 : Dynamic simulation. SQUAD simulation of apoptosis in hepatocytes
based on the integrated model of two hepatic cell types. Activation values for net-
work nodes are calculated in a time-resolved manner and normalized (values be-
tween 0 and 1). One time unit of the simulation (1.0 units) corresponds to one day
of hepatocytes in culture as shown according to experimental data. Figure: Schlatter
et al. (2011)
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Depending on the stimulatory conditions, four distinct system states de-
scribe here the principal course of the resulting behavior of the composed
cell system. Albeit it is a strong simplification to focus on just two inter-
cellular interactions while describing a interacting cell system, the model
represents a valuable approximation: The two key interactions that were
chosen to describe the cellular interplay were found to be important in cell
co-cultures of hepatocytes and Kupffer cells (Schmich et al., 2011). More-
over, current experimental data available from this system are compatible
with the presented behavior that can be concluded from the model. The
model predicts well the behavior of hepatocytes under different cultivation
conditions regarding viability and apoptosis as well as the intrinsic and
extrinsic pathway (Philippi et al., 2009). From that we conclude that the
demonstrated strategy for model integration represents a valuable tool to
get insights into the mutual interplay of two distinct cell types.
The presented combined model is part of the publication entitled "Inte-
gration of Boolean models exemplified on hepatocyte signal transduction"
(Schlatter et al., 2011). It reviews in detail the approach of Boolean modeling
in cell signaling and presents a strategy for combining distinct Boolean mo-
dels. The suggested strategy finds its application in two examples of model
combination. I scientifically contributed to this study in giving an extensive
comparison of existing methods for Boolean modeling and dynamic trans-
formation of discrete systems.
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5 Discussion and Conclusion
NOW THIS IS NOT THE END.
IT IS NOT EVEN THE BEGINNING OF THE END.
BUT IT IS, PERHAPS, THE END OF THE BEGINNING.
(Winston Churchill)
5.1 Platelet Systems Analysis
5.1.1 Applied Approaches
We introduced a general picture of how mathematical modeling can be ap-
plied while studying signaling cascades in thrombocytes, especially in hu-
man platelets (Section 4.1). We presented models of platelet signaling that
range from large-scale protein-protein models super-imposed with phos-
phorylation data (Section 4.1.2) over a discrete Boolean network model (Sec-
tion 4.1.3) to focused continuous ODE-based models (Section 4.1.4). Dif-
ferent modeling approaches serve as a basis for a comprehensive systems
analysis of platelets. Each approach bears its predictive power varying from
global, interaction-based insights over qualitative to a quantitative descrip-
tion of signaling cascades. The choice of the appropriate modeling approach
is highly dependent on the modeling task but also preset by the amount,
type and quality of experimental data about the pathway, its components
and its interactions. Because of that, the model needs to be validated and
adapted in a data-driven way to ensure the reliability of the model-based
predictability. Different modeling approaches for the systemic analysis of
platelet signaling and results thereof are discussed in detail in the following.
5.1 Platelet Systems Analysis
Integrated Networks We started with a static view of signaling network
modeling to further describe, analyze and predict platelet functioning. The
complexity of signal transduction networks, as outlined before, originates
from the large number of interactions and from non-linear network topolo-
gies motivating mathematical modeling and network analysis to get deeper
insight into the behavior of such networks. Characterizing protein-protein
interaction (PPI) networks establishes the global view. PPI networks can
be visualized as undirected graphs where nodes represent individual mole-
cular entities (proteins) and edges denote potential interactions within this
network. As time is excluded as a parameter, PPI networks are mainly used
to statically describe the topology of a network which can by analyzed by
means of graph theory. Nonetheless, the analysis of PPI networks sustain
the identification of so far unknown interaction partners in the network
hence placing functionally uncharacterized proteins in a biological network
context as it has been shown for different organisms (Guruharsha et al.,
2011; Stelzl et al., 2005; Uetz et al., 2000).
As anucleate platelets are not genetically manipulated, signal transduction
mainly occurs through phosphorylation events. Therefore, we superim-
posed PPI networks and subnetworks thereof, representing functional en-
tities, with phosphorylation data available via PlateletWeb. This results in
directed graphs, indicating the direction of the transmitted signal flow. Di-
rected networks offer a link between structural properties and their dyna-
mics through e.g. network motifs, forming basic building blocks and pat-
terns such as feed forward loops (Milo et al., 2002). Information of phos-
phorylation and dephosphorylation is replenished by kinase predictions.
Thereby, potential substrate candidates of pivotal platelet kinases such as
PKA and PKG can be placed in the functional network context, as we exem-
plified for platelet activation or inhibition.
Hence, static approaches are particularly informative at the beginning of
platelet studies in advancing biological questions like how potential sub-
strates of key kinases can be regulated.
Integrated network analysis together with kinase predictions represent a
useful approach for functional exploration of candidate proteins and phos-
phorylations especially in cases that are not easily accessible by experiments.
However it is limited in its predictive power, particularly concerning the dy-
namic and quantitative behavior of the modeled signaling pathway.
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Boolean Modeling We presented a Boolean model of gradual platelet ac-
tivation, describing and simulating the stepwise activation towards platelet
aggregation. Boolean networks become applicable to unravel the dynamical
rules that govern biological networks, especially when dynamical parame-
ter values are available only to a minor extend - still a common bottleneck
for simulating and predicting the dynamics of signaling networks. There-
fore, the Boolean approach is intuitive and well suited to simulate and re-
produce the qualitative behavior of networks of cell signaling and has been
frequently applied (cf. Morris et al. (2010)).
A dynamic model of platelet phosphoinositide and calcium regulation (P2Y1
activation) has already been established by Purvis et al. (2008), but it only
covers a sub-part of platelet activation. In contrast, we focused on the mode-
ling of the gradual platelet activation ultimately leading to platelet aggrega-
tion. As information and data on the kinetics have been insufficient to estab-
lish a dynamic model to quantitatively predict the signal cross-talk between
platelet inhibition and activation and to discriminate between the activation
steps, we focused on the Boolean approach combined with time-resolved
dynamic simulations using SQUAD (see Section 3.2 and 3.3). Moreover, our
group was one of the first to apply the promising combination of Boolean
(here multi-valued Boolean) with subsequent semi-quantitative dynamic
modeling to cell signaling networks (Philippi et al., 2009).
Multi-valued Boolean Model Boolean models belong to the class of qua-
litative logical networks used as abstract descriptions where system compo-
nents are either present or not and dependent on the state of other compo-
nents of the system. Regarding modeling discrete system behavior, a system
is characterized by its states, and by its behavior, which can be interpreted as
activities that define a sequence on the set of states. Though Boolean mode-
ling delivers a highly simplified view on the respective system, it has the ad-
vantage that no detailed kinetics are necessary and that fast changes can be
monitored as different system states. Simulations aim at reproducing the ac-
tivity of the system entities and thereby monitor the network performance.
Via discrete simulation, we here observed the gradual activation steps lea-
ding to the activation changes of the system states depending on different
initial conditions. To assess the different graduated activation levels we im-
plemented a multi-valued Boolean network. In comparison to pure binary
states of Boolean network models, states can be fanned out to a wider range
of positive integer-valued values. Simulations of the multi-valued model
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indicate and highlight different sub-parts of the network of platelet activa-
tion, becoming important during the separate activation phases. In the early
phases 0, 1 and 2, the system changes occur rapidly. Such fast kinetics are
challenging in terms of time-resolved measuring and dynamic modeling.
However, the respective time phases could be directly verified by different
phosphorylations and phosphorylation monitoring.
Data-based Dynamic Modeling ODE-based dynamic modeling has
emerged as a promising approach for mimicking and analyzing biological
systems and signaling pathways (Swameye et al., 2003; Hoffmann et al.,
2002; Witt et al., 2009; van Riel, 2006). This approach allows data-based
investigation and in particular quantitative predictions of pharmacological
effects on cellular signaling cascades in detail. In general, it is most appro-
priate for investigating moderate-sized networks, where sufficient data are
available for model validation and to estimate model parameters in an iden-
tifiable way.
In this sense, the cyclic nucleotide signaling pathway in human platelets is
especially well-suited for such an approach as there is detailed information
on the kinetics a priori available connecting the key components.
We present here a mathematical model, based on existing biological know-
ledge as well as on an extensive set of experimental measurements (cAMP
levels). Integrating the in vitro data by applying the powerful approach of
multi-experiment fitting, we optimized unknown model parameters. We
thereby not only estimate predictive model parameters but also statistically
verify the validity of a given model (Maiwald and Timmer, 2008; Coleman
and Li, 1996). Additionally, this serves as a foundation for data-based dis-
crimination between competing model hypotheses (Cox and Hinkley, 1994).
We thereby identified the most parsimonious model explaining the entire
set of N = 155 experimental data points (triplicates of cAMP measurements).
Models on thrombosis or endothelial function have already been published
(Wang et al., 2007b; Xu et al., 2011b) as well as mechanistic models (Woot-
ton et al., 2001; Xu et al., 2008). But we are the first to investigate and model
the fine-tuned cAMP mediated signaling in the platelet in detail and in a
dynamic, data-based approach.
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5.1.2 Model-based Results
Results: Integrated Networks
Network Context and Platelet-specificity Based on protein-protein in-
teraction networks, we here applied an extended, integrative approach. With
the PlateletWeb knowledge base (Boyanova et al., 2012), we have a unique
assembly of data bases and additional information at hand to conduct an
integrative platelet-specific network analysis as well as to guide further ex-
periments concerning regulatory questions in human platelets. We showed
how potential substrates of PKA and PKG can be integrated into such a
PPI network. This results in directing further experiments thereon by pro-
viding a functional and platelet-specific network context (e.g. platelet acti-
vation, inhibition). Following this approach, our group could predict CLK1
as the kinase responsible for phosphorylating Ser269 on DOK1, a yet func-
tionally uncharacterized phosphorylation site in unstimulated human pla-
telets (Boyanova et al., 2012). DOK1 and its phosphorylation function as a
switch for integrin activation as detected in various tissues and cell types
(Calderwood et al., 2003) and has also been investigated by means of a rule-
based modeling approach (Geier et al., 2011). Kinase CLK1 is expressed in
megakaryocytes, proplatelets, and platelets (Schwertz et al., 2006) and can
be inhibited by debromohymenialdisine (Bullock et al., 2009), a drug being
associated with anti-Alzheimer and anti-osteoarthritis treatment.
Results: Discrete Dynamic Model of Gradual Platelet Activation
Dynamic Transformation and Simulation As outlined before, Boolean
networks are mainly qualitative in nature and hence may not cover all fea-
tures that govern the signaling dynamics. This is partially due to the fact
that Boolean networks do not represent realistic time-scales and continuous
concentrations of the signaling and its components. The dynamic trans-
formation of our logically connected model into a dynamic system using
SQUAD allows the introduction of time-scales and concentrations, albeit in
a normalized, semi-quantitative way. Transformed into a continuous dy-
namic model, its simulations also revealed the necessity of inherent feed-
back loops for successful platelet aggregation (Mischnik et al., 2013). Fur-
thermore, the transformation allows tracing an activating (GPVI signal) or
inhibiting stimulus (PTGDR signal) throughout the network in a dynamic
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way. Following a GPVI trigger, the model reacts with activating signaling
components being necessary for platelet aggregation and shape change. For
the irreversible activation however the increase in input strength by au-
tocrine messengers like ADP and thromboxane is necessary. Physiological
conditions also mirror this observation, as the migration of cytosolic vesi-
cles to the plasma membrane is realized by a time-consuming cytoskeletal
transport. This needs to be accompanied by at least one additional posi-
tive feedback in order to force the platelet to aggregate irreversibly, even
in the absence of an inhibitory input. Physiologically, either calcium entry
via SOCE or autocrine thromboxane production can accomplish this. Being
stimulated with both activatory and inhibitory input signals, the system has
to be stabilized by integrin outside-in signaling and a subsequent release of
thromboxane to pass the threshold towards irreversible aggregation. Dis-
crete and continuous simulations show that several sub-networks increase
the system stability which underpins the platelet’s enormous susceptibility
to versatile inputs which are integrated over different receptors.
Threshold Behavior and Application Combinatorial effects demonstrate
that the relative activating strength (GPVIthr/PTGDR) transgressing the
threshold diminishes with elevating inhibiting inputs (Mischnik et al., 2013).
Thus, the system adapts for higher prostaglandin-concentrations by increa-
sing its sensitivity for activators such as von Willebrand factor and collagen.
Thereby it commits platelet-dependent active processes like wound healing
even if subsequent prostaglandin-levels in the blood are augmented after-
wards. In a model-based way, different efficiencies for various combinations
of agonists and antagonists regarding platelet activation can thus be com-
pared, following either over- or sub-threshold behavior. This approach can
concretely be applied to model the effect of different prostanoid receptor an-
tagonists that have been experimentally compared for therapeutic strategies
(Jones et al., 2011). In general, it can be adapted to various pharmacological
conditions, e.g. effects of Aspirin, Milrinone or Iloprost, while modifying
the activity of network nodes.
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Results: Data-based Dynamic Model
PDE Concentrations Experimental data integrated in a mathematical mo-
del can serve as a basis to gain a deeper insight into the basic effects of pla-
telet cyclic nucleotide signaling and the underlying kinetics. Here, simula-
tions of the basal in silico model indicate that there is only a very small frac-
tion of the PDEs enzymatically active under resting conditions compared
to experimentally measured values (Wangorsch et al., 2011). We speculate
that this might be a result of PDE compartmentalization which has been ob-
served for adipocytes (PDE3), HEK293 cells and cardiac myocytes (PDE4)
as well as for PDE5 in platelets (Wilson et al., 2008; Baillie, 2009; Houslay,
2010; Shakur et al., 2000).
Pathway Integration Focusing on VASP, a prominent PKA and PKG sub-
strate, we monitored the integration of both branches of cyclic nucleotide
signaling in human platelet (cAMP- and cGMP related). Signal integra-
tion by the VASP protein, an intensively connected hub protein, relies on
the activation of the downstream cytoskeletal regulating signaling cascade
(Geiger et al., 2010; Dittrich et al., 2010). Taking into account the differential
regulation of the two main known phosphorylation sites of PKA and PKG,
respectively (Ser157 and Ser239), we accurately predict and experimentally
validate the evoked downstream activation in quantitative terms of specific
PKA-mediated phosphorylations on the VASP protein (Wangorsch et al.,
2011).
Anti-platelet Drugs and Drug Combinations As platelets play a key role
in thrombosis and hemostasis, the maintenance of the intricate balance be-
tween activation and inhibition is highly important as well as the avoidance
of accidental activation of platelets. Thus, the inhibitory pathway represents
a promising starting point for pharmacological fine-tuning of the hemostatic
system.
A variety of pharmacological substances affecting cAMP signaling in hu-
man platelets (anti-platelet drugs) are in clinical use. They mainly have an
impact on the most prominent mechanisms of anti-platelet therapy: the in-
hibition of P2Y12 receptors (Clopridogrel, Prasugrel, Ticlopidine), of COX1
and thromboxane (Acetylsalicyclic acid), of platelet PDEs (Dipyridamole,
Cilostazol, Milrinone) as well as antagonistic effects on integrin αIIbβ3 (Ti-
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rofiban, Eptifibatide, Abciximab) (Michelson, 2010; Rao and Xi, 2009). An-
tagonists of platelet prostaglandin receptor EP3 or ACs as potential drug
targets are currently under development (Rao and Xi, 2009; Pierre et al.,
2009). Anti-platelet therapy potentially benefits of the over-additive effect of
platelet drugs when applied in combination (Michelson, 2010; Lobato et al.,
2006). Thus, the investigation of drug interactions (Mackenzie et al., 2010)
in vitro as well as in silico may finally result in decreased drug dosages and
undesirable side effects such as bleeding. Hence, an in-depth understan-
ding of the interactions and effects of substances affecting platelet activation
and inhibition is not only of scientific interest but also of clinical importance.
Having calibrated the model with experimental time-resolved data of dif-
ferent drug effects, we succeed in predicting not only the effect of single
drugs but combinations thereof (Wangorsch et al., 2011). Modeling syner-
gistic, additive or antagonistic drug interactions represents a challenging
task (Yan et al., 2010; Geva-Zatorsky et al., 2010). We captured combinato-
rial drug effects by introducing just one unique cAMP-dependent parame-
ter, offering different types of interactions which become apparent on the
cAMP level. Albeit the assumed simplification led to reliable and robust
predictions compatible with the observed experimental data, we are aware
that more complex effects and different modes of action have to be imple-
mented depending on the range of considered anti-platelet drugs.
Feedback-regulated cAMP Level The system analysis based on experi-
ments of platelet stimulation with anti-platelet drugs points to a pivotal role
of feedback effects towards AC and PDE. It has been observed that PKA, ac-
tivated by elevated cAMP concentration, induces the inhibition of AC but
activates PDE3 as well (Iwami et al., 1995; Murthy et al., 2002; Hunter et al.,
2009). A short-term feedback regulation of cyclic nucleotide concentrations
evoked by activation of cAMP-dependent PKA have been indicated in diffe-
rent cell types (rat hepatocytes, adipocytes, myoblasts, smooth muscle cells,
osteoclasts, U937 cells) and also in platelets (Macphee et al., 1988; Murthy
et al., 2002; Corbin et al., 1985; Gettys et al., 1988; Ball et al., 1980; Alvarez
et al., 1995; Ahlstrom and Lamberg-Allardt, 1997) underpinning the ubi-
quitous nature of this mechanism. The PKA-driven activation of PDE3A
and PDE4A has been observed in smooth muscle cells (Murthy et al., 2002).
Moreover, it is known that PDE3A is phosphorylated by PKA at phospho-
site Ser312 in a response to Forskolin treatment (Pozuelo Rubio et al., 2005)
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which entails the activation of PDE3A in human platelets (Macphee et al.,
1988). Our model results indicate a greater impact of AC inhibition by
PKA-mediated phosphorylation. This inhibitory effect has already been de-
scribed for adenylyl cyclase subtypes 5 (AC5) and 6 (AC6) in smooth muscle
cells (Murthy et al., 2002). Besides the expression of AC subtype 3 and 7 in
human platelets, platelet proteomics data indicate the expression AC5 and
AC6 as well. Thus, a direct phosphorylation of AC5 or AC6 subtypes by
PKA may contribute to the feedback inhibition of cAMP synthesis in hu-
man platelets (Iwami et al., 1995; Chen et al., 1997).
Statistical model selection revealed that both described feedback regulations
are to be involved to achieve optimal signal strengths becoming apparent on
the cAMP level in human platelets. Our data suggest that the inhibitory ef-
fect on AC thereby outweighs the positive feedback effect on PDE3 (Table 7).
Cross-talk Raised concentrations of cyclic nucleotides potently contribute
to platelet inhibition via targeted cyclic nucleotide-dependent protein ki-
nases (PKA, PKG) which in turn affect and phosphorylate their specific
substrates. Via cAMP degrading phosphodiesterases, cGMP is capable to
regulate the cAMP level in cardiac cells including platelets (Zaccolo and
Movsesian, 2007; Schwarz et al., 2001). Referring to this, we show system
state transitions from the non-activated cAMP pathway in platelets to an ac-
tivated state as well as inhibitory and activatory cross-linking directed from
cGMP- and cAMP-branches of the pathway (Figure 37). Data showed that
the cAMP pathway is highly specific in human platelets. Even at compa-
ratively high cAMP levels no cross-talk to the cGMP pathway is observed,
validated here including experimental measurements.
In contrast, cGMP is known to interact with the cAMP pathway (Aktas
et al., 2002; Schwarz et al., 2001), mainly by activating PDE2 and inhibi-
ting PDE3. We speculated on this cross-talk and future model extensions
will focus on a data-driven integration of the cGMP branch. Preliminary
time-resolved cGMP data have already been collected by our collabora-
tors (team of Dr. Stepan Gambaryan) at the Institute for Clinical Bioche-
mistry and Pathobiochemistry. The quantification and in-depth understan-
ding of cGMP-mediated cross-talk effects is of high clinical relevance, not
only in platelets but also in cardiac muscle cells (cardiomyocytes). Here,
one has to discriminate between an acute and chronic stimulation of the
cAMP pathway (Fischmeister et al., 2006). In the heart, cAMP plays a pi-
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votal role in the sympathetic nerve/β-adrenergic receptor (β-AR)/adenylyl
cyclase (AC)/protein kinase A (PKA) axis that stimulates cardiac rhythm
as well as contractile force and relaxation (Bers, 2002). While an acute sti-
mulation of the cAMP pathway is beneficial for the heart, a sustained acti-
vation leads to hypertrophic growth, ventricular dysfunction and to heart
failure (Movsesian and Bristow, 2005; Port and Bristow, 2001). In human,
different forms of chronic heart failure are all associated with elevated ca-
techolamines (Wehrens et al., 2005; Lohse et al., 2003; Brodde et al., 2006).
Catecholamines such as epinephrine, norepinephrine and dopamine stimu-
late β-adrenoceptor signaling evoking raised cAMP levels and thus PKA
activation. To prevent this, blockers of the β-AR are normally administered,
which are on the one hand cheap but on the other hand often not well tole-
rated by the patient and affect globally the entire β-adrenoceptor signaling
pathway which bears side-effects. Other starting points to pharmacologi-
cally modulate the signal response via β-AR in a more specific way repre-
sent the cAMP-degrading PDEs or PKA-affecting steps. Among the PDE
isoforms expressed in the heart, PDE2 is unique in being potently stimula-
ted by cGMP, e.g. induced by atrial natriuretic peptide (ANP) (MacFarland
et al., 1991). PDE2 activity and ANP production (Takahashi et al., 2003)
have been shown to be impaired in human and experimental heart failure.
Thus, the research group of Prof. Ali El-Armouche at the Heart Centre Göt-
tingen hypothesizes that a reinforcement of PDE2 may restore part of the
dysfunction in the cAMP signaling under heart failure conditions and may
protect against arrhythmias. This interesting project will be accompanied
by model-based predictions on the impact of cAMP-affecting cross-talk of
cGMP, adapting our platelet-focused model to the appropriate conditions in
cardiomyocytes. Once calibrated, the model allows the testing of hypothe-
ses supporting the process to answer the question whether enhancing PDEs
is a worthwhile therapeutic strategy.
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5.2 Modeling Inflammatory Signaling
Modeling Cross-talk between Signaling Pathways Modeling and in-
vestigating specific signaling cascades or even parts thereof in a separate
manner is useful and can reveal novel regulatory cell-biological insights.
The presented model of cAMP signaling pathway as sub-branch of platelet
cyclic nucleotide signaling cascade (Section 4.1.4) or mathematical models
of the IκB-NFκB- module (Hoffmann et al., 2002) constitute representative
examples in this dirtection. However, to understand a cell’s systemic re-
sponse e.g. the overall NFκB activation with respect to inflammation, it is
indispensable to consider the signaling cross-talk between the distinct cas-
cades. This becomes particularly evident in addressing apoptotic cross-talks
(Fotin-Mleczek et al., 2002; Nakayama et al., 2002). In particular, the apop-
totic cross-talk is measurable and quantifiable which is crucial for model
calibration and validation.
Multi-valued Boolean model simulation could precisely reproduce the dif-
ferential effects on NFκB activation and apoptotic cross-talk of TNF-R1 and
TNF-R2 (Table 8). Thus, mathematical modeling underpins experimental
observations and could serve as a basis for further investigations and for
predicting hypotheses of molecular regulations. However, to describe the
cross-talk events more precisely, detailed and more specific data are needed
not only to further distinguish the receptor effects, but also to validate the
already established model. TWEAK stimulation data (gained from Fn14-
transfected cells) in combination with TNF-R1 stimulation is of special value
as the TWEAK/Fn14-system acts similarly compared to TNF-R2 signaling
but TWEAK acts specifically on Fn14. As time-resolved data are available,
the model can be trained against and be extended to describe cross-talk dy-
namics in more detail, as McClean et al. (2007) could realize for the MAP
kinase pathways and cross-talk thereof.
Moreover, a detailed understanding of the underlying apoptotic cross-talk
is also of great value for therapeutic interventions and represent potential
drug targets (Pezzino et al., 2011; Faustman and Davis, 2010). Exemplary,
Vince et al. (2008) could show that the Fn14 receptor is expressed by most
tumor cell lines and IAP antagonists are beneficial as tumor therapy.
Modeling Cluster Formation We presented a mathematical model to il-
lustrate different scenarios of TNF receptor cluster formation upon ligand
binding. The phenomenon of receptor clustering is not restricted to mem-
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bers of the TNF receptor family. It is a generally observed process during
cell signaling (Stel et al., 2007; Feng et al., 1998; Torres et al., 2011). However,
the TNF-R1 and TNF-R2 systems are of key importance as they mediate and
regulate NFκB activation, a pivotal transcription factor for several cellular
processes.
It is especially the first step of signaling cascade, thus the ligand-receptor-
binding, that is crucial for the amplitude and formation of the signal to
be transduced. Therefore, a detailed understanding of signal creation at
this level is highly important also in the sense of pharmacological interven-
tion. However, identifying receptor properties that tightly determine the
processing of ligand-encoded information is still a bottleneck in cell sig-
naling studies. Becker et al. (2010) revealed in a systems biological study
the dynamic characteristics of the erythropoietin receptor during signal pro-
cessing. They used mathematical ODE-based modeling of quantitative data
together with experimental validation to investigate the receptor properties.
The ODE-based approach however fails in modeling cluster formation, as
generally spatial effects or structural features of molecules are neglected.
This is mainly due to the fact that each and every state of the molecule and
its interactions require a concrete deterministic description. This way, mo-
deling would face a tough combinatorial complexity when addressing clus-
ter formation. Because of that, we opted for the rule-based approach, which
is appropriately suited for the structure-orientated modeling task. It has al-
ready been successfully applied in a variety of cell signaling studies (Geier
et al., 2011; Monine et al., 2010; Hsieh et al., 2010).
On the basis of rule-based modeling, we could simulate the signal proces-
sing at TNF-R1 and TNF-R2, using the resulting cluster size as indicator
for the processed signal strength. TNF-R2 is different to TNF-R1 as it of-
fers a broad range for evoking TNF-mediated signals. Together with the
potential apoptotic cross-talk to TNF-R1 signaling, this renders TNF-R2 a
potential drug target. Experimental and computational unraveling the de-
tailed structure of TNF-R2 as well as manipulative contact points to mo-
dulate cluster formation may sustain the development of receptor-specific
therapies (Mukai et al., 2010). Equally, a meticulous investigation of the
PLAD structure of TNF-R1 with respect to cluster formation has led to an
improvement in the treatment of autoimmune diseases (Wang et al., 2011).
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5.3 Cell Signaling - Models in Different Cell Types
5.3.1 Linking Inflammation and Cardiac Damage
Cardiomyocytes bear several points where mathematical modeling can ope-
rate in order to beneficially sustain biomedical research. We mentioned
PDE2 and its regulation via cross-talks as a promising target for modulating
β-adrenergic receptor signaling. Here, we focused more on inflammation
that is highly cross-linked to cardiac damage. TWEAK and inflammatory
cytokines in general are supposed to represent new potential drug targets
(Givertz and Colucci, 1998; Winkles, 2008). We demonstrated that TWEAK
treatment affects infarct size after ischemia reperfusion as well as the distri-
bution of immune cells and leads to the upregulation of genes being impor-
tant for recruitment (namely MIP2, MCP-1 and MCP-5) and differentiation
of leukocytes (IL-5, IL-12 and IFNγ).
By setting these genes into a functional network context, we revealed that
TWEAK stimulation interacts with the TNF pathways potentially changing
the balance between proliferation and apoptosis. TWEAK tightly regulates
the activation of NFκB which, together with Rac1, link cytokines and the
JAK/STAT pathway. This connections and pathway inter-linkage could not
have been detected from data alone. The network based approach may
serve as a basis for the creation of further model-based predictions. Exem-
plary, this may address the hypothesis whether and to what extent TWEAK-
induced apoptotic cross-talk, e.g. to TNF-R1-mediated signaling, is engaged
(Nakayama et al., 2002). Moreover, this potential cross-talk pin-points to the
increased cardiac ruptures that have been observed under TWEAK treat-
ment conditions. Here, one can also speculate if platelets are involved in
the occurrence of cardiac ruptures, as human platelets contain and release
TWEAK (Meyer et al., 2010). In general, transferring results that were gained
from mice to human is challenging and not trivial. That is why our group is
currently developing a mouse-specific knowledge base.
5.3.2 Modeling in Plant Signaling and Immunity
Approach Networking of hormones is a newly emerging aspect in the
field of plant immunity where the interplay between growth regulators and
stress-specific hormones modulate plant-pathogen interactions. Pathogen
infection, as presented in our study on Pst, thereby profoundly alters the
hormonal profile as well as the network dynamics of the plant cell (Naseem
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et al., 2012). Thus, dynamic modeling is a valuable approach for elucidating
and a better understanding of hormonal implications in plant immunity.
Several mathematical models of plant signaling networks have emerged.
Plant signaling models range from logical (Espinosa-Soto et al., 2004), over
ODE-based models (Agrawal et al., 2004) to stochastic (Guerriero et al.,
2012) and multi-scale models (Grieneisen et al., 2007).
We applied the promising combination of Boolean modeling and dynamic
transformation of the resulting logically connected network to simulate and
model plant signaling cascades. This is especially appropriate as kinetic
data itself are scarce on the complex hormonal interplay. Moreover, the
combination of both approaches is ideal to investigate synergistic or antago-
nistic effects of hormones as shown here for auxin and cytokinin. Respective
hormonal or pathogenic factors that serve as input (stimulus) can simply be
assigned by activation values of a desired degree, whereas all other factors
are switched off by setting them to value zero. Thereby, various effects to
the host plant can be investigated and speculated on. We showed several
simulation studies with respect to cytokinin, being one of the most impor-
tant, but immunologically least deciphered plant hormones.
Model-based Results The presented modeling approach illustrates the
impact of integrating bacterial effectors and host hormonal cues. The sam-
pling over the whole network documents the eventual outcome for the en-
tire host-pathogen system.
Model simulations revealed the impact of plant hormones on Pst infection.
JA, auxin and ABA reduce Pst-mediated PR1 activation and promote sus-
ceptibility, whereas SA and GA further increase PR1 activation and enhance
resistance (Figure 46A). Moreover, model-based predictions of increased
plant cytokinin with/without the addition of Pst regarding plant immunity
revealed a boosting effect on plant immunity (Figures 46B). Experiments
supported these findings by showing reduced disease symptoms with ab-
rogated in planta bacterial multiplication as well as by monitoring higher
expression of marker PR1 upon treatment with cytokinin. Additionally, in-
creased cytokinin levels are found to enhance resistance to Pst in transgenic
plants (Choi et al., 2010) and Pst tabaci (Grosskinsky et al., 2011), whereas
decreased cytokinin level indicated a reduced expression of marker PR1
(Uchida and Tasaka, 2010).
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We took up the challenge to set up a logically connected network to dyna-
mically model these various influences. Simulations reflect that modulation
in plant cytokinin changes the infection dynamics in such a way that an
increase in cytokinin level favors protection whereas its decrease adds to
vulnerability.
The auxin-cytokinin cross-talk is quite prevalent in biological processes re-
lated to plant development and growth (Moubayidin et al., 2009; Liu et al.,
2010), however literature-based information is scarce regarding its impact
on plant immunity. Model-based simulation as well as the subsequent ex-
periments helped in elucidating the interplay between auxin and cytokinin.
Moreover, we could thereby reveal a carefully controlled balance of im-
munity and susceptibility (Figure 47A). Activation states of cytokinin over
auxin direct toward resistance whereas the opposite holds true for suscepti-
bility (Figure 47A), which could also be observed experimentally.
Cytokinin is involved in a variety of vital processes such as cell division,
tissue differentiation, lateral bud growth, photosynthetic activity and floral
development (Kudo et al., 2010). It is complexly engaged in cell signaling,
indicating the immense potential in enhancement of crop yield (Gan and
Amasino, 1995; Rivero et al., 2007). Resuming this topic, our systems bio-
logically driven experiments and modeling suggest cross-talk possibilities
for cytokinin in complex hormonal disease networks that may have impli-
cations for advanced yield protection strategies in agriculture.
5.3.3 Modeling Hepatic Cell-Cell-Interaction
Approach We showed the integration of distinct Boolean models of two
different hepatic cell types in order to describe their interaction (Schlatter
et al., 2011). The combination of partial models into a more comprehensive
network model is a crucial move towards a broader level of understanding
in the sense of systems biology. Combining dynamic ODE-based models is
particularly challenging because of model and kinetic parameters. More-
over, combinatorial explosion of complexity renders a definite parameter
estimation in a detailed ODE model of the whole liver cell impossible in the
light of current technical possibilities.
Boolean models however allow a comprehensive understanding of the com-
plex signaling network that governs the fate of liver cells, mainly based on
the topology rather then on kinetic information. Several integrative Boolean
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and discrete models on hepatic signaling have already been established.
Saez-Rodriguez et al. (2011) developed a cell-specific Boolean model of im-
mediate-early signaling networks in normal and transformed hepatocytes
revealing biochemical differences in signal transduction among normal and
tumor cells. Huard et al. (2012) established a large-scale logical model that
integrates over a broad variety of receptors and connected signaling path-
ways and thus provides a broad picture of proliferation control in primary
hepatocytes. Moreover, a first multi-scale model includes the quantitative
description of metabolic behavior in the context of time-resolved metabolite
concentration profiles (Krauss et al., 2012).
We demonstrate that the integration of logical sub-models facilitated by mo-
deling standards is a valuable example for the next step towards a systems
biological understanding. The analysis of systems response to different
combined inputs or different environmental conditions (e.g. cell cultures)
is a special potency that is offered by this approach. Furthermore, the im-
pact of cross-talks is of outstanding importance for the resulting behavior of
the cell and the whole organ.
We believe that the presented approach has the potential to be expanded to-
wards a comprehensive cell-covering model structure. Critically validated
and trained against biochemical data, comprehensive Boolean models can
be transformed into dynamic systems. Thereby, they serve as textures for
dynamic ODE-based modeling and sustain the overall long-term goal of a
dynamic whole cell and a whole organ model.
Applications Besides Boolean modeling of liver signaling behavior pro-
motes our knowledge about hepatocytes, there are also promising clinical
application aspects. Exemplary, viral apoptosis blocking was demonstrated
for M36 and M45 cytomegaly virus proteins (Philippi et al., 2009). Further-
more, infection evoked by cytomegaly virus as well as oncolysis by vaccinia
virus have been tested (Zhang et al., 2009) and are currently investigated
further. Viral infections of liver cells can be better understood on the ba-
sis of Boolean cellular models, but now with inclusion of specific cell-cell
interactions. This sustains the development of new drugs in general inclu-
ding therapeutic approaches such as the action of an oncolytic virus (Zhang
et al., 2009) on liver tissue plus metastases. SMAC-mimetics that are used
as anti-cancer treatment are included in the mathematical model of apopto-
sis (Schlatter et al., 2009) constituting another example of a pharmacology-
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driven logical model.
Combined Boolean models are beneficial in immediately generating semi-
quantitative data on all involved nodes, highlighting qualitative and even
cell-type specific changes in the system. Due to the inherent model features,
comprehensive Boolean models can contribute to address important biolo-
gical research questions. This includes the elucidation of changes induced
by the cultivation of cells under distinct conditions, since this modifies the
cellular properties and differentiation. Tissue engineering (Schanz et al.,
2010) constitutes another field of application for cell-cell interaction models
including modified Akt signaling in the different cell types.
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5.4 Conclusion and Outlook
For a functional understanding of a single cell, of cellular cross-talks or even
of higher organization units, it is often valuable to conceptualize and sim-
plify them as systems of interacting elements or in other words, as models.
This especially applies to the process of cell signaling. Signaling cascades
play a key role in adapting the cell’s behavior to environmental changes,
internal stimuli or pharmacological modulation. Such a systems-level de-
scription requires knowledge about the identity of model components, their
dynamic behavior (e.g. condition-dependent change of concentrations or
activity over time) and the kind of interactions between the model compo-
nents (Kitano, 2002). The quality, amount and accessibility of experimental
data is still one of the main limiting factors, not only for model establish-
ment but also for model validation and calibration. Thus, prior knowledge
and data explicitly determine the type and scale of a model.
Within the framework of this thesis, we presented main types of mathema-
tical models at different scales that are beneficial for investigating signaling
cascades: interaction networks, Boolean models as well as dynamic ODE-
based and rule-based models. Each modeling approach provides new in-
sights into the behavior of the system. In particular, every approach bears
its predictive power for either qualitative or quantitative forecasts.
Protein-protein interaction networks sustained the systemic view and re-
vealed signaling connections and modules that were not apparent from data
alone. Cytokine array data that were gained from experiments in cardio-
myocytes was brought into a functional signaling context. Network-based
representation advanced the data visualization and showed interconnec-
tions to different proliferative and apoptotic signaling pathways. Superim-
posing protein-protein networks with phosphorylation data and knowledge
about drug interactions further enhanced the network information content.
Connecting edges are thereby assigned by directions. This includes infor-
mation about kinases that are directed to their corresponding (de)phospho-
rylated substrates. In this way, potential substrates of key kinases in hu-
man platelets were set in a functional surrounding. Subnetworks compri-
sing key nodes of platelet activation and inhibition formed the basis. Thus,
network-based insights sustain the functional integration of signaling pro-
teins or small molecules and guide further experimental investigations.
The power of Boolean dynamic modeling relies on the model construction
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itself. Binary model nodes, the components of a signal cascade, are logi-
cally connected. Bi-valued model nodes reflect the state "on" or "off", active
or inactive, expressed or not expressed, respectively. In the context of sig-
nal cascade models, logic connections can be understood as gates through
which a signal is propagated. The model structure of Boolean models ren-
ders their combination comparatively easy. We demonstrated the coupling
of two distinct logic models of different liver cells. From this we conclude
that Boolean models are useful precursors for large-scale quantitative mo-
dels, strengthening the systemic understanding of the liver as a multi-cellu-
lar organ.
Multi-valued Boolean models represent a special subtype of Boolean mo-
dels, where the binary states are fanned out to a wider range of positive in-
teger values. The Boolean approach thereby allows predicting the outcomes
of the signal system (steady states), testing of hypotheses (e.g. potential ef-
fects of different input stimuli, of knockouts or overexpressed nodes) and
directing validating and promising wet lab experiments. Here, we applied
Boolean modeling to understand the effect of different input signals and
how they cross-talk towards differential cellular responses. First, we eluci-
dated the gradual process of platelet aggregation. Resulting simulation ex-
periments categorized platelet activation into different phases and assigned
corresponding key nodes. Second, by applying the multi-valued Boolean
approach we established an in silico platform for investigating the regu-
latory cross-talk between two different TNF receptors, TNF-R1 and TNF-
R2. Experiments have shown that the signaling of TNF-R2 affects TNF-R1-
mediated activation of NFκB and shifts TNF-R1 down-stream signaling to
apoptosis. We successfully captured these time-dependent effects in our
model that now offers the generation of testable hypotheses about dynamic
cross-talk regulations at the molecular level. From these results, we can con-
clude that (multi-valued) Boolean networks can serve as a basis for mode-
ling interlinked signaling networks. Moreover, detailed continuous models
can be built on the foundation of logic models as kinetic and quantitative
data become available.
One step towards this goal is the transformation of Boolean models to dy-
namic semi-quantitative systems. The rapidly increasing number of mode-
ling approaches addressing the dynamic transformation (Stoll et al., 2012;
Terfve et al., 2012; MacNamara et al., 2012; Krumsiek et al., 2010; Di Cara
et al., 2007) show the need for a dynamic model-based description of sig-
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naling pathways if detailed data are lacking. We applied SQUAD (Di Cara
et al., 2007), one of the first approaches that evolved, to transform Boolean
models and to deduce regulatory insights from dynamic simulations.
Simulation experiments elucidated and separated activatory and inhibitory
signaling pathways during the platelet activation process. We concluded
a threshold behavior by testing different activation-to-inhibition ratios that
served as input for dynamic simulations. In the same way, we tested the
impact of hormonal interplay with respect to plant immunity in Arabidop-
sis. Dynamic simulations identified and predicted systems effect and mul-
tiple cytokinin-mediated regulatory interactions in plant disease networks.
Besides offering insights into the dynamics of regulatory processes, semi-
quantitative model predictions are scaled to arbitrary time units and activa-
tion values between 0 and 1.
Quantitative prediction can be deduced from models that are based on or-
dinary differential equations. They comprise kinetic information and pa-
rameters of the modeled process. Extensive model calibration on the foun-
dation of time series data of model components allows quantitative predic-
tions such as concentration levels at a realistic time-scale. Sufficient data is
needed to estimate unknown model parameter from the data in an identi-
fiable way. Therefore, data-based dynamic modeling mostly focuses on spe-
cific parts of signaling pathways. In that way, we modeled the cAMP branch
of the platelet inhibitory pathway. We were able to quantify key regulators
in platelet signaling from model simulations. For the first time, active con-
centrations of cAMP-regulating phosphodiesterases could be predicted and
quantified. Comprehensive calibration of the model with time-series data
from cAMP-elevating drugs revealed a feed-back regulation of cAMP levels
in the platelet. From statistical analyses we concluded that two feedback
effects are involved. On this basis, the established model serves for quanti-
tatively predicting various effects of anti-platelet drugs in a dose-dependent
manner. Simulations deciphered synergistic effects among drug combina-
tions and showed that the raise of cAMP-levels leaves the cGMP branch of
the signaling cascade unaffected. These findings are sustained by predic-
ting phosphorylation effects on VASP, a protein that is capable to integrate
down-stream effects from both branches. The reverse cross-talk from cGMP
to the cAMP branch is known. Due to the lack of dynamic data, we could
not quantify the cross-talk effect but simulate the possible impact at a rea-
listic time-scale.
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Furthermore, adapting the observations we derived from the quantitative
platelet model to cardiomyocytes will probably offer novel starting points
for pharmacological interventions. Here, phosphodiesterases and their cross-
talk between cyclic nucleotides are involved in transmitting signals from the
β-adrenergic receptor that plays a pivotal role in heart failure. Quantitative
model predictions of this interplay will support the investigation of new
types of therapeutic strategies in this connection.
Besides the enormous predictive power of data-based dynamic models, they
bear the problem of combinatorial complexity as each state of a model com-
ponent has to be defined deterministically. Therefore, we opted for the
structure-orientated rule-based approach for modeling cluster formation at
TNF receptors. This process seems to be critical for the creation of a proper
ligand-encoded signal at TNF-R1 and TNF-R2. On the basis of rule-based
modeling, we could simulate the signal creation at both receptor types. The
resulting cluster size thereby indicates the evoked signal strength. Together
with the potential apoptotic cross-talk to TNF-R1 signaling, this renders
TNF-R2 and the PLAD structure of TNF-R1 a potential drug target.
I close by referring to the famous quote of the statistician George Box:
"All models are wrong, but some are useful" (Box, 1976).
Results from this thesis show that indeed every mathematical model is
"wrong" in being a simplification, or better a compromise, that weights up
a priori knowledge and data against preciseness, predictability and compu-
tational complexity. However, by choosing the appropriate approach, mo-
dels are "useful" in assigning a physiological and functional context, unco-
vering regulatory principles, generating testable hypotheses and model pre-
dictions. Hence, mathematical modeling and computational systems bio-
logy are and will be a substantial element in pharmacological and clinical
research.
152
REFERENCES
References
Abrahamsen, H., Vang, T., and Taskén, K. (2003). Protein kinase a intersects src signaling
in membrane microdomains. J Biol Chem, 278(19):17170–17177.
Agrawal, V., Zhang, C., Shapiro, A. D., and Dhurjati, P. S. (2004). A dynamic mathema-
tical model to clarify signaling circuitry underlying programmed cell death control in
arabidopsis disease resistance. Biotechnol Prog, 20(2):426–442.
Ahlstrom, M. and Lamberg-Allardt, C. (1997). Rapid protein kinase a–mediated activation
of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like
cells. Journal of bone and mineral research : the official journal of the American Society for Bone
and Mineral Research, 12:172–8. 2.
Akaike, H. (1973). Information theory and an extension of the maximum likelihood princi-
ple. In 2nd International Symposium on Information Theory.
Akaike, H. (1974). A new look at the statistical model identification. IEEE Transactions on
Automatic Control, 19(6):716 – 723.
Aktas, B., Honig-Liedl, P., Walter, U., and Geiger, J. (2002). Inhibition of platelet P2Y12 and
alpha2A receptor signaling by cGMP-dependent protein kinase. Biochemical pharmacol-
ogy, 64:433–9. 3.
Aktas, B., Utz, A., Hoenig-Liedl, P., Walter, U., and Geiger, J. (2003). Dipyridamole enhances
NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and sig-
naling in human platelets: in vitro and in vivo/ex vivo studies. Stroke, 34:764–9. 3.
Albert, I., Thakar, J., Li, S., Zhang, R., and Albert, R. (2008). Boolean network simulations
for life scientists. Source Code Biol Med, 3:16.
Aldridge, B. B., Burke, J. M., Lauffenburger, D. A., and Sorger, P. K. (2006). Physicochemical
modelling of cell signalling pathways. Nat Cell Biol, 8(11):1195–1203.
Altschuler, D. and Lapetina, E. G. (1993). Mutational analysis of the camp-dependent pro-
tein kinase-mediated phosphorylation site of rap1b. J Biol Chem, 268(10):7527–7531.
Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R., Shelton, E. R., and Conti, M.
(1995). Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase,
PDE-4D3. Molecular pharmacology, 48:616–22. 4.
Andrews, R. K., Harris, S. J., McNally, T., and Berndt, M. C. (1998). Binding of purified 14-3-
3 zeta signaling protein to discrete amino acid sequences within the cytoplasmic domain
of the platelet membrane glycoprotein ib-ix-v complex. Biochemistry, 37(2):638–647.
Anker, S. D. and von Haehling, S. (2004). Inflammatory mediators in chronic heart failure:
an overview. Heart, 90(4):464–470.
Antl, M., von Brühl, M.-L., Eiglsperger, C., Werner, M., Konrad, I., Kocher, T., Wilm,
M., Hofmann, F., Massberg, S., and Schlossmann, J. (2007). Irag mediates no/cgmp-
dependent inhibition of platelet aggregation and thrombus formation. Blood, 109(2):552–
559.
Arehart, E., Stitham, J., Asselbergs, F. W., Douville, K., MacKenzie, T., Fetalvero, K. M.,
Gleim, S., Kasza, Z., Rao, Y., Martel, L., Segel, S., Robb, J., Kaplan, A., Simons, M., Pow-
ell, R. J., Moore, J. H., Rimm, E. B., Martin, K. A., and Hwa, J. (2008). Acceleration
of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential
implications for cyclooxygenase-2 inhibition. Circulation research, 102:986–93. 8.
153
REFERENCES
Argueso, C. T., Ferreira, F. J., Epple, P., To, J. P. C., Hutchison, C. E., Schaller, G. E., Dangl,
J. L., and Kieber, J. J. (2012). Two-component elements mediate interactions between
cytokinin and salicylic acid in plant immunity. PLoS Genet, 8(1):e1002448.
Arrell, D. K. and Terzic, A. (2012). Systems proteomics for translational network medicine.
Circ Cardiovasc Genet, 5(4):478.
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis,
A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., Harris, M. A., Hill, D. P., Issel-Tarver, L.,
Kasarskis, A., Lewis, S., Matese, J. C., Richardson, J. E., Ringwald, M., Rubin, G. M., and
Sherlock, G. (2000). Gene ontology: tool for the unification of biology. the gene ontology
consortium. Nat Genet, 25(1):25–29.
Assmann, S. M. and Albert, R. (2009). Discrete dynamic modeling with asynchronous
update, or how to model complex systems in the absence of quantitative information.
Methods Mol Biol, 553:207–225.
Aszódi, A., Pfeifer, A., Ahmad, M., Glauner, M., Zhou, X. H., Ny, L., Andersson, K. E.,
Kehrel, B., Offermanns, S., and Fässler, R. (1999). The vasodilator-stimulated phospho-
protein (vasp) is involved in cgmp- and camp-mediated inhibition of agonist-induced
platelet aggregation, but is dispensable for smooth muscle function. EMBO J, 18(1):37–
48.
Aukrust, P., Gullestad, L., Ueland, T., Dam?s, J. K., and Yndestad, A. (2005). Inflammatory
and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implica-
tions. Ann Med, 37(2):74–85.
Authi, K. S. and Crawford, N. (1985). Inositol 1,4,5-trisphosphate-induced release of se-
questered ca2+ from highly purified human platelet intracellular membranes. Biochem J,
230(1):247–253.
Authi, K. S., Evenden, B. J., and Crawford, N. (1986). Metabolic and functional conse-
quences of introducing inositol 1,4,5-trisphosphate into saponin-permeabilized human
platelets. Biochem J, 233(3):707–718.
Bailey, J. M., Levy, J. H., Kikura, M., Szlam, F., and Hug, C. C. (1994). Pharmacokinetics of
intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology, 81(3):616–
622.
Baillie, G. S. (2009). Compartmentalized signalling: spatial regulation of cAMP by the
action of compartmentalized phosphodiesterases. FEBS J, 276:1790–9. 7.
Ball, E. H., Seth, P. K., and Sanwal, B. D. (1980). Regulatory mechanisms involved in the
control of cyclic adenosine 3’:5’-monophosphate phosphodiesterases in myoblasts. The
Journal of biological chemistry, 255:2962–8. 7.
Balsinde, J., Balboa, M. A., and Dennis, E. A. (1998). Functional coupling between secre-
tory phospholipase a2 and cyclooxygenase-2 and its regulation by cytosolic group iv
phospholipase a2. Proc Natl Acad Sci U S A, 95(14):7951–7956.
Banno, A. and Ginsberg, M. H. (2008). Integrin activation. Biochem Soc Trans, 36(Pt 2):229–
234.
Barabási, A. and Oltvai, Z. N. (2004). Network biology: understanding the cell’s functional
organization. Nat Rev Genet, 5(2):101–113.
Bari, R. and Jones, J. D. G. (2009). Role of plant hormones in plant defence responses. Plant
Mol Biol, 69(4):473–488.
154
REFERENCES
Battinelli, E. M., Hartwig, J. H., and Italiano, Jr, J. E. (2007). Delivering new insight into the
biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol, 14(5):419–426.
Bauman, A. L., Soughayer, J., Nguyen, B. T., Willoughby, D., Carnegie, G. K., Wong, W.,
Hoshi, N., Langeberg, L. K., Cooper, D. M. F., Dessauer, C. W., and Scott, J. D. (2006). Dy-
namic regulation of camp synthesis through anchored pka-adenylyl cyclase v/vi com-
plexes. Mol Cell, 23(6):925–931.
Bazzoni, F. and Beutler, B. (1996). The tumor necrosis factor ligand and receptor families.
N Engl J Med, 334(26):1717–1725.
Beazely, M. A., Alan, J. K., and Watts, V. J. (2005). Protein kinase c and epidermal growth
factor stimulation of raf1 potentiates adenylyl cyclase type 6 activation in intact cells.
Mol Pharmacol, 67(1):250–259.
Beck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., and De
Bosscher, K. (2009). Crosstalk in inflammation: the interplay of glucocorticoid receptor-
based mechanisms and kinases and phosphatases. Endocr Rev, 30(7):830–882.
Becker, V., Schilling, M., Bachmann, J., Baumann, U., Raue, A., Maiwald, T., Timmer, J., and
Klingmüller, U. (2010). Covering a broad dynamic range: information processing at the
erythropoietin receptor. Science, 328(5984):1404–1408.
Bell, E. T. (1986). Men of Mathematics. Touchstone.
Bender, A. T. and Beavo, J. A. (2006). Cyclic nucleotide phosphodiesterases: molecular
regulation to clinical use. Pharmacol Rev, 58:488–520. 3.
Bergmeier, W., Oh-Hora, M., McCarl, C.-A., Roden, R. C., Bray, P. F., and Feske, S. (2009).
R93w mutation in orai1 causes impaired calcium influx in platelets. Blood, 113(3):675–
678.
Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature, 415(6868):198–205.
Beyer, E. M. and MacBeath, G. (2012). Cross-talk between receptor tyrosine kinase and
tumor necrosis factor-? signaling networks regulates apoptosis but not proliferation.
Mol Cell Proteomics, 11(6):M111.013292.
Billah, M. M., Lapetina, E. G., and Cuatrecasas, P. (1980). Phospholipase a2 and phos-
pholipase c activities of platelets. differential substrate specificity, ca2+ requirement, ph
dependence, and cellular localization. J Biol Chem, 255(21):10227–10231.
Bilodeau, M. L. and Hamm, H. E. (2007). Regulation of protease-activated receptor (par) 1
and par4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
J Pharmacol Exp Ther, 322(2):778–788.
Blank, U., Karlsson, G., and Karlsson, S. (2008). Signaling pathways governing stem-cell
fate. Blood, 111(2):492–503.
Blumer, K. J. and Thorner, J. (1991). Receptor-g protein signaling in yeast. Annu Rev Physiol,
53:37–57.
Bodnar, R. J., Xi, X., Li, Z., Berndt, M. C., and Du, X. (2002). Regulation of glycoprotein ib-
ix-von willebrand factor interaction by camp-dependent protein kinase-mediated phos-
phorylation at ser 166 of glycoprotein ib(beta). J Biol Chem, 277(49):47080–47087.
Boess, F. G., Hendrix, M., van der Staay, F.-J., Erb, C., Schreiber, R., van Staveren, W.,
de Vente, J., Prickaerts, J., Blokland, A., and Koenig, G. (2004). Inhibition of phosphodi-
esterase 2 increases neuronal cgmp, synaptic plasticity and memory performance. Neu-
ropharmacology, 47(7):1081–1092.
155
REFERENCES
Boole, G. (1847). The Mathematical Analysis of Logic. Barclay and Macmillan, Cambridge.
Boole, G. (1848). The calculus of logic. Cambridge and Dublin Mathematical Journal, 3:183–98.
Boole, G. (1854). An investigation of the laws of thought: on which are founded the mathematical
theories of logic and probabilities. Walton and Maberly.
Boschert, V., Krippner-Heidenreich, A., Branschädel, M., Tepperink, J., Aird, A., and
Scheurich, P. (2010). Single chain tnf derivatives with individually mutated receptor
binding sites reveal differential stoichiometry of ligand receptor complex formation for
tnfr1 and tnfr2. Cell Signal, 22(7):1088–1096.
Bouwens, L., De Bleser, P., Vanderkerken, K., Geerts, B., and Wisse, E. (1992). Liver cell
heterogeneity: functions of non-parenchymal cells. Enzyme, 46(1-3):155–168.
Box, G. E. P. (1976). Science and statistics. Journal of the American Statistical Association,
71:791–799.
Boyanova, D., Nilla, S., Birschmann, I., Dandekar, T., and Dittrich, M. (2012). Plateletweb:
a systems biologic analysis of signaling networks in human platelets. Blood, 119(3):e22–
e34.
Bradley, J. R. (2008). Tnf-mediated inflammatory disease. J Pathol, 214(2):149–160.
Braun, A., Varga-Szabo, D., Kleinschnitz, C., Pleines, I., Bender, M., Austinat, M., Bösl,
M., Stoll, G., and Nieswandt, B. (2009). Orai1 (cracm1) is the platelet soc channel and
essential for pathological thrombus formation. Blood, 113(9):2056–2063.
Briggs, G. E. and Haldane, J. B. (1925). A note on the kinetics of enzyme action. Biochem J,
19(2):338–339.
Brodde, O.-E., Bruck, H., and Leineweber, K. (2006). Cardiac adrenoceptors: physiological
and pathophysiological relevance. J Pharmacol Sci, 100(5):323–337.
Broos, K., De Meyer, S. F., Feys, H. B., Vanhoorelbeke, K., and Deckmyn, H. (2012). Blood
platelet biochemistry. Thromb Res, 129(3):245–249.
Buck, L. B. (2000). The molecular architecture of odor and pheromone sensing in mammals.
Cell, 100(6):611–618.
Bullock, A. N., Das, S., Debreczeni, J. E., Rellos, P., Fedorov, O., Niesen, F. H., Guo, K.,
Papagrigoriou, E., Amos, A. L., Cho, S., Turk, B. E., Ghosh, G., and Knapp, S. (2009). Ki-
nase domain insertions define distinct roles of clk kinases in sr protein phosphorylation.
Structure, 17(3):352–362.
Burnham, K. P. and Anderson, D. R. (2002). Model Selection and Multi-Model Inference: A
Practical Information-Theoretic Approach. Springer.
Butt, E., Abel, K., Krieger, M., Palm, D., Hoppe, V., Hoppe, J., and Walter, U. (1994).
cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion
vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J
Biol Chem, 269:14509–17. 20.
Butt, E., Gambaryan, S., Göttfert, N., Galler, A., Marcus, K., and Meyer, H. E. (2003). Actin
binding of human lim and sh3 protein is regulated by cgmp- and camp-dependent pro-
tein kinase phosphorylation on serine 146. J Biol Chem, 278(18):15601–15607.
156
REFERENCES
Butt, E., Immler, D., Meyer, H. E., Kotlyarov, A., Laass, K., and Gaestel, M. (2001). Heat
shock protein 27 is a substrate of cgmp-dependent protein kinase in intact human pla-
telets: phosphorylation-induced actin polymerization caused by hsp27 mutants. J Biol
Chem, 276(10):7108–7113.
Butt, E. and Walter, U. (1997). Platelet phosphodiesterases. Handbook of experimental phar-
macology, 126:219–230.
Cabal-Hierro, L. and Lazo, P. S. (2012). Signal transduction by tumor necrosis factor recep-
tors. Cell Signal, 24(6):1297–1305.
Calderwood, D. A., Fujioka, Y., de Pereda, J. M., García-Alvarez, B., Nakamoto, T., Mar-
golis, B., McGlade, C. J., Liddington, R. C., and Ginsberg, M. H. (2003). Integrin beta
cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural
prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A, 100(5):2272–2277.
Campbell, P. (1999). Can physics deliver another biological revolution? Nature,
397(6715):89.
Carlotti, F., Dower, S. K., and Qwarnstrom, E. E. (2000). Dynamic shuttling of nuclear factor
kappa b between the nucleus and cytoplasm as a consequence of inhibitor dissociation.
J Biol Chem, 275(52):41028–41034.
Cattaneo, M., Canciani, M. T., Lecchi, A., Kinlough-Rathbone, R. L., Packham, M. A.,
Mannucci, P. M., and Mustard, J. F. (1990). Released adenosine diphosphate stabilizes
thrombin-induced human platelet aggregates. Blood, 75(5):1081–1086.
Cattaneo, M. and Gachet, C. (2001). The platelet adp receptors. Haematologica, 86(4):346–
348.
Cer, R. Z., Mudunuri, U., Stephens, R., and Lebeda, F. J. (2009). Ic50-to-ki: a web-based
tool for converting ic50 to ki values for inhibitors of enzyme activity and ligand binding.
Nucleic Acids Res, 37(Web Server issue):W441–W445.
Chan, F. K., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L., and Lenardo, M. J. (2000). A
domain in tnf receptors that mediates ligand-independent receptor assembly and signa-
ling. Science, 288(5475):2351–2354.
Chatterjee, M. S., Denney, W. S., Jing, H., and Diamond, S. L. (2010). Systems biology of
coagulation initiation: kinetics of thrombin generation in resting and activated human
blood. PLoS Comput Biol, 6(9).
Chen, G. and Goeddel, D. V. (2002). Tnf-r1 signaling: a beautiful pathway. Science,
296(5573):1634–1635.
Chen, M. and Stracher, A. (1989). In situ phosphorylation of platelet actin-binding protein
by camp-dependent protein kinase stabilizes it against proteolysis by calpain. J Biol
Chem, 264(24):14282–14289.
Chen, W. W., Niepel, M., and Sorger, P. K. (2010). Classic and contemporary approaches to
modeling biochemical reactions. Genes Dev, 24(17):1861–1875.
Chen, Y., Harry, A., Li, J., Smit, M. J., Bai, X., Magnusson, R., Pieroni, J. P., Weng, G.,
and Iyengar, R. (1997). Adenylyl cyclase 6 is selectively regulated by protein kinase a
phosphorylation in a region involved in galphas stimulation. Proceedings of the National
Academy of Sciences of the United States of America, 94:14100–4. 25.
157
REFERENCES
Chen, Z., Agnew, J. L., Cohen, J. D., He, P., Shan, L., Sheen, J., and Kunkel, B. N. (2007).
Pseudomonas syringae type iii effector avrrpt2 alters arabidopsis thaliana auxin physi-
ology. Proc Natl Acad Sci U S A, 104(50):20131–20136.
Cheong, R., Hoffmann, A., and Levchenko, A. (2008). Understanding nf-kappab signaling
via mathematical modeling. Mol Syst Biol, 4:192.
Choi, J., Huh, S. U., Kojima, M., Sakakibara, H., Paek, K.-H., and Hwang, I. (2010). The
cytokinin-activated transcription factor arr2 promotes plant immunity via tga3/npr1-
dependent salicylic acid signaling in arabidopsis. Dev Cell, 19(2):284–295.
Chuang, H.-Y., Hofree, M., and Ideker, T. (2010). A decade of systems biology. Annu Rev
Cell Dev Biol, 26:721–744.
Cicmil, M., Thomas, J. M., Leduc, M., Bon, C., and Gibbins, J. M. (2002). Platelet endothe-
lial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood,
99(1):137–144.
Cohen, J. E. (2004). Mathematics is biology’s next microscope, only better; biology is ma-
thematics’ next physics, only better. PLoS Biol, 2(12):e439.
Coleman, T. F. and Li, A. Y. (1996). An interior trust region approach for nonlinear mini-
mization subject to bounds. SIAM Journal on Optimization, 6:418–455.
Colvin, J., Monine, M. I., Gutenkunst, R. N., Hlavacek, W. S., Von Hoff, D. D., and Posner,
R. G. (2010). Rulemonkey: software for stochastic simulation of rule-based models. BMC
Bioinformatics, 11:404.
Corbin, J. D., Beebe, S. J., and Blackmore, P. F. (1985). cAMP-dependent protein kinase
activation lowers hepatocyte cAMP. The Journal of biological chemistry, 260:8731–5. 15.
Cornish-Bowden, A. (2012). Fundamentals of enzyme kinetics. Wiley-VCH.
Coussens, L. M. and Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917):860–867.
Cox, D. R. and Hinkley, D. V. (1974). Theoretical Statistics. Chapman & Hall.
Cox, D. R. and Hinkley, D. V. (1994). Theoretical Statistics. Chapman and Hall, New York.
Crittenden, J. R., Bergmeier, W., Zhang, Y., Piffath, C. L., Liang, Y., Wagner, D. D., Hous-
man, D. E., and Graybiel, A. M. (2004). Caldag-gefi integrates signaling for platelet
aggregation and thrombus formation. Nat Med, 10(9):982–986.
Croft, M. (2009). The role of tnf superfamily members in t-cell function and diseases. Nat
Rev Immunol, 9(4):271–285.
Daniel, J. L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J. B., and Kunapuli, S. P. (1998).
Molecular basis for adp-induced platelet activation. i. evidence for three distinct adp
receptors on human platelets. J Biol Chem, 273(4):2024–2029.
Daniel, J. L., Dangelmaier, C., Jin, J., Kim, Y. B., and Kunapuli, S. P. (1999). Role of intracel-
lular signaling events in adp-induced platelet aggregation. Thromb Haemost, 82(4):1322–
1326.
Danos, V., Feret, J., Fontana, W., Harmer, R., and Krivine, J. (2007). Rule-based modelling
of cellular signalling. CONCUR 2007–Concurrency Theory, pages 17–41.
Davi, G. and Patrono, C. (2007). Platelet activation and atherothrombosis. N Engl J Med,
357(24):2482–2494.
158
REFERENCES
de Almagro, M. C. and Vucic, D. (2012). The inhibitor of apoptosis (iap) proteins are crit-
ical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol,
34(3):200–211.
De Jong, H., Geiselmann, J., Hernandez, C., and Page, M. (2003). Genetic network analyzer:
qualitative simulation of genetic regulatory networks. Bioinformatics, 19(3):336–344.
Di Cara, A., Garg, A., De Micheli, G., Xenarios, I., and Mendoza, L. (2007). Dynamic simu-
lation of regulatory networks using squad. BMC Bioinformatics, 8:462.
Diamond, S. L. (2009). Systems biology to predict blood function. J Thromb Haemost, 7
Suppl 1:177–180.
Dittrich, M., Birschmann, I., Mietner, S., Sickmann, A., Walter, U., and Dandekar, T. (2008).
Platelet protein interactions: map, signaling components, and phosphorylation ground-
state. Arterioscler Thromb Vasc Biol, 28:1326–31. 7.
Dittrich, M., Birschmann, I., Pfrang, J., Herterich, S., Smolenski, A., Walter, U., and Dan-
dekar, T. (2006). Analysis of SAGE data in human platelets: features of the transcriptome
in an anucleate cell. Thromb Haemost, 95:643–51. 4.
Dittrich, M., Strassberger, V., Fackler, M., Tas, P., Lewandrowski, U., Sickmann, A., Wal-
ter, U., Dandekar, T., and Birschmann, I. (2010). Characterization of a novel interaction
between vasodilator-stimulated phosphoprotein and abelson interactor 1 in human pla-
telets: a concerted computational and experimental approach. Arterioscler Thromb Vasc
Biol, 30:843–50. 4.
Dohlman, H. G., Thorner, J., Caron, M. G., and Lefkowitz, R. J. (1991). Model systems for
the study of seven-transmembrane-segment receptors. Annu Rev Biochem, 60:653–688.
Dragovich, T., Rudin, C. M., and Thompson, C. B. (1998). Signal transduction pathways
that regulate cell survival and cell death. Oncogene, 17(25):3207–3213.
Dunkern, T. R. and Hatzelmann, A. (2005). The effect of sildenafil on human platelet secre-
tory function is controlled by a complex interplay between phosphodiesterases 2, 3 and
5. Cell Signal, 17(3):331–339.
Ea, C.-K., Deng, L., Xia, Z.-P., Pineda, G., and Chen, Z. J. (2006). Activation of ikk by
tnfalpha requires site-specific ubiquitination of rip1 and polyubiquitin binding by nemo.
Mol Cell, 22(2):245–257.
Eigenthaler, M., Nolte, C., Halbrügge, M., and Walter, U. (1992). Concentration and regula-
tion of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their
major substrates in human platelets. estimating the rate of camp-regulated and cgmp-
regulated protein phosphorylation in intact cells. Eur J Biochem, 205(2):471–481.
El-Daher, S. S., Patel, Y., Siddiqua, A., Hassock, S., Edmunds, S., Maddison, B., Patel, G.,
Goulding, D., Lupu, F., Wojcikiewicz, R. J., and Authi, K. S. (2000). Distinct localization
and function of (1,4,5)ip(3) receptor subtypes and the (1,3,4,5)ip(4) receptor gap1(ip4bp)
in highly purified human platelet membranes. Blood, 95(11):3412–3422.
Enyedi, A., Sarkadi, B., Földes-Papp, Z., Monostory, S., and Gárdos, G. (1986). Demonstra-
tion of two distinct calcium pumps in human platelet membrane vesicles. J Biol Chem,
261(20):9558–9563.
Erdoes, P. and Renyi, A. (1960). On the evolution of random graphs. Publ Math Inst Hung
Acad Sci, 5:17–61.
159
REFERENCES
Espinosa-Soto, C., Padilla-Longoria, P., and Alvarez-Buylla, E. R. (2004). A gene regula-
tory network model for cell-fate determination during arabidopsis thaliana flower de-
velopment that is robust and recovers experimental gene expression profiles. Plant Cell,
16(11):2923–2939.
Euler, L. (1736). Solutio Problematis ad Geometriam Situs Pertinentis, Commentarii
Academiae Scientiarum Imperialis Petropolitanae. Commentarii Academiae Scientiarum
Imperialis Petropolitanae, 8:128–140.
Ewens, W. J. (1972). The sampling theory of selectively neutral alleles. Theor Popul Biol,
3(1):87–112.
Eykhoff, P. (1974). System Identification: Parameter and State Estimation. John Wiley & Sons.
Faeder, J. R., Blinov, M. L., and Hlavacek, W. S. (2009). Rule-based modeling of biochemical
systems with bionetgen. Methods Mol Biol, 500:113–167.
Faustman, D. and Davis, M. (2010). Tnf receptor 2 pathway: drug target for autoimmune
diseases. Nat Rev Drug Discov, 9(6):482–493.
Feijge, M. A., Ansink, K., Vanschoonbeek, K., and Heemskerk, J. W. (2004). Control of pla-
telet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Biochem Pharmacol, 67:1559–67. 8.
Feng, G., Tintrup, H., Kirsch, J., Nichol, M. C., Kuhse, J., Betz, H., and Sanes, J. R. (1998).
Dual requirement for gephyrin in glycine receptor clustering and molybdoenzyme acti-
vity. Science, 282(5392):1321–1324.
Fink, L., Hölschermann, H., Kwapiszewska, G., Muyal, J. P., Lengemann, B., Bohle, R. M.,
and Santoso, S. (2003). Characterization of platelet-specific mrna by real-time pcr after
laser-assisted microdissection. Thromb Haemost, 90(4):749–756.
Fischmeister, R., Castro, L. R. V., Abi-Gerges, A., Rochais, F., Jurevicius, J., Leroy, J., and
Vandecasteele, G. (2006). Compartmentation of cyclic nucleotide signaling in the heart:
the role of cyclic nucleotide phosphodiesterases. Circ Res, 99(8):816–828.
Floreani, M., Fossa, P., Gessi, S., Mosti, L., Borea, P. A., and Dorigo, P. (2003). New milrinone
analogues: in vitro study of structure-activity relationships for positive inotropic effect,
antagonism towards endogenous adenosine, and inhibition of cardiac type iii phospho-
diesterase. Naunyn Schmiedebergs Arch Pharmacol, 367(2):109–118.
Fontana, D., Wong, T. Y., Theibert, A., and Devreotes, P. (1986). Cell-cell interactions in the
development of dictyostelium. Dev Biol (N Y 1985), 3:261–281.
Forsell, P. K. A., Olsson, A. O., Andersson, E., Nallan, L., and Gelb, M. H. (2005). Poly-
chlorinated biphenyls induce arachidonic acid release in human platelets in a tamoxifen
sensitive manner via activation of group iva cytosolic phospholipase a2-alpha. Biochem
Pharmacol, 71(1-2):144–155.
Fotin-Mleczek, M., Henkler, F., Hausser, A., Glauner, H., Samel, D., Graness, A., Scheurich,
P., Mauri, D., and Wajant, H. (2004). Tumor necrosis factor receptor-associated fac-
tor (traf) 1 regulates cd40-induced traf2-mediated nf-kappab activation. J Biol Chem,
279(1):677–685.
Fotin-Mleczek, M., Henkler, F., Samel, D., Reichwein, M., Hausser, A., Parmryd, I.,
Scheurich, P., Schmid, J. A., and Wajant, H. (2002). Apoptotic crosstalk of tnf recep-
tors: Tnf-r2-induces depletion of traf2 and iap proteins and accelerates tnf-r1-dependent
activation of caspase-8. J Cell Sci, 115(Pt 13):2757–2770.
160
REFERENCES
Frantz, S., Fraccarollo, D., Wagner, H., Behr, T. M., Jung, P., Angermann, C. E., Ertl, G.,
and Bauersachs, J. (2003). Sustained activation of nuclear factor kappa b and activator
protein 1 in chronic heart failure. Cardiovasc Res, 57(3):749–756.
Fraser, I. D. C. and Germain, R. N. (2009). Navigating the network: signaling cross-talk in
hematopoietic cells. Nat Immunol, 10(4):327–331.
Funahashi, A., Matsuoka, Y., Jouraku, A., Morohashi, M., Kikuchi, N., and Kitano, H.
(2008). Celldesigner 3.5 : A versatile modeling tool for biochemical networks. Proceedings
of the IEEE, 96:1254–1265.
Gambaryan, S., Kobsar, A., Hartmann, S., Birschmann, I., Kuhlencordt, P. J., Müller-Esterl,
W., Lohmann, S. M., and Walter, U. (2008). No-synthase-/no-independent regulation
of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost,
6(8):1376–1384.
Gambaryan, S., Kobsar, A., Rukoyatkina, N., Herterich, S., Geiger, J., Smolenski, A.,
Lohmann, S. M., and Walter, U. (2010). Thrombin and collagen induce a feedback in-
hibitory signaling pathway in platelets involving dissociation of the catalytic subunit of
protein kinase a from an nfkappab-ikappab complex. J Biol Chem, 285(24):18352–18363.
Gan, S. and Amasino, R. M. (1995). Inhibition of leaf senescence by autoregulated produc-
tion of cytokinin. Science, 270(5244):1986–1988.
Garcia, A., Kim, S., Bhavaraju, K., Schoenwaelder, S. M., and Kunapuli, S. P. (2010). Role of
phosphoinositide 3-kinase beta in platelet aggregation and thromboxane a2 generation
mediated by gi signalling pathways. Biochem J, 429(2):369–377.
Garcia, A., Prabhakar, S., Brock, C. J., Pearce, A. C., Dwek, R. A., Watson, S. P., Hebestreit,
H. F., and Zitzmann, N. (2004). Extensive analysis of the human platelet proteome by
two-dimensional gel electrophoresis and mass spectrometry. Proteomics, 4(3):656–668.
Garg, A., Xenarios, I., Mendoza, L., and DeMicheli, G. (2007). An efficient method for dy-
namic analysis of gene regulatory networks. In: Lecture Notes in Computer Science (Vol. 4453).
Springer.
Gazzarrini, S. and McCourt, P. (2003). Cross-talk in plant hormone signalling: what ara-
bidopsis mutants are telling us. Ann Bot, 91(6):605–612.
Geier, F., Fengos, G., and Iber, D. (2011). A computational analysis of the dynamic roles of
talin, dok1, and pipki for integrin activation. PLoS One, 6(11):e24808.
Geiger, J., Brandmann, T., Hubertus, K., Tjahjadi, B., Schinzel, R., and Walter, U. (2010). A
protein phosphorylation-based assay for screening and monitoring of drugs modulating
cyclic nucleotide pathways. Anal Biochem, 407:261–9. 2.
Geiger, J., Honig-Liedl, P., Schanzenbacher, P., and Walter, U. (1998). Ligand specificity and
ticlopidine effects distinguish three human platelet ADP receptors. European journal of
pharmacology, 351:235–46. 2.
Gettys, T. W., Vine, A. J., Simonds, M. F., and Corbin, J. D. (1988). Activation of the partic-
ulate low km phosphodiesterase of adipocytes by addition of cAMP-dependent protein
kinase. The Journal of biological chemistry, 263:10359–63. 21.
Geva-Zatorsky, N., Dekel, E., Cohen, A. A., Danon, T., Cohen, L., and Alon, U. (2010).
Protein dynamics in drug combinations: a linear superposition of individual-drug re-
sponses. Cell, 140:643–51. 5.
161
REFERENCES
Ghosh, S. and Karin, M. (2002). Missing pieces in the nf-kappab puzzle. Cell, 109 Suppl:S81–
S96.
Gillespie, D. T. (2007). Stochastic simulation of chemical kinetics. Annu Rev Phys Chem,
58:35–55.
Givertz, M. M. and Colucci, W. S. (1998). New targets for heart-failure therapy: endothelin,
inflammatory cytokines, and oxidative stress. Lancet, 352 Suppl 1:SI34–SI38.
Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., and Barabási, A.-L. (2007). The
human disease network. Proc Natl Acad Sci U S A, 104(21):8685–8690.
Gomberg-Maitland, M. and Olschewski, H. (2008). Prostacyclin therapies for the treatment
of pulmonary arterial hypertension. The European respiratory journal : official journal of the
European Society for Clinical Respiratory Physiology, 31:891–901. 4.
Gonzalez, A. G., Naldi, A., Sánchez, L., Thieffry, D., and Chaouiya, C. (2006). Ginsim: a
software suite for the qualitative modelling, simulation and analysis of regulatory net-
works. Biosystems, 84(2):91–100.
Grell, M. (1995). Tumor necrosis factor (tnf) receptors in cellular signaling of soluble and
membrane-expressed tnf. J Inflamm, 47(1-2):8–17.
Grell, M., Douni, E., Wajant, H., Löhden, M., Clauss, M., Maxeiner, B., Georgopoulos, S.,
Lesslauer, W., Kollias, G., Pfizenmaier, K., and Scheurich, P. (1995). The transmembrane
form of tumor necrosis factor is the prime activating ligand of the 80 kda tumor necrosis
factor receptor. Cell, 83(5):793–802.
Grell, M. and Scheurich, P. (1997). Growth Factors and Cytokines in Health and Disease. JAI
Press Inc., Greenwich, CT.
Grell, M., Wajant, H., Zimmermann, G., and Scheurich, P. (1998). The type 1 receptor
(cd120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad
Sci U S A, 95(2):570–575.
Grieneisen, V. A., Xu, J., Marée, A. F. M., Hogeweg, P., and Scheres, B. (2007). Auxin trans-
port is sufficient to generate a maximum and gradient guiding root growth. Nature,
449(7165):1008–1013.
Grima, R. and Schnell, S. (2006). A systematic investigation of the rate laws valid in intra-
cellular environments. Biophys Chem, 124(1):1–10.
Gross, L. (2006). When evidence is scant, mathematical modeling offers a roadmap for
discovery. PLoS Biol, 4(10):e323.
Grosse, J., Braun, A., Varga-Szabo, D., Beyersdorf, N., Schneider, B., Zeitlmann, L., Hanke,
P., Schropp, P., Mühlstedt, S., Zorn, C., Huber, M., Schmittwolf, C., Jagla, W., Yu,
P., Kerkau, T., Schulze, H., Nehls, M., and Nieswandt, B. (2007). An ef hand muta-
tion in stim1 causes premature platelet activation and bleeding in mice. J Clin Invest,
117(11):3540–3550.
Grosskinsky, D. K., Naseem, M., Abdelmohsen, U. R., Plickert, N., Engelke, T., Griebel,
T., Zeier, J., Novák, O., Strnad, M., Pfeifhofer, H., van der Graaff, E., Simon, U., and
Roitsch, T. (2011). Cytokinins mediate resistance against pseudomonas syringae in to-
bacco through increased antimicrobial phytoalexin synthesis independent of salicylic
acid signaling. Plant Physiol, 157(2):815–830.
Guerriero, M. L., Pokhilko, A., Fernández, A. P., Halliday, K. J., Millar, A. J., and Hillston, J.
(2012). Stochastic properties of the plant circadian clock. J R Soc Interface, 9(69):744–756.
162
REFERENCES
Guldberg, C. M. and Waage, P. (1864). Studies concerning affinities. Forhandlinger:
Videnskabs-Selskabet i Christiana, 35.
Guldberg, C. M. and Waage, P. (1879). Über die chemische Affinität. Journal fuer Praktische
Chemie, 19:69.
Guruharsha, K. G., Rual, J.-F., Zhai, B., Mintseris, J., Vaidya, P., Vaidya, N., Beekman, C.,
Wong, C., Rhee, D. Y., Cenaj, O., McKillip, E., Shah, S., Stapleton, M., Wan, K. H., Yu, C.,
Parsa, B., Carlson, J. W., Chen, X., Kapadia, B., VijayRaghavan, K., Gygi, S. P., Celniker,
S. E., Obar, R. A., and Artavanis-Tsakonas, S. (2011). A protein complex network of
drosophila melanogaster. Cell, 147(3):690–703.
Haberstock-Debic, H., Andre, P., Mills, S., Phillips, D. R., and Conley, P. B. (2011). A
clopidogrel-insensitive inducible pool of p2y12 receptors contributes to thrombus for-
mation: inhibition by elinogrel, a direct-acting, reversible p2y12 antagonist. J Pharmacol
Exp Ther, 339(1):54–61.
Halbrügge, M. and Walter, U. (1989). Purification of a vasodilator-regulated phosphopro-
tein from human platelets. Eur J Biochem, 185(1):41–50.
Hall, P. and Wilson, S. R. (1991). Two guidelines for bootstrap hypothesis testing. Biometrics,
47:757 – 762.
Hanada, T. and Yoshimura, A. (2002). Regulation of cytokine signaling and inflammation.
Cytokine Growth Factor Rev, 13(4-5):413–421.
Hanson, M. S., Stephenson, A. H., Bowles, E. A., Sridharan, M., Adderley, S., and Sprague,
R. S. (2008). Phosphodiesterase 3 is present in rabbit and human erythrocytes and its in-
hibition potentiates iloprost-induced increases in cAMP. Am J Physiol Heart Circ Physiol,
295:H786–93. 2.
Harbeck, B., Hüttelmaier, S., Schluter, K., Jockusch, B. M., and Illenberger, S. (2000). Phos-
phorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with
actin. J Biol Chem, 275(40):30817–30825.
Hardy, G. H. (1908). Mendelian proportions in a mixed population. Science, 28(706):49–50.
Haslam, R. J., Dickinson, N. T., and Jang, E. K. (1999). Cyclic nucleotides and phosphodi-
esterases in platelets. Thromb Haemost, 82(2):412–423.
Hassock, S. R., Zhu, M. X., Trost, C., Flockerzi, V., and Authi, K. S. (2002). Expression and
role of trpc proteins in human platelets: evidence that trpc6 forms the store-independent
calcium entry channel. Blood, 100(8):2801–2811.
Hathaway, D. R. and Adelstein, R. S. (1979). Human platelet myosin light chain kinase
requires the calcium-binding protein calmodulin for activity. Proc Natl Acad Sci U S A,
76(4):1653–1657.
Hauser, W., Knobeloch, K. P., Eigenthaler, M., Gambaryan, S., Krenn, V., Geiger, J., Glazova,
M., Rohde, E., Horak, I., Walter, U., and Zimmer, M. (1999). Megakaryocyte hyperplasia
and enhanced agonist-induced platelet activation in vasodilator-stimulated phospho-
protein knockout mice. Proc Natl Acad Sci U S A, 96(14):8120–8125.
Hayden, M. S. and Ghosh, S. (2004). Signaling to nf-kappab. Genes Dev, 18(18):2195–2224.
Hechler, B. and Gachet, C. (2011). P2 receptors and platelet function. Purinergic Signal,
7(3):293–303.
163
REFERENCES
Hechler, B., Léon, C., Vial, C., Vigne, P., Frelin, C., Cazenave, J. P., and Gachet, C. (1998). The
p2y1 receptor is necessary for adenosine 5’-diphosphate-induced platelet aggregation.
Blood, 92(1):152–159.
Heemskerk, J. W. M., Bevers, E. M., and Lindhout, T. (2002). Platelet activation and blood
coagulation. Thromb Haemost, 88(2):186–193.
Heidbreder, M., Zander, C., Malkusch, S., Widera, D., Kaltschmidt, B., Kaltschmidt, C.,
Nair, D., Choquet, D., Sibarita, J.-B., and Heilemann, M. (2012). Tnf-? influences the
lateral dynamics of tnf receptor i in living cells. Biochim Biophys Acta, 1823(10):1984–
1989.
Heinrich, R. and Schuster, S. (1996). The Regulation Of Cellular Systems. Chapman & Hall.
Hengl, S., Kreutz, C., Timmer, J., and Maiwald, T. (2007). Data-based identifiability analysis
of non-linear dynamical models. Bioinformatics, 23(19):2612–2618.
Herget, S., Lohse, M. J., and Nikolaev, V. O. (2008). Real-time monitoring of phosphodi-
esterase inhibition in intact cells. Cell Signal, 20(8):1423–1431.
Hettasch, J. M. and Sellers, J. R. (1991). Caldesmon phosphorylation in intact human plate-
lets by camp-dependent protein kinase and protein kinase c. J Biol Chem, 266(18):11876–
11881.
Heyninck, K. and Beyaert, R. (2005). A20 inhibits nf-kappab activation by dual ubiquitin-
editing functions. Trends Biochem Sci, 30(1):1–4.
Hines, L. M. and Tabakoff, B. (2005). Platelet adenylyl cyclase activity: a biological marker
for major depression and recent drug use. Biological psychiatry, 58:955–62. 12.
Hlavacek, W. S., Faeder, J. R., Blinov, M. L., Perelson, A. S., and Goldstein, B. (2003). The
complexity of complexes in signal transduction. Biotechnol Bioeng, 84(7):783–794.
Hlavacek, W. S., Faeder, J. R., Blinov, M. L., Posner, R. G., Hucka, M., and Fontana, W.
(2006). Rules for modeling signal-transduction systems. Sci STKE, 2006(344):re6.
Ho, K. L. and Harrington, H. A. (2010). Bistability in apoptosis by receptor clustering. PLoS
Comput Biol, 6(10):e1000956.
Hoffmann, A., Levchenko, A., Scott, M. L., and Baltimore, D. (2002). The IkappaB-NF-
kappaB signaling module: temporal control and selective gene activation. Science,
298(5596):1241–1245.
Hoffmeister, M., Riha, P., Neumüller, O., Danielewski, O., Schultess, J., and Smolenski,
A. P. (2008). Cyclic nucleotide-dependent protein kinases inhibit binding of 14-3-3 to the
gtpase-activating protein rap1gap2 in platelets. J Biol Chem, 283(4):2297–2306.
Hofmann, F. (2005). The biology of cyclic gmp-dependent protein kinases. J Biol Chem,
280(1):1–4.
Hornbeck, P. V., Chabra, I., Kornhauser, J. M., Skrzypek, E., and Zhang, B. (2004). Phos-
phosite: A bioinformatics resource dedicated to physiological protein phosphorylation.
Proteomics, 4(6):1551–1561.
Hornberg, J. J., Bruggeman, F. J., Binder, B., Geest, C. R., de Vaate, A. J. M. B., Lankelma,
J., Heinrich, R., and Westerhoff, H. V. (2005). Principles behind the multifarious control
of signal transduction. erk phosphorylation and kinase/phosphatase control. FEBS J,
272(1):244–258.
164
REFERENCES
Hotamisligil, G. S. (2003). Inflammatory pathways and insulin action. Int J Obes Relat Metab
Disord, 27 Suppl 3:S53–S55.
Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. Nature, 444(7121):860–
867.
Houslay, M. D. (2010). Underpinning compartmentalised cAMP signalling through tar-
geted cAMP breakdown. Trends Biochem Sci, 35:91–100. 2.
Hoylaerts, M. F., Oury, C., Toth-Zsamboki, E., and Vermylen, J. (2000). Adp receptors in
platelet activation and aggregation. Platelets, 11(6):307–309.
Hsieh, M. Y., Yang, S., Raymond-Stinz, M. A., Edwards, J. S., and Wilson, B. S. (2010).
Spatio-temporal modeling of signaling protein recruitment to EGFR. BMC Syst Biol,
4:57.
Huard, J., Mueller, S., Gilles, E. D., Klingmüller, U., and Klamt, S. (2012). An integrative
model links multiple inputs and signaling pathways to the onset of dna synthesis in
hepatocytes. FEBS J, 279(18):3290–3313.
Hubertus, K. (2012). Regulation of cAMP level and signaltransduction in human platelets by
prostanoid-receptors. PhD thesis, University of Wuerzburg, Faculty of Biology.
Hunter, R. W., Mackintosh, C., and Hers, I. (2009). Protein kinase c-mediated phosphory-
lation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem,
284:12339–48. 18.
Iadevaia, S., Lu, Y., Morales, F. C., Mills, G. B., and Ram, P. T. (2010). Identification of op-
timal drug combinations targeting cellular networks: integrating phospho-proteomics
and computational network analysis. Cancer Res, 70(17):6704–6714.
Ishii-Watabe, A., Uchida, E., Mizuguchi, H., and Hayakawa, T. (2001). Involvement of
a calcium-independent pathway in plasmin-induced platelet shape change. Life Sci,
69(8):945–960.
Iwami, G., Kawabe, J., Ebina, T., Cannon, P. J., Homcy, C. J., and Ishikawa, Y. (1995). Regu-
lation of adenylyl cyclase by protein kinase a. J Biol Chem, 270:12481–4. 21.
Iyú, D., Glenn, J. R., White, A. E., Fox, S. C., Dovlatova, N., and Heptinstall, S. (2011). P2y12
and ep3 antagonists promote the inhibitory effects of natural modulators of platelet ag-
gregation that act via camp. Platelets, 22(7):504–515.
Iyu, D., Jüttner, M., Glenn, J. R., White, A. E., Johnson, A. J., Fox, S. C., and Heptinstall, S.
(2011). Pge1 and pge2 modify platelet function through different prostanoid receptors.
Prostaglandins Other Lipid Mediat, 94(1-2):9–16.
Jay, D., García, E. J., Lara, J. E., Medina, M. A., and de la Luz Ibarra, M. (2000). Determina-
tion of a camp-dependent protein kinase phosphorylation site in the c-terminal region
of human endothelial actin-binding protein. Arch Biochem Biophys, 377(1):80–84.
Jensen, F. V. (1996). An Introduction To Bayesian Networks. UCL Press.
Jeyaraj, S. C., Unger, N. T., and Chotani, M. A. (2011). Rap1 gtpases: an emerging role in
the cardiovasculature. Life Sci, 88(15-16):645–652.
Jin, J., Quinton, T. M., Zhang, J., Rittenhouse, S. E., and Kunapuli, S. P. (2002). Adeno-
sine diphosphate (adp)-induced thromboxane a(2) generation in human platelets re-
quires coordinated signaling through integrin alpha(iib)beta(3) and adp receptors. Blood,
99(1):193–198.
165
REFERENCES
Jin, Z. and El-Deiry, W. S. (2005). Overview of cell death signaling pathways. Cancer Biol
Ther, 4(2):139–163.
Jones, C. I., Barrett, N. E., Moraes, L. A., Gibbins, J. M., and Jackson, D. E. (2012). Endoge-
nous inhibitory mechanisms and the regulation of platelet function. Methods Mol Biol,
788:341–366.
Jones, J. D. G. and Dangl, J. L. (2006). The plant immune system. Nature, 444(7117):323–329.
Jones, R. L., Woodward, D. F., Wang, J. W., and Clark, R. L. (2011). Roles of affinity and
lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth
muscle preparations. Br J Pharmacol, 162(4):863–879.
Jordan, J. D., Landau, E. M., and Iyengar, R. (2000). Signaling networks: the origins of
cellular multitasking. Cell, 103(2):193–200.
Juska, A. and Farndale, R. W. (1999). Inhibition of human platelet adenylate cyclase acti-
vity by adrenaline, thrombin and collagen: analysis and reinterpretation of experimental
data. The Biochemical journal, 340 ( Pt 1):245–53.
Kahlem, P. and Birney, E. (2006). Dry work in a wet world: computation in systems biology.
Mol Syst Biol, 2:40.
Karniguian, A., Grelac, F., Levy-Toledano, S., Legrand, Y. J., and Rendu, F. (1990). Collagen-
induced platelet activation mainly involves the protein kinase c pathway. Biochem J,
268(2):325–331.
Kauffman, S. A. (1969). Metabolic stability and epigenesis in randomly constructed genetic
nets. J Theor Biol, 22(3):437–467.
Kawata, M., Kikuchi, A., Hoshijima, M., Yamamoto, K., Hashimoto, E., Yamamura, H., and
Takai, Y. (1989). Phosphorylation of smg p21, a ras p21-like gtp-binding protein, by cyclic
amp-dependent protein kinase in a cell-free system and in response to prostaglandin e1
in intact human platelets. J Biol Chem, 264(26):15688–15695.
Kenyon, C. J. (2010). The genetics of ageing. Nature, 464(7288):504–512.
Keshava Prasad, T. S., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan,
S., Telikicherla, D., Raju, R., Shafreen, B., Venugopal, A., Balakrishnan, L., Marimuthu,
A., Banerjee, S., Somanathan, D. S., Sebastian, A., Rani, S., Ray, S., Harrys Kishore, C. J.,
Kanth, S., Ahmed, M., Kashyap, M. K., Mohmood, R., Ramachandra, Y. L., Krishna,
V., Rahiman, B. A., Mohan, S., Ranganathan, P., Ramabadran, S., Chaerkady, R., and
Pandey, A. (2009). Human protein reference database–2009 update. Nucleic Acids Res,
37(Database issue):D767–D772.
Kholodenko, B. N. (2006). Cell-signalling dynamics in time and space. Nat Rev Mol Cell
Biol, 7(3):165–176.
Kirk, R. I., Sanderson, M. R., and Lerea, K. M. (2000). Threonine phosphorylation of the beta
3 integrin cytoplasmic tail, at a site recognized by pdk1 and akt/pkb in vitro, regulates
shc binding. J Biol Chem, 275(40):30901–30906.
Kitano, H. (2002). Systems biology: a brief overview. Science, 295(5560):1662–1664.
Klamt, S., Saez-Rodriguez, J., and Gilles, E. D. (2007). Structural and functional analysis of
cellular networks with cellnetanalyzer. BMC Syst Biol, 1:2.
Klipp, E., Liebermeister, W., Wierling, C., Kowald, A., Lehrach, H., and Herwig, R. (2009).
Systems Biology: A Textbook. WILEY-VCH.
166
REFERENCES
Kloeze, J. (1966). Influence of prostaglandins on platelet adhesiveness and platelet aggregation.
In: Bergström S, Samuelsson B, eds. Prostaglandins: Proceedings of the 2nd Nobel Symposium.
Almqvist and Wicksell.
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu,
V., Djoumbou, Y., Eisner, R., Guo, A. C., and Wishart, D. S. (2011). Drugbank 3.0: a
comprehensive resource for ’omics’ research on drugs. Nucleic Acids Res, 39(Database
issue):D1035–D1041.
Kohn, A. D., Takeuchi, F., and Roth, R. A. (1996). Akt, a pleckstrin homology domain
containing kinase, is activated primarily by phosphorylation. J Biol Chem, 271(36):21920–
21926.
Kollmann, M., L?vdok, L., Bartholomé, K., Timmer, J., and Sourjik, V. (2005). Design prin-
ciples of a bacterial signalling network. Nature, 438(7067):504–507.
Kopelman, R. (1988). Fractal reaction kinetics. Science, 241(4873):1620–1626.
Krauss, M., Schaller, S., Borchers, S., Findeisen, R., Lippert, J., and Kuepfer, L. (2012). In-
tegrating cellular metabolism into a multiscale whole-body model. PLoS Comput Biol,
8(10):e1002750.
Krippner-Heidenreich, A., Tübing, F., Bryde, S., Willi, S., Zimmermann, G., and Scheurich,
P. (2002). Control of receptor-induced signaling complex formation by the kinetics of
ligand/receptor interaction. J Biol Chem, 277(46):44155–44163.
Krumsiek, J., Pölsterl, S., Wittmann, D. M., and Theis, F. J. (2010). Odefy–from discrete to
continuous models. BMC Bioinformatics, 11:233.
Kudo, T., Kiba, T., and Sakakibara, H. (2010). Metabolism and long-distance translocation
of cytokinins. J Integr Plant Biol, 52(1):53–60.
Lalli, E. and Sassone-Corsi, P. (1994). Signal transduction and gene regulation: the nuclear
response to camp. J Biol Chem, 269(26):17359–17362.
Lapetina, E. G., Lacal, J. C., Reep, B. R., and Molina y Vedia, L. (1989). A ras-related pro-
tein is phosphorylated and translocated by agonists that increase camp levels in human
platelets. Proc Natl Acad Sci U S A, 86(9):3131–3134.
Lapetina, E. G., Reep, B., Ganong, B. R., and Bell, R. M. (1985). Exogenous sn-1,2-
diacylglycerols containing saturated fatty acids function as bioregulators of protein ki-
nase c in human platelets. J Biol Chem, 260(3):1358–1361.
Lewandrowski, U., Wortelkamp, S., Lohrig, K., Zahedi, R. P., Wolters, D. A., Walter, U., and
Sickmann, A. (2009). Platelet membrane proteomics: a novel repository for functional
research. Blood, 114(1):e10–e19.
Li, Y., Tai, B.-C., Sia, W., Phua, Q.-H., Richards, M. A., Low, A., Chan, K.-H., Teo, S.-G.,
Sim, T.-B., Lee, C.-H., Roe, M. T., Yeo, T.-C., Tan, H.-C., and Chan, M. Y. (2012). Angio-
graphic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopi-
dogrel 600 mg pretreatment in primary percutaneous coronary intervention. J Thromb
Thrombolysis, 34(4):499–505.
Liebenhoff, U., Greinacher, A., and Presek, P. (1994). The protein tyrosine kinase pp60c-src
is activated upon platelet stimulation. Cell Mol Biol (Noisy-le-grand), 40(5):645–652.
Linde, A., Mosier, D., Blecha, F., and Melgarejo, T. (2007). Innate immunity and
inflammation–new frontiers in comparative cardiovascular pathology. Cardiovasc Res,
73(1):26–36.
167
REFERENCES
Lindemann, S., Tolley, N. D., Dixon, D. A., McIntyre, T. M., Prescott, S. M., Zimmerman,
G. A., and Weyrich, A. S. (2001a). Activated platelets mediate inflammatory signaling
by regulated interleukin 1beta synthesis. J Cell Biol, 154(3):485–490.
Lindemann, S., Tolley, N. D., Eyre, J. R., Kraiss, L. W., Mahoney, T. M., and Weyrich, A. S.
(2001b). Integrins regulate the intracellular distribution of eukaryotic initiation factor 4e
in platelets. a checkpoint for translational control. J Biol Chem, 276(36):33947–33951.
Linding, R., Jensen, L. J., Ostheimer, G. J., van Vugt, M. A. T. M., J?rgensen, C., Miron, I. M.,
Diella, F., Colwill, K., Taylor, L., Elder, K., Metalnikov, P., Nguyen, V., Pasculescu, A.,
Jin, J., Park, J. G., Samson, L. D., Woodgett, J. R., Russell, R. B., Bork, P., Yaffe, M. B.,
and Pawson, T. (2007). Systematic discovery of in vivo phosphorylation networks. Cell,
129(7):1415–1426.
Lipniacki, T., Paszek, P., Brasier, A. R. A. R., Luxon, B., and Kimmel, M. (2004). Mathema-
tical model of nf-kappab regulatory module. J Theor Biol, 228(2):195–215.
Liu, J., Fitzgerald, M. E., Berndt, M. C., Jackson, C. W., and Gartner, T. K. (2006). Bruton
tyrosine kinase is essential for botrocetin/vwf-induced signaling and gpib-dependent
thrombus formation in vivo. Blood, 108(8):2596–2603.
Liu, J., Mehdi, S., Topping, J., Tarkowski, P., and Lindsey, K. (2010). Modelling and experi-
mental analysis of hormonal crosstalk in arabidopsis. Mol Syst Biol, 6:373.
Liu, J., Pestina, T. I., Berndt, M. C., Steward, S. A., Jackson, C. W., and Gartner, T. K. (2004).
The roles of adp and txa in botrocetin/vwf-induced aggregation of washed platelets. J
Thromb Haemost, 2(12):2213–2222.
Llorente, F., Muskett, P., Sánchez-Vallet, A., López, G., Ramos, B., Sánchez-Rodríguez, C.,
Jordá, L., Parker, J., and Molina, A. (2008). Repression of the auxin response pathway
increases arabidopsis susceptibility to necrotrophic fungi. Mol Plant, 1(3):496–509.
Lobato, E. B., Beaver, T., Muehlschlegel, J., Kirby, D. S., Klodell, C., and Sidi, A. (2006).
Treatment with phosphodiesterase inhibitors type III and v: milrinone and sildenafil is
an effective combination during thromboxane-induced acute pulmonary hypertension.
British journal of anaesthesia, 96:317–22. 3.
Lohmann, S. M. and Walter, U. (2005). Tracking functions of cgmp-dependent protein ki-
nases (cgk). Front Biosci, 10:1313–1328.
Lohse, M. J., Engelhardt, S., and Eschenhagen, T. (2003). What is the role of beta-adrenergic
signaling in heart failure? Circ Res, 93(10):896–906.
Léon, C., Hechler, B., Freund, M., Eckly, A., Vial, C., Ohlmann, P., Dierich, A., LeMeur, M.,
Cazenave, J. P., and Gachet, C. (1999). Defective platelet aggregation and increased resis-
tance to thrombosis in purinergic p2y(1) receptor-null mice. J Clin Invest, 104(12):1731–
1737.
Lorenz, K., Schmitt, J. P., Schmitteckert, E. M., and Lohse, M. J. (2009). A new type of erk1/2
autophosphorylation causes cardiac hypertrophy. Nat Med, 15(1):75–83.
Lotka, A. J. (1925). Elements of physical biology. Baltimore: Williams and Wilkins.
MacFarland, R. T., Zelus, B. D., and Beavo, J. A. (1991). High concentrations of a cgmp-
stimulated phosphodiesterase mediate anp-induced decreases in camp and steroidoge-
nesis in adrenal glomerulosa cells. J Biol Chem, 266(1):136–142.
Mackenzie, I. S., Coughtrie, M. W., MacDonald, T. M., and Wei, L. (2010). Antiplatelet drug
interactions. Journal of internal medicine, 268:516–29. 6.
168
REFERENCES
MacNamara, A., Terfve, C., Henriques, D., Bernabé, B. P., and Saez-Rodriguez, J. (2012).
State-time spectrum of signal transduction logic models. Phys Biol, 9(4):045003.
Macphee, C. H., Reifsnyder, D. H., Moore, T. A., Lerea, K. M., and Beavo, J. A. (1988).
Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets.
J Biol Chem, 263:10353–8. 21.
Maglott, D., Ostell, J., Pruitt, K. D., and Tatusova, T. (2007). Entrez gene: gene-centered
information at ncbi. Nucleic Acids Res, 35(Database issue):D26–D31.
Mahoney, D. J., Cheung, H. H., Mrad, R. L., Plenchette, S., Simard, C., Enwere, E., Arora,
V., Mak, T. W., Lacasse, E. C., Waring, J., and Korneluk, R. G. (2008). Both ciap1
and ciap2 regulate tnfalpha-mediated nf-kappab activation. Proc Natl Acad Sci U S A,
105(33):11778–11783.
Maiwald, T. and Timmer, J. (2008). Dynamical modeling and multi-experiment fitting with
potterswheel. Bioinformatics, 24(18):2037–2043.
Malumbres, M. and Barbacid, M. (2009). Cell cycle, cdks and cancer: a changing paradigm.
Nat Rev Cancer, 9(3):153–166.
Mangan, S. and Alon, U. (2003). Structure and function of the feed-forward loop network
motif. Proc Natl Acad Sci U S A, 100(21):11980–11985.
Manganello, J. M., Djellas, Y., Borg, C., Antonakis, K., and Le Breton, G. C. (1999). Cyclic
amp-dependent phosphorylation of thromboxane a(2) receptor-associated galpha(13). J
Biol Chem, 274(39):28003–28010.
Manganello, J. M., Huang, J.-S., Kozasa, T., Voyno-Yasenetskaya, T. A., and Le Breton, G. C.
(2003). Protein kinase a-mediated phosphorylation of the galpha13 switch i region alters
the galphabetagamma13-g protein-coupled receptor complex and inhibits rho activa-
tion. J Biol Chem, 278(1):124–130.
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The protein
kinase complement of the human genome. Science, 298(5600):1912–1934.
Marchetti, L., Klein, M., Schlett, K., Pfizenmaier, K., and Eisel, U. L. M. (2004). Tumor
necrosis factor (tnf)-mediated neuroprotection against glutamate-induced excitotoxicity
is enhanced by n-methyl-d-aspartate receptor activation. essential role of a tnf receptor
2-mediated phosphatidylinositol 3-kinase-dependent nf-kappa b pathway. J Biol Chem,
279(31):32869–32881.
Margarucci, L., Roest, M., Preisinger, C., Bleijerveld, O. B., van Holten, T. C., Heck, A.
J. R., and Scholten, A. (2011). Collagen stimulation of platelets induces a rapid spatial
response of camp and cgmp signaling scaffolds. Mol Biosyst, 7(7):2311–2319.
Markov, A. A. (1906). Extension of the law of large numbers to dependent quantities.
Izvestiia Fiz Matem Obsch Kazan Univ, 15:135–156.
Marks, F., Klingmüller, U., and Müller-Decker, K. (2009). Cellular Signal Processing. Garland
Science.
Marquis, N. R., Vigdahl, R. L., and Tavormina, P. A. (1969). Platelet aggregation. i. regula-
tion by cyclic amp and prostaglandin e1. Biochem Biophys Res Commun, 36(6):965–972.
Marshall, S. J., Senis, Y. A., Auger, J. M., Feil, R., Hofmann, F., Salmon, G., Peterson, J. T.,
Burslem, F., and Watson, S. P. (2004). GPIb-dependent platelet activation is dependent
on src kinases but not map kinase or cgmp-dependent kinase. Blood, 103(7):2601–2609.
169
REFERENCES
Massberg, S., Grüner, S., Konrad, I., Garcia Arguinzonis, M. I., Eigenthaler, M., Hemler,
K., Kersting, J., Schulz, C., Muller, I., Besta, F., Nieswandt, B., Heinzmann, U., Walter,
U., and Gawaz, M. (2004). Enhanced in vivo platelet adhesion in vasodilator-stimulated
phosphoprotein (vasp)-deficient mice. Blood, 103(1):136–142.
MATLAB (2010). version 7.10.0 (R2010a). The MathWorks Inc, Natick, Massachusetts.
Matsumoto, T., Kobayashi, T., and Kamata, K. (2003). Phosphodiesterases in the vascular
system. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 39:67–86. 4.
Maurice, D. H. (2003). Does sildenafil indirectly inhibit phosphodiesterase 3 in vascular
smooth muscle? Hypertension, 41(3):e2.
May, F., Hagedorn, I., Pleines, I., Bender, M., Vögtle, T., Eble, J., Elvers, M., and Nieswandt,
B. (2009). Clec-2 is an essential platelet-activating receptor in hemostasis and thrombosis.
Blood, 114(16):3464–3472.
Mazzucato, M., Pradella, P., Cozzi, M. R., De Marco, L., and Ruggeri, Z. M. (2002). Sequen-
tial cytoplasmic calcium signals in a 2-stage platelet activation process induced by the
glycoprotein ibalpha mechanoreceptor. Blood, 100(8):2793–2800.
McClean, M. N., Mody, A., Broach, J. R., and Ramanathan, S. (2007). Cross-talk and decision
making in map kinase pathways. Nat Genet, 39(3):409–414.
Mellion, B. T., Ignarro, L. J., Ohlstein, E. H., Pontecorvo, E. G., Hyman, A. L., and Kad-
owitz, P. J. (1981). Evidence for the inhibitory role of guanosine 3’, 5’-monophosphate
in adp-induced human platelet aggregation in the presence of nitric oxide and related
vasodilators. Blood, 57(5):946–955.
Mendoza, L. and Xenarios, I. (2006). A method for the generation of standardized qualita-
tive dynamical systems of regulatory networks. Theor Biol Med Model, 3:13.
Menten, L. and Michaelis, M. (1913). Die Kinetik der Invertinwirkung. Biochem Z, 49:333–
369.
Meyer, R., D’Alessandro, L. A., Kar, S., Kramer, B., She, B., Kaschek, D., Hahn, B., Wrang-
borg, D., Karlsson, J., Kvarnström, M., Jirstrand, M., Lehmann, W.-D., Timmer, J., Höfer,
T., and Klingmüller, U. (2012). Heterogeneous kinetics of akt signaling in individual cells
are accounted for by variable protein concentration. Front Physiol, 3:451.
Meyer, T., Amaya, M., Desai, H., Robles-Carrillo, L., Hatfield, M., Francis, J. L., and
Amirkhosravi, A. (2010). Human platelets contain and release tweak. Platelets, 21(7):571–
574.
Michelson, A. D. (2006). Platelets. Academic Press.
Michelson, A. D. (2010). Antiplatelet therapies for the treatment of cardiovascular disease.
Nature reviews. Drug discovery, 9:154–69. 2.
Miller, M. L., Jensen, L. J., Diella, F., J?rgensen, C., Tinti, M., Li, L., Hsiung, M., Parker, S. A.,
Bordeaux, J., Sicheritz-Ponten, T., Olhovsky, M., Pasculescu, A., Alexander, J., Knapp, S.,
Blom, N., Bork, P., Li, S., Cesareni, G., Pawson, T., Turk, B. E., Yaffe, M. B., Brunak, S.,
and Linding, R. (2008). Linear motif atlas for phosphorylation-dependent signaling. Sci
Signal, 1(35):ra2.
Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D., and Alon, U. (2002). Net-
work motifs: simple building blocks of complex networks. Science, 298(5594):824–827.
170
REFERENCES
Mischnik, M., Boyanova, D., Hubertus, K., Geiger, J., Philippi, N., Dittrich, M., Wangorsch,
G., TImmer, J., and Dandekar, T. (2013). A boolean view separates platelet activatory
and inhibitory signalling as verified by phosphorylation monitoring including threshold
behaviour and integrin modulation. Mol Biosyst, page (accepted).
Monine, M. I., Posner, R. G., Savage, P. B., Faeder, J. R., and Hlavacek, W. S. (2010). Mode-
ling multivalent ligand-receptor interactions with steric constraints on configurations of
cell-surface receptor aggregates. Biophys J, 98(1):48–56.
Moore, C., Tymvios, C., and Emerson, M. (2010). Functional regulation of vascular and
platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase.
Thromb Haemost, 104(2):342–349.
Morris, M. K., Saez-Rodriguez, J., Sorger, P. K., and Lauffenburger, D. A. (2010). Logic-
based models for the analysis of cell signaling networks. Biochemistry, 49(15):3216–3224.
Moser, M., Nieswandt, B., Ussar, S., Pozgajova, M., and Fässler, R. (2008). Kindlin-3 is
essential for integrin activation and platelet aggregation. Nat Med, 14(3):325–330.
Moubayidin, L., Di Mambro, R., and Sabatini, S. (2009). Cytokinin-auxin crosstalk. Trends
Plant Sci, 14(10):557–562.
Movsesian, M. A. and Bristow, M. R. (2005). Alterations in camp-mediated signaling and
their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol, 68:25–48.
Mukai, Y., Nakamura, T., Yoshikawa, M., Yoshioka, Y., Tsunoda, S.-i., Nakagawa, S., Yam-
agata, Y., and Tsutsumi, Y. (2010). Solution of the structure of the tnf-tnfr2 complex. Sci
Signal, 3(148):ra83.
Mukhtar, M. S., Carvunis, A.-R., Dreze, M., Epple, P., Steinbrenner, J., Moore, J., Tasan, M.,
Galli, M., Hao, T., Nishimura, M. T., Pevzner, S. J., Donovan, S. E., Ghamsari, L., San-
thanam, B., Romero, V., Poulin, M. M., Gebreab, F., Gutierrez, B. J., Tam, S., Monachello,
D., Boxem, M., Harbort, C. J., McDonald, N., Gai, L., Chen, H., He, Y., , E. U. E. C.,
Vandenhaute, J., Roth, F. P., Hill, D. E., Ecker, J. R., Vidal, M., Beynon, J., Braun, P., and
Dangl, J. L. (2011). Independently evolved virulence effectors converge onto hubs in a
plant immune system network. Science, 333(6042):596–601.
Mullershausen, F., Friebe, A., Feil, R., Thompson, W. J., Hofmann, F., and Koesling, D.
(2003). Direct activation of pde5 by cgmp: long-term effects within no/cgmp signaling.
J Cell Biol, 160(5):719–727.
Murray, J. D. (2003). Mathematical Biology: Spatial models and biomedical applications. Springer.
Murthy, K. S. and Zhou, H. (2003). Selective phosphorylation of the ip3r-i in vivo by
cgmp-dependent protein kinase in smooth muscle. Am J Physiol Gastrointest Liver Physiol,
284(2):G221–G230.
Murthy, K. S., Zhou, H., and Makhlouf, G. M. (2002). PKA-dependent activation of PDE3A
and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. American journal
of physiology. Cell physiology, 282:C508—C517. 3.
Nakahata, N. (2008). Thromboxane a2: physiology/pathophysiology, cellular signal trans-
duction and pharmacology. Pharmacol Ther, 118(1):18–35.
Nakayama, M., Ishidoh, K., Kayagaki, N., Kojima, Y., Yamaguchi, N., Nakano, H., Komi-
nami, E., Okumura, K., and Yagita, H. (2002). Multiple pathways of tweak-induced cell
death. J Immunol, 168(2):734–743.
171
REFERENCES
Naseem, M. and Dandekar, T. (2012). The role of auxin-cytokinin antagonism in plant-
pathogen interactions. PLoS Pathog, 8(11):e1003026.
Naseem, M., Philippi, N., Hussain, A., Wangorsch, G., Ahmed, N., and Dandekar, T. (2012).
Integrated systems view on networking by hormones in arabidopsis immunity reveals
multiple crosstalk for cytokinin. Plant Cell.
Natarajan, M., Lin, K.-M., Hsueh, R. C., Sternweis, P. C., and Ranganathan, R. (2006). A
global analysis of cross-talk in a mammalian cellular signalling network. Nat Cell Biol,
8(6):571–580.
Naudé, P. J. W., den Boer, J. A., Luiten, P. G. M., and Eisel, U. L. M. (2011). Tumor necrosis
factor receptor cross-talk. FEBS J, 278(6):888–898.
Navarro, L., Dunoyer, P., Jay, F., Arnold, B., Dharmasiri, N., Estelle, M., Voinnet, O., and
Jones, J. D. G. (2006). A plant mirna contributes to antibacterial resistance by repressing
auxin signaling. Science, 312(5772):436–439.
Nelson, J. (2009). Structure and Funtion in Cell Signalling. John Wiley and Sons.
Netherton, S. J., Jimmo, S. L., Palmer, D., Tilley, D. G., Dunkerley, H. A., Raymond, D. R.,
Russell, J. C., Absher, P. M., Sage, E. H., Vernon, R. B., and Maurice, D. H. (2002).
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile
phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for
diabetes-associated cardiovascular disease. Diabetes, 51:1194–200. 4.
Newman, M. E. J. (2003). The structure and function of complex networks. SIAM reviews,
45:167 – 256.
Newman, P. J. (1999). Switched at birth: a new family for pecam-1. J Clin Invest, 103(1):5–9.
Nikolsky, Y. and Kleemann, R. (2010). Systems biology approaches to the study of cardio-
vascular drugs. Methods Mol Biol, 662:221–243.
Nolte, C., Eigenthaler, M., Horstrup, K., Honig-Liedl, P., and Walter, U. (1994). Synergistic
phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphopro-
tein in intact human platelets in response to cGMP- and cAMP-elevating platelet in-
hibitors. Biochem Pharmacol, 48:1569–75. 8.
Oeckinghaus, A., Hayden, M. S., and Ghosh, S. (2011). Crosstalk in nf-kb signaling path-
ways. Nat Immunol, 12(8):695–708.
Offermanns, S. (2006). Activation of platelet function through g protein-coupled receptors.
Circ Res, 99(12):1293–1304.
Omori, K. and Kotera, J. (2007). Overview of PDEs and their regulation. Circulation research,
100:309–27. 3.
Ozüyaman, B., Gödecke, A., Küsters, S., Kirchhoff, E., Scharf, R. E., and Schrader, J. (2005).
Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus
formation. Thromb Haemost, 93(6):1161–1167.
Parsian, A., Todd, R. D., Cloninger, C. R., Hoffman, P. L., Ovchinnikova, L., Ikeda, H.,
and Tabakoff, B. (1996). Platelet adenylyl cyclase activity in alcoholics and subtypes of
alcoholics. WHO/ISBRA study clinical centers. Alcohol Clin Exp Res, 20:745–51. 4.
172
REFERENCES
Patrignani, P., Di Febbo, C., Tacconelli, S., Douville, K., Guglielmi, M. D., Horvath, R. J.,
Ding, M., Sierra, K., Stitham, J., Gleim, S., Baccante, G., Moretta, V., Di Francesco, L.,
Capone, M. L., Porreca, E., and Hwa, J. (2008). Differential association between human
prostacyclin receptor polymorphisms and the development of venous thrombosis and
intimal hyperplasia: a clinical biomarker study. Pharmacogenetics and genomics, 18:611–
20. 7.
Pearson, K. and Lee, A. (1903). On the laws of inheritance in man: I. inheritance of physical
characters. Biometrika, 2(4):pp. 357–462.
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, 3rd, R. O., Criqui,
M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, Jr, S. C., Taubert,
K., Tracy, R. P., Vinicor, F., , C. f. D. C., Prevention, and , A. H. A. (2003). Markers
of inflammation and cardiovascular disease: application to clinical and public health
practice: A statement for healthcare professionals from the centers for disease control
and prevention and the american heart association. Circulation, 107(3):499–511.
Perrault, C., Mangin, P., Santer, M., Baas, M.-J., Moog, S., Cranmer, S. L., Pikovski, I.,
Williamson, D., Jackson, S. P., Cazenave, J.-P., and Lanza, F. (2003). Role of the intra-
cellular domains of gpib in controlling the adhesive properties of the platelet gpib/v/ix
complex. Blood, 101(9):3477–3484.
Pertry, I., Václavíková, K., Depuydt, S., Galuszka, P., Spíchal, L., Temmerman, W., Stes,
E., Schmülling, T., Kakimoto, T., Van Montagu, M. C. E., Strnad, M., Holsters, M.,
Tarkowski, P., and Vereecke, D. (2009). Identification of rhodococcus fascians cytokinins
and their modus operandi to reshape the plant. Proc Natl Acad Sci U S A, 106(3):929–934.
Petrich, B. G., Marchese, P., Ruggeri, Z. M., Spiess, S., Weichert, R. A. M., Ye, F., Tiedt,
R., Skoda, R. C., Monkley, S. J., Critchley, D. R., and Ginsberg, M. H. (2007). Talin is
required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp
Med, 204(13):3103–3111.
Pezzino, S., Paratore, S., and Cavallaro, S. (2011). Systems biology of apoptosis and sur-
vival: implications for drug development. Curr Pharm Des, 17(3):190–203.
Philippi, N., Walter, D., Schlatter, R., Ferreira, K., Ederer, M., Sawodny, O., Timmer, J.,
Borner, C., and Dandekar, T. (2009). Modeling system states in liver cells: survival,
apoptosis and their modifications in response to viral infection. BMC Syst Biol, 3:97.
Pierre, S., Eschenhagen, T., Geisslinger, G., and Scholich, K. (2009). Capturing adenylyl
cyclases as potential drug targets. Nature reviews. Drug discovery, 8:321–35. 4.
Podzuweit, T., Nennstiel, P., and Müller, A. (1995). Isozyme selective inhibition of cgmp-
stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) ade-
nine. Cell Signal, 7(7):733–738.
Poppe, H., Rybalkin, S. D., Rehmann, H., Hinds, T. R., Tang, X. B., Christensen, A. E.,
Schwede, F., Genieser, H. G., Bos, J. L., Doskeland, S. O., Beavo, J. A., and Butt, E. (2008).
Cyclic nucleotide analogs as probes of signaling pathways. Nature methods, 5:277–8. 4.
Port, J. D. and Bristow, M. R. (2001). beta-adrenergic receptors, transgenic mice, and phar-
macological model systems. Mol Pharmacol, 60(4):629–631.
Pozuelo Rubio, M., Campbell, D. G., Morrice, N. A., and Mackintosh, C. (2005). Phospho-
diesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of
ser428. The Biochemical journal, 392:163–72. Pt 1.
Premsler, T., Lewandrowski, U., Sickmann, A., and Zahedi, R. P. (2011). Phosphoproteome
analysis of the platelet plasma membrane. Methods Mol Biol, 728:279–290.
173
REFERENCES
Purvis, J. E., Chatterjee, M. S., Brass, L. F., and Diamond, S. L. (2008). A molecular signaling
model of platelet phosphoinositide and calcium regulation during homeostasis and p2y1
activation. Blood, 112(10):4069–4079.
Qiao, J., Holian, O., Lee, B.-S., Huang, F., Zhang, J., and Lum, H. (2008). Phosphorylation
of gtp dissociation inhibitor by pka negatively regulates rhoa. Am J Physiol Cell Physiol,
295(5):C1161–C1168.
Ramsey, S. A., Gold, E. S., and Aderem, A. (2010). A systems biology approach to under-
standing atherosclerosis. EMBO Mol Med, 2(3):79–89.
Rao, Y. J. and Xi, L. (2009). Pivotal effects of phosphodiesterase inhibitors on myocyte
contractility and viability in normal and ischemic hearts. Acta pharmacologica Sinica, 30:1–
24. 1.
Raue, A., Kreutz, C., Maiwald, T., Bachmann, J., Schilling, M., Klingmüller, U., and Timmer,
J. (2009). Structural and practical identifiability analysis of partially observed dynamical
models by exploiting the profile likelihood. Bioinformatics, 25(15):1923–1929.
Rauert, H., Wicovsky, A., Müller, N., Siegmund, D., Spindler, V., Waschke, J., Kneitz, C.,
and Wajant, H. (2010). Membrane tumor necrosis factor (tnf) induces p100 processing
via tnf receptor-2 (tnfr2). J Biol Chem, 285(10):7394–7404.
Ren, M.-Y. and Sui, S.-J. (2012). The role of tweak/fn14 in cardiac remodeling. Mol Biol Rep,
39(11):9971–9977.
Riba, R., Oberprieler, N. G., Roberts, W., and Naseem, K. M. (2006). Von willebrand fac-
tor activates endothelial nitric oxide synthase in blood platelets by a glycoprotein ib-
dependent mechanism. J Thromb Haemost, 4(12):2636–2644.
Riba, R., Sharifi, M., Farndale, R. W., and Naseem, K. M. (2005). Regulation of platelet
guanylyl cyclase by collagen: evidence that glycoprotein vi mediates platelet nitric oxide
synthesis in response to collagen. Thromb Haemost, 94(2):395–403.
Rink, T. J., Smith, S. W., and Tsien, R. Y. (1982). Cytoplasmic free ca2+ in human platelets:
Ca2+ thresholds and ca-independent activation for shape-change and secretion. FEBS
Lett, 148(1):21–26.
Rittenhouse, S. E. and Sasson, J. P. (1985). Measurement of ip3 mass as a monitor of phos-
pholipase c activation in stimulated human platelets. Nouv Rev Fr Hematol, 27(4):239–242.
Rivero, R. M., Kojima, M., Gepstein, A., Sakakibara, H., Mittler, R., Gepstein, S., and
Blumwald, E. (2007). Delayed leaf senescence induces extreme drought tolerance in a
flowering plant. Proc Natl Acad Sci U S A, 104(49):19631–19636.
Rivet-Bastide, M., Vandecasteele, G., Hatem, S., Verde, I., Bénardeau, A., Mercadier, J. J.,
and Fischmeister, R. (1997). cgmp-stimulated cyclic nucleotide phosphodiesterase regu-
lates the basal calcium current in human atrial myocytes. J Clin Invest, 99(11):2710–2718.
Robert-Seilaniantz, A., Grant, M., and Jones, J. D. G. (2011). Hormone crosstalk in plant dis-
ease and defense: more than just jasmonate-salicylate antagonism. Annu Rev Phytopathol,
49:317–343.
Robert-Seilaniantz, A., Navarro, L., Bari, R., and Jones, J. D. G. (2007). Pathological hor-
mone imbalances. Curr Opin Plant Biol, 10(4):372–379.
Rodius, S., Chaloin, O., Moes, M., Schaffner-Reckinger, E., Landrieu, I., Lippens, G., Lin,
M., Zhang, J., and Kieffer, N. (2008). The talin rod ibs2 alpha-helix interacts with the
beta3 integrin cytoplasmic tail membrane-proximal helix by establishing charge com-
plementary salt bridges. J Biol Chem, 283(35):24212–24223.
174
REFERENCES
Rolf, M. G., Brearley, C. A., and Mahaut-Smith, M. P. (2001). Platelet shape change evoked
by selective activation of p2x1 purinoceptors with alpha,beta-methylene atp. Thromb
Haemost, 85(2):303–308.
Rolf, M. G. and Mahaut-Smith, M. P. (2002). Effects of enhanced p2x1 receptor ca2+ influx
on functional responses in human platelets. Thromb Haemost, 88(3):495–502.
Rosen, O. M. (1987). After insulin binds. Science, 237(4821):1452–1458.
Rota, G., Kac, M., and Schwartz, J. T. (1986). Discrete Thoughts: Essays on Mathematics, Science
and Philosophy. Birkhaeuser Boston.
Rothe, M., Pan, M. G., Henzel, W. J., Ayres, T. M., and Goeddel, D. V. (1995a). The tnfr2-
traf signaling complex contains two novel proteins related to baculoviral inhibitor of
apoptosis proteins. Cell, 83(7):1243–1252.
Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995b). Traf2-mediated activation of
nf-kappa b by tnf receptor 2 and cd40. Science, 269(5229):1424–1427.
Rowley, J. W., Oler, A. J., Tolley, N. D., Hunter, B. N., Low, E. N., Nix, D. A., Yost, C. C.,
Zimmerman, G. A., and Weyrich, A. S. (2011). Genome-wide rna-seq analysis of human
and mouse platelet transcriptomes. Blood, 118(14):e101–e111.
Rual, J.-F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., Berriz, G. F.,
Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., Klitgord, N., Simon, C., Boxem,
M., Milstein, S., Rosenberg, J., Goldberg, D. S., Zhang, L. V., Wong, S. L., Franklin, G.,
Li, S., Albala, J. S., Lim, J., Fraughton, C., Llamosas, E., Cevik, S., Bex, C., Lamesch,
P., Sikorski, R. S., Vandenhaute, J., Zoghbi, H. Y., Smolyar, A., Bosak, S., Sequerra, R.,
Doucette-Stamm, L., Cusick, M. E., Hill, D. E., Roth, F. P., and Vidal, M. (2005). To-
wards a proteome-scale map of the human protein-protein interaction network. Nature,
437(7062):1173–1178.
Ruggeri, Z. M. and Mendolicchio, G. L. (2007). Adhesion mechanisms in platelet function.
Circ Res, 100(12):1673–1685.
Rukoyatkina, N., Walter, U., Friebe, A., and Gambaryan, S. (2011). Differentiation of cgmp-
dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxy-
gen species production using platelets lacking soluble guanylyl cyclase. Thromb Haemost,
106(5):922–933.
Saez-Rodriguez, J., Alexopoulos, L. G., Epperlein, J., Samaga, R., Lauffenburger, D. A.,
Klamt, S., and Sorger, P. K. (2009). Discrete logic modelling as a means to link protein
signalling networks with functional analysis of mammalian signal transduction. Mol
Syst Biol, 5:331.
Saez-Rodriguez, J., Alexopoulos, L. G., Zhang, M., Morris, M. K., Lauffenburger, D. A., and
Sorger, P. K. (2011). Comparing signaling networks between normal and transformed
hepatocytes using discrete logical models. Cancer Res, 71(16):5400–5411.
Saez-Rodriguez, J., Simeoni, L., Lindquist, J. A., Hemenway, R., Bommhardt, U., Arndt, B.,
Haus, U.-U., Weismantel, R., Gilles, E. D., Klamt, S., and Schraven, B. (2007). A logical
model provides insights into t cell receptor signaling. PLoS Comput Biol, 3(8):e163.
Saitoh, T., Nakayama, M., Nakano, H., Yagita, H., Yamamoto, N., and Yamaoka, S. (2003).
Tweak induces nf-kappab2 p100 processing and long lasting nf-kappab activation. J Biol
Chem, 278(38):36005–36012.
175
REFERENCES
Samaga, R., Saez-Rodriguez, J., Alexopoulos, L. G., Sorger, P. K., and Klamt, S. (2009). The
logic of egfr/erbb signaling: theoretical properties and analysis of high-throughput data.
PLoS Comput Biol, 5(8):e1000438.
Santner, A. and Estelle, M. (2009). Recent advances and emerging trends in plant hormone
signalling. Nature, 459(7250):1071–1078.
Sauro, H. M. and Kholodenko, B. N. (2004). Quantitative analysis of signaling networks.
Prog Biophys Mol Biol, 86(1):5–43.
Savageau, M. A. (1995). Michaelis-menten mechanism reconsidered: implications of fractal
kinetics. J Theor Biol, 176(1):115–124.
Savi, P., Labouret, C., Delesque, N., Guette, F., Lupker, J., and Herbert, J. M. (2001).
P2y(12), a new platelet adp receptor, target of clopidogrel. Biochem Biophys Res Commun,
283(2):379–383.
Sawyers, C. (2004). Targeted cancer therapy. Nature, 432(7015):294–297.
Schanz, J., Pusch, J., Hansmann, J., and Walles, H. (2010). Vascularised human tissue mo-
dels: a new approach for the refinement of biomedical research. J Biotechnol, 148(1):56–63.
Schäfer, A., Burkhardt, M., Vollkommer, T., Bauersachs, J., Münzel, T., Walter, U., and
Smolenski, A. (2003). Endothelium-dependent and -independent relaxation and vasp
serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta.
Biochem Pharmacol, 65(3):397–405.
Schinner, E., Salb, K., and Schlossmann, J. (2011). Signaling via irag is essential for
no/cgmp-dependent inhibition of platelet activation. Platelets, 22(3):217–227.
Schlatter, R., Philippi, N., Wangorsch, G., Pick, R., Sawodny, O., Borner, C., Timmer, J.,
Ederer, M., and Dandekar, T. (2011). Integration of boolean models exemplified on hep-
atocyte signal transduction. Brief Bioinform.
Schlatter, R., Schmich, K., Avalos Vizcarra, I., Scheurich, P., Sauter, T., Borner, C., Ederer, M.,
Merfort, I., and Sawodny, O. (2009). On/off and beyond–a boolean model of apoptosis.
PLoS Comput Biol, 5(12):e1000595.
Schmich, K., Schlatter, R., Corazza, N., Sá Ferreira, K., Ederer, M., Brunner, T., Borner, C.,
and Merfort, I. (2011). Tumor necrosis factor ? sensitizes primary murine hepatocytes to
fas/cd95-induced apoptosis in a bim- and bid-dependent manner. Hepatology, 53(1):282–
292.
Schmidt, K., Schrammel, A., Koesling, D., and Mayer, B. (2001). Molecular mechanisms in-
volved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide
in endothelial cells. Molecular pharmacology, 59:220–4. 2.
Schnell, S. and Turner, T. E. (2004). Reaction kinetics in intracellular environments with
macromolecular crowding: simulations and rate laws. Prog Biophys Mol Biol, 85(2-3):235–
260.
Schultess, J., Danielewski, O., and Smolenski, A. P. (2005). Rap1gap2 is a new gtpase-
activating protein of rap1 expressed in human platelets. Blood, 105(8):3185–3192.
Schulz, R. and Heusch, G. (2009). Tumor necrosis factor-alpha and its receptors 1 and 2:
Yin and yang in myocardial infarction? Circulation, 119(10):1355–1357.
Schwarz, G. (1978). Estimating the dimension of a model. Annals of Statistics, 6(2):461 – 464.
176
REFERENCES
Schwarz, U. R., Geiger, J., Walter, U., and Eigenthaler, M. (1999). Flow cytometry analysis
of intracellular vasp phosphorylation for the assessment of activating and inhibitory
signal transduction pathways in human platelets–definition and detection of ticlopi-
dine/clopidogrel effects. Thromb Haemost, 82(3):1145–1152.
Schwarz, U. R., Walter, U., and Eigenthaler, M. (2001). Taming platelets with cyclic nu-
cleotides. Biochemical pharmacology, 62:1153–61. 9.
Schwertz, H., Tolley, N. D., Foulks, J. M., Denis, M. M., Risenmay, B. W., Buerke, M., Tilley,
R. E., Rondina, M. T., Harris, E. M., Kraiss, L. W., Mackman, N., Zimmerman, G. A., and
Weyrich, A. S. (2006). Signal-dependent splicing of tissue factor pre-mrna modulates the
thrombogenicity of human platelets. J Exp Med, 203(11):2433–2440.
Seber, G. A. F. and Wild, C. J. (1989). Nonlinear regression. New York: Wiley.
Self, S. G. and Liang, K. Y. (1987). Asymptotic properties of maximum likelihood estimators
and likelihood ratio tests under nonstandard conditions. Journal of the American Statistical
Association, 82:605 – 610.
Seybold, J., Thomas, D., Witzenrath, M., Boral, S., Hocke, A. C., Bürger, A., Hatzelmann,
A., Tenor, H., Schudt, C., Krüll, M., Schütte, H., Hippenstiel, S., and Suttorp, N. (2005).
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in en-
dothelial hyperpermeability. Blood, 105(9):3569–3576.
Shakur, Y., Takeda, K., Kenan, Y., Yu, Z. X., Rena, G., Brandt, D., Houslay, M. D., Degerman,
E., Ferrans, V. J., and Manganiello, V. C. (2000). Membrane localization of cyclic nu-
cleotide phosphodiesterase 3 (PDE3). two n-terminal domains are required for the effi-
cient targeting to, and association of, PDE3 with endoplasmic reticulum. The Journal of
biological chemistry, 275:38749–61. 49.
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N.,
Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for inte-
grated models of biomolecular interaction networks. Genome Res, 13(11):2498–2504.
Shattil, S. J., Kim, C., and Ginsberg, M. H. (2010). The final steps of integrin activation: the
end game. Nat Rev Mol Cell Biol, 11(4):288–300.
Shattil, S. J. and Newman, P. J. (2004). Integrins: dynamic scaffolds for adhesion and signa-
ling in platelets. Blood, 104(6):1606–1615.
Siess, W., Winegar, D. A., and Lapetina, E. G. (1990). Rap1-b is phosphorylated by protein
kinase a in intact human platelets. Biochem Biophys Res Commun, 170(2):944–950.
Silvey, S. D. (1975). Statistical Inference. Chapman & Hall.
Sim, D. S., Merrill-Skoloff, G., Furie, B. C., Furie, B., and Flaumenhaft, R. (2004). Initial
accumulation of platelets during arterial thrombus formation in vivo is inhibited by ele-
vation of basal camp levels. Blood, 103(6):2127–2134.
Smith, A. M., Xu, W., Sun, Y., Faeder, J. R., and Marai, G. E. (2012). Rulebender: integrated
modeling, simulation and visualization for rule-based intracellular biochemistry. BMC
Bioinformatics, 13 Suppl 8:S3.
Smith, R. A. and Baglioni, C. (1987). The active form of tumor necrosis factor is a trimer. J
Biol Chem, 262(15):6951–6954.
Smolenski, A. (2012). Novel roles of camp/cgmp-dependent signaling in platelets. J Thromb
Haemost, 10(2):167–176.
177
REFERENCES
Smolenski, A., Bachmann, C., Reinhard, K., Honig-Liedl, P., Jarchau, T., Hoschuetzky, H.,
and Walter, U. (1998). Analysis and regulation of vasodilator-stimulated phosphopro-
tein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific mon-
oclonal antibody. J Biol Chem, 273:20029–35. 32.
Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P.-L., and Ideker, T. (2011). Cytoscape 2.8: new
features for data integration and network visualization. Bioinformatics, 27(3):431–432.
Sneddon, M. W., Faeder, J. R., and Emonet, T. (2011). Efficient modeling, simulation and
coarse-graining of biological complexity with nfsim. Nat Methods, 8(2):177–183.
Soderling, S. H., Bayuga, S. J., and Beavo, J. A. (1998). Identification and characterization
of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem, 273(25):15553–8.
0021-9258 (Print) Journal Article Research Support, U.S. Gov’t, P.H.S.
Sontag, E. D. (2002). For differential equations with r parameters, 2r+1 experiments are
enough for identification. Journal of Nonlinear Science, 12 (6):553 – 583.
Stegner, D. and Nieswandt, B. (2011). Platelet receptor signaling in thrombus formation. J
Mol Med (Berl), 89(2):109–121.
Stel, A. J., Ten Cate, B., Jacobs, S., Kok, J. W., Spierings, D. C. J., Dondorff, M., Helfrich,
W., Kluin-Nelemans, H. C., de Leij, L. F. M. H., Withoff, S., and Kroesen, B. J. (2007).
Fas receptor clustering and involvement of the death receptor pathway in rituximab-
mediated apoptosis with concomitant sensitization of lymphoma b cells to fas-induced
apoptosis. J Immunol, 178(4):2287–2295.
Stelzl, U., Worm, U., Lalowski, M., Haenig, C., Brembeck, F. H., Goehler, H., Stroedicke, M.,
Zenkner, M., Schoenherr, A., Koeppen, S., Timm, J., Mintzlaff, S., Abraham, C., Bock, N.,
Kietzmann, S., Goedde, A., Toksöz, E., Droege, A., Krobitsch, S., Korn, B., Birchmeier,
W., Lehrach, H., and Wanker, E. E. (2005). A human protein-protein interaction network:
a resource for annotating the proteome. Cell, 122(6):957–968.
Stoll, G., Viara, E., Barillot, E., and Calzone, L. (2012). Continuous time boolean modeling
for biological signaling: application of gillespie algorithm. BMC Syst Biol, 6:116.
Subramaniam, P. S., Torres, B. A., and Johnson, H. M. (2001). So many ligands, so few
transcription factors: a new paradigm for signaling through the stat transcription factors.
Cytokine, 15(4):175–187.
Suzuki, K., Saito, S.-y., and Ishikawa, T. (2012). Involvement of phosphatidylcholine-
specific phospholipase c in thromboxane a2 receptor-mediated extracellular ca? influx
in rat aorta. Eur J Pharmacol, 677(1-3):123–130.
Suzuki, Y., Yamamoto, M., Wada, H., Ito, M., Nakano, T., Sasaki, Y., Narumiya, S., Shiku, H.,
and Nishikawa, M. (1999). Agonist-induced regulation of myosin phosphatase activity
in human platelets through activation of rho-kinase. Blood, 93(10):3408–3417.
Swameye, I., Muller, T. G., Timmer, J., Sandra, O., and Klingmuller, U. (2003). Identifica-
tion of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased
modeling. Proc Natl Acad Sci U S A, 100:1028–33. 3.
Takahashi, M., Takeda, S., Kurokawa, S., Kubo, T., Fukuda, N., and Izumi, T. (2003). Cyclic
gmp production by anp, bnp, and no during worsening and improvement of chronic
heart failure. Jpn Heart J, 44(5):713–724.
Tang, K. M., Jang, E. K., and Haslam, R. J. (1994). Photoaffinity labelling of cyclic gmp-
inhibited phosphodiesterase (pde iii) in human and rat platelets and rat tissues: effects
of phosphodiesterase inhibitors. Eur J Pharmacol, 268(1):105–114.
178
REFERENCES
Tansey, M. G. and Szymkowski, D. E. (2009). The tnf superfamily in 2009: new pathways,
new indications, and new drugs. Drug Discov Today, 14(23-24):1082–1088.
Terfve, C. D. A., Cokelaer, T., Henriques, D., Macnamara, A., Gonçalves, E., Morris, M. K.,
van Iersel, M., Lauffenburger, D. A., and Saez-Rodriguez, J. (2012). Cellnoptr: a flexible
toolkit to train protein signaling networks to data using multiple logic formalisms. BMC
Syst Biol, 6(1):133.
Tertyshnikova, S., Yan, X., and Fein, A. (1998). cgmp inhibits ip3-induced Ca2+ release in
intact rat megakaryocytes via cgmp- and camp-dependent protein kinases. J Physiol, 512
( Pt 1):89–96.
Thakar, J., Schleinkofer, K., Borner, C., and Dandekar, T. (2006). Rip death domain structural
interactions implicated in tnf-mediated proliferation and survival. Proteins, 63(3):413–
423.
Timmer, J. and Mueller, T. G. (2004). Modeling the nonlinear dynamics of cellular signal
transduction. International Journal of Bifurcation and Chaos, 14:2069 – 2079.
Timmer, J., Rust, H., Horbelt, W., and Voss, H. U. (2000). Parametric, nonparametric and
parametric modelling of a chaotic circuit time series. Physics Letters A, 274:123 – 134.
Tokunaga, F. and Iwai, K. (2012). Lubac, a novel ubiquitin ligase for linear ubiquitination,
is crucial for inflammation and immune responses. Microbes Infect, 14(7-8):563–572.
Tolhurst, G., Carter, R. N., Amisten, S., Holdich, J. P., Erlinge, D., and Mahaut-Smith, M. P.
(2008). Expression profiling and electrophysiological studies suggest a major role for
orai1 in the store-operated ca2+ influx pathway of platelets and megakaryocytes. Plate-
lets, 19(4):308–313.
Torres, A. J., Holowka, D., and Baird, B. A. (2011). Micropatterned ligand arrays to study
spatial regulation in fc receptor signaling. Methods Mol Biol, 748:195–207.
Tracey, K. J. and Cerami, A. (1993). Tumor necrosis factor, other cytokines and disease.
Annu Rev Cell Biol, 9:317–343.
Turner, T. E., Schnell, S., and Burrage, K. (2004). Stochastic approaches for modelling in
vivo reactions. Comput Biol Chem, 28(3):165–178.
Uchida, N. and Tasaka, M. (2010). Intersections between immune responses and morpho-
logical regulation in plants. J Exp Bot, 61(10):2539–2547.
Uetz, P., Giot, L., Cagney, G., Mansfield, T. A., Judson, R. S., Knight, J. R., Lockshon, D.,
Narayan, V., Srinivasan, M., Pochart, P., Qureshi-Emili, A., Li, Y., Godwin, B., Conover,
D., Kalbfleisch, T., Vijayadamodar, G., Yang, M., Johnston, M., Fields, S., and Rothberg,
J. M. (2000). A comprehensive analysis of protein-protein interactions in saccharomyces
cerevisiae. Nature, 403(6770):623–627.
Ulitsky, I., Gat-Viks, I., and Shamir, R. (2008). Metareg: a platform for modeling, analysis
and visualization of biological systems using large-scale experimental data. Genome Biol,
9(1):R1.
Vallabhapurapu, S. and Karin, M. (2009). Regulation and function of nf-kappab transcrip-
tion factors in the immune system. Annu Rev Immunol, 27:693–733.
van Riel, N. A. (2006). Dynamic modelling and analysis of biochemical networks:
mechanism-based models and model-based experiments. Brief Bioinform, 7:364–74. 4.
179
REFERENCES
Vandamme, J., Castermans, D., and Thevelein, J. M. (2012). Molecular mechanisms of
feedback inhibition of protein kinase a on intracellular camp accumulation. Cell Signal,
24(8):1610–1618.
Varga-Szabo, D., Braun, A., and Nieswandt, B. (2009). Calcium signaling in platelets. J
Thromb Haemost, 7(7):1057–1066.
Varga-Szabo, D., Pleines, I., and Nieswandt, B. (2008). Cell adhesion mechanisms in plate-
lets. Arterioscler Thromb Vasc Biol, 28(3):403–412.
Verhulst, P. F. (1838). Notice sur la loi que la population suit dans son accroissement. corre-
spondance mathematique et physique publiee par a. Quetelet, 10:113–121.
Vince, J. E., Chau, D., Callus, B., Wong, W. W.-L., Hawkins, C. J., Schneider, P., McKinlay,
M., Benetatos, C. A., Condon, S. M., Chunduru, S. K., Yeoh, G., Brink, R., Vaux, D. L.,
and Silke, J. (2008). Tweak-fn14 signaling induces lysosomal degradation of a ciap1-traf2
complex to sensitize tumor cells to tnfalpha. J Cell Biol, 182(1):171–184.
Volterra, V. (1931). Variations and fluctuations of the number of individuals in animal species
living together.
von Neumann, J. and Morgenstern, O. (1953). Theory of Games and Economic Behavior. John
Wiley and Sons.
Vuong, Q. H. (1989). Likelihood ratio tests for model selection and non-nested hypotheses.
Econometrica, 57(2):307 – 333.
Wajant, H. (2011). Increasing complexity in tnfr1 signaling. FEBS J, 278(6):861.
Wajant, H. and Scheurich, P. (2001). Tumor necrosis factor receptor-associated factor (traf)
2 and its role in tnf signaling. Int J Biochem Cell Biol, 33(1):19–32.
Wajant, H. and Scheurich, P. (2011). Tnfr1-induced activation of the classical nf-?b pathway.
FEBS J, 278(6):862–876.
Walter, U. and Gambaryan, S. (2009). cgmp and cgmp-dependent protein kinase in platelets
and blood cells. Handb Exp Pharmacol, (191):533–548.
Walters, D. R. and McRoberts, N. (2006). Plants and biotrophs: a pivotal role for cytokinins?
Trends Plant Sci, 11(12):581–586.
Wang, D., Pajerowska-Mukhtar, K., Culler, A. H., and Dong, X. (2007a). Salicylic acid in-
hibits pathogen growth in plants through repression of the auxin signaling pathway.
Curr Biol, 17(20):1784–1790.
Wang, L., Du, F., and Wang, X. (2008). Tnf-alpha induces two distinct caspase-8 activation
pathways. Cell, 133(4):693–703.
Wang, S., Liu, Z., Wang, L., and Zhang, X. (2009). Nf-kappab signaling pathway, inflam-
mation and colorectal cancer. Cell Mol Immunol, 6(5):327–334.
Wang, Y., Aguda, B. D., and Friedman, A. (2007b). A continuum mathematical model of
endothelial layer maintenance and senescence. Theor Biol Med Model, 4:30.
Wang, Y.-L., Chou, F.-C., Chen, S.-J., Lin, S.-H., Chang, D.-M., and Sytwu, H.-K. (2011).
Targeting pre-ligand assembly domain of tnfr1 ameliorates autoimmune diseases - an
unrevealed role in downregulation of th17 cells. J Autoimmun, 37(3):160–170.
180
REFERENCES
Wangorsch, G., Butt, E., Mark, R., Hubertus, K., Geiger, J., Dandekar, T., and Dittrich, M.
(2011). Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feed-
back loops, titrated phosphorylations and pharmacological modulation. BMC Syst Biol,
5:178.
Wardell, M. R., Reynolds, C. C., Berndt, M. C., Wallace, R. W., and Fox, J. E. (1989). Platelet
glycoprotein ib beta is phosphorylated on serine 166 by cyclic amp-dependent protein
kinase. J Biol Chem, 264(26):15656–15661.
Watanabe, N., Bodin, L., Pandey, M., Krause, M., Coughlin, S., Boussiotis, V. A., Ginsberg,
M. H., and Shattil, S. J. (2008). Mechanisms and consequences of agonist-induced talin
recruitment to platelet integrin alphaiibbeta3. J Cell Biol, 181(7):1211–1222.
Weber, A. A., Hohlfeld, T., and Schrör, K. (1999). camp is an important messenger for
adp-induced platelet aggregation. Platelets, 10(4):238–241.
Weckwerth, W. (2011). Green systems biology - from single genomes, proteomes and
metabolomes to ecosystems research and biotechnology. J Proteomics, 75(1):284–305.
Wehrens, X. H. T., Lehnart, S. E., and Marks, A. R. (2005). Intracellular calcium release and
cardiac disease. Annu Rev Physiol, 67:69–98.
Weinberg, W. (1908). Ueber den nachweis der vererbung beim menschen. Jahreshefte d Ver
f vaterlaendische Naturkunde in Wuerttemberg, 64:368–82.
Wertz, I. E., O’Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wies-
mann, C., Baker, R., Boone, D. L., Ma, A., Koonin, E. V., and Dixit, V. M. (2004). De-
ubiquitination and ubiquitin ligase domains of a20 downregulate nf-kappab signalling.
Nature, 430(7000):694–699.
Weyrich, A. S., Lindemann, S., Tolley, N. D., Kraiss, L. W., Dixon, D. A., Mahoney, T. M.,
Prescott, S. P., McIntyre, T. M., and Zimmerman, G. A. (2004). Change in protein phe-
notype without a nucleus: translational control in platelets. Semin Thromb Hemost,
30(4):491–498.
White, J. S. (1999). The 1653 english edition of de motu cordis, shown to be harvey’s vernac-
ular original and revealing crucial aspects of his pre-circulation theory and its connection
to the discovery of the circulation of the blood. Hist Philos Life Sci, 21(1):65–91.
Wicovsky, A., Henkler, F., Salzmann, S., Scheurich, P., Kneitz, C., and Wajant, H.
(2009a). Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory
tnf receptor-2 signaling and modifies tnfr1-tnfr2 cooperation. Oncogene, 28(15):1769–
1781.
Wicovsky, A., Salzmann, S., Roos, C., Ehrenschwender, M., Rosenthal, T., Siegmund, D.,
Henkler, F., Gohlke, F., Kneitz, C., and Wajant, H. (2009b). Tnf-like weak inducer of apop-
tosis inhibits proinflammatory tnf receptor-1 signaling. Cell Death Differ, 16(11):1445–
1459.
Willoughby, S., Holmes, A., and Loscalzo, J. (2002). Platelets and cardiovascular disease.
Eur J Cardiovasc Nurs, 1(4):273–288.
Wilson, L. S., Elbatarny, H. S., Crawley, S. W., Bennett, B. M., and Maurice, D. H. (2008).
Compartmentation and compartment-specific regulation of PDE5 by protein kinase g
allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S
A, 105:13650–5. 36.
Winkles, J. A. (2008). The tweak-fn14 cytokine-receptor axis: discovery, biology and thera-
peutic targeting. Nat Rev Drug Discov, 7(5):411–425.
181
REFERENCES
Witt, J., Barisic, S., Schumann, E., Allgower, F., Sawodny, O., Sauter, T., and Kulms, D.
(2009). Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological
approach. BMC Syst Biol, 3:71.
Wong, C., Liu, Y., Yip, J., Chand, R., Wee, J. L., Oates, L., Nieswandt, B., Reheman, A., Ni,
H., Beauchemin, N., and Jackson, D. E. (2009). Ceacam1 negatively regulates platelet-
collagen interactions and thrombus growth in vitro and in vivo. Blood, 113(8):1818–1828.
Wootton, D. M., Markou, C. P., Hanson, S. R., and Ku, D. N. (2001). A mechanistic model of
acute platelet accumulation in thrombogenic stenoses. Ann Biomed Eng, 29(4):321–329.
World Health Organization (2011). Fact sheet nr. 310.
Worth, D. C., Hodivala-Dilke, K., Robinson, S. D., King, S. J., Morton, P. E., Gertler, F. B.,
Humphries, M. J., and Parsons, M. (2010). Alpha v beta3 integrin spatially regulates
vasp and riam to control adhesion dynamics and migration. J Cell Biol, 189(2):369–383.
Wu, C. C., Ko, F. N., Kuo, S. C., Lee, F. Y., and Teng, C. M. (1995). YC-1 inhibited human
platelet aggregation through NO-independent activation of soluble guanylate cyclase.
British journal of pharmacology, 116:1973–8. 3.
Wu, C.-J., Conze, D. B., Li, T., Srinivasula, S. M., and Ashwell, J. D. (2006). Sensing of lys
63-linked polyubiquitination by nemo is a key event in nf-kappab activation [corrected].
Nat Cell Biol, 8(4):398–406.
Xiang, B., Zhang, G., Liu, J., Morris, A. J., Smyth, S. S., Gartner, T. K., and Li, Z. (2010).
A g(i) -independent mechanism mediating akt phosphorylation in platelets. J Thromb
Haemost, 8(9):2032–2041.
Xu, W., Smith, A. M., Faeder, J. R., and Marai, G. E. (2011a). Rulebender: a visual interface
for rule-based modeling. Bioinformatics, 27(12):1721–1722.
Xu, Z., Chen, N., Kamocka, M. M., Rosen, E. D., and Alber, M. (2008). A multiscale model
of thrombus development. J R Soc Interface, 5:705—722. 24.
Xu, Z., Kamocka, M., Alber, M., and Rosen, E. D. (2011b). Computational approaches to
studying thrombus development. Arterioscler Thromb Vasc Biol, 31(3):500–505.
Yan, H., Zhang, B., Li, S., and Zhao, Q. (2010). A formal model for analyzing drug combi-
nation effects and its application in TNF-alpha-induced NFkappaB pathway. BMC Syst
Biol, 4:50.
Zaccolo, M. and Movsesian, M. A. (2007). cAMP and cGMP signaling cross-talk: role of
phosphodiesterases and implications for cardiac pathophysiology. Circ Res, 100:1569–
78. 11.
Zahedi, R., Lewandrowski, U., Wiesner, J., Wortelkamp, S., Moebius, J., Schütz, C., Wal-
ter, U., Gambaryan, S., and Sickmann, A. (2008). Phosphoproteome of resting human
platelets. J Proteome Res, 7(2):526–534.
Zhang, G., Xiang, B., Dong, A., Skoda, R. C., Daugherty, A., Smyth, S. S., Du, X., and Li,
Z. (2011). Biphasic roles for soluble guanylyl cyclase (sgc) in platelet activation. Blood,
118(13):3670–3679.
Zhang, Q., Liang, C., Yu, Y. A., Chen, N., Dandekar, T., and Szalay, A. A. (2009). The
highly attenuated oncolytic recombinant vaccinia virus glv-1h68: comparative genomic
features and the contribution of f14.5l inactivation. Mol Genet Genomics, 282(4):417–435.
182
REFERENCES
Zhang, W. and Colman, R. W. (2007). Thrombin regulates intracellular cyclic amp concen-
tration in human platelets through phosphorylation/activation of phosphodiesterase 3a.
Blood, 110(5):1475–1482.
Zhang, W., Ke, H., and Colman, R. W. (2002). Identification of interaction sites of cyclic nu-
cleotide phosphodiesterase type 3a with milrinone and cilostazol using molecular mo-
deling and site-directed mutagenesis. Mol Pharmacol, 62(3):514–520.
Zhao, H., Quilley, J., Montrose, D. C., Rajagopalan, S., Guan, Q., and Smith, C. J. (2007). Dif-
ferential effects of phosphodiesterase pde-3/pde-4-specific inhibitors on vasoconstric-
tion and camp-dependent vasorelaxation following balloon angioplasty. Am J Physiol
Heart Circ Physiol, 292(6):H2973–H2981.
183
REFERENCES
184
List of Figures
1 Background: Signaling paradigm . . . . . . . . . . . . . . . . . 12
2 Background: Motifs in signaling networks . . . . . . . . . . . . 15
3 Background: TNF-R1 signaling pathway . . . . . . . . . . . . . 17
4 Background: Stem cell pathway/platelet formation . . . . . . 21
5 Background: Platelet shape change . . . . . . . . . . . . . . . . 22
6 Background: Major platelet surface receptors and effectors . . 23
7 Background: Thrombus formation . . . . . . . . . . . . . . . . 24
8 Background: Platelet inhibitory pathways . . . . . . . . . . . . 29
9 Background: Types of generic networks . . . . . . . . . . . . . 35
10 Background: Time courses (Michaelis-Menten kinetics) . . . . 42
11 Background: Hill equation/Enzyme inhibition . . . . . . . . . 43
12 Methods: The PlateletWeb knowledge base . . . . . . . . . . . . 48
13 Methods: Example Boolean network . . . . . . . . . . . . . . . 50
14 Methods: Modeling phases . . . . . . . . . . . . . . . . . . . . 55
15 Methods: χ2 distribution . . . . . . . . . . . . . . . . . . . . . . 61
16 Methods: Rule-based modeling . . . . . . . . . . . . . . . . . . 64
17 Platelet: Signaling cross-talk . . . . . . . . . . . . . . . . . . . . 67
18 Platelet: Activatory and inhibitory subnetworks . . . . . . . . 68
19 Platelet: Network-integrated PKA/PKG substrates . . . . . . 70
20 Platelet: Boolean network (directed graph) . . . . . . . . . . . 72
21 Platelet: System states after logical steady state computation . 75
22 Platelet: Threshold analysis by dynamic simulation . . . . . . 77
23 Platelet: Key kinases surrounded by phosphorylation events . 79
24 Platelet: Model development processes . . . . . . . . . . . . . 82
25 Platelet: Scheme of cyclic nucleotide signaling . . . . . . . . . 83
26 Platelet: Reaction scheme (basal conditions) . . . . . . . . . . . 84
27 Platelet: Simulated basal levels (cyclic nucleotides) . . . . . . . 87
28 Platelet: Multi-experiment data fit . . . . . . . . . . . . . . . . 89
29 Platelet: Reaction scheme (elevated cAMP conditions) . . . . . 90
30 Platelet: Detailed sensitivity analysis . . . . . . . . . . . . . . . 94
31 Platelet: Sensitivity analysis (feedback constants) . . . . . . . . 95
32 Platelet: Drug combinations . . . . . . . . . . . . . . . . . . . . 97
33 Platelet: VASP phosphorylation . . . . . . . . . . . . . . . . . . 99
34 Platelet: Simulations of different time-scales of drug stimuli . 101
35 Platelet: Probing transient prostacyclin stimuli . . . . . . . . . 102
36 Platelet: Cross-talk cAMP to cGMP . . . . . . . . . . . . . . . . 103
185
37 Platelet: Pathway states and intermediate regulations . . . . . 104
38 Platelet: Modeling the potential cross-talk via cGMP . . . . . . 105
39 Inflammation: Apoptotic cross-talk . . . . . . . . . . . . . . . . 108
40 Inflammation: Network topology . . . . . . . . . . . . . . . . . 110
41 Inflammation: Receptor clustering . . . . . . . . . . . . . . . . 113
42 Inflammation: Rule-based moldes of receptor clustering . . . . 114
43 Cardiomyocycte: Interaction network . . . . . . . . . . . . . . 117
44 Plant: Network topology . . . . . . . . . . . . . . . . . . . . . . 119
45 Plant: Infection modeling . . . . . . . . . . . . . . . . . . . . . 121
46 Plant: Impact of plant hormones on Pst-pathogenicity . . . . . 122
47 Plant: Auxin-cytokinin interaction . . . . . . . . . . . . . . . . 124
48 Hepatocytes: Cell-cell interaction network . . . . . . . . . . . . 126
49 Hepatocytes: Dynamic simulation . . . . . . . . . . . . . . . . 128
50 Annex B.5: Reaction scheme - VASP 1 . . . . . . . . . . . . . . 203
51 Annex B.5: Reaction scheme - VASP 2 . . . . . . . . . . . . . . 206
186
List of Tables
1 Methods: Truth tables . . . . . . . . . . . . . . . . . . . . . . . 50
2 Methods: Successively developed states . . . . . . . . . . . . . 51
3 Platelet: Activation thresholds . . . . . . . . . . . . . . . . . . . 78
4 Platelet: Reactions and rates (basal model) . . . . . . . . . . . . 85
5 Platelet: Dynamic variables and constants (basal model) . . . 86
6 Platelet: Evaluation - feedback loops . . . . . . . . . . . . . . . 91
7 Platelet: Hypothesis testing and model selection . . . . . . . . 93
8 Inflammation: Simulations of multi-valued Boolean model . . 111
9 Hepatocyte: Steady state analysis . . . . . . . . . . . . . . . . . 127
10 Annex B.1: Boolean model - edges . . . . . . . . . . . . . . . . 194
11 Annex B.2: Boolean model - logical connections . . . . . . . . 195
12 Annex B.3: Substrates for PKA and PKG . . . . . . . . . . . . . 197
13 Annex B.4: Model components and specific parameter values 198
14 Annex B.5: Modeling details (PDE inhibition) . . . . . . . . . . 199
15 Annex B.5: Modeling details (AC activation) . . . . . . . . . . 201
16 Annex B.5: Variables and constants - VASP 1 . . . . . . . . . . 204
17 Annex B.5: Variables and constants - VASP 2 . . . . . . . . . . 207
18 Annex B.6: Fitted parameter values . . . . . . . . . . . . . . . . 210
19 Annex B.7: Drug-specific parameters. . . . . . . . . . . . . . . 212
20 Annex C: Cross-talk model - Logical connections . . . . . . . . 214
187
188
LIST OF ABBREVIATIONS
List of Abbreviations
Pst . . . . . . . . . . . Pseudomonas syringae pv tomato DC3000
ABA . . . . . . . . . abscisic acid
AC . . . . . . . . . . . adenylyl cyclase
ADP . . . . . . . . . adenosine diphosphate
AIC . . . . . . . . . . Akaike information criterion
AKAP . . . . . . . A-kinase anchoring protein
AMP . . . . . . . . . adenosine monophosphate
ANP . . . . . . . . . atrial natriuretic peptide
ARAC . . . . . . . arachidonic acid
ATP . . . . . . . . . . adenosine triphosphate
Aux . . . . . . . . . . auxin
BCA . . . . . . . . . bicinchoninic acid
BID . . . . . . . . . . BH3 interacting-domain death agonist
BTK . . . . . . . . . . Bruton’s tyrosine kinase
CalDAG-GEFI Ca2+ and diacylglycerol regulated guanine nucleotide ex-
change factor I
cAMP . . . . . . . . cyclic adenosine monophosphate
CEACAM1 . . . carcinoembryonic antigen cell adhesion molecule 1
cGMP . . . . . . . . cyclic guanosine monophosphate
cIAP . . . . . . . . . cellular inhibitor of apoptosis protein
cIAP1 . . . . . . . . cellular inhibitors of apoptosis 1
cIAP2 . . . . . . . . cellular inhibitors of apoptosis 2
CK . . . . . . . . . . . cytokinin
CLEC2 . . . . . . . C-type lectin receptor
CLP . . . . . . . . . . Common lymphoid progenitor
CMP . . . . . . . . . Common myeloid progenitor
CO . . . . . . . . . . . carbon monoxide
DAG . . . . . . . . . 1,2-diacylglycerol
df . . . . . . . . . . . . degree of freedom
e.g. . . . . . . . . . . exempli gratia
ECM . . . . . . . . . extracellular matrix
EDRF . . . . . . . . endothelium-derived relaxing factor
EGF . . . . . . . . . . epidermal growth factor
eNOS . . . . . . . . endothelial NO synthase
ET . . . . . . . . . . . ethylene
ETI . . . . . . . . . . effector-triggered immunity
189
FADD . . . . . . . . Fas-associated death domain
FasL . . . . . . . . . Fas ligand
GA . . . . . . . . . . . gibberellic acid
GC . . . . . . . . . . . guanylyl cyclase
GDP . . . . . . . . . guanosine diphosphosphate
GKAP . . . . . . . G-kinase anchoring protein
GMP . . . . . . . . . Granulocyte/macrophage progenitor
GMP . . . . . . . . . guanosine monophosphate
GP . . . . . . . . . . . glycoprotein
GPCR . . . . . . . . G protein-coupled receptor
GR . . . . . . . . . . . glucocordocoid receptor
GTP . . . . . . . . . . guanosine triphosphate
H2S . . . . . . . . . . hydrogen sulphide
HGF . . . . . . . . . hepatocyte growth factor
HSC . . . . . . . . . Hematopoietic stem cell
IκB . . . . . . . . . . . inhibitor of κB proteins
IFNγ . . . . . . . . . interferon gamma
IL-1 . . . . . . . . . . interleukin-1
IP3 . . . . . . . . . . . inositol 1,4,5 triphosphate
IP3R . . . . . . . . . IP3 receptor
IPKB . . . . . . . . . Ingenuity Pathways Knowledge Base
IPTG . . . . . . . . . Isopropyl-β-D-thiogalactopyranosid
ITAM . . . . . . . . immunoreceptor tyrosine activation motif
JA . . . . . . . . . . . jasmonic acid
KEGG . . . . . . . . Kyoto Encyclopedia of Genes and Genomes
LASP . . . . . . . . Lim and SH3 domain protein
LRT . . . . . . . . . . likelihood ratio test
LUBAC . . . . . . linear ubiquitin chain assembly complex
LXR . . . . . . . . . . liver X receptor
memTNF . . . . membranous TNF
MEP . . . . . . . . . Megakaryocyte/erythrocyte progenitor
ML . . . . . . . . . . maximum likelihood
mRNA . . . . . . . messenger RNA
NEMO . . . . . . . NFκB essential modulator
NIK . . . . . . . . . . NFκB-inducing kinase
NO . . . . . . . . . . nitric oxide
NRD1 . . . . . . . . Nardilysin
190
LIST OF ABBREVIATIONS
ODE . . . . . . . . . ordinary differential equation
PAMP . . . . . . . . pathogen-associated molecular pattern
PAR . . . . . . . . . . protease-activated receptor
PDE . . . . . . . . . phosphodiesterase
PECAM-1 . . . . platelet-endothelial cell adhesion molecule-1
PGI2 . . . . . . . . . prostaglandin I2
PI3Kβ . . . . . . . . phosphoinositide 3-kinase β
PIP2 . . . . . . . . . phosphatidylinositol 4,5 bisphosphate
PITPNM2 . . . . phosphatidylinositol transfer protein, membrane-associated
2
PKA . . . . . . . . . cAMP-dependent protein kinase
PKC . . . . . . . . . protein kinase C
PKG . . . . . . . . . cGMP-dependent protein kinase
PLA2 . . . . . . . . . phospholipase A2
PLAD . . . . . . . . pre-ligand binding assembly domain
PLCβ2 . . . . . . . phospholipase Cβ2
PLCγ2 . . . . . . . phospholipase Cγ2
PMCA . . . . . . . plasma membrane Ca2+ ATPase
PPAR . . . . . . . . peroxisome proliferator-activated receptor
PPI . . . . . . . . . . . protein-protein interaction
PR1 . . . . . . . . . . pathogenesis-related protein 1
PTGDR . . . . . . prostaglandin receptor
PTI . . . . . . . . . . PAMP-triggered immunity
PYK2 . . . . . . . . protein tyrosine kinase 2
RBM . . . . . . . . . Rule-based modeling
RhoK . . . . . . . . Rho kinase
RIAM . . . . . . . . Rap1-interacting adapter molecule
RIP . . . . . . . . . . receptor-interacting protein
ROC . . . . . . . . . receptor-operated calcium
RXR . . . . . . . . . retinoic X receptor
SA . . . . . . . . . . . salicylic acid
SD . . . . . . . . . . . standard deviation
SEM . . . . . . . . . standard error of the mean
SERCA . . . . . . . sarcoplasmic/endoplasmic Ca2+ ATPase
sGC . . . . . . . . . . soluble guanylyl cyclase
SOC . . . . . . . . . store-operated calcium
SOCE . . . . . . . . store-operated calcium entry
191
STIM1 . . . . . . . stromal interaction molecule-1
STKE . . . . . . . . Signal Transduction Knowledge Environment
STMN1 . . . . . . Stathmin
sTNF . . . . . . . . . soluble TNF
Tab2 . . . . . . . . . Tak1 binding proteins 2
TACE . . . . . . . . TNF alpha converting enzyme
Tak1 . . . . . . . . . TGFβ-activated kinase 1
TF . . . . . . . . . . . tissue factor
TGF . . . . . . . . . . transforming growth factor
TNF . . . . . . . . . tumor necrosis factor
TNF-R1 . . . . . . tumor necrosis factor receptor 1
TNF-R2 . . . . . . tumor necrosis factor receptor 2
TRADD . . . . . . TNF receptor-associated death domain
TRAF . . . . . . . . TNF receptor-associated factor
TRAF1 . . . . . . . TNF receptor-associated factor 1
TRAF2 . . . . . . . TNF receptor-associated factor 2
TRPC6 . . . . . . . canonial transient receptor potential channel 6
TWEAK . . . . . . TNF-like weak inducer of apoptosis
TXA2 . . . . . . . . thromboxane
VASP . . . . . . . . vasodilator stimulated phosphoprotein
vWF . . . . . . . . . von Willebrand factor
XIAP . . . . . . . . . X-linked inhibitor of apoptosis protein
192
ANNEX
Annex
Annex A: Statistics
Annex A.1: Log-likelihood-ratio of a model is χ2-distributed
Here it will be shown that the log-likelihood-ratio between the likelihood
of a true parameter set θ0 and the estimated parameter vector θML follows
a χ2-distribution. This holds if the parameters are identifiable and are not
located at the border of the parameter space. Moreover it is assumed that
θML are normally distributed around θ0 with covariance matrix C:
P (θML − θ0) = 1√
2pi
|C|− 12 e(− 12 (θML−θ0)TC−1(θML−θ0)),
with
Ci,j = −
(
∂2L(θML|M,D)
∂θi∂θj
)−1
.
Covariance matrix C is given by the inverse of the Hessian matrix.
The log-LikelihoodL(θ0|M,D) can be approximated using the Taylor-expansion
L(θ0|M,D) ≈ L(θML|M,D) + ∂L(θML|M,D)
∂θ
(θ0 − θML)
+
1
2
(θ0 − θML)T ∂
2L(θML|M,D)
∂θi∂θj
(θ0 − θML).
(5.1)
The first derivatives ∂L(θML|M,D)
∂θ
equal zero at maximum likelihood, so that
the formula (5.1) reduces to
L(θ0|M,D) ≈ L(θML|M,D)− 1
2
(θ0 − θML)TC−1(θ0 − θML).
Concerning the log-Likelihood-ratio, this yields
2 (L(θML|M,D)− L(θ0|M,D)) ≈ (θ0 − θML)TC−1(θ0 − θML). (5.2)
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As the covariance is symmetric and positive definite, there exists a trans-
formation U under which C as well as the transformed inverse is diagonal
with
UTC−1U =: C˜−1 = diag(1/υ1, 1/υ2, . . . , 1/υr).
Thus, equation (5.2) can be reformulated as:
2 (L(θML|M,D)− L(θ0|M,D)) ≈ (θ0 − θML)TUC˜−1UT (θ0 − θML)
=
r∑
i=1
1
υi
(
UT (θ0 − θML)
)2
i
.
Transformation U was constructed such that the components of the trans-
formed parameter differences
(
UT (θ0 − θML)
)
i
have a variance υi but no co-
variances. Hence, the log-Likelihood-ratio can be expressed as a sum of r
normalized Gaussian distributed random numbers which is χ2-distributed
with r degrees of freedom.
This relation (Burnham and Anderson, 2002; Cox and Hinkley, 1994) is also
applied while comparing nested models (Annex A.2).
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Annex A.2: Comparison of Nested Models
Assuming one compares two nested models, meaning model M2 compri-
sing r2 parameters is a reduction of model M1 having p1 parameters. Hence,
in comparison to model M2 Model M1 has additional r1 − r2 parameters.
The log-ratio of their likelihoods under the null hypothesis that M2 repre-
sents the true model follows also a χ2-distribution. Following Annex A.1,
this becomes evident using the Taylor-expansion of both the log-likelihoods:
L(θ1,0|M1, D) ≈ L(θ1,ML|M1, D)− 1
2
(θ1,0 − θ1,ML)TC−11 (θ1,0 − θ1,ML)
L(θ2,0|M2, D) ≈ L(θ2,ML|M2, D)− 1
2
(θ2,0 − θ2,ML)TC−12 (θ2,0 − θ2,ML).
The first terms (log-likelihoods) L(θ1,0|M1, D) and L(θ2,0|M2, D) of these se-
ries are equal, as model M1 has the same solution under the null hypothesis
explaining the data equally well, so that:
L(θ1,ML|M1, D)− 1
2
(θ1,0 − θ1,ML)TC−11 (θ1,0 − θ1,ML) ≈
L(θ2,ML|M2, D)− 1
2
(θ2,0 − θ2,ML)TC−12 (θ2,0 − θ2,ML).
This can be reformulated as:
2(L(θ1,ML|M1, D)− L(θ2,ML|M2, D)) ≈ (5.3)
(θ1,0 − θ1,ML)TC−11 (θ1,0 − θ1,ML) − (θ2,0 − θ2,ML)TC−12 (θ2,0 − θ2,ML).
As the first r2 parameters of model M1 equal the parameters of M2, these
r2 values vanish in the scalar product in (5.3). Consequently, only the re-
maining r1 − r2 parameters contribute to the log-likelihood-ratio. Thus, the
log-ratio (5.3) follows a χ2-distribution with r1 − r2 degrees of freedom:
2(L(M1)− L(M2)) ∼ χ2r1−r2 .
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Annex A.3: Akaike’s Information Criterion (AIC)
Information criteria are based on information theory and give indication
of the discrepancy between the truth and the estimated model. Here, the
Kullback-Leibler distance (5.4) plays a essential role, being a a measure for
the difference between two probability distributions (Burnham and Ander-
son, 2002) - the true and the estimated distribution of the data:
KL =
∫
Pt(D) log
(
Pt(D)
PM(D|M, θ)
)
dD, (5.4)
with Pt and PM are the respective probability distributions. The Kullack-
Leibler distance thus expresses the information that is "lost" when appro-
ximating the truth by use of the model. Equation 5.4 can be expanded to:
KL =
∫
Pt(D) logPt(D)dD −
∫
Pt(D) logPM(D|M, θ)dD. (5.5)
As the first term of the right hand side of 5.5 is constant (true), only the
second term contributes to the evaluation of the difference. This which can
be formulated as:∫
Pt(D) logPM(D|M, θ)dD =
∫
Pt(D)L(θ|M,D)dD, (5.6)
with log-likelihood Lweighted with the probability distribution of the true
model.
For the computation of 5.6, two problems arise: Pt(D) is not known as well
as the best set of parameters, which however can be estimated by maxi-
mization of the likelihood. Akaike (1973) found that term (see 5.6) can be
approximated by
L(θML|M,D)− r, (5.7)
with r being the count of parameters of model M (Akaike, 1973, 1974).
Since usually χ2-values are computed during the fitting process, the formula
5.7 was multiplied by −2 (see equation 3.6). Hence, the value of AIC can be
expressed as:
AIC = −2L(θML|M,D) + 2 · r = χ2 + 2 · r. (5.8)
Regarding model selection, this suggests to use the model with the lowest
AIC value.
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Annex B: Platelet Signaling
Annex B.1: Boolean Model - Edges
The Boolean model is also available as xml-file and CellNetAnalyzer-files
(Annex D).
Table 10 : Boolean model of platelet activation - modeled edges.
Edge Reference
GPVI→PLCB (Karniguian et al., 1990)
PLCB→IP3 (Rittenhouse and Sasson, 1985)
PLCB→DAG (Billah et al., 1980)
DAG→PKC (Lapetina et al., 1985)
IP3→IP3R (Authi et al., 1986; Braun et al., 2009)
IP3R→CaC (Authi et al., 1986; Braun et al., 2009)
CaC→Orai1 (Braun et al., 2009)
Orai1→CaC (Braun et al., 2009)
P2X1→CaC (Hoylaerts et al., 2000)
PKC→SRC (Liebenhoff et al., 1994)
PI3→Akt (Kohn et al., 1996)
Src→Akt (Xiang et al., 2010)
CaC→ADP (Cattaneo et al., 1990; Daniel et al., 1998)
ADP→P2Y1 (Hechler et al., 1998)
ADP→P2Y12 (Savi et al., 2001)
CaC→CalDAG (Zahedi et al., 2008)
CalDAG→RAP1 (Zahedi et al., 2008)
RAP1→Talin (Watanabe et al., 2008)
ATP→P2X1 (Rolf and Mahaut-Smith, 2002)
P2X1→CaC (Rolf and Mahaut-Smith, 2002)
P2Y1→PLCB (Hechler et al., 1998; Daniel et al., 1999)
P2Y12→cAMP (Daniel et al., 1999)
P2Y12→PI3 (Daniel et al., 1999)
P2Y1→PLA2 (Liu et al., 2004)
PLA2→ARAC (Forsell et al., 2005; Balsinde et al., 1998)
ARAC→TXA (Balsinde et al., 1998)
TXA2R→PLCB (Suzuki et al., 2012)
TXA2R→RhoK (Suzuki et al., 1999; Nakahata, 2008)
RhoK→cellshape (Suzuki et al., 1999; Ishii-Watabe et al., 2001)
Talin→Inta2b3 (Petrich et al., 2007)
PTGDR→cAMP (Marquis et al., 1969; Iyu et al., 2011; Weber et al., 1999)
cAMP→PKA (Murthy et al., 2002)
PKA→Rap1 (Siess et al., 1990)
PKA→VASP (Butt et al., 1994; Weber et al., 1999)
PKA→RhoK (Qiao et al., 2008)
PKA→PDE3 (Murthy et al., 2002)
Akt→Inta2b3 (Kirk et al., 2000)
PKA→IP3R (Murthy and Zhou, 2003)
PKA→Src (Abrahamsen et al., 2003)
Inta2b3→ARAC (Jin et al., 2002)
Inta2b3→aggregation (Shattil and Newman, 2004)
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Annex B.2: Boolean Model - Logical Connections
Table 11 : Multi-valued Boolean model - logical connections.
Reaction Logical connection Phase
ADP 1 GPVI = 1 ADP 1
aggregation 5 Inta2b3 = 1 irrev.agg 3
Akt−activation 1 PI3 = 1 Akt 0
Akt−activation2 1 Src +2 PI3 = 2 Akt 1
Akt−activation3 2 Src + 2 PI3 = 3 Akt 3
ARAC−recruitment 1 PLA2 + 4 Inta2b3 = 1 ARAC 3
CaC 1 IP3R = 1 CaC 0
CaC2 2 IP3R + 1 P2X1 = 2 CaC 1
CaC3 1 Orai1 = 3 CaC 2
CaC4 3 IP3R + 1 P2X1 + 1 Orai1 = 4 CaC 3
CalDAG−activation 1 CaC = 1 CalDAG 0
CalDAG−activation2 2 CaC = 2 CalDAG 1
CalDAG−activation3 3 CaC = 3 CalDAG 2
CalDAG−activation4 4 CaC = 4 CalDAG 3
cAMP−production 1 !P2Y12 + 1 PTGDR + 1 !PDE3 = 1 cAMP 0
cellshape 1 CaC + 1 RAP1 + A !VASP = 1 cellshape 0
cellshape2 2 CaC + 2 RAP1 = 1 cellshape 1
cellshape3 2 CaC + 2 RAP1 + 1 RhoK = 2 cellshape 3
DAG−production 1 PLCB = 1 DAG 0
DAG−production2 2 PLCB = 2 DAG 1
DAG−production3 3 PLCB = 3 DAG 3
GPVI−activation = 1 GPVI 0 (INPUT)
Int−activation−talin 1 Talin = 1 Inta2b3 0
Int−activation−Akt 1 Akt = 1 Inta2b3 0
Int−activation−combi1 1 AKt + 1 Talin = 2 Inta2b3 0
Int−activation−combi2 2 Akt + 2 Talin = 3 Inta2b3 1
Int−activation−combi3 2 Akt + 3 Talin = 4 Inta2b3 2
Int−activation−combi4 3 AKT + 3 Talin = 5 Inta2b3 3
IP3−production 1 PLCB = 1 IP3 0
IP3−production2 2 PLCB = 2 IP3 1
IP3−production3 3 PLCB = 3 IP3 3
IP3R−activation 1 PKC + 1 IP3 + 1 !PKA = 1 IP3R 0
IP3R−activation2 2 PKC + 2 IP3 = 2 IP3R 1
IP3R−activation3 3 PKC + 3 IP3 = IP3R 3
Orai1−activation 2 CaC = 1 Orai1 2
P2X1 1 ADP = 1 P2X1 0
P2Y1 1 ADP = 1 P2Y1 1
P2Y12−activation 1 ADP = 1 P2Y12 1
Continued on next page
198
ANNEX
Table 11 – continued from previous page
Reaction Logical connection Phase
PDE3 1 PKA = 1 PDE3 2
PI3−activation 1 IP3 = 1 PI3 0
PI3−activation2 1 IP3 + 1 P2Y12 = 2 PI3 1
PKA−activation 1 cAMP = 1 PKA 0
PKC−activation 1 DAG = 1 PKC 0
PKC−activation2 1 CaC + 2 DAG = 2 PKC 1
PKC−activation3 3 CaC + 2 DAG = 3 PKC 2
PLA2−activation 1 P2Y1 = 1 PLA2 1
PLCB−activation2 1 P2Y1 = 2 PLCB 1
PLCB−activation3 1 TBXA2R = 2 PLCB 3
PLCB−GPVI 1 GPVI = 1 PLCB 0
PTGDR−activation = 1 PTGDR 0 (INPUT)
RAP1−activation1 1 CalDAG + 1 !PKA = 1 RAP1 0
RAP1−activation2 2 CalDAG + 1 PKA = 1 RAP1 1
RAP1−activation3 2 CalDAG + 1 !PKA = 2 RAP1 1
RAP1−activation4 3 CalDAG + 1 !PKA = 4 RAP1 2
RAP1−activation5 3 CalDAG + 1 PKA = 2 RAP1 2
RAP1−activation6 4 CalDAG = 4 RAP1 3
RhoK−activation 1 TBXA2R + 1 !PKA = 1 RhoK 3
Src−activation 1 PKC + 1 !PKA = 1 Src 0
Src−activation2 2 PKC = 1 Src 1
Src−activation3 3 PKC = 2 Src 2
Talin−activation 1 RAP1 = 1 Talin 0
Talin−activation2 2 RAP1 = 2 Talin 1
Talin−activation3 3 RAP1 = 3 Talin 2
Talin−activation4 4 RAP1 = 4 Talin 2
TBXA2R−activation 1 TXA = 1 TBXA2R 3
TXA−production 1 ARAC = 1 TXA 3
VASP−activation 1 PKA = 1 VASP 0
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ANNEX
Annex B.4: Model Components and Parameter
Table 13 : Model components and specific parameter values.
Component, parameter Parameter Values Reference
Cyclases and cyclic nucleotides
Adenylate cyclase (AC) HPRD, (Boyanova et al., 2012)
ADCY3, ADCY5, ADCY6, ADCY7
Basal AC activity 15.9 pmol/mg/min=7.16 µM/min (Hines and Tabakoff, 2005)
12.4 pmol/mg/min=5.6 µM/min (Parsian et al., 1996)
0.0376 amol/min/platelet=7.23 µM/min (Juska and Farndale, 1999)
cAMP 4.4 ± 1.0 µM/min (Eigenthaler et al., 1992)
Guanylyl cyclase (sGC) HPRD, (Boyanova et al., 2012)
GUCY1A3, GUCY1B3
Basal sGC activity 0.6 - 1 µM/min (Schmidt et al., 2001)
cGMP 0.4 ± 0.1 µM/min (Eigenthaler et al., 1992)
Phosphodiesterases (PDEs)
PDE2A, cGMP stimulated HPRD
(allosterically)
PDE2-specific parameters: (Butt and Walter, 1997)
(Bender and Beavo, 2006)
PDE2 concentration 63.46 mg/l This study
Hill coefficient 2
Km-value (cAMP turnover) 50 µM
Vmax-value (cAMP turnover) 120µmol/min/mg
Km-value (cGMP turnover) 35 µM
Vmax-value (cGMP turnover) 120 µmol/min/mg
PDE3A, cGMP-inhibitied HPRD
PDE3-specific parameters: (Butt and Walter, 1997)
(Bender and Beavo, 2006)
PDE3 concentration 225 mg/l This study
Km-value (cAMP turnover) 0.2 µM
Vmax-value (cAMP turnover) 3 µmol/min/mg
Km-value (cGMP turnover) 0.02 µM
Vmax-value (cGMP turnover) 0.3 µmol/min/mg
PDE5A, cGMP specific HPRD
PDE5-specific parameters: (Butt and Walter, 1997)
PDE5 concentration 1359 mg/l This study
Km-value (cGMP turnover) 5 µM
Vmax-value (cGMP turnover) 5 µmol/min/mg
PDE7A, PDE8B, PDE9A (Dittrich et al., 2006)
Vasodilator-stimulated phosphoprotein (VASP)
VASP HPRD
VASP-specific parameters:
Phosphorylation sites: (Smolenski et al., 1998)
Ser157, Ser239, Thr278 (Butt et al., 1994)
VASP concentration 25.2 ± 7.6 µM (Eigenthaler et al., 1992)
Protein kinases (PKA/PKG)
PKA concentration 3.1 ± 0.6 µM (Eigenthaler et al., 1992)
PKG concentration 7.3 ± 0.8 µM (Eigenthaler et al., 1992)
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Annex B.5: ODE Model Adapted to Anti-platelet Conditions
Core models (Matlab (PottersWheel) model definition files) as well as xml-
files of the basal and extended model are available (Annex D).
Variables, Constants, Rates and System of ODEs (PDE3 inhibition)
Variables and constants of modeled reactions (see Figure 29A,B) are listed
in Table 14.
Variables and Constants (PDE Inhibition Model)
Table 14 : Set of variables and constants for mathematical model of PDE inhibition.
Dynamic variables Values and fitting range Remarks
x1: c(PDE2) active [0.005, 0.2] mg/l
x2: c(PDE3) active [1.7, 3.5] mg/l
x3: c(PDE2) inactive [(63.46− c(PDE2)), 63.46] mg/l
x4: c(PDE3) inactive [(225− c(PDE3)), 225] mg/l
x5: c(cAMP) µmol, simulated
Startvalue: 4 µM
x6: c(AMP) µM
Input
u1: c(Cilostamide) 0.5, 1, 5, 10, 50 µM PDE3 inhibitor
u2: c(Milrinone) 1, 5, 10, 50, 100 µM
Constants
k1: Vmax PDE2 120 µmol/min/mg; fix
cAMP turnoverk2: Km PDE2 50 µM; fix
k3: Vmax PDE3 3 µmol/min/mg; fix
k4: Feedback regulation [0, 0.2] µmol−1 Activation of PDE3 via cAMP
k5: Km PDE3 0.2 µM; fix cAMP turnover
k6: kcAMP [5, 9] µmol/min Basal influx of cAMP (AC)
k7: hPDE2 2 ; fix Hill coefficient (PDE2)
k8: Deactivation of PDE2
[0, 1] min−1
k9: Activation of PDE2
k10: Deactivation of PDE3
k11: Activation of PDE3
k121 : ki Cilostamide [0.00001, 1] µM Inhibition constant (PDE3)
k122 : ki Milrinone
Parameter x1, x2, k4, k6, k8 − k122 fit to cAMP concentration measurements at several time
points using parameter values given in Table 13.
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Reaction Fate Formalism (PDE3 inhibition)
Basal AC influx of cAMP (r1) : ν1 = k6;
cAMP turnover via PDE2 (r2) : ν2 = k1 ·x
k7
5 ·x1/(k2 + x
k7
5 );
(De)activation of PDE (r3-r6) :

ν3 = k9 ·x3;
ν4 = k8 ·x1;
ν5 = k11 ·x4;
ν6 = k10 ·x2;
(5.9)
cAMP turnover via PDE3 (r7) : ν7 = (k3 + k4 ·x5) ·x5 ·x2/((1.0 + (ui/k12i )) · k5 + x5);
with ui : c(PDE3 inhibitor), k12i : Inhibition constant, i = 1, 2.
System of Differential Equations (PDE3 inhibition)
Variables are defined in Table 14.
dx1
dt
= + ν3 − ν4;
dx2
dt
= + ν5 − ν6;
dx3
dt
= − ν3 + ν4;
dx4
dt
= − ν5 + ν6;
dx5
dt
= + ν1 − ν2 − ν7;
dx6
dt
= + ν2 + ν7;
(5.10)
203
Variables, Constants, Rates and System of ODEs (AC activation)
Variables and constants of modeled reactions (see Figure 29) are listed in
Table 15.
Variables and Constants (AC activation model)
Table 15 : Set of variables and constants for mathematical model of adenylyl cyclase
activation.
Dynamic variables Values and fitting range Remarks
x1: c(PDE2) active [0.005, 0.2] mg/l
x2: c(PDE3) active [1.7, 3.5] mg/l
x3: c(PDE2) inactive [(63.46− c(PDE2)), 63.46] mg/l
x4: c(PDE3) inactive [(225− c(PDE3)), 225] mg/l
x51 : ACForskolin [0, 5000] µmol/min Response to Foskolin doses
x52 : ACIloprost Response to Iloprost doses
x6: c(cAMP) µM, simulated
Startvalue: 4 µM
x7: c(AMP) µM
Constants
k1: Vmax PDE2 120 µmol/min/mg; fix
cAMP turnoverk2: Km PDE2 50 µM; fix
k3: Vmax PDE3 3 µmol/min/mg; fix
k4: Feedback regulation [0, 0.2] µmol−1 Activation of PDE3 via cAMP
k5: Km PDE3 0.2 µM; fix cAMP turnover
k6: kcAMP [5, 9] µmol/min Basal influx of cAMP (AC)
k7: hPDE2 2 ; fix Hill coefficient (PDE2)
k8: Deactivation of PDE2
[0, 1] min−1
k9: Activation of PDE2
k10: Deactivation of PDE3
k11: Activation of PDE3
k121 : Activation constant 1 min−1; fix
Via Forskolin
k122 : of AC Via Iloprost
k13: Inhibition of AC [0, 10000] min−1 Via cAMP (PKA)
Parameter x1, x2, k4, k6, k8 − k11, k13 fit to cAMP concentration measurements at several
time points using parameter values given in Table 13.
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Reaction Rate Formalism (AC activation)
Basal AC influx of cAMP (r1) : ν1 = k6;
cAMP turnover via PDE2 (r2) : ν2 = k1 ·x
k7
6 ·x1/(k2 + x
k7
6 );
cAMP turnover via PDE3 (r3) : ν3 = (k3 + k4 ·x6) ·x6 ·x2/(k5 + x6);
(De)activation of PDE (r4-r7) :

ν4 = k9 ·x3;
ν5 = k8 ·x1;
ν6 = k11 ·x4;
ν7 = k10 ·x2;
(5.11)
cAMP influx via activated AC (r8) : ν8 = k12i ·x5i − k13 ·x6;
with x5i : ACForskolin, ACIloprost, k12i : Activation constant of AC, i = 1, 2.
System of Differential Equations (AC activation)
Variables are defined in Table 15.
dx1
dt
= + ν4 − ν5;
dx2
dt
= + ν6 − ν7;
dx3
dt
= − ν4 + ν5;
dx4
dt
= − ν6 + ν7;
dx5
dt
= 0;
dx6
dt
= + ν1 − ν2 − ν3 + ν8;
dx7
dt
= + ν2 + ν3;
(5.12)
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Variables, Constants, Rates and System of ODEs
(VASP phosphorylations 1)
Variables and constants of the underlying modeled reactions (see Figure 50)
are listed in Table 16.
Reaction Scheme
AC activation
PDE2*
PDE3*
PDE2
PDE3
PDE5*
cAMP
AMP
PDE5
ATP
GCAC
cGMP
GMP
GTP
PKG
PKG*
PKA
PKA*
  157      239
VASP
  157      239
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Figure 50 : Reaction scheme of VASP phosphorylation - modeled reactions.
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ANNEX
Variables and Constants (VASP Phosphorylations 1)
Table 16 : Set of variables and constants for the mathematical model of VASP activa-
tion.
Dynamic variables Values and fitting range Remarks
x1: c(PKAα) inactive Startvalue: 6.2 µM; fix Catalytic subunit PKAα
x2: c(VASP) Startvalue: 25 µM; fix Intracellular VASP concentration
x3: c(VASPSer157) unphosphorylated Startvalue: 25 µM; Concentration of unphosphorylated VASPSer157
x4: c(VASPSer239) unphosphorylated Range: [0, 25] µM Concentration of unphosphorylated VASPSer239
x5: c(PKG) active Startvalue: 1 µM; fix Active c(PKG) due to basal cGMP level
x6: c(PKAα) active Simulated
x7: c(VASPSer157) phosphorylated Simulated Concentration of phosphorylated VASPSer157
x8: c(VASPSer239) phosphorylated Concentration of phosphorylated VASPSer239
Constants
k1: kPKAαact Startvalue: 1 Activation of PKA through cAMP
Range: [0, 1000]
k2: kV ASPinact Startvalue: 1 Inactivation (dephosphorylation) of VASP
Range: [0, 1000000]
k3: Km VASPSer239 Startvalue: 10
PKA-specific
Range: [0, 10000]
k4: Vmax VASPSer239 Startvalue: 1
Range: [0, 10000]
k5: Km VASPSer157 Startvalue: 0.1
Range: [0, 10000]
k6: Vmax VASPSer157 Startvalue: 1
Range: [0, 10000]
k7: Km VASPSer239 Startvalue: 10
PKG-specific
Range: [0, 10000]
k8: Vmax VASPSer239 Startvalue: 10
Range: [0, 10000]
k9: Km VASPSer157 Startvalue: 10
Range: [0, 1000]
k10: Vmax VASPSer157 Startvalue: 10
Range: [0, 10000]
Assignment rules
a1: Ratio of VASPSer157 to VASP Experimental measurement
a2: Ratio of VASPSer239 to VASP
Driving input
u1: cAMP level Due to Iloprost stimulation (2, 5, 10 nM)Time series within [0, 10] min
Parameters k1 − k10 were fit to measured relations of phosphorylated VASP (Ser157, Ser239) to .
unphosphorylated VASP at several time points.
207
Reaction Rate Formalism (VASP Phosphorylations 1)
Defining the observed ratio between phosphorylated VASP and VASP in
total (important for the fitting procedure):
Ratio of VASPSer157 to VASP: a1 =
x7
x2
;
Ratio of VASPSer239 to VASP: a2 =
x8
x2
;
(5.13)
Activation of PKA via cAMP (r1) : ν1 = k1 ·x1 ·u1;
Phosphorylation of VASPSer157 by PKAα (r2) : ν2 = k6 ·x3 ·x6/(k5 + x3);
Phosphorylation of VASPSer239 by PKAα (r3) : ν3 = k4 ·x4 ·x6/(k3 + x4);
Dephosphorylation of VASPSer239 (r4) : ν4 = k2 ·x8;
Dephosphorylation of VASPSer157 (r5) : ν5 = k2 ·x7;
Phosphorylation of VASPSer157 by PKG (r6) : ν6 = k10 ·x3 ·x5/(k9 + x3);
Phosphorylation of VASPSer239 by PKG (r7) : ν7 = k8 ·x4 ·x5/(k7 + x4);
(5.14)
System of Differential Equations (VASP Phosphorylations 1)
Variables are defined in Table 16.
dx1
dt
= − ν1;
dx2
dt
= 0.0;
dx3
dt
= − ν2 + ν5 − ν6;
dx4
dt
= − ν3 + ν4 − ν7;
dx5
dt
= 0.0;
dx6
dt
= + ν1;
dx7
dt
= + ν2 − ν5 + ν6;
dx8
dt
= + ν3 − ν4 + ν7;
(5.15)
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ANNEX
Variables, Constants, Rates and System of ODEs
(VASP Phosphorylations 2)
Reaction Scheme
Similarly, we here consider the modeling of VASP phosphorylation as down-
stream event but with two distinct variants of PKA (Figure 51) of different
activity. Variables and constants of the underlying modeled reaction are
listed in Table 17. Available data was not sufficient to discriminate between
the two VASP phosphorylation approaches.
Figure 51 : Reaction scheme of VASP phosphorylation - modeled reactions.
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Variables and Constants (VASP Phosphorylations 2)
Table 17 : Set of variables and constants for the mathematical model of VASP activa-
tion.
Dynamic variables Values and fitting range Remarks
x1: c(PKAα) inactive Startvalue: 6.2 µM; fix Catalytic subunit PKAα
x2: c(PKAcs) inactive Startvalue: 6.2 µM; fix Distinct catalytic subunit of PKA
x3: c(VASP) Startvalue: 25 µM; fix Intracellular VASP concentration
x4: c(VASPSer157) unphosphorylated Startvalue: 25 µM; Concentration of unphosphorylated VASPSer157
x5: c(VASPSer239) unphosphorylated Range: [0, 25] µM Concentration of unphosphorylated VASPSer239
x6: c(PKAα) active Simulated Catalytic subunit PKAα
x7: c(PKAcs) active Catalytic subunit of PKA
x8: c(VASPSer157) phosphorylated Simulated Concentration of phosphorylated VASPSer157
x9: c(VASPSer239) phosphorylated Concentration of phosphorylated VASPSer239
Constants
k1: kPKAαact Startvalue: 1 Activation of PKAα through cAMP
Range: [0, 1000]
k2: kPKAcsact Startvalue: 1 Activation of PKAcs through cAMP
Range: [0, 1000]
k3: kV ASPinact Startvalue: 1 Inactivation (dephosphorylation) of VASP
Range: [0, 1000000]
k4: Km VASPSer239 Startvalue: 10
PKAα-specific
Range: [0, 1000000]
k5: Vmax VASPSer239 Startvalue: 1
Range: [0, 100000]
k6: Km VASPSer157 Startvalue: 0.1
Range: [0, 100000]
k7: Vmax VASPSer157 Startvalue: 1
Range: [0, 100000]
k8: Km VASPSer239 Startvalue: 1
PKAcs-specific
Range: [0, 1000000]
k9: Vmax VASPSer239 Startvalue: 1
Range: [0, 1000000]
k10: Km VASPSer157 Startvalue: 0.1
Range: [0, 100000]
k11: Vmax VASPSer157 Startvalue: 1
Range: [0, 1000000]
Assignment rules
a1: Ratio of VASPSer157 to VASP Experimental measurement
a2: Ratio of VASPSer239 to VASP
Driving input
u1: cAMP level Due to Iloprost stimulation (2, 5, 10 nM)Time series within [0, 10] min
Parameters k1 − k11 were fit to measured relations of phosphorylated VASP (Ser157, Ser239) to
unphosphorylated VASP at several time points.
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Reaction Rate Formalism (VASP Phosphorylations 2)
Defining the observed ratio between phosphorylated VASP and VASP in
total (necessary for the fitting procedure):
Ratio of VASPSer157 to VASP: a1 =
x8
x3
;
Ratio of VASPSer239 to VASP: a2 =
x9
x3
;
(5.16)
Activation of PKAα via cAMP (r1) : ν1 = k1 ·x1 ·u1;
Activation of PKAcs via cAMP (r2) : ν2 = k2 ·x2 ·u1;
Phosphorylation of VASPSer157 by PKAα (r3) : ν3 = k7 ·x4 ·x6/(k6 + x4);
Phosphorylation of VASPSer157 by PKAcs (r4) : ν4 = k11 ·x4 ·x7/(k10 + x4);
Phosphorylation of VASPSer239 by PKAα (r5) : ν5 = k5 ·x5 ·x6/(k4 + x5);
Phosphorylation of VASPSer239 by PKAcs (r6) : ν6 = k9 ·x5 ·x7/(k8 + x5);
Dephosphorylation of VASPSer239 (r7) : ν7 = k3 ·x9;
Dephosphorylation of VASPSer157 (r8) : ν8 = k3 ·x8;
(5.17)
System of Differential Equations (VASP Phosphorylations 2)
Variables are defined Table 17.
dx1
dt
= − ν1;
dx2
dt
= − ν2
dx3
dt
= 0.0;
dx4
dt
= − ν3 − ν4 + ν7;
dx5
dt
= − ν5 − ν6 + ν7;
dx6
dt
= + ν1;
dx7
dt
= + ν2
dx8
dt
= + ν3 + ν4 − ν8;
dx9
dt
= + ν5 − ν6 − ν7;
(5.18)
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ANNEX
Annex B.6: Fitted Parameters
Table 18 : Fitted parameter values.
Parameter description Symbol Value (best 50% of 1000 fits) Value (best fit)
PDE inhibition and AC activation
cAMP influx via AC in response to ACF(500) 595.60± 2.99 µmol/min 621.75 µmol/min
several application concentrations ACF(200) 386.83± 2.01 µmol/min 403.01 µmol/min
of Forskolin: ACF(100) 85.84± 0.36 µmol/min 87.89 µmol/min
(1 - 500 µM) ACF(30) 55.07± 0.30 µmol/min 55.60 µmol/min
ACF(10) 29.20± 0.18 µmol/min 28.56 µmol/min
ACF(3) 3.18± 0.14 µmol/min 2.10 µmol/min
ACF(1) 6.32± 0.13 µmol/min 5.22 µmol/min
cAMP influx via AC in response to ACI(100) 116.23± 0.75 µmol/min 119.82 µmol/min
several application concentrations ACI(50) 117.33± 0.75 µmol/min 120.93 µmol/min
of Iloprost: ACIt(10) 68.21± 0.43 µmol/min 69.57 µmol/min
(1 - 100 nM) ACI(5) 53.18± 0.35 µmol/min 53.89 µmol/min
ACI(1) 4.63± 0.12 µmol/min 3.53 µmol/min
Inhibition of AC k13 0.86± 0.017 min−1 0.69 min−1
ki Milrinone k122 0.16 ± 0.003 µM 0.14 µM
c(PDE2) x1 0.02± 0.003 µg/l 0.005 µg/l
c(PDE3) x2 1.78± 0.07 µg/l 1.70 µg/l
ki Cilostamide k121 0.99 ± 0.003 µM 1 µM
Deactivation of PDE2 k8 0.56± 0.018 min−1 0.67 min−1
Activation of PDE2 k9 0.0007± 2.25 · 10−5 min−1 0.0008 min−1
Deactivation of PDE3 k10 0.02± 0.04 min−1 0.95 min−1
Activation of PDE3 k11 6.39 · 10−5 ± 0.0002 min−1 0.0046 min−1
Basal influx of cAMP k6 8.93± 0.1 µmol/min 8.99 µmol/min
feedback regulation k4 0.01± 0.01 µmol−1 0.2 µmol−1
(cAMP→ PDE3)
VASP - model PKA and PKG
kPKAαact (2 nM) k1 0.00028± 1.64 · 10−5 min−1 0.00026 min−1
kPKAαact (5 nM) k1 0.008± 0.0015 min−1 0.006 min−1
kPKAαact (10 nM) k1 0.04± 0.01 min−1 0.03 min−1
kVASPinact k2 2.31± 0.53 min−1 3.26 min−1
KmVASPSer239 (PKAα) k3 135.59 ± 61.32 µM 197.01 µM
VmaxVASPSer239 (PKAα) k4 48.00± 22.95 µmol/min/mg 104.31 µmol/min/mg
KmVASPSer157 (PKAα) x5 88.11 ± 38.07 µM 130.42 µM
VmaxVASPSer157 (PKAα) x6 49.65± 22.05 µmol/min/mg 107.95 µmol/min/mg
KmVASPSer239 (PKG) k7 12.36 ± 38.09 µM 2.05 µM
VmaxVASPSer239 (PKG) k8 1.90± 2.45 µmol/min/mg 1.73 µmol/min/mg
KmVASPSer157 (PKG) x9 158.28 ± 133.33 µM 214.44 µM
VmaxVASPSer157 (PKG) x10 62.73± 47.46 µmol/min/mg 115.86 µmol/min/mg
VASP - model with two distinct catalytic PKA subunits
kPKAαact (2 nM) k1 63.54± 300.7 min−1 0.18 min−1
kPKAαact (5 nM) k1 113.41± 390.59 min−1 34.86 min−1
kPKAαact (10 nM) k1 930.42± 1670.26 min−1 1.02 min−1
kPKAcsact (2 nM) k2 0.00033± 3.99 · 10−5 min−1 0.00033 min−1
kPKAcsact (5 nM) k2 0.0068± 0.001 min−1 0.005 min−1
kPKAcsact (10 nM) k2 0.02± 0.002 min−1 0.02 min−1
Continued on next page
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Table 18 – continued from previous page
Parameter description Symbol Value (best 50% of 1000 fits) Value (best fit)
kVASPinact k3 491.28± 168.90 min−1 318.16 min−1
KmVASPSer239 (PKAα) k4 6.70 ± 11.49 µM 31.48 µM
VmaxVASPSer239 (PKAα) k5 54.02± 20.16 µmol/min/mg 63.66 µmol/min/mg
KmVASPSer157 (PKAα) x6 1.49 ± 4.58 µM 1.80 µM
VmaxVASPSer157 (PKAα) x7 249.56± 85.36 µmol/min/mg 173.28 µmol/min/mg
KmVASPSer239 (PKAcs) k8 0.76 ± 1.98 µM 0.01 µM
VmaxVASPSer239 (PKAcs) k9 1041.23± 374.71 µmol/min/mg 676.98 µmol/min/mg
KmVASPSer157 (PKAcs) x10 890.20 ± 445.65 µM 1805.42 µM
VmaxVASPSer157 (PKAcs) x11 87429.4± 37233.7 µmol/min/mg 114700 µmol/min/mg
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Annex B.7: Drug-specific Parameter Values
Table 19 : Drug-specific parameters.
Drug Pathway effect Drug specific parameter Reference
Modeled
Milrinone PDE3 inhibition IC50: 56 ± 12 nM (Tang et al., 1994)
(cAMP) IC50: 0.3 µM (Bailey et al., 1994)
IC50: 0.49 µM (Zhao et al., 2007)
IC50: 7.0 ± 0.9 µM (Herget et al., 2008)
resulting in ki values:
(0.05 - 0.3) µM (Cer et al., 2009)
ki: 0.55 µM (Floreani et al., 2003)
ki: 0.66 µM (Zhang et al., 2002)
here: ki: 0.15 µM (k122 ); Table 18
1
Cilostamide IC50: 70 ± 9 nM (Tang et al., 1994)
IC50: 0.37 ± 0.005 µM (Herget et al., 2008)
ki: 1 µM (k121 ); Table 18
1
Iloprost AC stimulation k12i section 4.3
(through GPCR)
Forskolin AC stimulation
(direct)
General/predictive
EHNA PDE2 inhibition IC50: 1 µM (Soderling et al., 1998)
(cAMP) IC50: 0.8 - 4 µM (Podzuweit et al., 1995)
Oxindole IC50: 40 nM (Rivet-Bastide et al., 1997)
Bay-60 7550 IC50: 4.7 nM (Boess et al., 2004)
PDP IC50: 0.6 nM (Seybold et al., 2005)
Trequisin PDE3 inhibition IC50: 13 ± 2 nM (Tang et al., 1994)
Lixazinone (cAMP) IC50: 22 ± 4 nM (Tang et al., 1994)
IBMX IC50: 3950 ± 22 nM (Tang et al., 1994)
Siguazodan IC50: 0.117 ± 0.029 µM (Tang et al., 1994)
Zaprinast PDE5 inhibition IC50: 0.76 µM (Soderling et al., 1998)
Dipyridamole (cGMP) IC50: 0.9 µM (Soderling et al., 1998)
(Herget et al., 2008)
Vardenafil IC50: 0.16 ± 0.03 µM (Herget et al., 2008)
Sildenafil IC50: 1.9 ± 0.4 µM (Herget et al., 2008)
Milrinone-like agonists PDE3 inhibition Variation of k122
2 see section 3.3, (r7)
Cilostamide-like agonists Variation of k121
2
Iloprost-like agonists AC stimulation Variation of k122
2 see section 4.3, (r8)
Forskolin-like agonists Variation of k121
2
Modeling drug combinations
Milrinone/Iloprost PDE3 inhibition / Modified AC activation by see section 4.3, (r8)
synergistic AC stimulation k12 = 1.443 = cAMPk 1syn
> 1
Cilostamide/Iloprost PDE3 inhibition Modified AC activation see section 4.3, (r8)
synergistic AC stimulation k12 = 1.443 = cAMPk 1syn
> 1
Milrinone/AC inhibitor PDE3 inhibition/ k3 (AC inhibitor (I) dependent) AC influx = k6 − k3 · log(c(I)),
AC inhibition here: k3 = 0.5 k6: basal AC influx of cAMP
Continued on next page
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Table 19 – continued from previous page
Drug Pathway effect Drug specific parameter Reference
Forskolin/Milrinone PDE3 inhibition/ Modified AC activation by see section 4.3, (r8)
synergistic AC stimulation k12 = 1.443 = cAMPk 1syn
> 1
Single drugs with
k12 = 1 see section 4.3, (r8)additive interaction
Single drugs with PDE3 inhibition/
k12 =
1
1.443
< 1
see section 4.3, (r8)
antagonistic interaction PDE5 inhibition (Maurice, 2003)
1Estimated from experimental data
2Range according to pharmacological relevant differences in agonist strengths
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ANNEX
Annex C: Cross-talk Model (TNF receptors)
CellNetAnalyzer-files are available (Annex D).
Table 20 : Cross-talk model - modeled logical connections.
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ANNEX
Annex D: Model Files
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